ducing PHARM	AC
ducing PHARM/	Δ

2

4

5

24

38

52

58

62

72

95

104

128

205

213

220

228

231

247

257

October 2020 Volume 8 Number 3 Editor:	Part I	General Rules
Kaye Wilson & Doris Chong email: enquiry@pharmac.govt.nz Telephone +64 4 460 4990 Facsimile +64 4 460 4995 Level 9, 40 Mercer Street PO Box 10 254 Wellington 6143	Part II	Alimentary Tract and Metabolism Blood and Blood Forming Organs Cardiovascular System
Freephone Information Line 0800 66 00 50 (9am – 5pm weekdays)		Dermatologicals
Circulation Published each March, July and November. Changes to the contents are published in monthly updates.		Genito-Urinary System Hormone Preparations
Accessible in an electronic format at no cost from the PHARMAC website www.pharmac.govt.nz/schedule. You can register to have an electronic		Infections Musculoskeletal System Nervous System
version of the Pharmaceutical Schedule, Section H for Hospital Pharmaceuticals (link to PDF copy) emailed to your nominated email address each month by subscribing at www.pharmac.govt.nz/subscriptions.		Oncology Agents and Immunosuppressants Respiratory System and Allergies
Production		Sensory Organs
Typeset automatically from XML and T _E X. XML version of the Schedule available from schedule.pharmac.govt.nz/pub/HML		Various Extemporaneous Compounds (ECPs)
Programmers		Special Foods
Anrik Drenth & John Geering email: texschedule@pharmac.govt.nz ©Pharmaceutical Management Agency		Vaccines
This work is licensed under the Creative Commons Attribution 4.0 International licence.	Part III	Optional Pharmaceuticals
In essence, you are free to copy, distribute		Index

arising there from.

and adapt it, as long as you attribute the work to PHARMAC and abide by the other licence terms. To view a copy of this licence, visit: creativecommons.org/licenses/by/4.0/. Attribution to PHARMAC should be in written form and not by reproduction of the PHARMAC logo. While care has been taken in compiling this Schedule, PHARMAC takes no responsibility for any errors or omissions, and shall not be liable for any consequences

258

Introducing PHARMAC

The Pharmaceutical Management Agency (PHARMAC) makes decisions that help control Government spending on pharmaceuticals. This includes community pharmaceuticals, hospital pharmaceuticals, vaccines and increasingly, hospital medical devices. PHARMAC negotiates prices, sets subsidy levels and conditions, and makes decisions on changes to the subsidised list. The funding for pharmaceuticals comes from District Health Boards.

PHARMAC's role:

"Secure for eligible people in need of pharmaceuticals, the best health outcomes that can reasonably be achieved, and from within the amount of funding provided."

New Zealand Public Health and Disability Act 2000

To ensure our decisions are as fair and robust as possible we use a decision-making process that incorporates clinical, economic and commercial issues. We also seek the views of users and the wider community through consultation. The processes we generally use are outlined in our Operating Policies and Procedures.

Further information about PHARMAC and the way we make funding decisions can be found on the PHARMAC website at https://www.pharmac.govt.nz/about.

Glossary


Units of Measure

gramg kilogramkg international unitiu	microgrammcg milligrammg millilitreml	
Abbreviations		
applicationapp capsulecap creamcrm dispersibledisp effervescenteff emulsioneff	enteric coatedEC granulesgrans injectioninj liquidliq lotionlotn ointmentoint	suppositorysuppos tablettab

HSS Hospital Supply Status

Guide to Section H listings

Example



General Rules for Section H of the Pharmaceutical Schedule are included in Section A.

Read the General Rules : https://www.pharmac.govt.nz/section-a.

PART II: ALIMENTARY TRACT AND METABOLISM

	Price (ex man. excl. (\$	GST) Per	Brand or Generic Manufacturer
Antacids and Antiflatulents			
Antacids and Reflux Barrier Agents			
ALUMINIUM HYDROXIDE WITH MAGNESIUM HYDROXIDE AND S Tab 200 mg with magnesium hydroxide 200 mg and simeticone 2 Oral liq 400 mg with magnesium hydroxide 400 mg and simeticon 30 mg per 5 ml	20 mg		e.g. Mylanta e.g. Mylanta Double
SIMETICONE Oral drops 100 mg per ml Oral drops 20 mg per 0.3 ml Oral drops 40 mg per ml			Strength
SODIUM ALGINATE WITH MAGNESIUM ALGINATE Powder for oral soln 225 mg with magnesium alginate 87.5 mg, s SODIUM ALGINATE WITH SODIUM BICARBONATE AND CALCIUN Tab 500 mg with sodium bicarbonate 267 mg and calcium carbon	I CARBONATE		e.g. Gaviscon Infant
160 mg	hanata		e.g. Gaviscon Double Strength
Oral liq 500 mg with sodium bicarbonate 267 mg and calcium ca 160 mg per 10 ml SODIUM CITRATE Oral liq 8.8% (300 mmol/l)		500 ml	Acidex
Phosphate Binding Agents			
ALUMINIUM HYDROXIDE Tab 600 mg			
CALCIUM CARBONATE – Restricted see terms below ↓ Oral liq 250 mg per ml (100 mg elemental per ml)		500 ml	Roxane
Initiation Only when prescribed for patients unable to swallow calcium carbona inappropriate	te tablets or where	e calcium carb	onate tablets are
Antidiarrhoeals and Intestinal Anti-Inflammatory A	gents		
Antipropulsives			
DIPHENOXYLATE HYDROCHLORIDE WITH ATROPINE SULPHAT Tab 2.5 mg with atropine sulphate 25 mcg LOPERAMIDE HYDROCHLORIDE	E		
Tab 2 mg		400 400	Nodia Diamide Relief
Rectal and Colonic Anti-Inflammatories			
BUDESONIDE – Restricted see terms on the next page Cap 3 mg			

Pi	rice		Brand or
(ex man.	excl. GST		Generic
	\$	Per	Manufacturer

→ Restricted (RS1723)

Initiation - Crohn's disease

Both:

- 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and
- 2 Any of the following:
 - 2.1 Diabetes; or
 - 2.2 Cushingoid habitus; or
 - 2.3 Osteoporosis where there is significant risk of fracture; or
 - 2.4 Severe acne following treatment with conventional corticosteroid therapy; or
 - 2.5 History of severe psychiatric problems associated with corticosteroid treatment; or
 - 2.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or
 - 2.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated).

Initiation - Collagenous and lymphocytic colitis (microscopic colitis)

Patient has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies.

Initiation - Gut Graft versus Host disease

Patient has gut Graft versus Host disease following allogenic bone marrow transplantation.

Initiation - non-cirrhotic autoimmune hepatitis

Re-assessment required after 6 months

All of the following:

- 1 Patient has autoimmune hepatitis*; and
- 2 Patient does not have cirrhosis; and
- 3 Any of the following:
 - 3.1 Diabetes; or
 - 3.2 Cushingoid habitus; or
 - 3.3 Osteoporosis where there is significant risk of fracture; or
 - 3.4 Severe acne following treatment with conventional corticosteroid therapy; or
 - 3.5 History of severe psychiatric problems associated with corticosteroid treatment; or
 - 3.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or

7

Pentasa

- 3.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated); or
- 3.8 Adolescents with poor linear growth (where conventional corticosteroid use may limit further growth).

Note: Indications marked with * are unapproved indications.

Continuation - non-cirrhotic autoimmune hepatitis

Re-assessment required after 6 months

Treatment remains appropriate and the patient is benefitting from the treatment.

HYDROCORTISONE ACETATE

Rectal foam 10%, CFC free (14 applications)	26.55	21.1 g	Colifoam
HYDROCORTISONE ACETATE WITH PRAMOXINE HYDROCHLORIDE Topical Aerosol foam, 1% with pramoxine hydrochloride 1%			
MESALAZINE			
Tab EC 400 mg	49.50	100	Asacol
Tab EC 500 mg	49.50	100	Asamax
Tab long-acting 500 mg - 1% DV Jul-20 to 2023	56.10	100	Pentasa
Tab 800 mg	85.50	90	Asacol
Modified release granules 1 g		120 g	Pentasa
Suppos 500 mg	22.80	20	Asacol
Suppos 1 g	54.60	30	Pentasa

e.g. Brand indicates brand example only. It is not a contracted product.

		Price excl. GST)		Brand or Generic
		\$	Per	Manufacturer
OLSALAZINE				
Tab 500 mg		.93.37	100	Dipentum
Cap 250 mg		.53.00	100	Dipentum
PREDNISOLONE SODIUM				
Rectal foam 20 mg per dose (14 applications)		74.10	1	Essential Prednisolone
SODIUM CROMOGLICATE			•	
Cap 100 mg				
SULFASALAZINE				
Tab 500 mg			100	Salazopyrin
Tab EC 500 mg - 1% DV Dec-19 to 2022		.15.53	100	Salazopyrin EN
Local Preparations for Anal and Rectal Disorders				
Antihaemorrhoidal Preparations				
CINCHOCAINE HYDROCHLORIDE WITH HYDROCORTISONE				
Oint 5 mg with hydrocortisone 5 mg per g		15.00	30 g	Proctosedyl
Suppos 5 mg with hydrocortisone 5 mg per g			12	Proctosedyl
FLUOCORTOLONE CAPROATE WITH FLUOCORTOLONE PIVALATE			IE	,
Oint 950 mcg with fluocortolone pivalate 920 mcg and cinchocaine		INCHOURIN		
		6.95	20 a	Liltroproct
hydrochloride 5 mg per g Suppos 630 mcg with fluocortolone pivalate 610 mcg and cinchocai		0.35	30 g	Ultraproct
hydrochloride 1 mg		2.66	12	Ultraproct
, ,		2.00	12	Olliapioci
Management of Anal Fissures				
GLYCERYL TRINITRATE				
Oint 0.2%		.22.00	30 g	Rectogesic
Rectal Sclerosants				
OILY PHENOL [PHENOL OILY]				
Inj 5%, 5 ml vial				
Antispasmodics and Other Agents Altering Gut Motil	ity			
GLYCOPYRRONIUM BROMIDE				
Inj 200 mcg per ml, 1 ml ampoule		.17.14	10	Max Health
HYOSCINE BUTYLBROMIDE				
Tab 10 mg - 1% DV Oct-20 to 2023		6.35	100	Buscopan
Inj 20 mg, 1 ml ampoule – 1% DV Jul-20 to 2023			5	Buscopan
		0.00	U	Duotopuli
		0.00	00	Oslafas
Tab 135 mg – 1% DV Jul-20 to 2023		9.20	90	Colofac
Antiulcerants				
Antisecretory and Cytoprotective				
MISOPROSTOL				
Tab 200 mcg		.41.50	120	Cytotec
-u			-	,

Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	F (ex man.	Price excl. G8 \$	ST) Per	Brand or Generic Manufacturer
H2 Antagonists				
CIMETIDINE Tab 200 mg Tab 400 mg FAMOTIDINE Tab 20 mg Tab 40 mg Inj 10 mg per ml, 2 ml vial Inj 10 mg per ml, 4 ml vial RANITIDINE – Restricted see terms below I Tab 150 mg I Tab 150 mg I Tab 300 mg I Oral liq 150 mg per 10 ml I Inj 25 mg per ml, 2 ml ampoule to be delisted 1 March 2021) Restricted (RS1703) Initiation Either: 1 For continuation use; or 2 Routine prevention of allergic reactions			300 ml 5	Peptisoothe Zantac
Proton Pump Inhibitors				
LANSOPRAZOLE Cap 15 mg - 1% DV Sep-18 to 2021 Cap 30 mg - 1% DV Sep-18 to 2021 OMEPRAZOLE ↓ Tab dispersible 20 mg → Restricted (RS1027) Initiation			100 100	Lanzol Relief Lanzol Relief
Only for use in tube-fed patients.				
Cap 10 mg Cap 20 mg Cap 40 mg Powder for oral liq Inj 40 mg ampoule with diluent – 1% DV Oct-19 to 2022 Inj 40 mg vial – 1% DV Oct-19 to 2022 PANTOPRAZOLE Tab EC 20 mg – 1% DV Oct-19 to 2022 Tab EC 40 mg – 1% DV Oct-19 to 2022 Tab EC 40 mg – 1% DV Oct-19 to 2022		1.96 3.12 .42.50 .33.98 .11.46	90 90 5 g 5 5 100 100	Omeprazole actavis 10 Omeprazole actavis 20 Omeprazole actavis 40 Midwest Dr Reddy's Omeprazole Omezol IV Panzop Relief Panzop Relief
Inj 40 mg vial				
Site Protective Agents				
COLLOIDAL BISMUTH SUBCITRATE Tab 120 mg SUCRALFATE Tab 1 g		.14.51	50	Gastrodenol

e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Bile and Liver Therapy			
L-ORNITHINE L-ASPARTATE – Restricted see terms below ↓ Grans for oral liquid 3 g → Restricted (RS1261)			
Initiation For patients with chronic hepatic encephalopathy who have not response where lactulose is contraindicated.	onded to treatment with	h, or are in	tolerant to lactulose, or
RIFAXIMIN – Restricted see terms below ↓ Tab 550 mg → Restricted (RS1416) Initiation	625.00	56	Xifaxan
For patients with hepatic encephalopathy despite an adequate trial of	maximum tolerated d	oses of lac	tulose.
Diabetes			
Alpha Glucosidase Inhibitors			
ACARBOSE Tab 50 mg – 1% DV Sep-18 to 2021 Tab 100 mg – 1% DV Sep-18 to 2021		90 90	Glucobay Glucobay
Hyperglycaemic Agents			
DIAZOXIDE - Restricted see terms below ↓ Cap 25 mg ↓ Cap 100 mg ↓ Oral liq 50 mg per ml		100 100 30 ml	Proglicem Proglycem Glucagen Hypokit
Insulin - Intermediate-Acting Preparations			
INSULIN ASPART WITH INSULIN ASPART PROTAMINE Inj insulin aspart 30% with insulin aspart protamine 70%, 100 u p 3 ml prefilled pen INSULIN ISOPHANE Inj insulin human 100 u per ml, 10 ml vial Inj insulin human 100 u per ml, 3 ml cartridge		5	NovoMix 30 FlexPen

	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
INSULIN LISPRO WITH INSULIN LISPRO PROTAMINE	Ψ		Manufacturer
Inj insulin lispro 25% with insulin lispro protamine 75%, 100 u pe 3 ml cartridge		5	Humalog Mix 25
Inj insulin lispro 50% with insulin lispro protamine 50%, 100 u pe 3 ml cartridge	er ml,	5	Humalog Mix 50
INSULIN NEUTRAL WITH INSULIN ISOPHANE			-
Inj insulin neutral 30% with insulin isophane 70%, 100 u per ml, vial	10 ml		
Inj insulin neutral 30% with insulin isophane 70%, 100 u per ml, cartridge	3 ml		
Inj insulin neutral 40% with insulin isophane 60%, 100 u per ml, cartridge	3 ml		
Inj insulin neutral 50% with insulin isophane 50%, 100 u per ml, cartridge	3 ml		
Insulin - Long-Acting Preparations			
NSULIN GLARGINE Inj 100 u per ml, 3 ml disposable pen	94 50	5	Lantus SoloStar
Inj 100 u per ml, 3 ml cartridge		5	Lantus
lnj 100 u per ml, 10 ml vial	63.00	1	Lantus
Insulin - Rapid-Acting Preparations			
NSULIN ASPART Inj 100 u per ml, 10 ml vial			
Inj 100 u per ml, 3 ml cartridge Inj 100 u per ml, 3 ml syringe	51.19	5	NovoRapid FlexPen
NSULIN GLULISINE Inj 100 u per ml, 10 ml vial		1	Apidra
Inj 100 u per ml, 3 ml cartridge		5	Apidra
Inj 100 u per ml, 3 ml disposable pen		5	Apidra Solostar
NSULIN LISPRO			
Inj 100 u per ml, 10 ml vial Inj 100 u per ml, 3 ml cartridge			
Insulin - Short-Acting Preparations			
NSULIN NEUTRAL			
Inj human 100 u per ml, 10 ml vial Inj human 100 u per ml, 3 ml cartridge			
Oral Hypoglycaemic Agents			
	0.00	100	Deenil
Tab 5 mg – 1% DV Oct-18 to 2021 GLICLAZIDE	6.00	100	Daonil
Tab 80 mg - 1% DV Nov-20 to 2023		500	Glizide
GLIPIZIDE Tab 5 mg – 1% DV Dec-18 to 2021		100	Minidiab

t Item restricted (see → above); t Item restricted (see → below)

e.g. Brand indicates brand example only. It is not a contracted product.

	Price		Brand or
	(ex man. excl. GST \$) Per	Generic Manufacturer
	Ψ	1.01	Manufacturer
METFORMIN HYDROCHLORIDE	0.00	4 000	A
Tab immediate-release 500 mg - 1% DV Feb-19 to 2021		1,000	Apotex
Tab immediate-release 850 mg - 1% DV Feb-19 to 2021	7.04	500	Apotex
PIOGLITAZONE			
Tab 15 mg - 1% DV Oct-18 to 2021		90	Vexazone
Tab 30 mg - 1% DV Oct-18 to 2021	5.06	90	Vexazone
Tab 45 mg - 1% DV Oct-18 to 2021	7.10	90	Vexazone
VILDAGLIPTIN			
Tab 50 mg		60	Galvus
VILDAGLIPTIN WITH METFORMIN HYDROCHLORIDE			
Tab 50 mg with 1,000 mg metformin hydrochloride	40.00	60	Galvumet
Tab 50 mg with 850 mg metformin hydrochloride		60	Galvumet
		00	Gaivaniet
Digestives Including Enzymes			
PANCREATIC ENZYME			
Cap pancreatin (175 mg (25,000 U lipase, 22,500 U amylase, 1,250	U		
protease))			
Cap pancreatin 150 mg (amylase 8,000 Ph Eur U, lipase 10,000 Ph	Eur		
U, total protease 600 Ph Eur U) - 1% DV Sep-18 to 2021		100	Creon 10000
Cap pancreatin 300 mg (amylase 18,000 Ph Eur U, lipase 25,000 P			
Eur U, total protease 1,000 Ph Eur U) - 1% DV Sep-18 to 202		100	Creon 25000
Modified release granules pancreatin 60.12 mg (amylase 3,600 Ph			
U, lipase 5,000 Ph Eur U, protease 200 Ph Eur U)		20 g	Creon Micro
Powder pancreatin 60.12 mg (3,600 Ph. Eur. u/amylase, 5,000 Ph			
Eur. u/lipase and 200 Ph. Eur. u/protease)			
LIRSODEOXYCHOLIC ACID - Restricted see terms below			

URSODEOXYCHOLIC ACID - Restricted see terms below

Initiation – Alagille syndrome or progressive familial intrahepatic cholestasis Either:

1 Patient has been diagnosed with Alagille syndrome; or

2 Patient has progressive familial intrahepatic cholestasis.

Initiation - Chronic severe drug induced cholestatic liver injury

All of the following:

1 Patient has chronic severe drug induced cholestatic liver injury; and

2 Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults; and

3 Treatment with ursodeoxycholic acid may prevent hospital admission or reduce duration of stay.

Initiation - Primary biliary cholangitis

Both:

- 1 Primary biliary cholangitis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative by liver biopsy; and
- 2 Patient not requiring a liver transplant (bilirubin > 100 umol/l; decompensated cirrhosis.

Initiation - Pregnancy

Patient diagnosed with cholestasis of pregnancy.

Initiation - Haematological transplant

Both:

1 Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to

Price (ex man. excl. GST)		Brand or Generic
 \$	Per	Manufacturer

continued...

allogenic stem cell or bone marrow transplantation; and

2 Treatment for up to 13 weeks.

Initiation - Total parenteral nutrition induced cholestasis

Both:

- 1 Paediatric patient has developed abnormal liver function as indicated on testing which is likely to be induced by TPN; and
- 2 Liver function has not improved with modifying the TPN composition.

Laxatives

 CITRIC ACID WITH MAGNESIUM OXIDE AND SODIUM PICOSULFATE Powder for oral soln 12 g with magnesium oxide 3.5 g and sodium picosulfate 10 mg per sachet MACROGOL 3350 WITH ASCORBIC ACID, POTASSIUM CHLORIDE AND S Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 210 g sachet Powder for oral soln 755 68 mg with ascorbic acid 85 16 mg, potassium 	SODIUM CH	LORIDE	e.g. PicoPrep e.g. Glycoprep-C
 Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 70 g sachet MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATI Powder for oral soln 59 g with potassium chloride 0.7425 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g and sodium sulphate 			
5.685 g per sachet – 1% DV Aug-19 to 2022	14.31	4	Klean Prep
Bulk-Forming Agents			
ISPAGHULA (PSYLLIUM) HUSK Powder for oral soln – 1% DV Nov-20 to 2023 STERCULIA WITH FRANGULA – Restricted: For continuation only → Powder for oral soln	12.20	500 g	Konsyl-D
Faecal Softeners			
DOCUSATE SODIUM Tab 50 mg – 1% DV Oct-20 to 2023 Tab 120 mg – 1% DV Oct-20 to 2023 DOCUSATE SODIUM WITH SENNOSIDES	3.13	100 100	Coloxyl Coloxyl
Tab 50 mg with sennosides 8 mg – 1% DV Jun-18 to 2021 PARAFFIN Oral liquid 1 mg per ml Enema 133 ml	3.10	200	Laxsol
POLOXAMER Oral drops 10% – 1% DV Nov-20 to 2023	3.98	30 ml	Coloxyl
Opioid Receptor Antagonists - Peripheral			
METHYLNALTREXONE BROMIDE – Restricted see terms on the next page Inj 12 mg per 0.6 ml vial		1 7	Relistor Relistor

t Item restricted (see → above); t Item restricted (see → below)

e.g. Brand indicates brand example only. It is not a contracted product.

	exci. \$	GST)	Per	Generic Manufacturer
			erated.	
	9.2	5	20	PSM
	3.3	3	500 ml	Laevolac
odium sodium DV				Molaxole
nl – 1%	0.7	0	00	Moldxole
	.29.98	В	50	Micolette
	2.50	0	1	Fleet Phosphate Enema
			200 10	Lax-Tabs Lax-Suppositories
1, [.]	142.60	D	1	Myozyme
	rion are una RBONATE / podium sodium DV	tion are ineffectiv tion are unable to 	tion are ineffective; or tion are unable to be tole 9.25 	tion are ineffective; or tion are unable to be tolerated.

1 The patient is aged up to 24 months at the time of initial application and has been diagnosed with infantile Pompe disease; and

Price		Brand or
(ex man. excl. GS		Generic
 \$	Per	Manufacturer

continued...

- 2 Any of the following:
 - 2.1 Diagnosis confirmed by documented deficiency of acid alpha-glucosidase by prenatal diagnosis using chorionic villus biopsies and/or cultured amniotic cells; or
 - 2.2 Documented deficiency of acid alpha-glucosidase, and urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides; or
 - 2.3 Documented deficiency of acid alpha-glucosidase, and documented molecular genetic testing indicating a disease-causing mutation in the acid alpha-glucosidase gene (GAA gene); or
 - 2.4 Documented urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides, and molecular genetic testing indicating a disease-causing mutation in the GAA gene; and
- 3 Patient has not required long-term invasive ventilation for respiratory failure prior to starting enzyme replacement therapy (ERT); and
- 4 Patient does not have another life-threatening or severe disease where the prognosis is unlikely to be influenced by ERT or might be reasonably expected to compromise a response to ERT; and
- 5 Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks.

Continuation

Re-assessment required after 12 months

All of the following:

- 1 The treatment remains appropriate for the patient and the patient is benefiting from treatment; and
- 2 Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks; and
- 3 Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and
- 4 Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by ERT; and
- 5 Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT; and
- 6 There is no evidence of life threatening progression of respiratory disease as evidenced by the needed for > 14 days of invasive ventilation; and
- 7 There is no evidence of new or progressive cardiomyopathy.

ARGININE

Powder Inj 600 mg per ml, 25 ml vial

BETAINE - Restricted see terms below

→ Restricted (RS1751)

Initiation

Metabolic physician

Re-assessment required after 12 months

All of the following:

- 1 The patient has a confirmed diagnosis of homocystinuria; and
- 2 Any of the following:
 - 2.1 A cystathionine beta-synthase (CBS) deficiency; or
 - 2.2 A 5,10-methylene-tetrahydrofolate reductase (MTHFR) deficiency; or
 - 2.3 A disorder of intracellular cobalamin metabolism; and
- 3 An appropriate homocysteine level has not been achieved despite a sufficient trial of appropriate vitamin supplementation.

Continuation

Re-assessment required after 12 months

The treatment remains appropriate and the patient is benefiting from treatment.

14

		Price		Brand or
	(ex man.	excl. GST) \$	Per	Generic Manufacturer
BIOTIN – Restricted see terms below				
↓ Cap 50 mg				
Cap 100 mg				
Inj 10 mg per ml, 5 ml vial				
→ Restricted (RS1330)				
Metabolic physician or metabolic disorders dietitian				
GALSULFASE – Restricted see terms below				
Inj 1 mg per ml, 5 ml vial	2,2	234.00	1	Naglazyme
→ Restricted (RS1752)				
Initiation				
Metabolic physician				
Re-assessment required after 12 months				
Both:				
1 The patient has been diagnosed with mucopolysaccharidosis	s VI; and			
2 Either:				
2.1 Diagnosis confirmed by demonstration of N-acetyl-ga			(arylsulfa	tase B) deficiency confirme
by either enzyme activity assay in leukocytes or skin				
2.2 Detection of two disease causing mutations and patie	ent has a sibl	ling who is k	nown to h	ave mucopolysaccharidosi
VI.				
Continuation				
Re-assessment required after 12 months				
All of the following:				
1 The treatment remains appropriate for the patient and the pa				
2 Patient has not had severe infusion-related adverse reaction	s which were	e not preven	table by a	ppropriate pre-medication
and/or adjustment of infusion rates; and				
3 Patient has not developed another life threatening or severe	disease whe	ere the long	term prog	nosis is unlikely to be
influenced by Enzyme Replacement Therapy (ERT); and				
4 Patient has not developed another medical condition that mig EDT	gnt reasonat	by be expec	ted to con	npromise a response to
ERT.				
HAEM ARGINATE				
Inj 25 mg per ml, 10 ml ampoule				
IDURSULFASE – Restricted see terms below				
Inj 2 mg per ml, 3 ml vial	4,6	608.30	1	Elaprase
→ Restricted (RS1546)				
Initiation				
Metabolic physician				
Limited to 24 weeks treatment				
All of the following:				
 The patient has been diagnosed with Hunter Syndrome (muc 2 Either: 	copolysaccha	ardosis II); a	ina	
		<i></i>		d a a lla la craithe an annuna a
2.1 Diagnosis confirmed by demonstration of iduronate 2-	-suitatase de	eticlency in v		a cells by either enzyme
assay in cultured skin fibroblasts; or	ata 0 aulfata		d	
2.2 Detection of a disease causing mutation in the iduron		0		months and treatment will
3 Patient is going to proceed with a haematopoietic stem cell to	ranspiant (H	SCI) Within	me next 3	months and treatment with
idursulfase would be bridging treatment to transplant; and	niraton (fail)	iro prior to o	tartina En	zuma Danlagament Theres
4 Patient has not required long-term invasive ventilation for res (ERT); and	spiratory falle		larling En	zyme rieplacement Therap
(ERT), and E. Iduraulface to be administered for a total of 04 weeks (aguing				

5 Idursulfase to be administered for a total of 24 weeks (equivalent to 12 weeks pre- and 12 weeks post-HSCT) at doses no greater than 0.5 mg/kg every week.

		Price			Brand or
	(ex man		GST)	Per	Generic Manufacturer
LARONIDASE – Restricted see terms below ↓ Inj 100 U per ml, 5 ml vial	1,	335.1	6	1	Aldurazyme
Initiation Metabolic physician <i>Limited to 24 weeks</i> treatment All of the following: 1 The patient has been diagnosed with Hurler Syndrome (mucopo 2 Either:	olysaccha	ardosi	s I-H);	and	
 2.1 Diagnosis confirmed by demonstration of alpha-L-iduron assay in cultured skin fibroblasts; or 2.2 Detection of two disease causing mutations in the alphato to have Hurler syndrome; and 					
 3 Patient is going to proceed with a haematopoietic stem cell tran laronidase would be bridging treatment to transplant; and 4 Patient has not required long-term invasive ventilation for respir (ERT); and 5 Laronidase to be administered for a total of 24 weeks (equivalent than 100 units/kg every week. 	atory fail	ure pr	ior to s	tarting E	nzyme Replacement Therapy
LEVOCARNITINE - Restricted see terms below ↓ Cap 500 mg ↓ Oral soln 1,000 mg per 10 ml ↓ Oral soln 1,100 mg per 15 ml ↓ Inj 200 mg per ml, 5 ml vial → Restricted (RS1035) Neurologist, metabolic physician or metabolic disorders dietitian PYRIDOXAL-5-PHOSPHATE - Restricted see terms below ↓ Tab 50 mg → Restricted (RS1331) Neurologist, metabolic physician or metabolic disorders dietitian SAPROPTERIN DIHYDROCHLORIDE - Restricted see terms below					
Tab soluble 100 mg Restricted (RS1753) Initiation Metabolic physician Re-assessment required after 1 month All of the following:		452.7	0	30	Kuvan
 Patient has phenylketonuria (PKU) and is pregnant or actively p Treatment with sapropterin is required to support management Sapropterin to be administered at doses no greater than a total Sapropterin to be used alone or in combination with PKU dietar Total treatment duration with sapropterin will not exceed 22 mor becoming pregnant) and treatment will be stopped after delivery 	of PKU d daily dos y managenths for e	uring e of 2 ement	pregna 20 mg/k t; and	ancy; and (g; and	1
Continuation Re-assessment required after 12 months All of the following:					

1 Either:

	l (ex man.	Price excl. \$	GST)	Per	Brand or Generic Manufacturer
continued					
 1.1 Following the initial one-month approval, the patient h of sapropterin with a clinically appropriate reduction in pregnancy; or 1.2 On subsequent renewal applications, the patient has a sapropterin and maintained adequate phenylalanine here. 	ı phenylalan previously d	ine le [.] emon	vels to strated	support I respons	management of PKU during se to treatment with
2 Any of the following:					5 F 5 F 5
2.1 Patient continues to be pregnant and treatment with s2.2 Patient is actively planning a pregnancy and this is the2.3 Treatment with sapropterin is required for a second or during pregnancy; and	r subsequen	al for It preg	treatm nancy	ent with to suppo	sapropterin; or
 3 Sapropterin to be administered at doses no greater than a toi 4 Sapropterin to be used alone or in combination with PKU diet 5 Total treatment duration with sapropterin will not exceed 22 r becoming pregnant) and treatment will be stopped after deliv 	tary manage nonths for e	ement	; and	0	des time for planning and
SODIUM BENZOATE Cap 500 mg Powder Soln 100 mg per ml Inj 20%, 10 ml ampoule					
SODIUM PHENYLBUTYRATE - Some items restricted see terms	below				
Tab 500 mg Grans 483 mg per g Oral liq 250 mg per ml liq 200 mg per ml	1,9	920.00	0	174 g	Pheburane
Inj 200 mg per ml, 10 ml ampoule → Restricted (RS1754) Initiation Metabolic physician					
Re-assessment required after 12 months For the chronic management of a urea cycle disorder involving a def transcarbamylase or argininosuccinate synthetase. Continuation	ficiency of ca	arbam	lylphos	phate sy	nthetase, ornithine
Re-assessment required after 12 months The treatment remains appropriate and the patient is benefiting from TALIGLUCERASE ALFA – Restricted see terms below	n treatment.				
Inj 200 unit vial Restricted (RS1034) Initiation	1,(072.00	0	1	Elelyso
Only for use in patients with approval by the Gaucher Treatment Par TRIENTINE DIHYDROCHLORIDE Cap 300 mg	nel.				
Minerals					
Calcium					
CALCIUM CARBONATE Tab 1.25 g (500 mg elemental) Tab eff 1.25 g (500 mg elemental) Tab eff 1.75 g (1 g elemental)		7.52	2	250	Arrow-Calcium

	l (ex man.	Price excl. \$	GST)	Per	Brand or Generic Manufacturer
Fluoride					
SODIUM FLUORIDE Tab 1.1 mg (0.5 mg elemental)					
lodine					
POTASSIUM IODATE Tab 253 mcg (150 mcg elemental iodine) – 1% DV Oct-20 to 202 POTASSIUM IODATE WITH IODINE Oral liq 10% with iodine 5%	3	4.58	3	90	NeuroTabs
Iron					
ERRIC CARBOXYMALTOSE – Restricted see terms below Inj 50 mg per ml, 10 ml vial → Restricted (RS1417) nitiation		150.00)	1	Ferinject
Freatment with oral iron has proven ineffective or is clinically inappropr FERROUS FUMARATE Tab 200 mg (65 mg elemental) – 1% DV Jan-19 to 2021 FERROUS FUMARATE WITH FOLIC ACID		3.09	Э	100	Ferro-tab
Tab 310 mg (100 mg elemental) with folic acid 350 mcg – 1% DV Jun-18 to 2021		4.68	3	60	Ferro-F-Tabs
ERROUS SULFATE Oral liq 30 mg (6 mg elemental) per ml – 1% DV Nov-19 to 2022. ERROUS SULPHATE		.12.08	3	500 ml	Ferodan
Tab long-acting 325 mg (105 mg elemental) – 1% DV Jun-18 to 2 ERROUS SULPHATE WITH ASCORBIC ACID	2021	2.00	6	30	Ferrograd
Tab long-acting 325 mg (105 mg elemental) with ascorbic acid 500 RON POLYMALTOSE) mg				
Inj 50 mg per ml, 2 ml ampoule		.34.50	0	5	Ferrosig
RON SUCROSE Inj 20 mg per ml, 5 ml ampoule		100.00	D	5	Venofer

Magnesium

MAGNESIUM AMINO ACID CHELATE Cap 750 mg (150 mg elemental)
MAGNESIUM CHLORIDE
lnj 1 mmol per 1 ml, 100 ml bag
MAGNESIUM HYDROXIDE Tab 311 mg (130 mg elemental)
MAGNESIUM OXIDE
Cap 663 mg (400 mg elemental)
Cap 696 mg (420 mg elemental)

18

	Price (ex man. excl. GS \$	T) Per	Brand or Generic Manufacturer
MAGNESIUM OXIDE WITH MAGNESIUM ASPARTATE, MAGNESIL Cap 500 mg with magnesium aspartate 100 mg, magnesium ami chelate 100 mg and magnesium citrate 100 mg (360 mg eler magnesium)	no acid	IELATE AN	D MAGNESIUM CITRATE
MAGNESIUM SULPHATE Inj 0.4 mmol per ml, 250 ml bag Inj 2 mmol per ml, 5 ml ampoule Inj 100 mg per ml, 50 ml bag		10	DBL
Zinc			
ZINC Oral liq 5 mg per 5 drops ZINC CHLORIDE Inj 5.3 mg per ml (5.1 mg per ml elemental), 2 ml ampoule ZINC SULPHATE Cap 137.4 mg (50 mg elemental) – 1% DV Dec-19 to 2022		100	Zincaps
Mouth and Throat			
Agents Used in Mouth Ulceration			
BENZYDAMINE HYDROCHLORIDE Soln 0.15% Spray 0.15% Spray 0.3%			
BENZYDAMINE HYDROCHLORIDE WITH CETYLPYRIDINIUM CHL Lozenge 3 mg with cetylpyridinium chloride	ORIDE		
CARBOXYMETHYLCELLULOSE Oral spray			
CARMELLOSE SODIUM WITH PECTIN AND GELATINE Paste Powder			
CHLORHEXIDINE GLUCONATE Mouthwash 0.2%	2.57	200 ml	healthE
CHOLINE SALICYLATE WITH CETALKONIUM CHLORIDE Adhesive gel 8.7% with cetalkonium chloride 0.01%			
DICHLOROBENZYL ALCOHOL WITH AMYLMETACRESOL Lozenge 1.2 mg with amylmetacresol 0.6 mg			
TRIAMCINOLONE ACETONIDE Paste 0.1% - 1% DV Nov-20 to 2023	5.33	5 g	Kenalog in Orabase
Oropharyngeal Anti-Infectives			
AMPHOTERICIN B Lozenge 10 mg	5.96	20	Fungilin
MICONAZOLE			Ū
Oral gel 20 mg per g – 1% DV Sep-18 to 2021	4.74	40 g	Decozol

Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
NYSTATIN Oral liquid 100,000 u per ml – 1% DV Oct-20 to 2023		24 ml	Nilstat
Other Oral Agents			
HYALURONIC ACID WITH LIDOCAINE [LIGNOCAINE] Inj 20 mg per ml			
SODIUM HYALURONATE [HYALURONIC ACID] - Restricted see ↓ Inj 20 mg per ml, 1 ml syringe → Restricted (RS1175) Otolaryngologist	e terms below		
THYMOL GLYCERIN Compound, BPC	9.15	500 ml	PSM
Vitamins			
Multivitamin Preparations			
MULTIVITAMIN AND MINERAL SUPPLEMENT - Restricted see t		180	Clinicians Multivit &
 → Restricted (RS1498) Initiation Limited to 3 months treatment Both: Patient was admitted to hospital with burns; and Any of the following:			Mineral Boost
2.3 Nutritional status prior to admission or dietary intake i MULTIVITAMIN RENAL – Restricted see terms below			
↓ Cap → Restricted (RS1499) Initiation Fither	6.49	30	Clinicians Renal Vit

Either:

1 The patient has chronic kidney disease and is receiving either peritoneal dialysis or haemodialysis; or

2 The patient has chronic kidney disease grade 5, defined as patient with an estimated glomerular filtration rate of < 15 ml/min/1.73m² body surface area (BSA).

		Price excl. GST) \$	Per	Brand or Generic Manufacturer
MULTIVITAMINS				
Tab (BPC cap strength) - 1% DV Mar-20 to 2022		. 11.45	1,000	Mvite
 cap vitamin A 2500 u, betacarotene 3 mg, cholecalciferol 11 mcg, a tocopherol 150 u, phytomenadione 150 mcg, folic acid 0.2 mg, ascorbic acid 100 mg, thiamine 1.5 mg, pantothenic acid 12 m riboflavin 1.7 mg, niacin 20 mg, pyridoxine hydrochloride 1.9 m cyanocobalamin 3 mcg, zinc 7.5 mg and biotin 100 mcg → Restricted (RS1620) 	g,			e.g. Vitabdeck
Initiation				
Any of the following:				
 Patient has cystic fibrosis with pancreatic insufficiency; or Patient is an infant or child with liver disease or short gut syndro Patient has severe malabsorption syndrome. 	me; or			
 I Powder vitamin A 4200 mcg with vitamin D 155.5 mcg, vitamin E 21.4 mg, vitamin C 400 mg, vitamin K1 166 mcg thiamine 3.2 m riboflavin 4.4 mg, niacin 35 mg, vitamin B6 3.4 mg, folic acid 303 mcg, vitamin B12 8.6 mcg, biotin 214 mcg, pantothenic ac 17 mg, choline 350 mg and inositol 700 mg → Restricted (RS1178) 	0			e.g. Paediatric Seravit
Initiation				
Patient has inborn errors of metabolism. Inj thiamine hydrochloride 250 mg with riboflavin 4 mg and pyridoxi hydrochloride 50 mg, 5 ml ampoule (1) and inj ascorbic acid 50				
with nicotinamide 160 mg and glucose 1000 mg, 5 ml ampoule Inj thiamine hydrochloride 250 mg with riboflavin 4 mg and pyridoxi hydrochloride 50 mg, 5 ml ampoule (1) and inj ascorbic acid 50	ne			e.g. Pabrinex IV
with nicotinamide 160 mg, 2 ml ampoule (1) Inj thiamine hydrochloride 500 mg with riboflavin 8 mg and pyridoxi hydrochloride 100 mg, 10 ml ampoule (1) and inj ascorbic acid 1000 mg with nicotinamide 320 mg and glucose 2000 mg, 10 r	ne			e.g. Pabrinex IM
ampoule (1)				e.g. Pabrinex IV
Vitamin A				

RETINOL

Tab 10,000 iu Cap 25,000 iu Oral liq 150,000 iu per ml Oral liq 666.7 mcg per 2 drops, 10 ml Oral liq 5,000 iu per drop, 30 ml

Vitamin B

HYDROXOCOBALAMIN		
Inj 1 mg per ml, 1 ml ampoule - 1% DV Sep-18 to 20211.89	3	Neo-B12
PYRIDOXINE HYDROCHLORIDE		
Tab 25 mg - 1% DV Oct-20 to 20232.70	90	Vitamin B6 25
Tab 50 mg 13.63	500	Apo-Pyridoxine
Inj 100 mg per ml, 2 ml vial		
Inj 100 mg per ml, 1 ml ampoule		
Inj 100 mg per ml, 30 ml vial		

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
THIAMINE HYDROCHLORIDE Tab 50 mg	100	Max Health e.g. Benerva
Inj 100 mg per ml, 2 ml vial VITAMIN B COMPLEX Tab strong, BPC7.15	500	Bplex
Vitamin C		'
ASCORBIC ACID Tab 100 mg – 1% DV Mar-20 to 2022 9.90 Tab chewable 250 mg	500	Cvite
Vitamin D		
ALFACALCIDOL Cap 0.25 mcg	100 100 20 ml	One-Alpha One-Alpha One-Alpha
CALCITRIOL Cap 0.25 mcg – 1% DV Oct-19 to 2022	100 100	Calcitriol-AFT Calcitriol-AFT
COLECALCIFEROL Cap 1.25 mg (50,000 iu)	12 4.8 ml	Vit.D3 Puria

Vitamin E

ALPHA TOCOPHERYL - Restricted see terms below

I Oral liq 156 u per ml

→ Restricted (RS1632)

Initiation – Cystic fibrosis

Both:

- 1 Cystic fibrosis patient; and
- 2 Either:
 - Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck); or
 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for the patient.

Initiation – Osteoradionecrosis

For the treatment of osteoradionecrosis.

Initiation - Other indications

All of the following:

- 1 Infant or child with liver disease or short gut syndrome; and
- 2 Requires vitamin supplementation; and
- 3 Either:
 - 3.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplements (Vitabdeck); or
 - 3.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for patient.

Price		Brand or
(ex man. excl. GST)	Generic
 \$	Per	Manufacturer

ALPHA TOCOPHERYL ACETATE - Restricted see terms below

- € Cap 500 u

↓ Oral liq 156 u per ml

→ Restricted (RS1176)

Initiation - Cystic fibrosis

Both:

- 1 Cystic fibrosis patient; and
- 2 Either:
 - 2.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck); or
 - 2.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for the patient.

Initiation – Osteoradionecrosis

For the treatment of osteoradionecrosis.

Initiation – Other indications

All of the following:

- 1 Infant or child with liver disease or short gut syndrome; and
- 2 Requires vitamin supplementation; and
- 3 Either:
 - 3.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplements (Vitabdeck); or
 - 3.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for patient.

	Price (ex man. excl. GST)		Brand or Generic
	\$	Per	Manufacturer
Antianaemics			
Hypoplastic and Haemolytic			
 EPOETIN ALFA - Restricted see terms below Inj 1,000 iu in 0.5 ml syringe - 1% DV Apr-19 to 2022	100.00 150.00 96.50 125.00 145.00 175.00 197.50 250.00	6 6 6 6 6 6 1	Binocrit Binocrit Binocrit Binocrit Binocrit Binocrit Binocrit Binocrit
4 Patient is on haemodialysis or peritoneal dialysis.			
Initiation – myelodysplasia* <i>Re-assessment required after 2 months</i> All of the following: 1 Patient has a confirmed diagnosis of myelodysplasia (MDS); a	and		
 2 Has had symptomatic anaemia with haemoglobin < 100g/L an 		-depende	ent; and

- 3 Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS); and
- 4 Other causes of anaemia such as B12 and folate deficiency have been excluded; and
- 5 Patient has a serum epoetin level of < 500 IU/L; and
- 6 The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Continuation - myelodysplasia*

Re-assessment required after 12 months

All of the following:

- 1 The patient's transfusion requirement continues to be reduced with epoetin treatment; and
- 2 Transformation to acute myeloid leukaemia has not occurred; and
- 3 The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Initiation - all other indications

Haematologist

24

For use in patients where blood transfusion is not a viable treatment alternative.

Note: Indications marked with * are unapproved indications

Price		Brand or
(ex man. excl. GST)	Generic
 \$	Per	Manufacturer

EPOETIN BETA - Restricted see terms below

Note: Epoetin beta is considered a Discretionary Variance Pharmaceutical for epoetin alfa.

- Inj 2,000 iu in 0.3 ml syringe
- Inj 3,000 iu in 0.3 ml syringe
- Inj 4,000 iu in 0.3 ml syringe
- Inj 5,000 iu in 0.3 ml syringe
- Inj 6,000 iu in 0.3 ml syringe
- Inj 10,000 iu in 0.6 ml syringe

➡ Restricted (RS1661)

Initiation - chronic renal failure

All of the following:

- 1 Patient in chronic renal failure; and
- 2 Haemoglobin is less than or equal to 100g/L; and
- 3 Either:
 - 3.1 Both:
 - 3.1.1 Patient does not have diabetes mellitus; and
 - 3.1.2 Glomerular filtration rate is less than or equal to 30ml/min; or
 - 3.2 Both:
 - 3.2.1 Patient has diabetes mellitus; and
 - 3.2.2 Glomerular filtration rate is less than or equal to 45ml/min; and
- 4 Patient is on haemodialysis or peritoneal dialysis.

Initiation - myelodysplasia*

Re-assessment required after 12 months

All of the following:

- 1 Patient has a confirmed diagnosis of myelodysplasia (MDS); and
- 2 Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent; and
- 3 Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS); and
- 4 Other causes of anaemia such as B12 and folate deficiency have been excluded; and
- 5 Patient has a serum epoetin level of < 500 IU/L; and
- 6 The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Continuation – myelodysplasia*

Re-assessment required after 2 months

All of the following:

- 1 The patient's transfusion requirement continues to be reduced with epoetin treatment; and
- 2 Transformation to acute myeloid leukaemia has not occurred; and
- 3 The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Initiation - all other indications

Haematologist.

For use in patients where blood transfusion is not a viable treatment alternative. *Note: Indications marked with * are unapproved indications.

Megaloblastic

FOLIC ACID

Tab 0.8 mg - 1% DV Oct-18 to 2021	21.84	1,000	Apo-Folic Acid
Tab 5 mg - 1% DV Oct-18 to 2021		500	Apo-Folic Acid
Oral lig 50 mcg per ml		25 ml	Biomed
Inj 5 mg per ml, 10 ml vial			

	Dries		Drand ar
	Price (ex man. excl. GST)		Brand or Generic
	\$	Per	Manufacturer
Antifibrinolytics, Haemostatics and Local Scleros	ants		
ALUMINIUM CHLORIDE – Restricted see terms below			
			e.g. Driclor
→ Restricted (RS1500)			
Initiation			
For use as a haemostatis agent.			
APROTININ – Restricted see terms below			
Inj 10,000 kIU per ml (equivalent to 200 mg per ml), 50 ml vial → Restricted (RS1332)			
Initiation			
Cardiac anaesthetist			
Either:			
 Paediatric patient undergoing cardiopulmonary bypass proce Adult patient undergoing cardiac surgical procedure where th adverse effects of the drug. 		sive blee	ding outweighs the potential
ELTROMBOPAG – Restricted see terms below			
Tab 25 mg	1,550.00	28	Revolade
↓ Tab 50 mg	3,100.00	28	Revolade
→ Restricted (RS1648)			
Initiation – idiopathic thrombocytopenic purpura - post-splenec	tomy		
Haematologist Re-assessment required after 6 weeks			
All of the following:			
1 Patient has had a splenectomy; and			
2 Two immunosuppressive therapies have been trialled and fai	led after therapy of 3 m	onths eac	h (or 1 month for rituximab):
and			
3 Any of the following:			
3.1 Patient has a platelet count of 20,000 to 30,000 platel	ets per microlitre and ha	as eviden	ce of significant
mucocutaneous bleeding; or			•
3.2 Patient has a platelet count of less than or equal to 20	,000 platelets per micro	litre and	has evidence of active
bleeding; or			
3.3 Patient has a platelet count of less than or equal to 10		litre.	
Initiation – idiopathic thrombocytopenic purpura - preparation f	or splenectomy		
Haematologist			
Limited to 6 weeks treatment	a atamu /		
The patient requires eltrombopag treatment as preparation for splen Continuation – idiopathic thrombocytopenic purpura - post-sple			
Haematologist	enectomy		
Re-assessment required after 12 months			
The patient has obtained a response (see Note) from treatment durin	ng the initial approval or	subseau	ent renewal periods and
further treatment is required.	ig ale illusi approval el	ousooqu	ent fononal ponodo and
Note: Response to treatment is defined as a platelet count of > 30,0	000 platelets per microlit	re	
Initiation - idiopathic thrombocytopenic purpura contraindicate			
Haematologist	•		
Re-assessment required after 3 months			
All of the following:			

All of the following:

1 Patient has a significant and well-documented contraindication to splenectomy for clinical reasons; and

Price		Brand or	
(ex man. excl. GST		Generic	
 \$	Per	Manufacturer	

continued...

- 2 Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab); and
- 3 Either:
 - 3.1 Patient has immune thrombocytopenic purpura* with a platelet count of less than or equal to 20,000 platelets per microliter; or
 - 3.2 Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant muccoutaneous bleeding.

Continuation - idiopathic thrombocytopenic purpura contraindicated to splenectomy

Haematologist

Re-assessment required after 12 months

All of the following:

- 1 The patient's significant contraindication to splenectomy remains; and
- 2 The patient has obtained a response from treatment during the initial approval period; and
- 3 Patient has maintained a platelet count of at least 50,000 platelets per microlitre on treatment; and
- 4 Further treatment with eltrombopag is required to maintain response.

Initiation - severe aplastic anaemia

Haematologist

Re-assessment required after 3 months

Both:

- 1 Two immunosuppressive therapies have been trialled and failed after therapy of at least 3 months duration; and
- 2 Either:
 - 2.1 Patient has severe aplastic anaemia with a platelet count of less than or equal to 20,000 platelets per microliter; or
 - 2.2 Patient has severe aplastic anaemia with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding.

Continuation - severe aplastic anaemia

Haematologist

Re-assessment required after 12 months Both:

- 1 The patient has obtained a response from treatment of at least 20,000 platelets per microlitre above baseline during the initial approval period; and
- 2 Platelet transfusion independence for a minimum of 8 weeks during the initial approval period.

FERRIC SUBSULFATE

Gel 25.9% Soln 500 ml

POLIDOCANOL

Inj 0.5%, 30 ml vial

SODIUM TETRADECYL SULPHATE

Inj 3%, 2 ml ampoule

THROMBIN

Powder

TRANEXAMIC ACID

Tab 500 mg - 1% DV May-20 to 2022	5 60	Mercury Pharma
Inj 100 mg per ml, 5 ml ampoule - 1% DV Sep-18 to 2021		Tranexamic-AFT
Inj 100 mg per ml, 10 ml ampoule - 1% DV Sep-18 to 2021	5 5	Tranexamic-AFT

Anticoagulant Reversal Agents

IDA	ARUCIZUMAB – Restricted see terms on the next page		
t	Inj 50 mg per ml, 50 ml vial4,250.00	2	Praxbind

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

Price		Brand or
(ex man. excl. GS		Generic
 \$	Per	Manufacturer

➡ Restricted (RS1535)

Initiation

For the reversal of the anticoagulant effects of dabigatran when required in situations of life-threatening or uncontrolled bleeding, or for emergency surgery or urgent procedures.

Blood Factors

EF	TRENONACOG ALFA [RECOMBINANT FACTOR IX] - Restricted see terms below	N	
t	Inj 250 iu vial	1	Alprolix
	Inj 500 iu vial		Alprolix
t	Inj 1,000 iu vial2,450.00	1	Alprolix
t	Inj 2,000 iu vial4,900.00	1	Alprolix
t		1	Alprolix

Restricted (RS1684)

Initiation

For patients with haemophilia B receiving prophylaxis treatment. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group

EPTACOG ALFA [RECOMBINANT FACTOR VIIA] - Restricted see terms below

t	Inj 1 mg syringe	1,178.30	1	NovoSeven RT
t	Inj 2 mg syringe	2,356.60	1	NovoSeven RT
	Inj 5 mg syringe		1	NovoSeven RT
	Inj 8 mg syringe		1	NovoSeven RT

➡ Restricted (RS1704)

Initiation

For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group. Rare Clinical Circumstances Brand of bypassing agent for > 14 days predicted use. Access to funded treatment for > 14 days predicted use is by named patient application to the Haemophilia Treaters Group, subject to access criteria

FACTOR EIGHT INHIBITOR BYPASSING FRACTION – Restricted see terms below

t	Inj 500 U	1	FEIBA NF
	Inj 1,000 U2,630.00	1	FEIBA NF
-	Inj 2,500 U6,575.00	1	FEIBA NF

Restricted (RS1705)

Initiation

For patients with haemophilia. Preferred Brand of bypassing agent for > 14 days predicted use. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group

MOROCTOCOG ALFA [RECOMBINANT FACTOR VIII] - Restricted see terms below

Inj 250 iu prefilled syringe	1	Xyntha
Inj 500 iu prefilled syringe	1	Xyntha
Inj 1,000 iu prefilled syringe	1	Xyntha
Inj 2,000 iu prefilled syringe2,300.00	1	Xyntha
	1	Xyntha
Destricted (D01700)		•

→ Restricted (RS1706)

Initiation

For patients with haemophilia. Rare Clinical Circumstances Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group, subject to criteria

NO	NACOG GAMMA, [RECOMBINANT FACTOR IX] – Restricted see terms on the r	iext page	
t	Inj 500 iu vial) 1	RIXUBIS
t	Inj 1,000 iu vial) 1	RIXUBIS
t	Inj 2,000 iu vial) 1	RIXUBIS
t	Inj 3,000 iu vial) 1	RIXUBIS

t Item restricted (see \rightarrow above); **f** Item restricted (see \rightarrow below)

e.g. Brand indicates brand example only. It is not a contracted product.

Pri	се		Brand or
(ex man. e	excl. GS		Generic
 \$	6	Per	Manufacturer

➡ Restricted (RS1679)

Initiation

For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group

OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (ADVATE) - Restricted see terms below

t	Inj 250 iu vial	210.00	1	Advate
t	Inj 500 iu vial		1	Advate
	Inj 1,000 iu vial		1	Advate
t	Inj 1,500 iu vial		1	Advate
	Inj 2,000 iu vial		1	Advate
t	Inj 3,000 iu vial	2,520.00	1	Advate

→ Restricted (RS1707)

Initiation

For patients with haemophilia. Preferred Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group

OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (KOGENATE FS) - Restricted see terms below

t	Inj 250 iu vial	7.50 1	Kogenate FS
t	Inj 500 iu vial	5.00 1	Kogenate FS
t	Inj 1,000 iu vial	0.00 1	Kogenate FS
t	Inj 2,000 iu vial	0.00 1	Kogenate FS
t	Inj 3,000 iu vial2,850	0.00 1	Kogenate FS

→ Restricted (RS1708)

Initiation

For patients with haemophilia. Rare Clinical Circumstances Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group, subject to criteria

RURIOCTOCOG ALFA PEGOL [RECOMBINANT FACTOR VIII] - Restricted see terms below

Inj 250 iu vial		1	Adynovate
Ini 500 iu vial	600.00	1	Adynovate
Inj 1,000 iu vial		1	Advnovate
Inj 2,000 iu vial		1	Adynovate
→ Restricted (RS1682)	,		,

Initiation

For patients with haemophilia A receiving prophylaxis treatment. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group

Vitamin K

PHYTOMENADIONE			
Inj 2 mg in 0.2 ml ampoule	8.00	5	Konakion MM
Inj 10 mg per ml, 1 ml ampoule	9.21	5	Konakion MM

Antithrombotics

Anticoagulants

BIVALIRUDIN - Restricted see terms below

Inj 250 mg vial

```
→ Restricted (RS1181)
Initiation
Fither:
```

	Price (ex man. excl. GST \$	Per	Brand or Generic Manufacturer
continued			
 For use in heparin-induced thrombocytopaenia, heparin resista For use in patients undergoing endovascular procedures. 	ance or heparin intole	rance; or	
CITRATE SODIUM			
Inj 4% (200 mg per 5 ml), 5 ml ampoule			
Inj 46.7% (1.4 g per 3 ml), 3 ml syringe Inj 46.7% (2.36 g per 5 ml), 5 ml ampoule			
DABIGATRAN			
Cap 75 mg	76 36	60	Pradaxa
Cap 110 mg		60	Pradaxa
Cap 150 mg		60	Pradaxa
DANAPAROID – Restricted see terms below			
Inj 750 u in 0.6 ml ampoule			
→ Restricted (RS1182)			
nitiation			
or use in heparin-induced thrombocytopaenia, heparin resistance or	heparin intolerance.		
DEFIBROTIDE - Restricted see terms below			
Inj 80 mg per ml, 2.5 ml ampoule			
→ Restricted (RS1183)			
nitiation			
laematologist ?atient has moderate or severe sinusoidal obstruction syndrome as a	result of chemothera	ny or regi	mon-related toxicities
DEXTROSE WITH SODIUM CITRATE AND CITRIC ACID [ACID CIT			
Inj 24.5 mg with sodium citrate 22 mg and citric acid 7.3 mg per n		1	
100 ml bag	п,		
Inj 20 mg in 0.2 ml syringe		10	Clexane
Inj 40 mg in 0.4 ml ampoule			
Inj 40 mg in 0.4 ml syringe		10	Clexane
Inj 60 mg in 0.6 ml syringe		10	Clexane
Inj 80 mg in 0.8 ml syringe		10	Clexane
Inj 100 mg in 1 ml syringe		10	Clexane
Inj 120 mg in 0.8 ml syringe		10	Clexane Clexane Forte
Inj 150 mg in 1 ml syringe	133.20	10	Clexane
,			Clexane Forte
Clexane Inj 120 mg in 0.8 ml syringe to be delisted 1 January 2021)			
Clexane Inj 150 mg in 1 ml syringe to be delisted 1 January 2021)			
ONDAPARINUX SODIUM - Restricted see terms below			

- Inj 2.5 mg in 0.5 ml syringe
- Inj 7.5 mg in 0.6 ml syringe
- ➡ Restricted (RS1184)

Initiation

For use in heparin-induced thrombocytopaenia, heparin resistance or heparin intolerance.

	Price		Brand or
	(ex man. excl. GST) Per	Generic Manufacturer
	\$	Fei	Manulaciulei
HEPARIN SODIUM			
Inj 100 iu per ml, 250 ml bag Inj 1,000 iu per ml, 1 ml ampoule	107.06	50	Hospira
Inj 1,000 iu per ml, 5 ml ampoule – 1% DV Nov-18 to 2021		50 50	Pfizer
Inj 5,000 iu in 0.2 ml ampoule		50	F 11201
Inj 5,000 iu per ml, 1 ml ampoule		5	Hospira
Inj 5,000 iu per ml, 5 ml ampoule – 1% DV Nov-18 to 2021		50	Pfizer
HEPARINISED SALINE			
Inj 10 iu per ml, 5 ml ampoule		50	Pfizer
Inj 100 iu per ml, 2 ml ampoule			
Inj 100 iu per ml, 5 ml ampoule			
PHENINDIONE			
Tab 10 mg			
Tab 25 mg			
Tab 50 mg			
PROTAMINE SULPHATE			
Inj 10 mg per ml, 5 ml ampoule			
RIVAROXABAN			
Tab 10 mg	83.10	30	Xarelto
Tab 15 mg		28	Xarelto
Tab 20 mg		28	Xarelto
SODIUM CITRATE WITH SODIUM CHLORIDE AND POTASSIUM C	HI ORIDE		
Inj 4.2 mg with sodium chloride 5.7 mg and potassium chloride 74	-		
per ml, 5,000 ml bag	no mog		
WARFARIN SODIUM			
Tab 1 mg		100	Marevan
Tab 2 mg			
Tab 3 mg		100	Marevan
Tab 5 mg	11.48	100	Marevan
Antiplatelets			
ASPIRIN			
Tab 100 mg - 10% DV Nov-19 to 2022	1.95	90	Ethics Aspirin EC
	10.80	990	Ethics Aspirin EC
Suppos 300 mg			
CLOPIDOGREL			
Tab 75 mg - 1% DV May-20 to 2022		84	Clopidogrel Multichem
DIPYRIDAMOLE		•	
Tab 25 mg			
Tab long-acting 150 mg – 1% DV Oct-19 to 2022	10.90	60	Pytazen SR
Inj 5 mg per ml, 2 ml ampoule			
EPTIFIBATIDE – Restricted see terms below			
Inj 2 mg per ml, 10 ml vial – 1% DV Nov-18 to 2021	138.75	1	Integrilin
Inj 250 mcg per ml, 100 ml vial − 1% DV Nov-18 to 2021		1	Integrilin
→ Restricted (RS1759)		-	
Initiation			
Any of the following:			

	(ex man	Price . excl. \$	GST)	Per	Brand or Generic Manufacturer
 continued 1 For use in patients with acute coronary syndromes undergoing 2 For use in patients with definite or strongly suspected intra-cor 3 For use in patients undergoing intra-cranial intervention. 					
LYSINE ACETYLSALICYLATE [LYSINE ASPRIN] - Restricted see ↓ Inj 500 mg → Restricted (RS1689) Initiation Both: 1 For use when an immediate antiplatelet effect is required prior cardiology procedure; and 2 Administration of oral aspirin would delay the procedure.			erventic	onal neuro	e.g. Aspegic o-radiology or interventional
PRASUGREL – Restricted: For continuation only → Tab 5 mg → Tab 10 mg (Effient Tab 5 mg to be delisted 1 February 2021) (Effient Tab 10 mg to be delisted 1 February 2021)				28 28	Effient Effient
TICAGRELOR - Restricted see terms below ↓ Tab 90 mg → Restricted (RS1774) Initiation		90.0	0	56	Brilinta

Restricted to treatment of acute coronary syndromes specifically for patients who have recently (within the last 60 days) been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome, and in whom fibrinolytic therapy has not been given in the last 24 hours and is not planned.

Initiation - thrombosis prevention neurological stenting

Re-assessment required after 12 months

Both:

- 1 Either:
 - 1.1 Patient has had a neurological stenting procedure* in the last 60 days; or
 - 1.2 Patient is about to have a neurological stenting procedure performed*; and
- 2 Either:
 - 2.1 Patient has demonstrated clopidogrel resistance using the P2Y12 (VerifyNow) assay or another appropriate platelet function assay and requires antiplatelet treatment with ticagrelor; or
 - 2.2 Either:
 - 2.2.1 Clopidogrel resistance has been demonstrated by the occurrence of a new cerebral ischemic event; or
 - 2.2.2 Clopidogrel resistance has been demonstrated by the occurrence of transient ischemic attack symptoms referable to the stent..

Continuation - thrombosis prevention neurological stenting

Re-assessment required after 12 months

Both:

- 1 Patient is continuing to benefit from treatment; and
- 2 Treatment continues to be clinically appropriate.

Initiation - Percutaneous coronary intervention with stent deployment

Limited to 12 months treatment

All of the following:

- 1 Patient has undergone percutaneous coronary intervention; and
- 2 Patient has had a stent deployed in the previous 4 weeks; and

e.g. Brand indicates brand example only. It is not a contracted product.

Price	Brand or	
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

3 Patient is clopidogrel-allergic**.

Initiation – Stent thrombosis

Patient has experienced cardiac stent thrombosis whilst on clopidogrel.

Initiation – Myocardial infarction

Limited to 1 week treatment

For short term use while in hospital following ST-elevated myocardial infarction.

Notes: Indications marked with * are unapproved indications.

Note: ** Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment

TICLOPIDINE

Tab 250 mg

Fibrinolytic Agents

ALTEPLASE

Inj 2 mg vial Inj 10 mg vial Inj 50 mg vial

TENECTEPLASE

Inj 50 mg vial

UROKINASE

Inj 5,000 iu vial Inj 10,000 iu vial Inj 50,000 iu vial Inj 100,000 iu vial Inj 500,000 iu vial

Colony-Stimulating Factors

Drugs Used to Mobilise Stem Cells

PLERIXAFOR – Restricted see terms below			
Inj 20 mg per ml, 1.2 ml vial	1	Mozobil	
➡ Restricted (RS1536)			
Initiation – Autologous stem cell transplant			
Haematologist			
Limited to 3 days treatment			
All of the following:			
1 Patient is to undergo stem cell transplantation; and			
2 Patient has not had a previous unsuccessful mobilisation attempt with plerixafor; and			
3 Any of the following:			
3.1 Both:			
3.1.1 Patient is undergoing G-CSF mobilisation; and			
3.1.2 Either:			
3.1.2.1 Has a suboptimal peripheral blood CD34 count of less than or eq 4 days of G-CSF treatment; or	ual to 10	$\times10^6/\rm{L}$ on day 5 after	er

3.1.2.2 Efforts to collect > 1 \times 10⁶ CD34 cells/kg have failed after one apheresis procedure; or

Pri	ice		Brand or
(ex man. e	excl. GST)		Generic
\$	\$	Per	Manufacturer

continued...

3.2 Both:

3.2.1 Patient is undergoing chemotherapy and G-CSF mobilisation; and

- 3.2.2 Any of the following:
 - 3.2.2.1 Both:

3.2.2.1.1 Has rising white blood cell counts of > 5 × 10^9 /L; and

3.2.2.1.2 Has a suboptimal peripheral blood CD34 count of less than or equal to 10 \times 10⁶/L; or

3.2.2.2 Efforts to collect > 1 $\times 10^{6}$ CD34 cells/kg have failed after one apheresis procedure; or

3.2.2.3 The peripheral blood CD34 cell counts are decreasing before the target has been received; or

3.3 A previous mobilisation attempt with G-CSF or G-CSF plus chemotherapy has failed.

Granulocyte Colony-Stimulating Factors

FILGRASTIM - Restricted see terms below

Inj 300 mcg in 0.5 ml prefilled syringe - 1% DV May-19 to 2021	10	Nivestim
Inj 300 mcg in 1 ml vial	4	Neupogen
Inj 480 mcg in 0.5 ml prefilled syringe – 1% DV Mar-19 to 2021	10	Nivestim
→ Restricted (RS1188)		
Haematologist or oncologist		
PEGFILGRASTIM – Restricted see terms below		
Inj 6 mg per 0.6 ml syringe	1	Neulastim
→ Restricted (RS1743)		

Initiation

For prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk greater than or equal to 5%*).

Note: *Febrile neutropenia risk greater than or equal to 5% after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines

Fluids and Electrolytes

Intravenous Administration

CALCIUM CHLORIDE Inj 100 mg per ml, 10 ml vial Inj 100 mg per ml, 50 ml svringe		e.g. Baxter
CALCIUM GLUCONATE		e.g. Danor
Inj 10%, 10 ml ampoule		e.g. Max Health
COMPOUND ELECTROLYTES		
Inj sodium 140 mmol/l, potassium 5 mmol/l, magnesium 1.5 mmol/l, chloride 98 mmol/l, acetate 27 mmol/l, gluconate 23 mmol/l, 500 ml		
bag – 1% DV Jun-18 to 2021	18	Plasma-Lyte 148
Inj sodium 140 mmol/l, potassium 5 mmol/l, magnesium 1.5 mmol/l, chloride 98 mmol/l, acetate 27 mmol/l, gluconate 23 mmol/l,		
1,000 ml bag – 1% DV Jun-18 to 202127.24	12	Plasma-Lyte 148
COMPOUND ELECTROLYTES WITH GLUCOSE [DEXTROSE]		
Inj sodium 140 mmol/l, 5 mmol/l potassium, 1.5 mmol/l magnesium,		
98 mmol/l chloride, 27 mmol/l acetate and 23 mmol/l gluconate,		
glucose 23 mmol/l (5%), 1,000 ml bag - 1% DV Jun-18 to 2021211.92	12	Plasma-Lyte 148 & 5% Glucose

e.g. Brand indicates brand example only. It is not a contracted product.

	Price		Brand or
	(ex man. excl. GST		Generic
	\$	Per	Manufacturer
COMPOUND SODIUM LACTATE [HARTMANN'S SOLUTION]			
Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l,			
bicarbonate 29 mmol/l, chloride 111 mmol/l, 500 ml bag - 1%			- .
Jun-18 to 2021 Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l,	23.40	18	Baxter
bicarbonate 29 mmol/l, chloride 111 mmol/l, 1,000 ml bag – 1%	NU		
Jun-18 to 2021		12	Baxter
GLUCOSE [DEXTROSE]		12	Buxton
Inj 5%, 1,000 ml bag – 1% DV Aug-18 to 2021	16.80	10	Fresenius Kabi
Inj 5%, 100 ml bag – 1% DV Aug-18 to 2021		50	Fresenius Kabi
Inj 5%, 250 ml bag – 1% DV Aug-18 to 2021		30	Fresenius Kabi
Inj 5%, 50 ml bag – 1% DV Jun-18 to 2021		60	Baxter Glucose 5%
Inj 5%, 500 ml bag – 1% DV Aug-18 to 2021		20	Fresenius Kabi
Inj 10%, 1,000 ml bag - 1% DV Jun-18 to 2021		12	Baxter Glucose 10%
Inj 10%, 500 ml bag - 1% DV Jun-18 to 2021		18	Baxter Glucose 10%
Inj 50%, 10 ml ampoule - 1% DV Nov-20 to 2023		5	Biomed
Inj 50%, 500 ml bag – 1% DV Jun-18 to 2021		18	Baxter Glucose 50%
Inj 50%, 90 ml bottle – 1% DV Nov-20 to 2023	15.00	1	Biomed
GLUCOSE WITH POTASSIUM CHLORIDE			
Inj 10% glucose with 20 mmol/l potassium chloride, 500 ml bag			
GLUCOSE WITH POTASSIUM CHLORIDE AND SODIUM CHLORIDE			
Inj 2.5% glucose with potassium chloride 20 mmol/l and sodium chlo	oride		
0.45%, 3,000 ml bag Inj 10% glucose with potassium chloride 10 mmol/l and sodium chlo	rido		
15 mmol/l, 500 ml bag			
Inj 4% glucose with potassium chloride 20 mmol/l and sodium chlori 0.18%, 1,000 ml bag – 1% DV Jun-18 to 2021		12	Baxter
Inj 5% glucose with potassium chloride 20 mmol/l and sodium chlori	de		
0.45%, 1,000 ml bag – 1% DV Jun-18 to 2021	159.96	12	Baxter
Inj 5% glucose with potassium chloride 20 mmol/l and sodium chlori			
0.9%, 1,000 ml bag – 1% DV Jun-18 to 2021		12	Baxter
GLUCOSE WITH SODIUM CHLORIDE			
Inj glucose 2.5% with sodium chloride 0.45%, 500 ml bag			
Inj 4% glucose and sodium chloride 0.18%, 1,000 ml bag - 1% DV			
Jun-18 to 2021	163.32	12	Baxter
Inj 5% glucose and sodium chloride 0.45%, 1,000 ml bag – 1% DV	100.00	10	Deviter
Jun-18 to 2021 Inj 5% glucose and sodium chloride 0.9%, 1,000 ml bag – 1% DV		12	Baxter
Jun-18 to 2021	173.40	12	Baxter
POTASSIUM CHLORIDE		.=	
Inj 75 mg (1 mmol) per ml, 10 ml ampoule			
Inj 225 mg (3 mmol) per ml, 20 ml ampoule			
POTASSIUM CHLORIDE WITH SODIUM CHLORIDE			
Inj 10 mmol potassium chloride with 0.29% sodium chloride, 100 ml	haq		
- 1% DV Jun-18 to 2021		48	Baxter
Inj 20 mmol potassium chloride with 0.9% sodium chloride, 1,000 m	bag	40	Buxtor
– 1% DV Jun-18 to 2021		12	Baxter
Inj 40 mmol potassium chloride with 0.9% sodium chloride, 1,000 m	bag		
– 1% DV Jun-18 to 2021		12	Baxter
Inj 40 mmol potassium chloride with 0.9% sodium chloride, 100 ml b	0	40	Baytar
– 1% DV Jun-18 to 2021	172.32	48	Baxter

	Price		Brand or
	(ex man. excl. GST) \$	Per	Generic Manufacturer
	Ψ	1 61	Manufacturer
POTASSIUM DIHYDROGEN PHOSPHATE	454.00	40	Useria
Inj 1 mmol per ml, 10 ml ampoule		10	Hospira
RINGER'S SOLUTION			
Inj sodium 147 mmol/l with potassium 4 mmol/l, calcium 2.2 mmol/l chloride 156 mmol/l, 1,000 ml bag	,		
SODIUM ACETATE			
Inj 4 mmol per ml, 20 ml ampoule			
SODIUM BICARBONATE			
Inj 8.4%, 10 ml vial			
Inj 8.4%, 50 ml vial		1	Biomed
Inj 8.4%, 100 ml vial	20.50	1	Biomed
SODIUM CHLORIDE			
Inj 0.9%, 5 ml ampoule – 1% DV Dec-19 to 2022	2.80	20	Fresenius Kabi
Inj 0.9%, 10 ml ampoule - 1% DV Dec-19 to 2022		50	Fresenius Kabi
Inj 0.9%, 3 ml syringe, non-sterile pack – 1% DV Sep-18 to 2021.		480	BD PosiFlush
→ Restricted (RS1297)			
Initiation			
For use in flushing of in-situ vascular access devices only.			
↓ Inj 0.9%, 5 ml syringe, non-sterile pack – 1% DV Sep-18 to 2021. → Restricted (RS1297)	162.91	480	BD PosiFlush
Initiation			
For use in flushing of in-situ vascular access devices only.			
↓ Inj 0.9%, 10 ml syringe, non-sterile pack - 1% DV Sep-18 to 2021 → Restricted (RS1297)	170.35	480	BD PosiFlush
Initiation			
For use in flushing of in-situ vascular access devices only.			
Inj 0.9%, 20 ml ampoule - 1% DV Dec-19 to 2022		20	Fresenius Kabi
Inj 23.4% (4 mmol/ml), 20 ml ampoule		5	Biomed
Inj 0.45%, 500 ml bag	71.28	18	Baxter
Inj 3%, 1,000 ml bag	91.20	12	Baxter
Inj 0.9%, 50 ml bag	109.80	60	Baxter
Inj 0.9%, 100 ml bag		48	Baxter
Inj 0.9%, 250 ml bag		24	Baxter
Inj 0.9%, 500 ml bag		18	Baxter
Inj 0.9%, 1,000 ml bag	15.12	12	Baxter
Inj 1.8%, 500 ml bottle			
SODIUM DIHYDROGEN PHOSPHATE [SODIUM ACID PHOSPHATE]		_	
Inj 1 mmol per ml, 20 ml ampoule - 1% DV Oct-18 to 2021		5	Biomed
WATER			
Inj 5 ml ampoule	7.00	50	InterPharma
Inj 10 ml ampoule		50	Pfizer
Inj 20 ml ampoule		20	Fresenius Kabi
	7.50	30	InterPharma
	5.00	20	Multichem
Inj 250 ml bag			
Inj 500 ml bag	10.09	12	Poytor
Inj, 1,000 ml bag		12	Baxter

BLOOD AND BLOOD FORMING ORGANS

	Price (ex man. excl. GS \$	ST) Per	Brand or Generic Manufacturer
Oral Administration			
CALCIUM POLYSTYRENE SULPHONATE Powder		300 g	Calcium Resonium
COMPOUND ELECTROLYTES Powder for oral soln – 1% DV Apr-20 to 2022	9.77	50	Electral
COMPOUND ELECTROLYTES WITH GLUCOSE [DEXTROSE] Soln with electrolytes (2 × 500 ml) - 1% DV Nov-18 to 2021	6.55	1,000 ml	Pedialyte - Bubblegum
PHOSPHORUS Tab eff 500 mg (16 mmol)			
POTASSIUM CHLORIDE Tab eff 548 mg (14 mmol) with chloride 285 mg (8 mmol) Tab long-acting 600 mg (8 mmol) – 1% DV Oct-18 to 2021 Oral lig 2 mmol per ml	8.90	200	Span-K
SODIUM BICARBONATE Cap 840 mg	8.52	100	Sodibic
SODIUM CHLORIDE Tab 600 mg Oral liq 2 mmol/ml			
SODIUM POLYSTYRENE SULPHONATE Powder – 1% DV Sep-18 to 2021		454 g	Resonium A
Plasma Volume Expanders			
GELATINE, SUCCINYLATED Inj 4%, 500 ml bag – 1% DV Jun-18 to 2021		10	Gelofusine

	Price (ex man. excl. GST \$	[[]) Per	Brand or Generic Manufacturer
Agents Affecting the Renin-Angiotensin System			
ACE Inhibitors			
CAPTOPRIL Ø Oral liq 5 mg per ml		95 ml	Capoten
→ Restricted (RS1263) Initiation			
Any of the following: 1 For use in children under 12 years of age; or			
 For use in tube-fed patients; or For management of rebound transient hypertension followin 	g cardiac surgery.		
CILAZAPRIL			
Tab 0.5 mg - 1% DV Sep-19 to 2022		90	Zapril
Tab 2.5 mg – 1% DV Feb-20 to 2022		90	Zapril
Tab 5 mg - 1% DV Feb-20 to 2022	8.35	90	Zapril
ENALAPRIL MALEATE Tab 5 mg – 1% DV Jun-20 to 2022	1 90	100	Acetec
Tab 10 mg - 1% DV Jun-20 to 2022		100	Acetec
Tab 20 mg - 1% DV Jun-20 to 2022		100	Acetec
LISINOPRIL			
Tab 5 mg - 1% DV Dec-18 to 2021		90	Ethics Lisinopril
Tab 10 mg – 1% DV Dec-18 to 2021		90	Ethics Lisinopril
Tab 20 mg - 1% DV Dec-18 to 2021		90	Ethics Lisinopril
PERINDOPRIL			
Tab 2 mg		30	Apo-Perindopril
Tab 4 mg		30	Apo-Perindopril
QUINAPRIL			
Tab 5 mg - 1% DV Nov-18 to 2021	6.01	90	Arrow-Quinapril 5
Tab 10 mg - 1% DV Nov-18 to 2021	3.16	90	Arrow-Quinapril 10
Tab 20 mg - 1% DV Nov-18 to 2021	4.89	90	Arrow-Quinapril 20
ACE Inhibitors with Diuretics			
CILAZAPRIL WITH HYDROCHLOROTHIAZIDE - Restricted: Fo	r continuation only		
➡ Tab 5 mg with hydrochlorothiazide 12.5 mg		100	Apo-Cilazapril/ Hydrochlorothiazide
(Apo-Cilazapril/ Hydrochlorothiazide Tab 5 mg with hydrochlorothia QUINAPRIL WITH HYDROCHLOROTHIAZIDE	zide 12.5 mg to be deli	sted 1 May	(2021)
Tab 10 mg with hydrochlorothiazide 12.5 mg – 1% DV Dec-18	to 2021	30	Accuretic 10
Tab 20 mg with hydrochlorothiazide 12.5 mg - 1% DV Dec-18		30	Accuretic 20
Angiotensin II Antagonists			
CANDESARTAN CILEXETIL			
Tab 4 mg - 1% DV Sep-18 to 2021	1.90	90	Candestar
Tab 8 mg - 1% DV Sep-18 to 2021		90	Candestar
Tab 16 mg - 1% DV Sep-18 to 2021		90	Candestar
Tab 32 mg - 1% DV Sep-18 to 2021	6.39	90	Candestar

t Item restricted (see → above); t Item restricted (see → below)

38

	Price		Brand or
	(ex man. excl. GST)		Generic
	(ex man. exci. GOT) \$	Per	Manufacturer
	\$	rei	Manufacturer
LOSARTAN POTASSIUM			
Tab 12.5 mg - 1% DV Jan-21 to 2023	1 56	84	Losartan Actavis
Tab 25 mg - 1% DV Jan-21 to 2023		84	Losartan Actavis
Tab 50 mg – 1% DV Jan-21 to 2023	2.25	84	Losartan Actavis
Tab 100 mg - 1% DV Jan-21 to 2023	3.50	84	Losartan Actavis
		•	
Angiotensin II Antagonists with Diuretics			
Angiotensin'il Antagonists with Diarctics			
LOSARTAN POTASSIUM WITH HYDROCHLOROTHIAZIDE			
Tab 50 mg with hydrochlorothiazide 12.5 mg – 1% DV Jan-1	9 to 20211.88	30	Arrow-Losartan &
			Hydrochlorothiazid
			.,
Angiotensin II Antagonists with Neprilysin Inhib	itors		
SACUBITRIL WITH VALSARTAN - Restricted see terms below			
Tab 24.3 mg with valsartan 25.7 mg	190.00	56	Entresto 24/26
Tab 48.6 mg with valsartan 51.4 mg		56	Entresto 49/51
Tab 97.2 mg with valsartan 102.8 mg		56	Entresto 97/103
➡ Restricted (RS1738)			
Initiation			
Re-assessment required after 12 months			
All of the following:			
 Patient has heart failure; and 			
2 Any of the following:			
, ,			
2.1 Patient is in NYHA/WHO functional class II; or			
2.2 Patient is in NYHA/WHO functional class III; or			
2.3 Patient is in NYHA/WHO functional class IV; and			
3 Either:			
3.1 Patient has a documented left ventricular ejection from the section of the	action (LVEF) of less thar	n or equal	to 35%; or
3.2 An ECHO is not reasonably practical, and in the op	inion of the treating practit	ioner the	patient would benefit from
treatment: and	51		
	a and failt we have also and a		
4 Patient is receiving concomitant optimal standard chronic h	leart failure treatments.		
Continuation			
Re-assessment required after 12 months			
The treatment remains appropriate and the patient is benefiting fro	om treatment		
Note: Due to the angiotensin II receptor blocking activity of sacub	itrii with vaisartan it shoul	a not be c	co-administered with an ACE
inhibitor or another ARB.			
Alaba Advanceanter Bleekere			
Alpha-Adrenoceptor Blockers			
DOXAZOSIN			
	0.05	E00	Ano Dovozcoin
Tab 2 mg		500	Apo-Doxazosin
Tab 4 mg		500	Apo-Doxazosin
PHENOXYBENZAMINE HYDROCHLORIDE			
Cap 10 mg			
Inj 50 mg per ml, 1 ml ampoule			
Inj 50 mg per ml, 2 ml ampoule			
PHENTOLAMINE MESYLATE			
Inj 5 mg per ml, 1 ml ampoule			
Inj 10 mg per ml, 1 ml ampoule			

	Price (ex man. excl. GST)		Brand or Generic
	\$	Per	Manufacturer
PRAZOSIN			
Tab 1 mg	5.53	100	Apo-Prazosin
Tab 2 mg	7.00	100	Apo-Prazosin
Tab 5 mg		100	Apo-Prazosin
ERAZOSIN – Restricted: For continuation only			
→ Tab 1 mg			
 Tab 2 mg 	7 50	500	Apo-Terazosin
 Tab 2 mg Tab 5 mg 		500	Apo-Terazosin
- Tab 3 mg		500	Apo-Terazosiii
Antiarrhythmics			
ADENOSINE			
Inj 3 mg per ml, 2 ml vial – 1% DV Feb-20 to 2022	62.73	6	Adenocor
Inj 3 mg per ml, 10 ml vial		-	
→ Restricted (RS1266)			
nitiation			
For use in cardiac catheterisation, electrophysiology and MRI.			
JMALINE – Restricted see terms below			
Inj 5 mg per ml, 10 ml ampoule			
→ Restricted (RS1001)			
Cardiologist			
MIODARONE HYDROCHLORIDE			
Tab 100 mg – 1% DV Dec-19 to 2022	3.80	30	Aratac
Tab 200 mg – 1% DV Dec-19 to 2022		30	Aratac
Inj 50 mg per ml, 3 ml ampoule – 1% DV Feb-20 to 2022		10	Max Health
		10	max rioutin
	10.07	10	Mautindala
Inj 600 mcg per ml, 1 ml ampoule - 1% DV Oct-18 to 2021		10	Martindale
DIGOXIN			
Tab 62.5 mcg - 1% DV Nov-19 to 2022		240	Lanoxin PG
Tab 250 mcg – 1% DV Nov-19 to 2022	15.20	240	Lanoxin
Oral liq 50 mcg per ml			
lnj 250 mcg per ml, 2 ml vial			
DISOPYRAMIDE PHOSPHATE			
Cap 100 mg			
Tab 50 mg – 1% DV Feb-20 to 2022	10 OF	60	Flecainide BNM
0		60 90	Flecainide BNM
Cap long-acting 100 mg - 1% DV Dec-19 to 2022		90	Release Teva
Cap long-acting 200 mg - 1% DV Dec-19 to 2022	61.06	90	Flecainide Controlled
			Release Teva
Inj 10 mg per ml, 15 ml ampoule		5	Tambocor
VABRADINE - Restricted see terms below			
Tab 5 mg			
→ Restricted (RS1566)			
nitiation			
Both:			
1. Deficit is indicated for commuted terror works community			

1 Patient is indicated for computed tomography coronary angiography; and

Pr	rice		Brand or
(ex man.	excl. GST)		Generic
	\$	Per	Manufacturer
r minute while ta	aking a ma	aximally t	olerated dose of beta blocke
16	62.00	100	Mexiletine Hydrochloride USP
20	02.00	100	Mexiletine Hydrochloride USP
	(ex man.	Price (ex man. excl. GST) \$ or minute while taking a ma 	(ex man. excl. GST) \$ Per er minute while taking a maximally t

Antihypotensives

MIDODRINE - Restricted see terms below

- Tab 2.5 mg

→ Restricted (RS1427)

Initiation

Patient has disabling orthostatic hypotension not due to drugs.

Beta-Adrenoceptor Blockers

ATENOLOL		
Tab 50 mg - 1% DV Sep-18 to 2021	500	Mylan Atenolol
Tab 100 mg - 1% DV Sep-18 to 2021	500	Mylan Atenolol
Oral liq 5 mg per ml21.25	300 ml	Atenolol-AFT
BISOPROLOL FUMARATE		
Tab 2.5 mg	90	Bosvate
Tab 5 mg5.15	90	Bosvate
Tab 10 mg9.40	90	Bosvate
CARVEDILOL		
Tab 6.25 mg2.24	60	Carvedilol Sandoz
Tab 12.5 mg2.30	60	Carvedilol Sandoz
Tab 25 mg2.95	60	Carvedilol Sandoz
CELIPROLOL - Restricted: For continuation only		
→ Tab 200 mg	180	Celol
(Celol Tab 200 mg to be delisted 1 April 2021)		
ESMOLOL HYDROCHLORIDE		
Inj 10 mg per ml, 10 ml vial		
LABETALOL		
Tab 50 mg		
Tab 100 mg - 1% DV Sep-20 to 2024 14.50	100	Trandate
Tab 200 mg - 1% DV Sep-20 to 2024	100	Trandate
Inj 5 mg per ml, 20 ml ampoule		
METOPROLOL SUCCINATE		
Tab long-acting 23.75 mg1.45	30	Betaloc CR
Tab long-acting 47.5 mg1.43	30	Betaloc CR
Tab long-acting 95 mg2.15	30	Betaloc CR
Tab long-acting 190 mg4.27	30	Betaloc CR

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price		Brand or
	(ex man. excl. GST)		Generic
	\$	Per	Manufacturer
METOPROLOL TARTRATE			
Tab 50 mg - 1% DV Oct-18 to 2021	5.66	100	Apo-Metoprolol
Tab 100 mg - 1% DV Oct-18 to 2021	7.55	60	Apo-Metoprolol
Tab long-acting 200 mg		28	Slow-Lopresor
Inj 1 mg per ml, 5 ml vial - 1% DV Feb-19 to 31 Jan 2022	29.50	5	Metroprolol IV Mylan
NADOLOL			
Tab 40 mg - 1% DV Oct-18 to 2021		100	Apo-Nadolol
Tab 80 mg - 1% DV Oct-18 to 2021		100	Apo-Nadolol
PINDOLOL			•
Tab 5 mg - 1% DV Oct-18 to 2021	13.22	100	Apo-Pindolol
Tab 10 mg - 1% DV Oct-18 to 2021		100	Apo-Pindolol
Tab 15 mg - 1% DV Oct-18 to 2021		100	Apo-Pindolol
PROPRANOLOL			
	1 61	100	Ano Bronzonalal
Tab 10 mg - 1% DV Oct-18 to 2021		100	Apo-Propranolol
Tab 40 mg – 1% DV Oct-18 to 2021		100	Apo-Propranolol Cardinol LA
Cap long-acting 160 mg		100	Galuinoi LA
Oral liq 4 mg per ml			
Inj 1 mg per ml, 1 ml ampoule			
SOTALOL			
Tab 80 mg - 1% DV Oct-19 to 2022		500	Mylan
Tab 160 mg - 1% DV Oct-19 to 2022	10.98	100	Mylan
TIMOLOL MALEATE			

Tab 10 mg

Calcium Channel Blockers

Dihydropyridine Calcium Channel Blockers

AMLODIPINE		
Tab 2.5 mg - 1% DV Jun-21 to 2023	100	Apo-Amlodipine
1.08	90	Vasorex
Tab 5 mg	250	Apo-Amlodipine
Tab 10 mg	250	Apo-Amlodipine
(Apo-Amlodipine Tab 2.5 mg to be delisted 1 June 2021)		
FELODIPINE		
Tab long-acting 2.5 mg - 1% DV Sep-18 to 2021	30	Plendil ER
Tab long-acting 5 mg – 1% DV Dec-18 to 2021	90	Felo 5 ER
Tab long-acting 10 mg - 1% DV Dec-18 to 2021	90	Felo 10 ER

ISRADIPINE

Tab 2.5 mg Cap 2.5 mg

Jap 2.5 mg

NICARDIPINE HYDROCHLORIDE - Restricted see terms below

Inj 2.5 mg per ml, 10 ml vial

➡ Restricted (RS1699)

Initiation

Anaesthetist, intensivist, cardiologist or paediatric cardiologist Any of the following:

- 1 Patient has hypertension requiring urgent treatment with an intravenous agent; or
- 2 Patient has excessive ventricular afterload; or
- 3 Patient is awaiting or undergoing cardiac surgery using cardiopulmonary bypass.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
NIFEDIPINE			
Tab long-acting 10 mg		60	Adalat 10
Tab long-acting 20 mg		100	Nyefax Retard
Tab long-acting 30 mg	3.14	30	Adalat Oros
Tab long-acting 60 mg Cap 5 mg	5.67	30	Adalat Oros
NIMODIPINE			
Tab 30 mg - 1% DV Jul-20 to 2022		100	Nimotop
Inj 200 mcg per ml, 50 ml vial - 1% DV Jul-20 to 2022		1	Nimotop
Other Calcium Channel Blockers			
DILTIAZEM HYDROCHLORIDE			
Tab 30 mg		100	Dilzem
Tab 60 mg	8.50	100	Dilzem
Cap long-acting 120 mg - 1% DV Oct-18 to 2021		500	Apo-Diltiazem CD
Cap long-acting 180 mg - 1% DV Oct-18 to 2021		500	Apo-Diltiazem CD
Cap long-acting 240 mg – 1% DV Oct-18 to 2021 Inj 5 mg per ml, 5 ml vial		500	Apo-Diltiazem CD
PERHEXILINE MALEATE			
Tab 100 mg - 1% DV Oct-19 to 2022		100	Pexsig
VERAPAMIL HYDROCHLORIDE			
Tab 40 mg	7.01	100	Isoptin
Tab 80 mg	11.74	100	Isoptin
Tab long-acting 120 mg		100	Isoptin SR
Tab long-acting 240 mg		30	Isoptin SR
Inj 2.5 mg per ml, 2 ml ampoule		5	Isoptin
Centrally-Acting Agents			
CLONIDINE			
Patch 2.5 mg, 100 mcg per day - 1% DV Nov-20 to 2023		4	Mylan
Patch 5 mg, 200 mcg per day - 1% DV Nov-20 to 2023		4	Mylan
Patch 7.5 mg, 300 mcg per day - 1% DV Nov-20 to 2023		4	Mylan
CLONIDINE HYDROCHLORIDE			
Tab 25 mcg – 1% DV Oct-18 to 2021	8.75	112	Clonidine BNM
Tab 150 mcg		100	Catapres
Inj 150 mcg per ml, 1 ml ampoule – 1% DV Oct-18 to 2021		10	Medsurge
METHYLDOPA			
Tab 250 mg	15.10	100	Methyldopa Mylan
Diuretics			
Loop Diuretics			
BUMETANIDE			
Tab 1 mg		100	Burinex
Inj 500 mcg per ml, 4 ml vial			

	Price	_	Brand or
	(ex man. excl. GS	I) Per	Generic Manufacturer
	\$	rei	Manulaclurer
FUROSEMIDE [FRUSEMIDE]			
Tab 40 mg - 1% DV Dec-19 to 2021		1,000	Apo-Furosemide
Tab 500 mg – 1% DV Mar-19 to 2021		50	Urex Forte
Oral liq 10 mg per ml - 1% DV Jan-20 to 2022	11.20	30 ml	Lasix
Inj 10 mg per ml, 2 ml ampoule - 1% DV Oct-19 to 2022	1.15	5	Frusemide-Claris
			Furosemide-Baxter
Inj 10 mg per ml, 25 ml ampoule - 1% DV Jan-20 to 2022	60.65	6	Lasix
Frusemide-Claris Inj 10 mg per ml, 2 ml ampoule to be delisted 1 Mai	rch 2021)		
Osmotic Diuretics			
/ANNITOL			
Inj 10%, 1,000 ml bag – 1% DV Jun-18 to 2021	747 24	12	Baxter
Inj 20%, 500 ml bag – 1% DV Jun-18 to 2021		18	Baxter
	1,000.02	10	Duxiei
Potassium Sparing Combination Diuretics			
MILORIDE HYDROCHLORIDE WITH FUROSEMIDE			
Tab 5 mg with furosemide 40 mg			
MILORIDE HYDROCHLORIDE WITH HYDROCHLOROTHIAZIDE			
Tab 5 mg with hydrochlorothiazide 50 mg			
Potassium Sparing Diuretics			
MILORIDE HYDROCHLORIDE			
Tab 5 mg			
Oral liq 1 mg per ml		25 ml	Biomed
PLERENONE – Restricted see terms below			
Tab 25 mg - 1% DV Sep-18 to 2021		30	Inspra
Tab 50 mg - 1% DV Dec-18 to 2021		30	Inspra
Restricted (RS1640)			
hitiation			
oth:			
	nd		
 Patient has heart failure with ejection fraction less than 40%; at 2 Either: 	nu		
 Patient is intolerant to optimal dosing of spironolactone; Patient has a spironolactorial dosing of spironolactoriactorial dosing			Contractor de la contractor
2.2 Patient has experienced a clinically significant adverse	effect while on optim	hai dosing c	of spironolactone.
PIRONOLACTONE			
Tab 25 mg	4.38	100	Spiractin
Tab 100 mg	11.80	100	Spiractin
Oral liq 5 mg per ml - 1% DV Nov-19 to 2022		25 ml	Biomed
Thiazide and Related Diuretics			
BENDROFLUMETHIAZIDE [BENDROFLUAZIDE]	00.00	500	Arrow-Bendrofluazide
Tab 2.5 mg – 1% DV Dec-20 to 2023			
Tab 5 mg - 1% DV Dec-20 to 2023		500	Arrow-Bendrofluazide
CHLOROTHIAZIDE			
Oral liq 50 mg per ml		25 ml	Biomed
HLORTALIDONE [CHLORTHALIDONE]			
Tab 25 mg – 1% DV Dec-19 to 2022	6 50	50	Hygroton
		00	

t Item restricted (see → above); t Item restricted (see → below)

CARDIOVASCULAR SYSTEM Price Brand or (ex man. excl. GST) Generic Per Manufacturer \$ 90 Dapa-Tabs

Lipid-Modifying Agents

Fibrates

INDAPAMIDE

METOLAZONE Tab 5 mg

BEZAFIBRATE		
Tab 200 mg - 1% DV Dec-18 to 2021 19.01	90	Bezalip
Tab long-acting 400 mg - 1% DV Dec-18 to 2021	30	Bezalip Retard
GEMFIBROZIL – Restricted: For continuation only		
→ Tab 600 mg	60	Lipazil
(Lipazil Tab 600 mg to be delisted 1 January 2021)		

HMG CoA Reductase Inhibitors (Statins)

ATORVASTATIN 500 Lorstat 500 Lorstat 500 Lorstat 500 Lorstat PRAVASTATIN Tab 10 mg 100 Apo-Pravastatin 100 Apo-Pravastatin SIMVASTATIN 90 Simvastatin Mylan 90 Simvastatin Mylan 90 Simvastatin Mylan Tab 80 mg - 1% DV Nov-20 to 2023......7.12 Simvastatin Mylan 90

Resins

CHOLESTYRAMINE Powder for oral lig 4 g

COLESTIPOL HYDROCHLORIDE Grans for oral lig 5 g

Selective Cholesterol Absorption Inhibitors

EZETIMIBE – Restricted see terms below			
	1.95	30	Ezetimibe Sandoz
→ Restricted (RS1005)			

Initiation

All of the following:

1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and

2 Patient's LDL cholesterol is 2.0 mmol/litre or greater: and

continued...

	Price (ex man. excl. GS \$	ST) Per	Brand or Generic Manufacturer
continued			
3 Any of the following:			
3.1 The patient has rhabdomyolysis (defined as m treated with one statin; or	uscle aches and creatine ki	nase more th	an 10 × normal) when
3.2 The patient is intolerant to both simvastatin and	d atorvastatin; or		
3.3 The patient has not reduced their LDL cholested dose of atorvastatin.		re with the u	se of the maximal tolerate
EZETIMIBE WITH SIMVASTATIN - Restricted see terms b	elow		
Tab 10 mg with simvastatin 10 mg	5.15	30	Zimybe
Tab 10 mg with simvastatin 20 mg	6.15	30	Zimybe
Tab 10 mg with simvastatin 40 mg	7.15	30	Zimybe
Tab 10 mg with simvastatin 80 mg	8.15	30	Zimybe
→ Restricted (RS1006)			
nitiation			
All of the following:			
1 Patient has a calculated absolute risk of cardiovascula	ar disease of at least 15% o	ver 5 years; a	and
2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; a	and		
 Patient's LDL cholesterol is 2.0 mmol/litre or greater; a The patient has not reduced their LDL cholesterol to let 	and		
2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; a	and		
 Patient's LDL cholesterol is 2.0 mmol/litre or greater; a The patient has not reduced their LDL cholesterol to let 	and		
 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; a 3 The patient has not reduced their LDL cholesterol to le atorvastatin. 	and		
 Patient's LDL cholesterol is 2.0 mmol/litre or greater; a The patient has not reduced their LDL cholesterol to le atorvastatin. Other Lipid-Modifying Agents 	and		
 Patient's LDL cholesterol is 2.0 mmol/litre or greater; a The patient has not reduced their LDL cholesterol to le atorvastatin. Other Lipid-Modifying Agents ACIPIMOX 	and		
 Patient's LDL cholesterol is 2.0 mmol/litre or greater; a The patient has not reduced their LDL cholesterol to le atorvastatin. Other Lipid-Modifying Agents ACIPIMOX Cap 250 mg 	and ess than 2.0 mmol/litre with		
 Patient's LDL cholesterol is 2.0 mmol/litre or greater; a The patient has not reduced their LDL cholesterol to le atorvastatin. Other Lipid-Modifying Agents ACIPIMOX Cap 250 mg NICOTINIC ACID 	and ess than 2.0 mmol/litre with	the use of th	e maximal tolerated dose
 Patient's LDL cholesterol is 2.0 mmol/litre or greater; a The patient has not reduced their LDL cholesterol to le atorvastatin. Other Lipid-Modifying Agents ACIPIMOX Cap 250 mg VICOTINIC ACID Tab 50 mg Tab 500 mg 	and ess than 2.0 mmol/litre with	the use of th	e maximal tolerated dose Apo-Nicotinic Acid
 Patient's LDL cholesterol is 2.0 mmol/litre or greater; a The patient has not reduced their LDL cholesterol to le atorvastatin. Other Lipid-Modifying Agents ACIPIMOX Cap 250 mg NICOTINIC ACID Tab 50 mg Tab 500 mg <i>Tab 500 mg to be delisted 1 May 2021</i> 	and ess than 2.0 mmol/litre with	the use of th	e maximal tolerated dose Apo-Nicotinic Acid
 Patient's LDL cholesterol is 2.0 mmol/litre or greater; a The patient has not reduced their LDL cholesterol to le atorvastatin. Other Lipid-Modifying Agents ACIPIMOX Cap 250 mg VICOTINIC ACID Tab 50 mg Tab 500 mg Tab 500 mg <i>Tab 500 mg and the parameter of th</i>	and ess than 2.0 mmol/litre with	the use of th	e maximal tolerated dose Apo-Nicotinic Acid
 Patient's LDL cholesterol is 2.0 mmol/litre or greater; a The patient has not reduced their LDL cholesterol to le atorvastatin. Other Lipid-Modifying Agents ACIPIMOX Cap 250 mg VICOTINIC ACID 	and ess than 2.0 mmol/litre with	the use of th	e maximal tolerated dose Apo-Nicotinic Acid
 Patient's LDL cholesterol is 2.0 mmol/litre or greater; a The patient has not reduced their LDL cholesterol to le atorvastatin. Other Lipid-Modifying Agents ACIPIMOX Cap 250 mg NICOTINIC ACID Tab 50 mg Aciona for the second s	and ess than 2.0 mmol/litre with	the use of th	e maximal tolerated dose Apo-Nicotinic Acid
 Patient's LDL cholesterol is 2.0 mmol/litre or greater; a The patient has not reduced their LDL cholesterol to le atorvastatin. Other Lipid-Modifying Agents ACIPIMOX Cap 250 mg NICOTINIC ACID Tab 50 mg Apo-Nicotinic Acid Tab 50 mg to be delisted 1 May 2021) Apo-Nicotinic Acid Tab 500 mg to be delisted 1 May 2021) Nitrates SLYCERYL TRINITRATE Inj 1 mg per ml, 5 ml ampoule 	and ess than 2.0 mmol/litre with	the use of th	e maximal tolerated dose Apo-Nicotinic Acid
 Patient's LDL cholesterol is 2.0 mmol/litre or greater; a The patient has not reduced their LDL cholesterol to le atorvastatin. Other Lipid-Modifying Agents ACIPIMOX Cap 250 mg VICOTINIC ACID 	and ess than 2.0 mmol/litre with	the use of th	e maximal tolerated dose Apo-Nicotinic Acid
 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; a 3 The patient has not reduced their LDL cholesterol to le atorvastatin. Other Lipid-Modifying Agents ACIPIMOX Cap 250 mg NICOTINIC ACID 	and ess than 2.0 mmol/litre with 4.12 	the use of th 100 100	e maximal tolerated dose Apo-Nicotinic Acid Apo-Nicotinic Acid
 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; a 3 The patient has not reduced their LDL cholesterol to le atorvastatin. Other Lipid-Modifying Agents ACIPIMOX Cap 250 mg NICOTINIC ACID Tab 50 mg Tab 500 mg Apo-Nicotinic Acid Tab 50 mg to be delisted 1 May 2021) Apo-Nicotinic Acid Tab 500 mg to be delisted 1 May 2021) Nitrates SLYCERYL TRINITRATE Inj 1 mg per ml, 5 ml ampoule Inj 1 mg per ml, 50 ml vial Inj 5 mg per ml, 10 ml ampoule 	and ess than 2.0 mmol/litre with 4.12 	the use of th 100 100	e maximal tolerated dose Apo-Nicotinic Acid Apo-Nicotinic Acid Hospira
 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; a 3 The patient has not reduced their LDL cholesterol to le atorvastatin. Other Lipid-Modifying Agents ACIPIMOX Cap 250 mg VICOTINIC ACID Tab 50 mg Tab 500 mg to be delisted 1 May 2021) Apo-Nicotinic Acid Tab 500 mg to be delisted 1 May 2021) Nitrates SLYCERYL TRINITRATE Inj 1 mg per ml, 5 ml ampoule Inj 1 mg per ml, 50 ml vial Inj 5 mg per ml, 10 ml ampoule Oral pump spray, 400 mcg per dose 	and ess than 2.0 mmol/litre with 4.12 17.89	the use of th 100 100 5 250 dose	e maximal tolerated dose Apo-Nicotinic Acid Apo-Nicotinic Acid Hospira Nitrolingual Pump Spra
 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; a 3 The patient has not reduced their LDL cholesterol to le atorvastatin. Other Lipid-Modifying Agents ACIPIMOX Cap 250 mg VICOTINIC ACID Tab 50 mg Tab 500 mg Tab 500 mg (Apo-Nicotinic Acid Tab 50 mg to be delisted 1 May 2021) Nicotinic Acid Tab 500 mg to be delisted 1 May 2021) Nitrates GLYCERYL TRINITRATE Inj 1 mg per ml, 5 ml ampoule Inj 1 mg per ml, 50 ml vial Inj 5 mg per ml, 10 ml ampoule 	and ass than 2.0 mmol/litre with 4.12 	the use of th 100 100	e maximal tolerated dose Apo-Nicotinic Acid Apo-Nicotinic Acid Hospira

ISOSORBIDE MONONITRATE

100 Ismo 20 30 Ismo 40 Retard Duride 90

Other Cardiac Agents

LEVOSIMENDAN - Restricted see terms on the next page

- Inj 2.5 mg per ml, 5 ml vial
- Inj 2.5 mg per ml, 10 ml vial

\$ Per Manufacturer

→ Restricted (RS1007)

Initiation - Heart transplant

Either:

- 1 For use as a bridge to heart transplant, in patients who have been accepted for transplant; or
- 2 For the treatment of heart failure following heart transplant.

Initiation – Heart failure

Cardiologist or intensivist

For the treatment of severe acute decompensated heart failure that is non-responsive to dobutamine.

Sympathomimetics		
ADRENALINE		
Inj 1 in 1,000, 1 ml ampoule4.9 10.7		Aspen Adrenaline
Inj 1 in 1,000, 30 ml vial	0	DDL Aurenaline
Inj 1 in 10,000, 10 ml ampoule	0 10	Aspen Adrenaline
27.0	0 5	Hospira
Inj 1 in 10,000, 10 ml syringe		
DOBUTAMINE Inj 12.5 mg per ml, 20 ml ampoule – 1% DV Jan-19 to 2021	3 5	Dobutamine-hameln
DOPAMINE HYDROCHLORIDE	0 0	Dobutanine-nameni
Inj 40 mg per ml, 5 ml ampoule - 1% DV Sep-18 to 2021	3 10	Max Health Ltd
EPHEDRINE		
Inj 3 mg per ml, 10 ml syringe		
Inj 30 mg per ml, 1 ml ampoule - 1% DV Oct-20 to 2023	3 10	Max Health
ISOPRENALINE [ISOPROTERENOL]		
Inj 200 mcg per ml, 1 ml ampoule Inj 200 mcg per ml, 5 ml ampoule		
METARAMINOL		
lnj 0.5 mg per ml, 10 ml syringe		
Inj 0.5 mg per ml, 20 ml syringe		
Inj 0.5 mg per ml, 5 ml syringe Inj 1 mg per ml, 1 ml ampoule		
Inj 1 mg per ml, 10 ml syringe		
Inj 10 mg per ml, 1 ml ampoule - 1% DV Jan-21 to 2023	0 10	Torbay
NORADRENALINE		
Inj 0.06 mg per ml, 100 ml bag		
Inj 0.06 mg per ml, 50 ml syringe Inj 0.1 mg per ml, 100 ml bag		
Inj 0.1 mg per ml, 50 ml syringe		
Inj 0.12 mg per ml, 100 ml bag		
Inj 0.12 mg per ml, 50 ml syringe Inj 0.16 mg per ml, 50 ml syringe		
Inj 1 mg per ml, 100 ml bag		
Inj 1 mg per ml, 4 ml ampoule - 1% DV Oct-19 to 2022	0 10	Noradrenaline BNM
PHENYLEPHRINE HYDROCHLORIDE		
Inj 10 mg per ml, 1 ml ampoule142.0	7 25	Neosynephrine HCL

	Price (ex man. excl. GST)		Brand or Generic
	\$	Per	Manufacturer
Vasodilators			
ALPROSTADIL HYDROCHLORIDE Inj 500 mcg per ml, 1 ml ampoule – 1% DV Dec-18 to 2021	1.765.50	5	Prostin VR
DIAZOXIDE			
Inj 15 mg per ml, 20 ml ampoule			
HYDRALAZINE HYDROCHLORIDE Tab 25 mg			
 ➡ Restricted (RS1008) 			
Initiation			
Either:			
 For the treatment of refractory hypertension; or For the treatment of heart failure, in combination with a nitrate ACE inhibitors and/or angiotensin receptor blockers. 	e, in patients who are int	olerant	or have not responded to
Inj 20 mg ampoule	25.90	5	Apresoline
MILRINONE			
Inj 1 mg per ml, 10 ml ampoule - 1% DV Sep-18 to 2021		10	Primacor
MINOXIDIL	70.00		
Tab 10 mg		100	Loniten
NICORANDIL Tab 10 mg - 1% DV Dec-19 to 2022	25 57	60	lkorel
Tab 20 mg - 1% DV Dec-19 to 2022		60	lkorel
PAPAVERINE HYDROCHLORIDE			
Inj 30 mg per ml, 1 ml vial			
Inj 12 mg per ml, 10 ml ampoule	217.90	5	Hospira
PENTOXIFYLLINE [OXPENTIFYLLINE] Tab 400 mg			
SODIUM NITROPRUSSIDE			
lnj 50 mg vial			
Endothelin Receptor Antagonists			
AMBRISENTAN - Restricted see terms below			
		30	Ambrisentan Mylan
↓ Tab 10 mg - 1% DV Mar-21 to 2023	4,585.00 1 550 00	30	Volibris Ambrisentan Mylan
	4,585.00	00	Volibris
(Volibris Tab 5 mg to be delisted 1 March 2021)			
(Volibris Tab 10 mg to be delisted 1 March 2021)			
→ Restricted (RS1621) Initiation			
Either:			
1 For use in patients with a valid Special Authority approval for or	ambrisentan by the Pulr	nonary /	Arterial Hypertension Panel;
2 In-hospital stabilisations in emergency situations.			
BOSENTAN - Restricted see terms on the next page			_
Tab 62.5 mg - 1% DV Dec-18 to 2021		60	Bosentan Dr Reddy's
Tab 125 mg – 1% DV Dec-18 to 2021	141.00	60	Bosentan Dr Reddy's

48

	Price		Brand or
(ex	man. excl. G	ST)	Generic
	\$	Per	Manufacturer

➡ Restricted (RS1622)

Initiation - Pulmonary arterial hypertension

Re-assessment required after 6 months Either:

- 1 All of the following:
 - 1.1 Patient has pulmonary arterial hypertension (PAH); and
 - 1.2 PAH is in Group 1, 4 or 5 of the WHO (Venice) clinical classifications; and
 - 1.3 PAH is at NYHA/WHO functional class II, III, or IV; and
 - 1.4 Any of the following:
 - 1.4.1 Both:
 - 1.4.1.1 Bosentan is to be used as PAH monotherapy; and
 - 1.4.1.2 Either:
 - 1.4.1.2.1 Patient is intolerant or contraindicated to sildenafil; or
 - 1.4.1.2.2 Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease; or
 - 1.4.2 Both:
 - 1.4.2.1 Bosentan is to be used as PAH dual therapy; and
 - 1.4.2.2 Either:
 - 1.4.2.2.1 Patient has tried a PAH monotherapy for at least three months and failed to respond; or
 - 1.4.2.2.2 Patient deteriorated while on a PAH monotherapy; or
 - 1.4.3 Both:
 - 1.4.3.1 Bosentan is to be used as PAH triple therapy; and
 - 1.4.3.2 Any of the following:
 - 1.4.3.2.1 Patient is on the lung transplant list; or
 - 1.4.3.2.2 Patient is presenting acutely with idiopathic pulmonary arterial hypertension (IPAH) in New York Heart Association/World Health Organization (NYHA/WHO) Functional Class IV; or
 - 1.4.3.2.3 Patient is deteriorating rapidly to NYHA/WHO Functional Class IV who may be lung transplant recipients in the future, if their disease is stabilised; or
 - 1.4.3.2.4 Patient has PAH associated with the scleroderma spectrum of diseases (APAHSSD) who have no major morbidities and are deteriorating despite combination therapy; or
- 2 In-hospital stabilisation in emergency situations.

Continuation - Pulmonary arterial hypertension

Re-assessment required after 6 months

Any of the following:

- 1 Both:
 - 1.1 Bosentan is to be used as PAH monotherapy; and
 - 1.2 Patient is stable or has improved while on bosentan; or
- 2 Both:
 - 2.1 Bosentan is to be used as PAH dual therapy; and
 - 2.2 Patient has tried a PAH monotherapy for at least three months and either failed to respond or later deteriorated; or
- 3 Both:
 - 3.1 Bosentan is to be used as PAH triple therapy; and
 - 3.2 Any of the following:
 - 3.2.1 Patient is on the lung transplant list; or
 - 3.2.2 Patient is presenting acutely with idiopathic pulmonary arterial hypertension (IPAH) in New York Heart Association/World Health Organization (NYHA/WHO) Functional Class IV; or
 - 3.2.3 Patient is deteriorating rapidly to NYHA/WHO Functional Class IV who may be lung transplant recipients in the future, if their disease is stabilised; or
 - 3.2.4 Patient has PAH associated with the scleroderma spectrum of diseases (APAHSSD) who have no major morbidities and are deteriorating despite combination therapy.

		Price excl. GST) \$	Per	Brand or Generic Manufacturer
Phosphodiesterase Type 5 Inhibitors				
SILDENAFIL - Restricted see terms below ↓ Tab 25 mg - 1% DV Sep-18 to 2021 ↓ Tab 50 mg - 1% DV Sep-18 to 2021 ↓ Tab 100 mg - 1% DV Sep-18 to 2021 ↓ Inj 0.8 mg per ml, 12.5 ml vial → Restricted (RS1740) Heijidition tablets Bausaud's Dhanamanan		0.64	4 4 12	Vedafil Vedafil Vedafil
 Initiation – tablets Raynaud's Phenomenon All of the following: Patient has Raynaud's phenomenon; and Patient has severe digital ischaemia (defined as severe pain ulceration; digital ulcers; or gangrene); and Patient is following lifestyle management (proper body insula avoidance of sympathomimetic drugs); and Patient has persisting severe symptoms despite treatment wi 	tion, avoidar	nce of cold e	xposure,	smoking cessation support,
contraindicated or not tolerated). Initiation – tablets Pulmonary arterial hypertension Any of the following:				
 All of the following: 1.1 Patient has pulmonary arterial hypertension (PAH); ar 1.2 Any of the following: 1.2.1 PAH is in Group 1 of the WHO (Venice) clinica 1.2.2 PAH is in Group 4 of the WHO (Venice) clinica 1.2.3 PAH is in Group 5 of the WHO (Venice) clinica 	I classification	ons; or		
 1.3 Any of the following: 1.3.1 PAH is in NYHA/WHO functional class II; or 1.3.2 PAH is in NYHA/WHO functional class III; or 1.3.3 PAH is in NYHA/WHO functional class IV; and 		Silo, and		
 1.4 Either: 1.4.1 All of the following: 1.4.1.1 Patient has a pulmonary capillary wedge 1.4.1.2 Either: 1.4.1.2.1 Patient has a mean pulmonary ar 		,		
1.4.1.2.2 Patient is peri Fontan repair; and 1.4.1.3 Patient has a pulmonary vascular resista 240 International Units (dyn s cm-5); or	,			
 1.4.2 Testing for PCWP, PAPm, or PVR cannot be p capacity constraints; or 2 For use in neonatal units for persistent pulmonary hypertensi 3 In-hospital stabilisation in emergency situations. 				ng age, or health system
Initiation – tablets other conditions Any of the following: 1 For use in weaning patients from inhaled nitric oxide; or 2 For perioperative use in cardiac surgery patients; or				

- 3 For use in intensive care as an alternative to nitric oxide; or
- 4 For use in the treatment of erectile dysfunction secondary to spinal cord injury in patients being treated in a spinal unit.

e.g. Brand indicates brand example only. It is not a contracted product.

Pr	ice		Brand or
(ex man. e	excl. GST)		Generic
 e e	\$	Per	Manufacturer

continued...

Initiation - injection

Both:

- 1 For use in the treatment of pulmonary hypertension in infants or children being treated in paediatric intensive care units and neonatal intensive care units when the enteral route is not accessible; and
- 2 Any of the following:
 - 2.1 For perioperative use following cardiac surgery; or
 - 2.2 For use in persistent pulmonary hypertension of the newborn (PPHN); or
 - 2.3 For use in congenital diaphragmatic hernia.

Prostacyclin Analogues

EPOPROSTENOL – Restricted see terms below		
Inj 500 mcg vial	1	Veletri
Inj 1.5 mg vial	1	Veletri
⇒ Restricted (RS1624)		

➡ Restricted (RS1624) Initiation

Either:

- 1 For use in patients with a valid Special Authority approval for epoprostenol by the Pulmonary Arterial Hypertension Panel; or
- 2 In-hospital stabilisation in emergency situations.

ILOPROST

	Inj 50 mcg in 0.5 ml ampoule - 1% DV Jan-20 to 2022) 5	Clinect
t	Nebuliser soln 10 mcg per ml, 2 ml - 1% DV Jan-20 to 2022) 30	Ventavis
⇒	Restricted (RS1625)		

Initiation

Any of the following:

- 1 For use in patients with a valid Special Authority approval for iloprost by the Pulmonary Arterial Hypertension Panel; or
- 2 For diagnostic use in catheter laboratories; or
- 3 For use following mitral or tricuspid valve surgery; or
- 4 In-hospital stabilisation in emergency situations.

	Price (ex man. excl. \$	GST) Per	Brand or Generic Manufacturer
Anti-Infective Preparations			
Antibacterials			
HYDROGEN PEROXIDE Crm 1% Soln 3% (10 vol) MAFENIDE ACETATE – Restricted see terms below	8.56	15 g	Crystaderm
↓ Powder 50 g sachet → Restricted (RS1299) Initiation			
For the treatment of burns patients. MUPIROCIN Oint 2%			
SODIUM FUSIDATE [FUSIDIC ACID] Crm 2% - 1% DV May-19 to 2021 Oint 2% - 1% DV May-19 to 2021			Foban Foban
SULFADIAZINE SILVER Crm 1%		50 g	Flamazine
Antifungals			
AMOROLFINE Nail soln 5% - 1% DV Oct-20 to 2023	14 93	5 ml	MycoNail
CICLOPIROX OLAMINE Nail soln 8% - 1% DV Sep-18 to 2021			Apo-Ciclopirox
CLOTRIMAZOLE Crm 1%	0.70	20 g	Clomazol
 ECONAZOLE NITRATE → Crm 1% - Restricted: For continuation only Foaming soln 1% 			
KETOCONAZOLE Shampoo 2% – 1% DV Nov-20 to 2023 METRONIDAZOLE	3.23	100 ml	Sebizole
Gel 0.75%			
MICONAZOLE NITRATE Crm 2%	0.74	15 g	Multichem
Tinc 2% NYSTATIN Crm 100,000 u per g			
Antiparasitics			
DIMETHICONE Lotn 4% – 1% DV Oct-19 to 2022	4.98	200 ml	healthE Dimethicone 4% Lotion

t Item restricted (see \Rightarrow above); **t** Item restricted (see \Rightarrow below)

DERMATOLOGICALS

	-			Durandiau
(ex	man.	ice excl. GS \$	ST) Per	Brand or Generic Manufacturer
MALATHION [MALDISON] Lotn 0.5% Shampoo 1%				
PERMETHRIN Crm 5% – 1% DV Nov-20 to 2023 Lotn 5% – 1% DV Nov-20 to 2023			30 g 30 ml	Lyderm A-Scabies
PHENOTHRIN Shampoo 0.5%				
Antiacne Preparations				
ADAPALENE Crm 0.1% Gel 0.1%				
BENZOYL PEROXIDE Soln 5%				
ISOTRETINOIN Cap 5 mg - 1% DV Oct-18 to 2021 Cap 10 mg - 1% DV Oct-18 to 2021 Cap 20 mg - 1% DV Oct-18 to 2021	1	3.34	60 120 120	Oratane Oratane Oratane
TRETINOIN Crm 0.05% – 1% DV Jun-18 to 2021			50 g	ReTrieve
Antipruritic Preparations				
CALAMINE Crm, aqueous, BP – 1% DV Nov-18 to 2021		.1.26	100 g	healthE Calamine Aqueous Cream BP
CROTAMITON Crm 10% – 1% DV Sep-18 to 2021		.3.29	20 g	Itch-Soothe
Barrier Creams and Emollients				
Barrier Creams				
DIMETHICONE Crm 5% tube - 1% DV Oct-19 to 2022		.1.53	100 g	healthE Dimethicone
Crm 5% pump bottle Crm 10% pump bottle – 1% DV Sep-18 to 2021			500 ml 500 ml	5% healthE Dimethicone 5% healthE Dimethicone 10%
ZINC Crm				e.g. Zinc Cream (Orion-) ;Zinc Cream (PSM)
Oint Paste				e.g. Zinc oxide (PSM)

DERMATOLOGICALS

	Price (ex man. exc \$		Per	Brand or Generic Manufacturer
ZINC AND CASTOR OIL				
Crm	1.	63	20 g	Orion
Oint		25	500 g	Boucher
Note: DV limit applies to the pack sizes of greater than 30 g	J.			
Oint, BP	1.:	26	20 g	healthE
Note: DV limit applies to the pack sizes of 30 g or less.				
ZINC WITH WOOL FAT				
Crm zinc 15.25% with wool fat 4%				e.g. Sudocrem
Emollients				
AQUEOUS CREAM				
Crm 100 g – 1% DV Oct-18 to 2021		05	100 g	Pharmacy Health
······································				SLS-free
Note: DV limit applies to the pack sizes of 100 g or less.				
Crm 500 g - 1% DV Dec-18 to 2021		92	500 g	Boucher
Note: DV limit applies to the pack sizes of greater than 100	g.			
CETOMACROGOL				
Crm BP, 500 g – 1% DV Sep-18 to 2021			500 g	healthE
Crm BP, 100 g - 1% DV Sep-18 to 2021	1.	42	1	healthE
CETOMACROGOL WITH GLYCEROL				
Crm 90% with glycerol 10%, - 1% DV Dec-19 to 2022	1.	65	100 g	healthE
Note: DV limit applies to the pack sizes of 100 g or less.				
Crm 90% with glycerol 10% - 1% DV Mar-20 to 2022			500 ml	ADE
			1,000 ml	ADE
		35	500 ml	Boucher
Note: DV limit applies to the pack sizes of greater than 100		10	1,000 ml	Boucher
	y.			
EMULSIFYING OINTMENT Oint BP – 1% DV Oct-20 to 2023	1	01	100 a	lovohom
Note: DV limit applies to pack sizes of less than 200 g.		04	100 g	Jaychem
Oint BP, 500 g – 1% DV Mar-21 to 2023	3	59	500 g	AFT
		40	000 g	Emulsifying Ointment
	-			ADE
Note: DV limit applies to pack sizes of greater than 200 g.				
AFT Oint BP, 500 g to be delisted 1 March 2021)				
GLYCEROL WITH PARAFFIN				
Crm glycerol 10% with white soft paraffin 5% and liquid paraffin	10%			e.g. QV cream
DIL IN WATER EMULSION				
Crm, 500 g - 1% DV Jan-19 to 2021	2.	19	500 g	O/W Fatty Emulsion
				Cream
Note: DV limit applies to the pack sizes of greater than 100	•			
Crm, 100 g - 1% DV Dec-18 to 2021	1.	44	1	healthE Fatty Cream
PARAFFIN				
Oint liquid paraffin 50% with white soft paraffin 50% - 1% DV Ja				
to 2021		97	100 g	healthE
Note: DV limit applies to the pack sizes of 100 g or greater.				
White soft – 1% DV Sep-18 to 2021			10 g	healthE
Note: DV limit applies to pack sizes of 30 g or less, and to the White soft, -1% DV Apr-20 to 2022			and yellow 450 g	v soft paraffin. healthE

t Item restricted (see → above); t Item restricted (see → below)

DERMATOLOGICALS

		Price excl. GST) \$	Per	Brand or Generic Manufacturer
PARAFFIN WITH WOOL FAT				
Lotn liquid paraffin 15.9% with wool fat 0.6%				e.g. AlphaKeri;BK ;DP; Hydroderm Lotn
Lotn liquid paraffin 91.7% with wool fat 3%				e.g. Alpha Keri Bath Oil
UREA Crm 10%		1 97	100 a	healthE Urea Cream
WOOL FAT		1.37	100 g	
Crm				
Corticosteroids				
BETAMETHASONE DIPROPIONATE				
Crm 0.05% - 1% DV Feb-21 to 2023		36.00	50 g	Diprosone
Note: DV limit applies to the pack sizes of greater than 30 g				
Oint 0.05% – 1% DV Feb-21 to 2023.		36.00	50 g	Diprosone
Note: DV limit applies to the pack sizes of greater than 30 g				
BETAMETHASONE VALERATE Crm 0.1% – 1% DV Oct-18 to 2021		3.45	50 g	Beta Cream
Oint 0.1% - 1% DV Oct-18 to 2021			50 g 50 g	Beta Ointment
Lotn 0.1% – 1% DV Dec-18 to 2021			50 ml	Betnovate
CLOBETASOL PROPIONATE				
Crm 0.05% - 1% DV Nov-19 to 2022			30 g	Dermol
Oint 0.05% - 1% DV Nov-19 to 2022		2.12	30 g	Dermol
CLOBETASONE BUTYRATE Crm 0.05%				
DIFLUCORTOLONE VALERATE - Restricted: For continuation on	ly			
→ Crm 0.1%				
➡ Fatty oint 0.1%				
HYDROCORTISONE				
Crm 1%, 100 g – 1% DV Sep-20 to 2022 Note: DV limit applies to the pack sizes of less than or equa		3.70	100 g	Hydrocortisone (PSM)
Crm 1%, 500 g $-$ 1% DV Dec-20 to 2023		17 15	500 g	Hydrocortisone (PSM)
HYDROCORTISONE ACETATE			000 g	
Crm 1%		2.48	14.2 g	AFT
(AFT Crm 1% to be delisted 1 November 2020)			0	
HYDROCORTISONE AND PARAFFIN LIQUID AND LANOLIN				
Lotn 1% with paraffin liquid 15.9% and lanolin 0.6% $-$ 1% DV Oc				
to 2023		10.57	250 ml	DP Lotn HC
HYDROCORTISONE BUTYRATE Crm 0.1%		6.85	100 a	Locoid Lipocroam
Oint 0.1% – 1% DV Mar-19 to 2021			100 g 100 g	Locoid Lipocream Locoid
Milky emul 0.1% – 1% DV Mar-19 to 2021			100 ml	Locoid Crelo
METHYLPREDNISOLONE ACEPONATE				
Crm 0.1% - 1% DV Dec-20 to 2023		4.46	15 g	Advantan
Oint 0.1% - 1% DV Dec-20 to 2023		4.46	15 g	Advantan

	Price (ex man. excl. GST \$	Per	Brand or Generic Manufacturer
MOMETASONE FUROATE			
Crm 0.1% – 1% DV Nov-18 to 2021		15 g	Elocon Alcohol Free
	2.50	50 g	Elocon Alcohol Free
Oint 0.1% - 1% DV Nov-18 to 2021	1.51	15 g	Elocon
	2.90	50 g	Elocon
Lotn 0.1% - 1% DV Nov-18 to 2021	6.30	30 ml	Elocon
TRIAMCINOLONE ACETONIDE			
Crm 0.02% – 1% DV Nov-20 to 2023	6.30	100 g	Aristocort
Oint 0.02% - 1% DV Nov-20 to 2023	6.35	100 g	Aristocort
		-	
Corticosteroids with Anti-Infective Agents			
BETAMETHASONE VALERATE WITH CLIOQUINOL - Restricted ↓ Crm 0.1% with clioquiniol 3% → Restricted (RS1125) Initiation Either:	see terms below		
 For the treatment of intertrigo; or For continuation use. 			
BETAMETHASONE VALERATE WITH SODIUM FUSIDATE [FUSID Crm 0.1% with sodium fusidate (fusidic acid) 2%	IC ACID]		
HYDROCORTISONE WITH MICONAZOLE			
Crm 1% with miconazole nitrate 2% - 1% DV Sep-18 to 2021	2.00	15 g	Micreme H
HYDROCORTISONE WITH NATAMYCIN AND NEOMYCIN		Ū	
Crm 1% with natamycin 1% and neomycin sulphate 0.5%	3.35	15 g	Pimafucort
Oint 1% with natamycin 1% and neomycin sulphate 0.5%		15 g	Pimafucort
TRIAMCINOLONE ACETONIDE WITH NEOMYCIN SULPHATE, GF		Ũ	
Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg ar gramicidin 250 mcg per g			
Psoriasis and Eczema Preparations			
ACITRETIN			
Cap 10 mg – 1% DV Oct-20 to 2023	17 86	60	Novatretin
Cap 25 mg – 1% DV Oct-20 to 2023		60 60	Novatretin
		00	
BETAMETHASONE DIPROPIONATE WITH CALCIPOTRIOL Foam spray 500 mcg with calcipotriol 50 mcg per g	50.05	60 a	Enctilor
		60 g	Enstilar Daivobet
Gel 500 mcg with calcipotriol 50 mcg per g – 1% DV Dec-18 to Oint 500 mcg with calcipotriol 50 mcg per g – 1% DV Dec-18 to		60 g 30 g	Daivobet
	EVET 13.30	50 y	Daivobel
CALCIPOTRIOL Oint 50 mag par a	40.00	100 ~	Doivonov
Oint 50 mcg per g	40.00	120 g	Daivonex
COAL TAR WITH SALICYLIC ACID AND SULPHUR Oint 12% with salicylic acid 2% and sulphur 4%			
METHOXSALEN [8-METHOXYPSORALEN] Tab 10 mg Lotn 1.2%			
PINE TAR WITH TROLAMINE LAURILSULFATE AND FLUORESCI Soln 2.3% with trolamine laurilsulfate and fluorescein sodium –	1% DV		
Nov-20 to 2023	4.44	500 ml	Pinetarsol

t Item restricted (see → above); t Item restricted (see → below)

Crm 5%, 250 mg sachet
POTASSIUM PERMANGANATE Tab 400 mg Crystals Scalp Preparations BETAMETHASONE VALERATE Scalp app 0.1% - 1% DV Oct-18 to 2021
Tab 400 mg Crystals Scalp Preparations BETAMETHASONE VALERATE Scalp app 0.1% - 1% DV Oct-18 to 2021
Scalp Preparations BETAMETHASONE VALERATE Scalp app 0.1% - 1% DV Oct-18 to 2021
BETAMETHASONE VALERATE Scalp app 0.1% - 1% DV Oct-18 to 2021
Scalp app 0.1% - 1% DV Oct-18 to 2021
CLOBETASOL PROPIONATE Scalp app 0.05% - 1% DV Nov-19 to 2022
Scalp app 0.05% - 1% DV Nov-19 to 2022
HYDROCORTISONE BUTYRATE Scalp lotn 0.1% - 1% DV Mar-19 to 2021
Scalp lotn 0.1% - 1% DV Mar-19 to 2021 7.30 100 ml Locoid Wart Preparations IMIQUIMOD 21.72 24 Perrigo PODOPHYLLOTOXIN 21.72 24 Perrigo Soln 0.5% 33.60 3.5 ml Condyline SILVER NITRATE 33.60 3.5 ml Condyline SILVER NITRATE Sticks with applicator DIPHEMANIL METILSULFATE Powder 2% SUNSCREEN, PROPRIETARY SUNSCREEN, PROPRIETARY SUNSCREEN, PROPRIETARY
IMIQUIMOD Crm 5%, 250 mg sachet
PODOPHYLLOTOXIN Soln 0.5%
PODOPHYLLOTOXIN Soln 0.5%
Soln 0.5%
SILVER NITRATE Sticks with applicator Other Skin Preparations DIPHEMANIL METILSULFATE Powder 2% SUNSCREEN, PROPRIETARY
Sticks with applicator Other Skin Preparations DIPHEMANIL METILSULFATE Powder 2% SUNSCREEN, PROPRIETARY
DIPHEMANIL METILSULFATE Powder 2% SUNSCREEN, PROPRIETARY
Powder 2% SUNSCREEN, PROPRIETARY
SUNSCREEN, PROPRIETARY
Loto 19/ DV Mor 20 to 2022
Lotn – 1% DV Mar-20 to 20225.10 200 g Marine Blue Lotion 50+
Antineoplastics
FLUOROURACIL SODIUM
Crm 5% – 1% DV Sep-18 to 2021
METHYL AMINOLEVULINATE HYDROCHLORIDE – Restricted see terms below Crm 16%
➡ Restricted (RS1127)
Dermatologist or plastic surgeon
Wound Management Products

Gel 2.5%

e.g. Orion

DERMATOLOGICALS

	Price		Brand or
	(ex man. excl. GST \$) Per	Generic Manufacturer
	Ψ	1 61	Manulacturer
Anti-Infective Agents			
ACETIC ACID			
Soln 3%			
Soln 5%			
ACETIC ACID WITH HYDROXYQUINOLINE, GLYCEROL AND RICIN Jelly 0.94% with hydroxyquinoline sulphate 0.025%, glycerol 5% ar ricinoleic acid 0.75% with applicator			
CHLORHEXIDINE GLUCONATE			
Crm 1%		50 g	healthE
Lotn 1%, 200 ml	2.98	1	healthE
(healthE Crm 1% to be delisted 1 November 2020) (healthE Lotn 1%, 200 ml to be delisted 1 November 2020)			
CLOTRIMAZOLE			
Vaginal crm 1% with applicator - 1% DV Jan-20 to 2022		35 g	Clomazol
Vaginal crm 2% with applicator – 1% DV Jan-20 to 2022	3.00	20 g	Clomazol
VIICONAZOLE NITRATE Vaginal crm 2% with applicator – 1% DV Nov-20 to 2023	6 89	40 g	Micreme
		τυg	moreme
Vaginal crm 100,000 u per 5 g with applicator(s) – 1% DV Oct-20 f	o 2023 4.00	75 g	Nilstat
Contracontines			
Contraceptives			
Antiandrogen Oral Contraceptives			
CYPROTERONE ACETATE WITH ETHINYLOESTRADIOL			
Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tablets	4.67	168	Ginet
Combined Oral Contraceptives			
ETHINYLOESTRADIOL WITH DESOGESTREL			
Tab 20 mcg with desogestrel 150 mcg			
Tab 30 mcg with desogestrel 150 mcg			
ETHINYLOESTRADIOL WITH LEVONORGESTREL			
Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets		84 84	Microgynon 20 ED Levlen ED
Tab 20 mcg with levonorgestrel 100 mcg		04	
Tab 30 mcg with levonorgestrel 150 mcg			
Tab 50 mcg with levonorgestrel 125 mcg	9.45	84	Microgynon 50 ED
THINYLOESTRADIOL WITH NORETHISTERONE Tab 35 mcg with norethisterone 1 mg			
Tab 35 mcg with norethisterone 1 mg and 7 inert tab – 1% DV Mai	-20		
to 2022		84	Brevinor 1/28
Tab 35 mcg with norethisterone 500 mcg			
NORETHISTERONE WITH MESTRANOL			
Tab 1 mg with mestranol 50 mcg			

58

GENITO-URINARY SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Contraceptive Devices			
INTRA-UTERINE DEVICE			
IUD 29.1 mm length × 23.2 mm width – 1% DV Nov-19 to 2022	18.45	1	Choice TT380 Short
IUD 33.6 mm length × 29.9 mm width – 1% DV Nov-19 to 2022		1	Choice TT380 Standard
IUD 35.5 mm length × 19.6 mm width - 1% DV Nov-19 to 2022		1	Choice Load 375
Emergency Contraception			
LEVONORGESTREL	4.05		
Tab 1.5 mg	4.95	1	Postinor-1
Progestogen-Only Contraceptives			
LEVONORGESTREL			
Tab 30 mcg - 1% DV May-20 to 2022		84	Microlut
Subdermal implant (2 × 75 mg rods) - 1% DV Dec-20 to 2023		1	Jadelle
Intra-uterine device 52 mg - 1% DV Nov-19 to 31 Oct 2022		1	Mirena
Intra-uterine device 13.5 mg - 1% DV Nov-19 to 31 Oct 2022	215.60	1	Jaydess
MEDROXYPROGESTERONE ACETATE			
Inj 150 mg per ml, 1 ml syringe - 1% DV Dec-19 to 2022	7.98	1	Depo-Provera
NORETHISTERONE			•
Tab 350 mcg – 1% DV Sep-18 to 2021	6.25	84	Noriday 28
			,
Obstetric Preparations			
Antiprogestogens			
MIFEPRISTONE			
Tab 200 mg			
Oxytocics			
CARBOPROST TROMETAMOL			
Inj 250 mcg per ml, 1 ml ampoule			
DINOPROSTONE			
Pessaries 10 mg			
Vaginal gel 1 mg in 3 g		1	Prostin E2
Vaginal gel 2 mg in 3 g		1	Prostin E2
ERGOMETRINE MALEATE			
Inj 500 mcg per ml, 1 ml ampoule		5	DBL Ergometrine
OXYTOCIN			ů –
Inj 5 iu per ml, 1 ml ampoule - 1% DV Nov-18 to 2021		5	Oxytocin BNM
Inj 10 iu per ml, 1 ml ampoule – 1% DV Nov-18 to 2021		5	Oxytocin BNM
OXYTOCIN WITH ERGOMETRINE MALEATE			
Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml ampoule –	1%		
DV Oct-18 to 2021		5	Syntometrine
Tocolytics			
•			
PROGESTERONE – Restricted see terms on the next page	10 50	20	Litragaatan
Cap 100 mg		30	Utrogestan

Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price			Brand or
(ex ma	n. excl	. GST)		Generic
	\$		Per	Manufacturer

➡ Restricted (RS1533)

Initiation

Gynaecologist or obstetrician

Re-assessment required after 12 months

Both:

- 1 For the prevention of pre-term labour*; and
- 2 Either:
 - 2.1 The patient has a short cervix on ultrasound (defined as < 25mm at 16 to 28 weeks); or
 - 2.2 The patient has a history of pre-term birth at less than 28 weeks.

Continuation

Gynaecologist or obstetrician

Re-assessment required after 12 months

All of the following:

- 1 For the prevention of pre-term labour*; and
- 2 Treatment is required for second or subsequent pregnancy; and
- 3 Either:
 - 3.1 The patient has a short cervix on ultrasound (defined as < 25mm at 16 to 28 weeks); or
 - 3.2 The patient has a history of pre-term birth at less than 28 weeks.

Note: Indications marked with * are unapproved indications.

TERBUTALINE - Restricted see terms below

Inj 500 mcg ampoule

⇒ Restricted (RS1130)

Obstetrician

Oestrogens

Crm 1 mg per g with applicator - 1% DV Oct-20 to 2023	6.62	15 g	Ovestin	
Pessaries 500 mcg - 1% DV Oct-20 to 2023	6.86	15	Ovestin	

Urologicals		
5-Alpha Reductase Inhibitors		
 FINASTERIDE - Restricted see terms below ↓ Tab 5 mg	100 dicated; or	Ricit
Alpha-1A Adrenoceptor Blockers		
TAMSULOSIN HYDROCHLORIDE - Restricted see terms below ↓ Cap 400 mcg - 1% DV Jan-20 to 2022	100	Tamsulosin-Rex

continued...

GENITO-URINARY SYSTEM

	I	Price			Brand or
(ex	man.		GST)	Der	Generic
		\$		Per	Manufacturer
ontinued					
 Patient has symptomatic benign prostatic hyperplasia; and The patient is intolerant of non-selective alpha blockers or these are 	e cont	traindi	icated.		
Urinary Alkalisers					
POTASSIUM CITRATE - Restricted see terms below					
Oral liq 3 mmol per ml – 1% DV Oct-18 to 2021		.31.8	0	200 ml	Biomed
Restricted (RS1133)					
nitiation					
Both:					
 The patient has recurrent calcium oxalate urolithiasis; and The patient has had more than two renal calculi in the two years pri- 	or to t	the ap	oplicati	on.	
ODIUM CITRO-TARTRATE					
Grans eff 4 g sachets - 1% DV Oct-20 to 2023		2.2	2	28	Ural
Urinary Antispasmodics					
DXYBUTYNIN					
Tab 5 mg		.11.7	0	500	Apo-Oxybutynin
Oral liq 5 mg per 5 ml				473 ml	Apo-Oxybutynin
OLIFENACIN SUCCINATE – Some items restricted see terms below					
Tab 5 mg - 1% DV Dec-18 to 2021		3.0	0	30	Solifenacin Mylan
Tab 10 mg - 1% DV Dec-18 to 2021		5.5	0	30	Solifenacin Mylan
→ Restricted (RS1274)					-
nitiation					

Patient has overactive bladder and a documented intolerance of, or is non-responsive to, oxybutynin.

(ex	Price man. excl. \$	GST)	Per	Brand or Generic Manufacturer
Anabolic Agents				
DXANDROLONE				
Tab 2.5 mg				
◆ Restricted (RS1302) nitiation				
For the treatment of burns patients.				
Androgen Agonists and Antagonists				
CYPROTERONE ACETATE				
Tab 50 mg - 1% DV Dec-18 to 2021		7	50	Siterone
Tab 100 mg - 1% DV Dec-18 to 2021			50	Siterone
ESTOSTERONE				
Patch 5 mg per day	90.0	0	30	Androderm
ESTOSTERONE CIPIONATE	70 5	•		Dana Tastastasaa
Inj 100 mg per ml, 10 ml vial		0	1	Depo-Testosterone
ESTOSTERONE ESTERS Inj testosterone decanoate 100 mg, testosterone isocarproate 60 mg,				
testosterone phenylpropionate 60 mg and testosterone propionate				
30 mg per ml, 1 ml ampoule				
ESTOSTERONE UNDECANOATE				
Cap 40 mg – 1% DV Nov-18 to 2021 Inj 250 mg per ml, 4 ml vial			60 1	Andriol Testocaps Reandron 1000
		0	I	Realition 1000
Calcium Homeostasis				
CALCITONIN				
Inj 100 iu per ml, 1 ml ampoule	121.0	0	5	Miacalcic
CINACALCET – Restricted see terms below				
Tab 30 mg - 1% DV Sep-18 to 2021	210.3	0	28	Sensipar
Restricted (RS1540) nitiation				
lephrologist or endocrinologist				
Re-assessment required after 6 months				
ither:				
1 All of the following:				
1.1 The patient has been diagnosed with a parathyroid carcinoma		<i>'</i> .		
1.2 The patient has persistent hypercalcaemia (serum calcium gr first-line treatments including sodium thiosulfate (where appro				
1.3 The patient is symptomatic; or	priatoj di	a bibpi	1000100	aco, ana
2 All of the following:				
2.1 The patient has been diagnosed with calciphylaxis (calcific ur	aemic arte	eriolopa	athy); ar	nd
2.2 The patient has symptomatic (e.g. painful skin ulcers) hypere	alcaemia	(serun	n calciur	n greater than or equal to

3 mmol/L); and 2.3 The patient's condition has not responded to previous first-line treatments including bisphosphonates and sodium thiosulfate.

continued...

Price (ex man. excl. (\$		Per	Brand or Generic Manufacturer
continued			
Continuation			
Nephrologist or endocrinologist			
Both:			
1 The patient's serum calcium level has fallen to < 3mmol/L; and			
2 The patient has experienced clinically significant symptom improvement.			
Note: This does not include parathyroid adenomas unless these have become malignation	ant.		
ZOLEDRONIC ACID			
Inj 4 mg per 5 ml, vial – 1% DV May-19 to 2021		1	Zoledronic acid Mylan
→ Restricted (RS1602)			
nitiation – bone metastases			
Dicologist, haematologist or palliative care specialist			
Any of the following:			
1 Patient has hypercalcaemia of malignancy; or			
2 Both:			
2.1 Patient has bone metastases or involvement; and			
2.2 Patient has severe bone pain resistant to standard first-line treatments; c	JL		
3 Both:			
3.1 Patient has bone metastases or involvement; and3.2 Patient is at risk of skeletal-related events (pathological fracture, spinal c	ord co	mpress	ion, radiation to bone or
surgery to bone).			
nitiation – early breast cancer			
Dncologist			
All of the following:			
1 Treatment to be used as adjuvant therapy for early breast cancer; and		اممر مالك.	
2 Patient has been amenorrhoeic for 12 months or greater, either naturally or indu a patheonogeneous state and	ucea, w	htn end	ocrine levels consistent wit
a postmenopausal state; and 2. Treatment to be administered at a minimum interval of 6 monthly for a maximum	m of 0 v		
3 Treatment to be administered at a minimum interval of 6-monthly for a maximum	n oi 2 y	lears.	
Corticosteroids			
BETAMETHASONE			
Tab 500 mcg			
Inj 4 mg per ml, 1 ml ampoule			
BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHASONE ACETATE			
Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml ampoule			
EXAMETHASONE			
Tab 0.5 mg - 1% DV Oct-18 to 2021		30	Dexmethsone
Tab 4 mg - 1% DV Oct-18 to 2021		30	Dexmethsone
Oral liq 1 mg per ml		25 ml	Biomed
DEXAMETHASONE PHOSPHATE			
Inj 4 mg per ml, 1 ml ampoule – 1% DV Jul-20 to 2022		10	Dexamethasone
, Jessing and provide the second s			Phosphate

Inj 4 mg per ml, 2 ml ampoule – 1% DV Jul-20 to 2022	6.37	10	Panpharma Dexamethasone Phosphate Panpharma
FLUDROCORTISONE ACETATE Tab 100 mcg14	4.32	100	Florinef

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price man. excl. GS	г)	Brand or Generic
(ex	\$	Per	Manufacturer
HYDROCORTISONE			
Tab 5 mg - 1% DV Sep-18 to 2021	8.10	100	Douglas
Tab 20 mg - 1% DV Sep-18 to 2021	20.32	100	Douglas
Inj 100 mg vial		1	Solu-Cortef
METHYLPREDNISOLONE (AS SODIUM SUCCINATE)			
Tab 4 mg – 1% DV Dec-18 to 2021	112.00	100	Medrol
Tab 100 mg - 1% DV Dec-18 to 2021		20	Medrol
Inj 40 mg vial – 1% DV Dec-18 to 2021		1	Solu-Medrol Act-O-Via
Inj 125 mg vial - 1% DV Dec-18 to 2021		1	Solu-Medrol Act-O-Via
Inj 500 mg vial - 1% DV Dec-18 to 2021		1	Solu-Medrol Act-O-Via
Inj 1 g vial – 1% DV Dec-18 to 2021	27.83	1	Solu-Medrol
METHYLPREDNISOLONE ACETATE			
Inj 40 mg per ml, 1 ml vial – 1% DV Dec-18 to 2021		5	Depo-Medrol
PREDNISOLONE			
Oral liq 5 mg per ml – 1% DV Jun-18 to 2021	6.00	30 ml	Redipred
Enema 200 mcg per ml, 100 ml		00 111	nealpieu
PREDNISONE			
Tab 1 mg	10.68	500	Apo-Prednisone
Tab 2.5 mg		500	Apo-Prednisone
Tab 5 mg		500	Apo-Prednisone
Tab 20 mg		500	Apo-Prednisone
TRIAMCINOLONE ACETONIDE		000	
	20.90	F	Kenacort-A 10
Inj 10 mg per ml, 1 ml ampoule - 5% DV Apr-21 to 2023		5 5	Kenacort-A 10 Kenacort-A 40
Inj 40 mg per ml, 1 ml ampoule – 1% DV Apr-21 to 2023		Э	Renacon-A 40
FRIAMCINOLONE HEXACETONIDE			

Inj 20 mg per ml, 1 ml vial

Hormone Replacement Therapy

Oestrogens

OESTRADIOL

Tab 1 mg		
Patch 25 mcg per day6.12	8	Estradot
Patch 50 mcg per day7.04	8	Estradot
Patch 75 mcg per day7.91	8	Estradot
Patch 100 mcg per day7.91	8	Estradot
OESTRADIOL VALERATE		
Tab 1 mg - 1% DV Sep-18 to 2021 12.36	84	Progynova
Tab 2 mg - 1% DV Sep-18 to 2021 12.36	84	Progynova
OESTROGENS (CONJUGATED EQUINE)		

Tab 300 mcg

Tab 625 mcg

Progestogen and Oestrogen Combined Preparations

OESTRADIOL WITH NORETHISTERONE ACETATE

Tab 1 mg with 0.5 mg norethisterone acetate

Tab 2 mg with 1 mg norethisterone acetate

Tab 2 mg with 1 mg norethisterone acetate (10), and tab 2 mg oestradiol (12) and tab 1 mg oestradiol (6)

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
OESTROGENS WITH MEDROXYPROGESTERONE ACETATE Tab 625 mcg conjugated equine with 2.5 mg medroxyprogesteron acetate Tab 625 mcg conjugated equine with 5 mg medroxyprogesterone acetate	e		
Progestogens			
MEDROXYPROGESTERONE ACETATE Tab 2.5 mg Tab 5 mg Tab 10 mg	14.00	30 100 30	Provera Provera Provera
Other Endocrine Agents CABERGOLINE – Restricted see terms below ↓ Tab 0.5 mg – 1% DV Sep-18 to 2021	3 75	2	Dostinex
 → Restricted (RS1319) Initiation Any of the following: Inhibition of lactation; or Patient has pathological hyperprolactinemia; or Patient has acromegaly. 	15.20	8	Dostinex
CLOMIFENE CITRATE Tab 50 mg	29.84	10	Mylan Clomiphen
DANAZOL Cap 100 mg Cap 200 mg (Mylan Cap 100 mg to be delisted 1 April 2021) (Azol Cap 200 mg to be delisted 1 April 2021) GESTRINONE Cap 2.5 mg METYRAPONE Cap 250 mg PENTAGASTRIN Inj 250 mcg per ml, 2 ml ampoule		28 100	Mylan Azol
Other Oestrogen Preparations ETHINYLOESTRADIOL			
Tab 10 mcg – 1% DV Sep-18 to 2021 OESTRADIOL Implant 50 mg OESTRIOL		100	NZ Medical and Scientific
Tab 2 mg - 1% DV Sep-20 to 2023	7.00	30	Ovestin
Other Progestogen Preparations MEDROXYPROGESTERONE Tab 100 mg		100	Provera HD

Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
NORETHISTERONE Tab 5 mg – 1% DV Dec-19 to 2021 18.29	100	Primolut N
Pituitary and Hypothalamic Hormones and Analogues CORTICOTRORELIN (OVINE) Inj 100 mcg vial THYROTROPIN ALFA Inj 900 mcg vial		
Adrenocorticotropic Hormones		
TETRACOSACTIDE [TETRACOSACTRIN] Inj 250 mcg per ml, 1 ml ampoule	1 1	Synacthen Synacthen Depot
GnRH Agonists and Antagonists		
BUSERELIN Inj 1 mg per ml, 5.5 ml vial GONADORELIN Inj 100 mcg vial		
GOSERELIN Implant 3.6 mg, syringe66.48 Implant 10.8 mg, syringe177.50 LEUPRORELIN ACETATE	1 1	Zoladex Zoladex
Inj 3.75 mg prefilled dual chamber syringe	1 1	Lucrin Depot 1-month Lucrin Depot 3-month
Gonadotrophins		
CHORIOGONADOTROPIN ALFA Inj 250 mcg in 0.5 ml syringe		
Growth Hormone		
SOMATROPIN - Restricted see terms below ↓ Inj 5 mg cartridge - 1% DV Oct-18 to 2021	1 1 1	Omnitrope Omnitrope Omnitrope
1 Growth hormone deficiency causing symptomatic hypoglycaemia, or with other sigr	nificant gro	owth hormone deficient

1 Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH < 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose < 2 mmol/l using a laboratory device); or</p>

continued...

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

- 2 All of the following:
 - 2.1 Height velocity < 25th percentile for age; and adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985); and</p>
 - 2.2 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
 - 2.3 Peak growth hormone value of < 5.0 mcg per litre in response to two different growth hormone stimulation tests. In children who are 5 years or older, GH testing with sex steroid priming is required; and</p>
 - 2.4 If the patient has been treated for a malignancy, they should be disease free for at least one year based upon follow-up laboratory and radiological imaging appropriate for the malignancy, unless there are strong medical reasons why this is either not necessary or appropriate; and
 - 2.5 Appropriate imaging of the pituitary gland has been obtained.

Continuation - growth hormone deficiency in children

Endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months

All of the following:

- 1 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 2 Height velocity is greater than or equal to 25th percentile for age (adjusted for bone age/pubertal status if appropriate) while on growth hormone treatment, as calculated over six months using the standards of Tanner and Davis (1985); and
- 3 Height velocity is greater than or equal to 2.0 cm per year, as calculated over 6 months; and
- 4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed since starting growth hormone.

Initiation – Turner syndrome

Endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months

All of the following:

- 1 The patient has a post-natal genotype confirming Turner Syndrome; and
- 2 Height velocity is < 25th percentile over 6-12 months using the standards of Tanner and Davies (1985); and
- 3 A current bone age is < 14 years.

Continuation - Turner syndrome

Endocrinologist or paediatric endocrinologist *Re-assessment required after 12 months*

All of the following:

- 1 Height velocity greater than or equal to 50th percentile for age (while on growth hormone calculated over 6 to 12 months using the Ranke's Turner Syndrome growth velocity charts); and
- 2 Height velocity is greater than or equal to 2 cm per year, calculated over six months; and
- 3 A current bone age is 14 years or under; and
- 4 No serious adverse effect that the specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed since starting growth hormone.

Initiation - short stature without growth hormone deficiency

Endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months

All of the following:

- 1 The patient's height is more than 3 standard deviations below the mean for age or for bone age if there is marked growth acceleration or delay; and
- 2 Height velocity is < 25th percentile for age (adjusted for bone age/pubertal status if appropriate), as calculated over 6 to 12 months using the standards of Tanner and Davies(1985); and

continued...

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

- 3 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
- 4 The patient does not have severe chronic disease (including malignancy or recognized severe skeletal dysplasia) and is not receiving medications known to impair height velocity.

Continuation - short stature without growth hormone deficiency

Endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months

All of the following:

- 1 Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
- 3 Current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred.

Initiation - short stature due to chronic renal insufficiency

Endocrinologist, paediatric endocrinologist or renal physician on the recommendation of a endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months All of the following:

- 1 The patient's height is more than 2 standard deviations below the mean; and
- 2 Height velocity is < 25th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 3 A current bone age is to 14 years or under (female patients) or to 16 years or under (male patients); and
- 4 The patient is metabolically stable, has no evidence of metabolic bone disease and absence of any other severe chronic disease; and
- 5 The patient is under the supervision of a specialist with expertise in renal medicine; and
- 6 Either:
 - 6.1 The patient has a GFR less than or equal to 30 ml/min/1.73 m² as measured by the Schwartz method (Height(cm)/plasma creatinine (umol/l × 40 = corrected GFR (ml/min/1.73 m²) in a child who may or may not be receiving dialysis; or
 - 6.2 The patient has received a renal transplant and has received < 5mg/ m² /day of prednisone or equivalent for at least 6 months.

Continuation - short stature due to chronic renal insufficiency

Endocrinologist, paediatric endocrinologist or renal physician on the recommendation of a endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months All of the following:

- 1 Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
- 3 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone has occurred; and
- 5 No malignancy has developed after growth hormone therapy was commenced; and
- 6 The patient has not experienced significant biochemical or metabolic deterioration confirmed by diagnostic results; and
- 7 The patient has not received renal transplantation since starting growth hormone treatment; and
- 8 If the patient requires transplantation, growth hormone prescription should cease before transplantation and a new application should be made after transplantation based on the above criteria.

Price Brand or (ex man. excl. GST) Generic \$ Per Manufacturer
--

Initiation - Prader-Willi syndrome

Endocrinologist or paediatric endocrinologist *Re-assessment required after 12 months* All of the following:

- 1 The patient has a diagnosis of Prader-Willi syndrome that has been confirmed by genetic testing or clinical scoring criteria; and
- 2 The patient is aged six months or older; and
- 3 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
- 4 Sleep studies or overnight eximetry have been performed and there is no obstructive sleep disorder requiring treatment, or if an obstructive sleep disorder is found, it has been adequately treated under the care of a paediatric respiratory physician and/or ENT surgeon; and
- 5 Either:
 - 5.1 Both:
 - 5.1.1 The patient is aged two years or older; and
 - 5.1.2 There is no evidence of type II diabetes or uncontrolled obesity defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months; or
 - 5.2 The patient is aged between six months and two years and a thorough upper airway assessment is planned to be undertaken prior to treatment commencement and at six to 12 weeks following treatment initiation.

Continuation – Prader-Willi syndrome

Endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months

All of the following:

- 1 Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
- 3 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 4 No serious adverse effect that the patient's specialist con siders is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed after growth hormone therapy was commenced; and
- 6 The patient has not developed type II diabetes or uncontrolled obesity as defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months.

Initiation - adults and adolescents

Endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months

All of the following:

- 1 The patient has a medical condition that is known to cause growth hormone deficiency (e.g. surgical removal of the pituitary for treatment of a pituitary tumour); and
- 2 The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses; and
- 3 The patient has severe growth hormone deficiency (see notes); and
- 4 The patient's serum IGF-I is more than 1 standard deviation below the mean for age and sex; and
- 5 The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA®).

Notes: For the purposes of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of less than or equal to 3 mcg per litre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test.

Patients with one or more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak

continued...

	Price			Brand or
(e	ex man. excl.	GST)		Generic
	\$		Per	Manufacturer

serum growth hormone level of less than or equal to 0.4 mcg per litre.

The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until it is within 1 standard deviation of the mean normal value for age and sex; and

The dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

Continuation - adults and adolescents

Endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months

Either:

- 1 All of the following:
 - 1.1 The patient has been treated with somatropin for < 12 months; and
 - 1.2 There has been an improvement in the Quality of Life Assessment defined as a reduction of at least 8 points on the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA®) score from baseline; and
 - 1.3 Serum IGF-I levels have increased to within ±1SD of the mean of the normal range for age and sex; and
- 1.4 The dose of somatropin does not exceed 0.7 mg per day for male patients, or 1 mg per day for female patients; or 2 All of the following:
 - 2.1 The patient has been treated with somatropin for more than 12 months; and
 - 2.2 The patient has not had a deterioration in Quality of Life defined as a 6 point or greater increase from their lowest QoL-AGHDA® score on treatment (other than due to obvious external factors such as external stressors); and
 - 2.3 Serum IGF-I levels have continued to be maintained within ±1SD of the mean of the normal range for age and sex (other than for obvious external factors); and
 - 2.4 The dose of somatropin has not exceeded 0.7 mg per day for male patients or 1 mg per day for female patients.

Thyroid and Antithyroid Preparations

CARBIMAZOLE Tab 5 mg		
IODINE		
Soln BP 50 mg per ml		
LEVOTHYROXINE		
Tab 25 mcg		
Tab 50 mcg		
Tab 100 mcg		
LIOTHYRONINE SODIUM		
↓ Tab 20 mcg		
➡ Restricted (RS1301)		
Initiation		
For a maximum of 14 days' treatment in patients with thyroid cancer who are due to receiv	/e radioiodii	ne therapy.
Inj 20 mcg vial		
POTASSIUM IODATE		
Tab 170 mg		
POTASSIUM PERCHLORATE		
Cap 200 mg		
PROPYLTHIOURACIL – Restricted see terms on the next page	100	וודס
Tab 50 mg	100	PTU

|--|

➡ Restricted (RS1276)

Initiation Both:

- 1 The patient has hyperthyroidism; and
- 2 The patient is intolerant of carbimazole or carbimazole is contraindicated.

Note: Propylthiouracil is not recommended for patients under the age of 18 years unless the patient is pregnant and other treatments are contraindicated.

PROTIRELIN

Inj 100 mcg per ml, 2 ml ampoule

Vasopressin Agents			
ARGIPRESSIN [VASOPRESSIN] Inj 20 u per ml, 1 ml ampoule			
DESMOPRESSIN ACETATE – Some items restricted see terms below			
↓ Tab 100 mcg	25.00	30	Minirin
↓ Tab 200 mcg		30	Minirin
Nasal spray 10 mcg per dose - 1% DV Nov-20 to 2023		6 ml	Desmopressin-PH&T
Inj 4 mcg per ml, 1 ml ampoule			
Inj 15 mcg per ml, 1 ml ampoule			
Nasal drops 100 mcg per ml			
➡ Restricted (RS1339)			
Initiation – Nocturnal enuresis			
Either:			
1 The nasal forms of desmopressin are contraindicated; or			
2 An enuresis alarm is contraindicated.			
Note: Cranial diabetes insipidus and the nasal forms of desmopressin are cor	ntraindicated.		
TERLIPRESSIN			
Inj 0.1 mg per ml, 8.5 ml ampoule	450.00	5	Glypressin
Inj 1 mg per 8.5 ml ampoule		5	Glypressin
			••



	Price (ex man. excl. GS \$	T) Per	Brand or Generic Manufacturer
Antibacterials			
Aminoglycosides			
AMIKACIN - Restricted see terms below Inj 5 mg per ml, 10 ml syringe			
Inj 5 mg per ml, 5 ml syringe		1	Biomed
 Inj 15 mg per ml, 5 ml syringe Inj 250 mg per ml, 2 ml vial – 1% DV Aug-18 to 2021 		5	DBL Amikacin
➡ Restricted (RS1041)			
Clinical microbiologist, infectious disease specialist or respiratory special	ist		
GENTAMICIN SULPHATE Inj 10 mg per ml, 1 ml ampoule	25.00	5	DBL Gentamicin
Inj 40 mg per ml, 2 ml ampoule		5 10	Pfizer
PAROMOMYCIN – Restricted see terms below		10	
Cap 250 mg	126.00	16	Humatin
➡ Restricted (RS1603)			
Clinical microbiologist, infectious disease specialist or gastroenterologist			
STREPTOMYCIN SULPHATE – Restricted see terms below			
Inj 400 mg per ml, 2.5 ml ampoule			
→ Restricted (RS1043)			
Clinical microbiologist, infectious disease specialist or respiratory special	ist		
TOBRAMYCIN Powder			
Powder → Restricted (RS1475)			
Initiation			
For addition to orthopaedic bone cement.			
Inj 40 mg per ml, 2 ml vial − 1% DV Sep-18 to 2021 → Restricted (R\$1044)	15.00	5	Tobramycin Mylan
Clinical microbiologist, infectious disease specialist or respiratory special	ist		
Inj 100 mg per ml, 5 ml vial → Restricted (R\$1044)			
Clinical microbiologist, infectious disease specialist or respiratory special	ist		
Solution for inhalation 60 mg per ml, 5 ml		56 dose	ТОВІ
→ Restricted (RS1435)		00 0000	1051
Initiation			
Patient has cystic fibrosis.			
Carbapenems			
ERTAPENEM – Restricted see terms below ↓ Inj 1 g vial – 1% DV Aug-19 to 2022 → Restricted (RS1045)	70.00	1	Invanz
Clinical microbiologist or infectious disease specialist			
IMIPENEM WITH CILASTATIN – Restricted see terms below	00.00		Iminonom Ollostativ
Inj 500 mg with 500 mg cilastatin vial − 1% DV Jul-19 to 2022	60.00	1	Imipenem+Cilastatin RBX
→ Restricted (RS1046)			
Clinical microbiologist or infectious disease specialist			

t Item restricted (see \Rightarrow above); **t** Item restricted (see \Rightarrow below) *e.g. Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
MEROPENEM – Restricted see terms below	•		
Inj 500 mg vial	4 00	1	Meropenem Ranbaxy
Inj 1 q vial		1	Meropenem Ranbaxy
→ Restricted (RS1047)			Meropeneni Hanbaxy
Clinical microbiologist or infectious disease specialist			
Cephalosporins and Cephamycins - 1st Generatio	n		
CEFALEXIN			
Cap 250 mg - 1% DV Nov-19 to 2022		20	Cephalexin ABM
Cap 500 mg		20	Cephalexin ABM
Grans for oral liq 25 mg per ml - 1% DV Oct-18 to 2021		100 ml	Cefalexin Sandoz
Grans for oral lig 50 mg per ml – 1% DV Oct-18 to 2021		100 ml	Cefalexin Sandoz
CEFAZOLIN			
Inj 500 mg vial – 1% DV Nov-20 to 2023	3 30	5	AFT
Inj 1 g vial – 1% DV Nov-20 to 2023		5 5	AFT
		5	
Cephalosporins and Cephamycins - 2nd Generation	on		
DEFACLOR			
Cap 250 mg - 1% DV Oct-19 to 2022	24.70	100	Ranbaxy-Cefaclor
Grans for oral liq 25 mg per ml - 1% DV Oct-19 to 2022		100 ml	Ranbaxy-Cefaclor
CEFOXITIN			•
Inj 1 g vial	58.00	10	Cefoxitin Actavis
Cefoxitin Actavis Inj 1 g vial to be delisted 1 January 2021)		10	
	15.00		-
Tab 250 mg - 1% DV Feb-20 to 2022		50	Zinnat
Inj 750 mg vial		10	Cefuroxime Actavis
Inj 1.5 g vial	14.36	10	Cefuroxime Actavis
Cephalosporins and Cephamycins - 3rd Generatio	n		
CEFOTAXIME			
Inj 500 mg vial		1	Cefotaxime Sandoz
Inj 1 g vial – 1% DV Nov-20 to 2023		10	DBL Cefotaxime
CEFTAZIDIME - Restricted see terms below		-	
• · · · · · · · · · · · · · · · · · · ·	24.00	5	Coftazidima Mulan
Inj 1 g vial – 1% DV Dec-20 to 2023		5 1	Ceftazidime Mylan Ceftazidime-AFT
Coffazidima Mulan Ini 1 a vial to be delicted 1 December 2020)	2.09	I	Centaziuline-AFT
Ceftazidime Mylan Inj 1 g vial to be delisted 1 December 2020) → Restricted (RS1048)			
Clinical microbiologist, infectious disease specialist or respiratory spe	acialist		
	solalist		
	<u> </u>		0.4.
Inj 500 mg vial – 1% DV Jan-20 to 2022		1	Ceftriaxone-AFT
Inj 1 g vial – 1% DV Jan-20 to 2022		5	Ceftriaxone-AFT
Inj 2 g vial – 1% DV Jan-20 to 2022	1.98	1	Ceftriaxone-AFT
Cephalosporins and Cephamycins - 4th Generatio	n		
CEFEPIME - Restricted see terms on the next page			
Inj 1 g vial – 1% DV Sep-18 to 2021	3 75	1	Cefepime-AFT
 Inj 2 g vial – 1% DV Sep-18 to 2021 		1	Cefepime-AFT
• III 2 9 VIAI - 1/0 DV JEP-10 10 2021		1	Selepine-AF I

Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated. INFECTIONS

		Price excl. GST \$	^T) Per	Brand or Generic Manufacturer
→ Restricted (RS1049) Clinical microbiologist or infectious disease specialist				
Cephalosporins and Cephamycins - 5th Generation	n			
CEFTAROLINE FOSAMIL – Restricted see terms below ↓ Inj 600 mg vial			10 apies.	Zinforo
Macrolides				
AZITHROMYCIN – Restricted see terms below 1 Tab 250 mg – 1% DV Sep-18 to 2021 1 Tab 500 mg – 1% DV Sep-18 to 2021 1 Grans for oral liq 200 mg per 5 ml (40 mg per ml) – 1% DV Dec-			30 2	Apo-Azithromycin Apo-Azithromycin
to 2021 Restricted (RS1598) Initiation – bronchiolitis obliterans syndrome, cystic fibrosis and Any of the following:			15 ml erium infe	Zithromax
 Patient has received a lung transplant, stem cell transplant or bronchiolitis obliterans syndrome*; or Patient has received a lung transplant and requires prophylax Patient has cystic fibrosis and has chronic infection with Pseu negative organisms*; or Patient has an atypical Mycobacterium infection. 	is for bronc	hiolitis obl	iterans syr	ndrome*; or
Note: Indications marked with * are unapproved indications Initiation – non-cystic fibrosis bronchiectasis * Respiratory specialist or paediatrician <i>Re-assessment required after 12 months</i> All of the following:				
 For prophylaxis of exacerbations of non-cystic fibrosis bronchi Patient is aged 18 and under; and Either: 3.1 Patient has had 3 or more exacerbations of their bronchi 			month pe	riod; or
3.2 Patient has had 3 acute admissions to hospital for trea 12 month period.	tment of inf	ective res	piratory ex	acerbations within a
Note: Indications marked with * are unapproved indications. A maxi fibrosis will be subsidised in the community. Continuation – non-cystic fibrosis bronchiectasis* Respiratory specialist or paediatrician <i>Re-assessment required after 12 months</i> All of the following:	mum of 24	months of	azithromy	cin treatment for non-cystic
1 The patient has completed 12 months of azithromycin treatme 2 Following initial 12 months of treatment, the patient has not re				

2 Following initial 12 months of treatment, the patient has not received any further azithromycin treatment for non-cystic

74

			INFECTIONS
	Price (ex man. excl. \$	GST) Per	Brand or Generic Manufacturer
ontinued			
fibrosis bronchiectasis for a further 12 months, unless considere			•
3 The patient will not receive more than a total of 24 months' azith	•		. ,
lote: Indications marked with * are unapproved indications. A maxim	um of 24 mont	hs of azithro	mycin treatment for non-cys
brosis will be subsidised in the community. nitiation – other indications			
Re-assessment required after 5 days			
or any other condition.			
continuation – other indications			
Re-assessment required after 5 days			
For any other condition.			
CLARITHROMYCIN – Restricted see terms below			
Tab 250 mg	3.0	8 14	Apo-Clarithromycin
Tab 500 mg			
Grans for oral lig 50 mg per ml			
Inj 500 mg vial – 1% DV Dec-20 to 2023			Martindale
Restricted (RS1709)		, ,	martindale
nitiation – Tab 250 mg and oral liquid			
ny of the following:			
1 Atypical mycobacterial infection; or			
2 Mycobacterium tuberculosis infection where there is drug resist	ance or intoler	ance to stan	dard pharmaceutical agents:
3 Helicobacter pylori eradication; or			uara priarriaceuticai agento,
 Prophylaxis of infective endocarditis associated with surgical or 	dental proced	ures if amox	icillin is contra-indicated.
nitiation – Tab 500 mg	donia proced		
lelicobacter pylori eradication.			
nitiation – Infusion			
ny of the following:			
, .			
1 Atypical mycobacterial infection: or			
 Atypical mycobacterial infection; or Mycobacterium tuberculosis infection where there is drug resist. 	ance or intoler	ance to stan	dard pharmaceutical agents:
2 Mycobacterium tuberculosis infection where there is drug resist	ance or intoler	ance to stan	dard pharmaceutical agents;
 Mycobacterium tuberculosis infection where there is drug resist. Community-acquired pneumonia. 	ance or intolera	ance to stan	dard pharmaceutical agents;
 2 Mycobacterium tuberculosis infection where there is drug resist. 3 Community-acquired pneumonia. RYTHROMYCIN (AS ETHYLSUCCINATE) 			
2 Mycobacterium tuberculosis infection where there is drug resist 3 Community-acquired pneumonia. RYTHROMYCIN (AS ETHYLSUCCINATE) Tab 400 mg		5 100	E-Mycin
2 Mycobacterium tuberculosis infection where there is drug resist 3 Community-acquired pneumonia. RYTHROMYCIN (AS ETHYLSUCCINATE) Tab 400 mg Grans for oral liq 200 mg per 5 ml		5 100 0 100 i) E-Mycin nl E-Mycin
2 Mycobacterium tuberculosis infection where there is drug resist 3 Community-acquired pneumonia. RYTHROMYCIN (AS ETHYLSUCCINATE) Tab 400 mg Grans for oral liq 200 mg per 5 ml Grans for oral liq 400 mg per 5 ml		5 100 0 100 i) E-Mycin nl E-Mycin
2 Mycobacterium tuberculosis infection where there is drug resist 3 Community-acquired pneumonia. RYTHROMYCIN (AS ETHYLSUCCINATE) Tab 400 mg Grans for oral liq 200 mg per 5 ml Grans for oral liq 400 mg per 5 ml RYTHROMYCIN (AS LACTOBIONATE)		5 100 0 100 r 7 100 r) E-Mycin nl E-Mycin
2 Mycobacterium tuberculosis infection where there is drug resist 3 Community-acquired pneumonia. RYTHROMYCIN (AS ETHYLSUCCINATE) Tab 400 mg Grans for oral liq 200 mg per 5 ml Grans for oral liq 400 mg per 5 ml		5 100 0 100 r 7 100 r) E-Mycin nl E-Mycin
 2 Mycobacterium tuberculosis infection where there is drug resist 3 Community-acquired pneumonia. RYTHROMYCIN (AS ETHYLSUCCINATE) Tab 400 mg Grans for oral liq 200 mg per 5 ml Grans for oral liq 400 mg per 5 ml RYTHROMYCIN (AS LACTOBIONATE) Inj 1 g vial – 1% DV Dec-19 to 2022 		5 100 0 100 r 7 100 r	e E-Mycin nl E-Mycin nl E-Mycin
2 Mycobacterium tuberculosis infection where there is drug resist 3 Community-acquired pneumonia. RYTHROMYCIN (AS ETHYLSUCCINATE) Tab 400 mg Grans for oral liq 200 mg per 5 ml Grans for oral liq 400 mg per 5 ml RYTHROMYCIN (AS LACTOBIONATE) Inj 1 g vial – 1% DV Dec-19 to 2022. RYTHROMYCIN (AS STEARATE) – Restricted: For continuation o		5 100 0 100 r 7 100 r	E-Mycin nl E-Mycin nl E-Mycin
2 Mycobacterium tuberculosis infection where there is drug resist 3 Community-acquired pneumonia. ERYTHROMYCIN (AS ETHYLSUCCINATE) Tab 400 mg Grans for oral liq 200 mg per 5 ml Grans for oral liq 400 mg per 5 ml Grans for oral liq 400 mg per 5 ml ERYTHROMYCIN (AS LACTOBIONATE) Inj 1 g vial – 1% DV Dec-19 to 2022. ERYTHROMYCIN (AS STEARATE) – Restricted: For continuation o ◆ Tab 250 mg		5 100 0 100 r 7 100 r	E-Mycin nl E-Mycin nl E-Mycin
 2 Mycobacterium tuberculosis infection where there is drug resist 3 Community-acquired pneumonia. RYTHROMYCIN (AS ETHYLSUCCINATE) Tab 400 mg		5 100 0 100 r 7 100 r	E-Mycin nl E-Mycin nl E-Mycin
 2 Mycobacterium tuberculosis infection where there is drug resist. 3 Community-acquired pneumonia. (RYTHROMYCIN (AS ETHYLSUCCINATE) Tab 400 mg		5 100 0 100 7 100 0 1	nl E-Mycin nl E-Mycin nl E-Mycin Erythrocin IV
 2 Mycobacterium tuberculosis infection where there is drug resist 3 Community-acquired pneumonia. 4 Community-acquired pneumonia. 4 Community-acquired pneumonia. 5 Community-acquire		5 100 0 100 7 100 0 1 9 10	e E-Mycin nl E-Mycin nl E-Mycin Erythrocin IV Rulide D
 2 Mycobacterium tuberculosis infection where there is drug resist 3 Community-acquired pneumonia. 4 Community-acquired pneumonia. 4 Community-acquired pneumonia. 5 Community-acquire		5 100 0 100 r 7 100 r 0 1 9 10 8 50	Rulide D
2 Mycobacterium tuberculosis infection where there is drug resist 3 Community-acquired pneumonia. ERYTHROMYCIN (AS ETHYLSUCCINATE) Tab 400 mg Grans for oral liq 200 mg per 5 ml Grans for oral liq 400 mg per 5 ml ERYTHROMYCIN (AS LACTOBIONATE) Inj 1 g vial − 1% DV Dec-19 to 2022 ERYTHROMYCIN (AS STEARATE) − Restricted: For continuation o → Tab 250 mg → Tab 500 mg ROXITHROMYCIN − Some items restricted see terms below Tab dispersible 50 mg		5 100 0 100 r 7 100 r 0 1 9 10 8 50	e E-Mycin nl E-Mycin nl E-Mycin Erythrocin IV Rulide D

Initiation

Only for use in patients under 12 years of age.

	Price (ex man. excl. GS \$	T) Per	Brand or Generic Manufacturer
Penicillins			
AMOXICILLIN			
Cap 250 mg - 1% DV Apr-20 to 2022		500	Alphamox
Cap 500 mg - 1% DV Apr-20 to 2022		500	Alphamox
Grans for oral liq 125 mg per 5 ml - 1% DV Nov-20 to 2023	1.40	100 ml	Alphamox 125
Grans for oral liq 250 mg per 5 ml - 1% DV Nov-20 to 2023	1.73	100 ml	Alphamox 250
Inj 250 mg vial	10.67	10	Ibiamox
Inj 500 mg vial	12.41	10	Ibiamox
Inj 1 g vial	17.29	10	Ibiamox
AMOXICILLIN WITH CLAVULANIC ACID			
Tab 500 mg with clavulanic acid 125 mg		20	Augmentin
Grans for oral lig 25 mg with clavulanic acid 6.25 mg per ml		100 ml	Augmentin
Grans for oral lig 50 mg with clavulanic acid 12.5 mg per ml		100 ml	Curam
Inj 500 mg with clavulanic acid 100 mg vial		10	m-Amoxiclav
Inj 1,000 mg with clavulanic acid 200 mg vial		10	m-Amoxiclav
BENZATHINE BENZYLPENICILLIN			
Inj 900 mg (1.2 million units) in 2.3 ml syringe – 1% DV Dec-18	to 2021 344.93	10	Bicillin LA
		10	
BENZYLPENICILLIN SODIUM [PENICILLIN G]	05.00	05	Den Denisillin O Cadium
Inj 600 mg (1 million units) vial – 1% DV Nov-20 to 2023		25	Pan-Penicillin G Sodium
(Pan-Penicillin G Sodium Inj 600 mg (1 million units) vial to be deliste	11.09 1 November 2020	10	Sandoz
	u i novembei 2020)	
FLUCLOXACILLIN			- · · ·
Cap 250 mg - 1% DV Sep-18 to 2021		250	Staphlex
Cap 500 mg - 1% DV Sep-18 to 2021		500	Staphlex
Grans for oral liq 25 mg per ml – 1% DV Oct-18 to 2021		100 ml	AFT
Grans for oral liq 50 mg per ml – 1% DV Oct-18 to 2021		100 ml	AFT
Inj 250 mg vial		10	Flucloxin
Inj 500 mg vial		10	Flucloxin
Inj 1 g vial – 1% DV Nov-20 to 2023	5.70	5	Flucil
PHENOXYMETHYLPENICILLIN [PENICILLIN V]			
Cap 250 mg - 1% DV Sep-18 to 2021		50	Cilicaine VK
Cap 500 mg - 1% DV Sep-18 to 2021	4.26	50	Cilicaine VK
Grans for oral liq 125 mg per 5 ml - 1% DV Jan-20 to 2022	2.99	100 ml	AFT
Grans for oral liq 250 mg per 5 ml - 1% DV Jan-20 to 2022	3.99	100 ml	AFT
PIPERACILLIN WITH TAZOBACTAM – Restricted see terms below	1		
Inj 4 g with tazobactam 0.5 g vial		10	PipTaz Sandoz
, ,			PiperTaz Sandoz
→ Restricted (RS1053)			
Clinical microbiologist, infectious disease specialist or respiratory spe	cialist		
PROCAINE PENICILLIN			
Inj 1.5 g in 3.4 ml syringe		5	Cilicaine
TICARCILLIN WITH CLAVULANIC ACID – Restricted see terms be		č	
 Inj 3 g with clavulanic acid 0.1 mg vial → Restricted (RS1054) 			
Clinical microbiologist, infectious disease specialist or respiratory spe	cialist		

Clinical microbiologist, infectious disease specialist or respiratory specialist

e.g. Brand indicates brand example only. It is not a contracted product.

INFECTIONS

	(ex man. excl. GST \$	Per	Brand or Generic Manufacturer
Quinolones			
CIPROFLOXACIN – Restricted see terms below			
Tab 250 mg – 1% DV Nov-20 to 2023	2.42	28	Cipflox
Tab 500 mg - 1% DV Nov-20 to 2023		28	Cipflox
Tab 750 mg - 1% DV Nov-20 to 2023	5.95	28	Cipflox
Oral liq 50 mg per ml			
Oral liq 100 mg per ml	60.00	10	Cinflor
Inj 2 mg per ml, 100 ml bag – 1% DV Oct-18 to 2021 → Restricted (RS1055)		10	Cipflox
Clinical microbiologist or infectious disease specialist			
AVXIFLOXACIN – Restricted see terms below			
Tab 400 mg – 1% DV Dec-20 to 2023	42 00	5	Avelox
Inj 1.6 mg per ml, 250 ml bottle − 1% DV Apr-20 to 2022		1	Moxifloxacin Kabi
→ Restricted (RS1644)		•	
nitiation – Mycobacterium infection			
nfectious disease specialist, clinical microbiologist or respiratory sp	pecialist		
Any of the following:			
1 Both:			
1.1 Active tuberculosis; and			
1.2 Any of the following:			
1.2.1 Documented resistance to one or more first-li			
1.2.2 Suspected resistance to one or more first-line			
area with known resistance), as part of regime		ond-line a	gents; or
1.2.3 Impaired visual acuity (considered to preclude			
1.2.4 Significant pre-existing liver disease or hepate			
1.2.3 Significant occumented intolerance ano/or sig			
			tions; or trial of first-line medications;
or	de effects following a rea	sonable	trial of first-line medications;
or 2 Mycobacterium avium-intracellulare complex not responding	te effects following a rea	sonable ere such t	trial of first-line medications; herapy is contraindicated; or
or 2 Mycobacterium avium-intracellulare complex not responding 3 Patient is under five years of age and has had close contact	te effects following a rea	sonable ere such t	trial of first-line medications; herapy is contraindicated; or
or 2 Mycobacterium avium-intracellulare complex not responding 3 Patient is under five years of age and has had close contact nitiation – Pneumonia	te effects following a rea	sonable ere such t	trial of first-line medications; herapy is contraindicated; o
or 2 Mycobacterium avium-intracellulare complex not responding 3 Patient is under five years of age and has had close contact nitiation – Pneumonia nfectious disease specialist or clinical microbiologist	te effects following a rea	sonable ere such t	trial of first-line medications; herapy is contraindicated; o
or 2 Mycobacterium avium-intracellulare complex not responding 3 Patient is under five years of age and has had close contact nitiation – Pneumonia nfectious disease specialist or clinical microbiologist Either:	de effects following a rea g to other therapy or whe s with a confirmed multi-	isonable ere such t drug resis	trial of first-line medications; herapy is contraindicated; or
or 2 Mycobacterium avium-intracellulare complex not responding 3 Patient is under five years of age and has had close contact nitiation – Pneumonia nfectious disease specialist or clinical microbiologist Either: 1 Immunocompromised patient with pneumonia that is unresp	de effects following a rea g to other therapy or who with a confirmed multi- nonsive to first-line treatr	ere such t drug resis	rrial of first-line medications; herapy is contraindicated; or tant tuberculosis case.
or 2 Mycobacterium avium-intracellulare complex not responding 3 Patient is under five years of age and has had close contact nitiation – Pneumonia nfectious disease specialist or clinical microbiologist Either: 1 Immunocompromised patient with pneumonia that is unresp 2 Pneumococcal pneumonia or other invasive pneumococcal	de effects following a rea g to other therapy or who with a confirmed multi- nonsive to first-line treatr	ere such t drug resis	rrial of first-line medications; herapy is contraindicated; o tant tuberculosis case.
or 2 Mycobacterium avium-intracellulare complex not responding 3 Patient is under five years of age and has had close contact Initiation – Pneumonia Infectious disease specialist or clinical microbiologist Either: 1 Immunocompromised patient with pneumonia that is unresp 2 Pneumococcal pneumonia or other invasive pneumococcal Initiation – Penetrating eye injury	de effects following a rea g to other therapy or who with a confirmed multi- nonsive to first-line treatr	ere such t drug resis	rrial of first-line medications; herapy is contraindicated; o tant tuberculosis case.
or 2 Mycobacterium avium-intracellulare complex not responding 3 Patient is under five years of age and has had close contact Initiation – Pneumonia Infectious disease specialist or clinical microbiologist Either: 1 Immunocompromised patient with pneumonia that is unresp 2 Pneumococcal pneumonia or other invasive pneumococcal Initiation – Penetrating eye injury Ophthalmologist	de effects following a rea g to other therapy or who with a confirmed multi- nonsive to first-line treatr disease highly resistant	ere such t drug resis	rrial of first-line medications; herapy is contraindicated; o tant tuberculosis case.
or 2 Mycobacterium avium-intracellulare complex not responding 3 Patient is under five years of age and has had close contact nitiation – Pneumonia nfectious disease specialist or clinical microbiologist Either: 1 Immunocompromised patient with pneumonia that is unresp 2 Pneumococcal pneumonia or other invasive pneumococcal nitiation – Penetrating eye injury Dphthalmologist Five days treatment for patients requiring prophylaxis following a pen nitiation – Mycoplasma genitalium	de effects following a rea g to other therapy or who with a confirmed multi- nonsive to first-line treatr disease highly resistant	ere such t drug resis	rrial of first-line medications; herapy is contraindicated; o tant tuberculosis case.
or 2 Mycobacterium avium-intracellulare complex not responding 3 Patient is under five years of age and has had close contact initiation – Pneumonia Infectious disease specialist or clinical microbiologist Either: 1 Immunocompromised patient with pneumonia that is unresp 2 Pneumococcal pneumonia or other invasive pneumococcal Initiation – Penetrating eye injury Ophthalmologist Five days treatment for patients requiring prophylaxis following a pe Initiation – Mycoplasma genitalium All of the following:	de effects following a rea g to other therapy or whe with a confirmed multi- nonsive to first-line treatr disease highly resistant enetrating eye injury.	asonable ere such t drug resis nent; or to other a	rrial of first-line medications; herapy is contraindicated; or tant tuberculosis case. antibiotics.
or 2 Mycobacterium avium-intracellulare complex not responding 3 Patient is under five years of age and has had close contact Initiation – Pneumonia Infectious disease specialist or clinical microbiologist Either: 1 Immunocompromised patient with pneumonia that is unresp 2 Pneumococcal pneumonia or other invasive pneumococcal Initiation – Penetrating eye injury Ophthalmologist Five days treatment for patients requiring prophylaxis following a peinitiation – Mycoplasma genitalium All of the following: 1 Has nucleic acid amplification test (NAAT) confirmed Mycop	de effects following a rea g to other therapy or whe with a confirmed multi- nonsive to first-line treatr disease highly resistant enetrating eye injury.	asonable ere such t drug resis nent; or to other a	rrial of first-line medications; herapy is contraindicated; or tant tuberculosis case. antibiotics.
or 2 Mycobacterium avium-intracellulare complex not responding 3 Patient is under five years of age and has had close contact nitiation – Pneumonia nfectious disease specialist or clinical microbiologist Either: 1 Immunocompromised patient with pneumonia that is unresp 2 Pneumococcal pneumonia or other invasive pneumococcal nitiation – Penetrating eye injury Dphthalmologist Eive days treatment for patients requiring prophylaxis following a penetritation – Mycoplasma genitalium All of the following: 1 Has nucleic acid amplification test (NAAT) confirmed Mycop 2 Either:	de effects following a rea g to other therapy or who with a confirmed multi- ponsive to first-line treatr disease highly resistant enetrating eye injury.	asonable ere such t drug resis nent; or to other a	rrial of first-line medications; herapy is contraindicated; o tant tuberculosis case. antibiotics.
or 2 Mycobacterium avium-intracellulare complex not responding 3 Patient is under five years of age and has had close contact nitiation – Pneumonia nfectious disease specialist or clinical microbiologist Either: 1 Immunocompromised patient with pneumonia that is unresp 2 Pneumococcal pneumonia or other invasive pneumococcal nitiation – Penetrating eye injury Dphthalmologist Five days treatment for patients requiring prophylaxis following a pe nitiation – Mycoplasma genitalium All of the following: 1 Has nucleic acid amplification test (NAAT) confirmed Mycop 2 Either: 2.1 Has tried and failed to clear infection using azithromy	de effects following a rea g to other therapy or who with a confirmed multi- consive to first-line treatr disease highly resistant enetrating eye injury. plasma genitalium and is ycin; or	asonable ere such t drug resis nent; or to other a	rrial of first-line medications; herapy is contraindicated; or tant tuberculosis case. antibiotics.
or 2 Mycobacterium avium-intracellulare complex not responding 3 Patient is under five years of age and has had close contact nitiation – Pneumonia nfectious disease specialist or clinical microbiologist Either: 1 Immunocompromised patient with pneumonia that is unresp 2 Pneumococcal pneumonia or other invasive pneumococcal nitiation – Penetrating eye injury Dphthalmologist Five days treatment for patients requiring prophylaxis following a penitiation – Mycoplasma genitalium All of the following: 1 Has nucleic acid amplification test (NAAT) confirmed Mycop 2 Either: 2.1 Has tried and failed to clear infection using azithromy 2.2 Has laboratory confirmed azithromycin resistance; and	de effects following a rea g to other therapy or who with a confirmed multi- consive to first-line treatr disease highly resistant enetrating eye injury. plasma genitalium and is ycin; or	asonable ere such t drug resis nent; or to other a	rrial of first-line medications; herapy is contraindicated; o tant tuberculosis case. antibiotics.
or 2 Mycobacterium avium-intracellulare complex not responding 3 Patient is under five years of age and has had close contact nitiation – Pneumonia nfectious disease specialist or clinical microbiologist Either: 1 Immunocompromised patient with pneumonia that is unresp 2 Pneumococcal pneumonia or other invasive pneumococcal nitiation – Penetrating eye injury Dphthalmologist Five days treatment for patients requiring prophylaxis following a penitiation – Mycoplasma genitalium All of the following: 1 Has nucleic acid amplification test (NAAT) confirmed Mycop 2 Either: 2.1 Has tried and failed to clear infection using azithromy	de effects following a rea g to other therapy or who with a confirmed multi- consive to first-line treatr disease highly resistant enetrating eye injury. plasma genitalium and is ycin; or	asonable ere such t drug resis nent; or to other a	rrial of first-line medications; herapy is contraindicated; o tant tuberculosis case. antibiotics.
or 2 Mycobacterium avium-intracellulare complex not responding 3 Patient is under five years of age and has had close contact nitiation – Pneumonia nfectious disease specialist or clinical microbiologist Either: 1 Immunocompromised patient with pneumonia that is unresp 2 Pneumococcal pneumonia or other invasive pneumococcal nitiation – Penetrating eye injury Dphthalmologist Five days treatment for patients requiring prophylaxis following a penitiation – Mycoplasma genitalium All of the following: 1 Has nucleic acid amplification test (NAAT) confirmed Mycop 2 Either: 2.1 Has tried and failed to clear infection using azithromy 2.2 Has laboratory confirmed azithromycin resistance; and	de effects following a rea g to other therapy or who with a confirmed multi- consive to first-line treatr disease highly resistant enetrating eye injury. plasma genitalium and is ycin; or	asonable ere such t drug resis nent; or to other a	rrial of first-line medications; herapy is contraindicated; o tant tuberculosis case. antibiotics.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Tetracyclines			
DEMECLOCYCLINE HYDROCHLORIDE Tab 150 mg Cap 150 mg Cap 300 mg DOXYCYCLINE → Tab 50 mg - Restricted: For continuation only Tab 100 mg - Inj 5 mg per ml, 20 ml vial MINOCYCLINE Tab 50 mg → Cap 100 mg - Restricted: For continuation only	64.43	500	Doxine
TETRACYCLINE Tab 250 mg Cap 500 mg (<i>Tetracyclin Wolff Cap 500 mg to be delisted 1 December 2020</i>) TIGECYCLINE – Restricted see terms below ↓ Inj 50 mg vial → Restricted (R\$1059) Clinical microbiologist or infectious disease specialist		28 30	Accord Tetracyclin Wolff
Other Antibacterials			
AZTREONAM – Restricted see terms below ↓ Inj 1 g vial → Restricted (RS1277) Clinical microbiologist or infectious disease specialist CHLORAMPHENICOL – Restricted see terms below ↓ Inj 1 g vial → Restricted (RS1277) Clinical microbiologist or infectious disease specialist CLINDAMYCIN – Restricted see terms below		10	Azactam
	4.61	24	Dalacin C
 ↓ Oral liq 15 mg per ml ↓ Inj 150 mg per ml, 4 ml ampoule - 1% DV Oct-19 to 2022 → Restricted (RS1061) Clinical microbiologist or infectious disease specialist 		10	Dalacin C
COLISTIN SULPHOMETHATE [COLESTIMETHATE] – Restricted se Inj 150 mg per ml, 1 ml vial Restricted (RS1062) Clinical microbiologist, infectious disease specialist or respiratory speci DAPTOMYCIN – Restricted see terms below	65.00	1	Colistin-Link
 Inj 500 mg vial	243.52	1	Cubicin
FOSFOMYCIN – Restricted see terms on the next page Powder for oral solution, 3 g sachet			e.g. UroFos

	Price		Brand or
	(ex man. excl. GST)	Per	Generic
	\$	rei	Manufacturer
→ Restricted (RS1315)			
Clinical microbiologist or infectious disease specialist			
LINCOMYCIN – Restricted see terms below			
Inj 300 mg per ml, 2 ml vial			
→ Restricted (RS1065)			
Clinical microbiologist or infectious disease specialist			
LINEZOLID – Restricted see terms below			_
Tab 600 mg – 1% DV Oct-18 to 2021		10	Zyvox
Oral liq 20 mg per ml – 1% DV Dec-18 to 2021		150 ml	Zyvox
↓ Inj 2 mg per ml, 300 ml bottle – 1% DV Feb-19 to 2021		1	Linezolid Kabi
→ Restricted (RS1066) Clinical microbiologist or infectious disease specialist			
METHENAMINE (HEXAMINE) HIPPURATE	40.01	100	Linnov
Tab 1 g	40.01	100	Hiprex
NITROFURANTOIN			
Tab 50 mg - 1% DV Apr-19 to 2021		100	Nifuran
Tab 100 mg - 1% DV Apr-19 to 2021		100	Nifuran
PIVMECILLINAM – Restricted see terms below			
Tab 200 mg			
→ Restricted (RS1322)			
Clinical microbiologist or infectious disease specialist			
SODIUM FUSIDATE [FUSIDIC ACID] – Restricted see terms below			
Tab 250 mg		12	Fucidin
→ Restricted (RS1064)			
Clinical microbiologist or infectious disease specialist			
SULPHADIAZINE – Restricted see terms below			
Tab 500 mg			
→ Restricted (RS1067)	adicina anacialist		
Clinical microbiologist, infectious disease specialist or maternal-foetal m	ledicine specialist		
TEICOPLANIN – Restricted see terms below	50.50		- · · · · ·
↓ Inj 400 mg vial – 1% DV Jul-20 to 2021		1	Teicoplanin Mylan
→ Restricted (RS1068) Clinical microbiologist or infectious disease specialist			
.			
TRIMETHOPRIM			
Tab 100 mg Tab 300 mg – 1% DV Oct-18 to 2021	16 50	50	ТМР
5		50	
TRIMETHOPRIM WITH SULPHAMETHOXAZOLE [CO-TRIMOXAZOLI	=]		
Tab 80 mg with sulphamethoxazole 400 mg Oral lig 8 mg with sulphamethoxazole 40 mg per ml	2.07	100 ml	Donrim
Inj 16 mg with sulphamethoxazole 80 mg per ml, 5 ml ampoule	2.97	100 111	Deprim
VANCOMYCIN – Restricted see terms below	0.05	4	Mulan
Inj 500 mg vial – 1% DV Oct-20 to 2023	2.35	1	Mylan
Clinical microbiologist or infectious disease specialist			
טווווינמו ווווניטטוטוטעוזי טו וווובנווטעז עוזבמשב ארבומווזי			

INFECTIONS



(ex	Price man. excl \$. GST)	Per	Brand or Generic Manufacturer
Antifungals				
Imidazoles				
KETOCONAZOLE ↓ Tab 200 mg → Restricted (RS1410) Dncologist				
Polyene Antimycotics				
AMPHOTERICIN B Inj (liposomal) 50 mg vial	3,450.0	0	10	AmBisome
→ Restricted (RS1071)				
nitiation Clinical microbiologist, haematologist, infectious disease specialist, oncolog Either:	ist, respir	atory sp	ecialist c	or transplant specialist
1 Proven or probable invasive fungal infection, to be prescribed under 2 Both:	an establ	ished p	rotocol; c	pr
2.1 Possible invasive fungal infection; and2.2 A multidisciplinary team (including an infectious disease phys treatment to be appropriate.	ician or a	clinical	microbic	logist) considers the
 Inj 50 mg vial Restricted (RS1316) Clinical microbiologist, haematologist, infectious disease specialist, oncolog 	ist, respir	atory sp	ecialist c	or transplant specialist
→ Restricted (RS1316) Clinical microbiologist, haematologist, infectious disease specialist, oncolog NYSTATIN			ecialist c	or transplant specialist
→ Restricted (RS1316) Clinical microbiologist, haematologist, infectious disease specialist, oncolog	17.0)9	ecialist c 50 50	or transplant specialist Nilstat Nilstat
→ Restricted (RS1316) Clinical microbiologist, haematologist, infectious disease specialist, oncolog NYSTATIN Tab 500,000 u	17.0)9	50	Nilstat
→ Restricted (RS1316) Clinical microbiologist, haematologist, infectious disease specialist, oncolog NYSTATIN Tab 500,000 u Cap 500,000 u Triazoles FLUCONAZOLE - Restricted see terms below	17.0 15.4)9 7	50 50	Nilstat Nilstat
 → Restricted (RS1316) Clinical microbiologist, haematologist, infectious disease specialist, oncolog NYSTATIN Tab 500,000 u Cap 500,000 u Triazoles FLUCONAZOLE - Restricted see terms below Cap 50 mg - 1% DV Nov-20 to 2023 Son 2023 		99 17 75	50 50 28	Nilstat Nilstat Mylan
→ Restricted (RS1316) Clinical microbiologist, haematologist, infectious disease specialist, oncolog NYSTATIN Tab 500,000 u Cap 500,000 u Triazoles FLUCONAZOLE - Restricted see terms below Cap 50 mg - 1% DV Nov-20 to 2023 Cap 150 mg - 1% DV Nov-20 to 2023		99 17 75 55	50 50 28 1	Nilstat Nilstat Mylan Mylan
 → Restricted (RS1316) Clinical microbiologist, haematologist, infectious disease specialist, oncolog NYSTATIN Tab 500,000 u Cap 500,000 u Triazoles ELUCONAZOLE - Restricted see terms below Cap 50 mg - 1% DV Nov-20 to 2023 Cap 150 mg - 1% DV Nov-20 to 2023 Cap 200 mg - 1% DV Nov-20 to 2023 		99 17 75 15 19	50 50 28 1 28	Nilstat Nilstat Mylan Mylan Mylan
→ Restricted (RS1316) Dinical microbiologist, haematologist, infectious disease specialist, oncolog MYSTATIN Tab 500,000 u Cap 500,000 u Triazoles FLUCONAZOLE - Restricted see terms below Cap 50 mg - 1% DV Nov-20 to 2023 Cap 150 mg - 1% DV Nov-20 to 2023 Cap 200 mg - 1% DV Nov-20 to 200 mg - 1% DV Nov-		99 17 75 55 59 99	50 50 28 1	Nilstat Nilstat Mylan Mylan
 → Restricted (RS1316) Clinical microbiologist, haematologist, infectious disease specialist, oncolog AVSTATIN Tab 500,000 u Cap 500,000 u Cap 500,000 u Cap 500,000 u Cap 50 mg - 1% DV Nov-20 to 2023 Cap 150 mg - 1% DV Nov-20 to 2023 Cap 200 mg - 1% DV Nov-20 to 2023 Cap 200 mg - 1% DV Nov-20 to 2023 Cap 150 mg per 5 ml Inj 2 mg per ml, 50 ml vial - 1% DV Oct-19 to 2022 		99 17 75 55 55 59 84 80	50 50 28 1 28 35 ml	Nilstat Nilstat Mylan Mylan Mylan Diflucan
→ Restricted (RS1316) Clinical microbiologist, haematologist, infectious disease specialist, oncolog NYSTATIN Tab 500,000 u Cap 500,000 u Triazoles ELUCONAZOLE - Restricted see terms below Cap 50 mg - 1% DV Nov-20 to 2023 Cap 150 mg - 1% DV Nov-20 to 2023 Cap 200 mg - 1% DV Nov-20 to 2023 Cap 200 mg - 1% DV Nov-20 to 2023 Cap 100 mg per 5 ml Inj 2 mg per ml, 50 ml vial - 1% DV Oct-19 to 2022 Inj 2 mg per ml, 100 ml vial - 1% DV Oct-19 to 2022		99 17 75 55 55 59 84 80	50 50 28 1 28 35 ml 1	Nilstat Nilstat Mylan Mylan Diflucan Fluconazole-Claris
→ Restricted (RS1316) Clinical microbiologist, haematologist, infectious disease specialist, oncolog NYSTATIN Tab 500,000 u Cap 500,000 u Triazoles FLUCONAZOLE - Restricted see terms below Cap 50 mg - 1% DV Nov-20 to 2023 Cap 150 mg - 1% DV Nov-20 to 2023 Cap 200 mg - 1% DV Nov-20 to 2023 Cap 200 mg - 1% DV Nov-20 to 2023 Cap 200 mg - 1% DV Nov-20 to 2023 Cap 200 mg - 1% DV Nov-20 to 2023 Cap 10 mg per 5 ml Inj 2 mg per ml, 50 ml vial - 1% DV Oct-19 to 2022 Inj 2 mg per ml, 100 ml vial - 1% DV Oct-19 to 2022 Restricted (RS1072) Consultant		99 17 75 55 55 59 84 80	50 50 28 1 28 35 ml 1	Nilstat Nilstat Mylan Mylan Diflucan Fluconazole-Claris
 → Restricted (RS1316) Clinical microbiologist, haematologist, infectious disease specialist, oncolog MYSTATIN Tab 500,000 u Cap 500,000 u Triazoles FLUCONAZOLE - Restricted see terms below Cap 50 mg - 1% DV Nov-20 to 2023 Cap 150 mg - 1% DV Nov-20 to 2023 Cap 150 mg - 1% DV Nov-20 to 2023 Cap 150 mg - 1% DV Nov-20 to 2023 Cap 100 mg per 5 ml Inj 2 mg per ml, 50 ml vial - 1% DV Oct-19 to 2022 Inj 2 mg per ml, 100 ml vial - 1% DV Oct-19 to 2022 Restricted (RS1072) Consultant TRACONAZOLE - Restricted see terms below 		99 77 75 55 59 89 80 55	50 50 28 1 28 35 ml 1 1	Nilstat Nilstat Mylan Mylan Diflucan Fluconazole-Claris Fluconazole-Claris
 → Restricted (RS1316) Clinical microbiologist, haematologist, infectious disease specialist, oncolog MYSTATIN Tab 500,000 u Cap 500,000 u Triazoles FLUCONAZOLE - Restricted see terms below Cap 50 mg - 1% DV Nov-20 to 2023 Cap 150 mg - 1% DV Nov-20 to 2023 Cap 150 mg - 1% DV Nov-20 to 2023 Cap 150 mg - 1% DV Nov-20 to 2023 Cap 100 mg - 1% DV Nov-20 to 2023 Inj 2 mg per ml, 50 ml vial - 1% DV Oct-19 to 2022 Inj 2 mg per ml, 100 ml vial - 1% DV Oct-19 to 2022 Restricted (RS1072) Consultant TRACONAZOLE - Restricted see terms below Cap 100 mg - 1% DV Nov-19 to 2022 		99 77 75 55 59 89 80 55	50 50 28 1 28 35 ml 1	Nilstat Nilstat Mylan Mylan Diflucan Fluconazole-Claris
 → Restricted (RS1316) Clinical microbiologist, haematologist, infectious disease specialist, oncolog NYSTATIN Tab 500,000 u Cap 500,000 u Cap 500,000 u Triazoles FLUCONAZOLE - Restricted see terms below Cap 50 mg - 1% DV Nov-20 to 2023 Cap 150 mg - 1% DV Nov-20 to 2023 Cap 200 mg - 1% DV Nov-20 to 2023 Cap 200 mg - 1% DV Nov-20 to 2023 Cap 200 mg - 1% DV Nov-20 to 2023 Cap 100 mg per 5 ml Inj 2 mg per ml, 50 ml vial - 1% DV Oct-19 to 2022 Inj 2 mg per ml, 100 ml vial - 1% DV Oct-19 to 2022 Consultant TRACONAZOLE - Restricted see terms below Cap 100 mg - 1% DV Nov-19 to 2022 Oral liquid 10 mg per ml 		99 77 75 55 59 89 80 55	50 50 28 1 28 35 ml 1 1	Nilstat Nilstat Mylan Mylan Diflucan Fluconazole-Claris Fluconazole-Claris
 → Restricted (RS1316) Clinical microbiologist, haematologist, infectious disease specialist, oncolog NYSTATIN Tab 500,000 u Cap 500,000 u Triazoles Tubeling the system of the syste		99 77 75 55 99 94 40 95 7	50 50 28 1 28 35 ml 1 1	Nilstat Nilstat Mylan Mylan Diflucan Fluconazole-Claris Fluconazole-Claris
 → Restricted (RS1316) Clinical microbiologist, haematologist, infectious disease specialist, oncolog NYSTATIN Tab 500,000 u Cap 500,000 u Triazoles Tubeling the system of the syste		99 77 75 55 99 94 40 95 7	50 50 28 1 28 35 ml 1 1	Nilstat Nilstat Mylan Mylan Diflucan Fluconazole-Claris Fluconazole-Claris
 → Restricted (RS1316) Clinical microbiologist, haematologist, infectious disease specialist, oncolog NYSTATIN Tab 500,000 u Cap 500,000 u Triazoles Tubeling the system of the syste		99 77 55 59 99 44 80 15 7 27 5ialist	50 50 28 1 28 35 ml 1 1	Nilstat Nilstat Mylan Mylan Diflucan Fluconazole-Claris Fluconazole-Claris

t Item restricted (see → above); t Item restricted (see → below)

e.g. Brand indicates brand example only. It is not a contracted product.

\$ Per Manufacturer	Price Brand or (ex man. excl. GST) Generic
---------------------	---

➡ Restricted (RS1074)

Initiation

Haematologist or infectious disease specialist *Re-assessment required after 6 weeks* Both:

Both:

- 1 Either:
 - 1.1 Patient has acute myeloid leukaemia; or
 - 1.2 Patient is planned to receive a stem cell transplant and is at high risk for aspergillus infection; and
- 2 Patient is to be treated with high dose remission induction therapy or re-induction therapy.

Continuation

Haematologist or infectious disease specialist

Re-assessment required after 6 weeks

Both:

1 Patient has previously received posaconazole prophylaxis during remission induction therapy; and

- 2 Any of the following:
 - 2.1 Patient is to be treated with high dose remission re-induction therapy; or
 - 2.2 Patient is to be treated with high dose consolidation therapy; or
 - 2.3 Patient is receiving a high risk stem cell transplant.

VORICONAZOLE - Restricted see terms below

t	Tab 50 mg - 1% DV Sep-18 to 2021	56	Vttack
t	Tab 200 mg - 1% DV Sep-18 to 2021	56	Vttack
t	Powder for oral suspension 40 mg per ml - 1% DV Dec-18 to 20211,437.00	70 ml	Vfend
	Inj 200 mg vial - 1% DV Oct-19 to 2022	1	Neo Health

→ Restricted (RS1075)

Initiation - Proven or probable aspergillus infection

Clinical microbiologist, haematologist or infectious disease specialist Both:

- 1 Patient is immunocompromised; and
- 2 Patient has proven or probable invasive aspergillus infection.

Initiation - Possible aspergillus infection

Clinical microbiologist, haematologist or infectious disease specialist All of the following:

- 1 Patient is immunocompromised; and
- 2 Patient has possible invasive aspergillus infection; and
- 3 A multidisciplinary team (including an infectious disease physician) considers the treatment to be appropriate.

Initiation - Resistant candidiasis infections and other moulds

Clinical microbiologist, haematologist or infectious disease specialist

All of the following:

- 1 Patient is immunocompromised; and
- 2 Either:
 - 2.1 Patient has fluconazole resistant candidiasis; or
 - 2.2 Patient has mould strain such as Fusarium spp. and Scedosporium spp; and
- 3 A multidisciplinary team (including an infectious disease physician or clinical microbiologist) considers the treatment to be appropriate.

Other Antifungals

CA	SPOFUNGIN - Restricted see terms on the next page			
	Inj 50 mg vial - 1% DV Dec-19 to 2022	220.28	1	Max Health
t	Inj 70 mg vial - 1% DV Dec-19 to 2022	284.63	1	Max Health

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	(ex man	Price . excl. \$	GST)	Per	Brand or Generic Manufacturer
→ Restricted (RS1076)					
Initiation Clinical microbiologist, haematologist, infectious disease specialist, onco Either:	ologist, r	espira	atory sp	oecialist	or transplant specialist
1 Proven or probable invasive fungal infection, to be prescribed un 2 Both:	der an e	establi	shed p	rotocol;	or
2.1 Possible invasive fungal infection; and2.2 A multidisciplinary team (including an infectious disease p treatment to be appropriate.	hysicia	n or a	clinical	microbi	ologist) considers the
FLUCYTOSINE – Restricted see terms below					
Cap 500 mg					
Restricted (RS1279) Clinical microbiologist or infectious disease specialist					
TERBINAFINE					
Tab 250 mg		1.3	3	14	Deolate
Antimycobacterials					
Antileprotics					
CLOFAZIMINE – Restricted see terms below					
Cap 50 mg					
→ Restricted (RS1077)					
Clinical microbiologist, dermatologist or infectious disease specialist					
DAPSONE – Restricted see terms below Tab 25 mg		268 5	0	100	Dapsone
↓ Tab 20 mg				100	Dapsone
→ Restricted (RS1078)					·
Clinical microbiologist, dermatologist or infectious disease specialist					
Antituberculotics					
CYCLOSERINE – Restricted see terms below					
Cap 250 mg → Restricted (RS1079)					
Clinical microbiologist, infectious disease specialist or respiratory specia	list				
ETHAMBUTOL HYDROCHLORIDE – Restricted see terms below					
↓ Tab 100 mg					
Tab 400 mg		49.3	4	56	Myambutol
→ Restricted (RS1080)	1:-+				
Clinical microbiologist, infectious disease specialist or respiratory specia	liist				
ISONIAZID – Restricted see terms below Tab 100 mg – 1% DV Oct-18 to 2021		220	0	100	PSM
→ Restricted (RS1281)		0	0	100	
Clinical microbiologist, dermatologist, paediatrician, public health physic	ian or in	ternal	medic	ine phys	ician
ISONIAZID WITH RIFAMPICIN - Restricted see terms below					
Tab 100 mg with rifampicin 150 mg - 1% DV Sep-18 to 2021		.85.5	4	100	Rifinah
■ Tab 150 mg with rifampicin 300 mg – 1% DV Sep-18 to 2021				100	Rifinah
Restricted (RS1282)					

Clinical microbiologist, dermatologist, paediatrician, public health physician or internal medicine physician

INFECTIONS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
PARA-AMINOSALICYLIC ACID - Restricted see terms below			
Grans for oral liq 4 g		30	Paser
→ Restricted (RS1083)	- 11-4		
Clinical microbiologist, infectious disease specialist or respiratory speci	lalist		
PROTIONAMIDE – Restricted see terms below	005.00	100	Databa
↓ Tab 250 mg		100	Peteha
→ Restricted (RS1084) Clinical microbiologist, infectious disease specialist or respiratory speci	ialiet		
PYRAZINAMIDE – Restricted see terms below	lalist		
I Tab 500 mg			
→ Restricted (RS1085)			
Clinical microbiologist, infectious disease specialist or respiratory speci	ialist		
RIFABUTIN – Restricted see terms below			
Cap 150 mg		30	Mycobutin
→ Restricted (RS1086)			,
Clinical microbiologist, gastroenterologist, infectious disease specialist	or respiratory specia	alist	
RIFAMPICIN – Restricted see terms below			
↓ Cap 150 mg - 1% DV Nov-20 to 2023		100	Rifadin
Cap 300 mg - 1% DV Nov-20 to 2023		100	Rifadin
↓ Oral liq 100 mg per 5 ml – 1% DV Nov-20 to 2023		60 ml	Rifadin
↓ Inj 600 mg vial – 1% DV Nov-20 to 2023	134.98	1	Rifadin
→ Restricted (RS1087) Clinical microbiologist, dermatologist, internal medicine physician, paed	diatrician or public b	alth physi	ioion
	diatrician of public ne	ann priys	ICIAII
Antiparasitics			
Anthelmintics			
ALBENDAZOLE – Restricted see terms below			
Tab 200 mg			
Tab 400 mg			
➡ Restricted (RS1088)			
Clinical microbiologist or infectious disease specialist			
IVERMECTIN – Restricted see terms below			
	17.20	4	Stromectol
➡ Restricted (RS1283)			
Clinical microbiologist, dermatologist or infectious disease specialist			
MEBENDAZOLE			
Tab 100 mg	24.19	24	De-Worm
Oral liq 100 mg per 5 ml			
(De-Worm Tab 100 mg to be delisted 1 March 2021)			
PRAZIQUANTEL			
Tab 600 mg			
Authoritorials			

Antiprotozoals

ARTEMETHER WITH LUMEFANTRINE - Restricted see terms below

↓ Tab 20 mg with lumefantrine 120 mg

→ Restricted (RS1090)

Clinical microbiologist or infectious disease specialist

	Price (ex man. excl. GS	T) Per	Brand or Generic
	\$	Per	Manufacturer
ARTESUNATE – Restricted see terms below			
Inj 60 mg vial → Restricted (RS1091)			
Clinical microbiologist or infectious disease specialist			
ATOVAQUONE WITH PROGUANIL HYDROCHLORIDE – Restricted	l ooo tormo bolow		
Tab 62.5 mg with proguanil hydrochloride 25 mg		12	Malarone Junior
Tab 250 mg with proguanil hydrochloride 100 mg		12	Malarone
Restricted (RS1092)		12	Malarone
Clinical microbiologist or infectious disease specialist			
CHLOROQUINE PHOSPHATE – Restricted see terms below			
Tab 250 mg			
→ Restricted (RS1093)			
linical microbiologist, dermatologist, infectious disease specialist or rh	eumatologist		
IEFLOQUINE – Restricted see terms below	0		
Tab 250 mg			
→ Restricted (RS1094)			
Clinical microbiologist, dermatologist, infectious disease specialist or rh	eumatologist		
IETRONIDAZOLE	-		
Tab 200 mg – 1% DV Dec-20 to 2023		250	Metrogyl
Tab 400 mg - 1% DV Dec-20 to 2023	5.23	21	Metrogyl
Oral liq benzoate 200 mg per 5 ml		100 ml	Flagyl-S
Injection 5 mg per ml, 100 ml bottle		100 ml	AFT
Inj 5 mg per ml, 100 ml bottle		20	Colpocin-T
Inj 5 mg per ml, 100 ml bag - 1% DV Feb-21 to 2023		10	Baxter
Suppos 500 mg		10	Flagyl
AFT Injection 5 mg per ml, 100 ml bottle to be delisted 1 February 202	,		
Colpocin-T Inj 5 mg per ml, 100 ml bottle to be delisted 1 February 20.	21)		
IITAZOXANIDE – Restricted see terms below			
Tab 500 mg	1,680.00	30	Alinia
Oral liq 100 mg per 5 ml			
 Restricted (RS1095) Ilinical microbiologist or infectious disease specialist 			
5			
RNIDAZOLE	20.05	10	Arrow Ornidozala
Tab 500 mg		10	Arrow-Ornidazole
ENTAMIDINE ISETHIONATE – Restricted see terms below	010.00	-	Dentereduct
Inj 300 mg vial – 1% DV Nov-19 to 2022		5	Pentacarinat
 Restricted (RS1096) Ilinical microbiologist or infectious disease specialist 			
5			
RIMAQUINE - Restricted see terms below Tab 15 mg			
Tab 15 mg Tab 7.5 mg			
→ Restricted (RS1097)			
Clinical microbiologist or infectious disease specialist			
PYRIMETHAMINE – Restricted see terms below			
Tab 25 mg			
→ Restricted (RS1098)			
Clinical microbiologist, infectious disease specialist or maternal-foetal r	nedicine specialist		
	sheet speekalor		

84

INFECTIONS

	(ex man	Price . excl. \$	GST)	Per	Brand or Generic Manufacturer
QUININE DIHYDROCHLORIDE – Restricted see terms below Inj 60 mg per ml, 10 ml ampoule Inj 300 mg per ml, 2 ml vial Restricted (RS1099) Clinical microbiologist or infectious disease specialist QUININE SULPHATE Tab 300 mg SODIUM STIBOGLUCONATE – Restricted see terms below Inj 100 mg per ml, 1 ml vial Restricted (RS1100) Clinical microbiologist or infectious disease specialist SPIRAMYCIN – Restricted see terms below I Tab 500 mg Restricted (RS1101) Maternal-foetal medicine specialist		61.9	1	500	Q 300
Antiretrovirals Non-Nucleoside Reverse Transcriptase Inhibitors Restricted (RS1571) Initiation – Confirmed HIV Patient has confirmed HIV Infection.					
Initiation – Prevention of maternal transmission Either: 1 Prevention of maternal foetal transmission; or					

2 Treatment of the newborn for up to eight weeks.

Initiation – Post-exposure prophylaxis following non-occupational exposure to HIV

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Initiation – Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

EFAVIRENZ – **Restricted** see terms above

t	Tab 200 mg	.190.15	90	Stocrin
t	Tab 600 mg	63.38	30	Stocrin
t	Oral liq 30 mg per ml			
	RAVIRINE – Restricted see terms above			
t	Tab 200 mg	.770.00	60	Intelence
NE	VIRAPINE – Restricted see terms above			
	Tab 200 mg - 1% DV Sep-18 to 2021		60	Nevirapine Alphapharm
t	Oral suspension 10 mg per ml	.203.55	240 ml	Viramune Suspension

		Price excl. GS \$	ST) Per	Brand or Generic Manufacturer
Nucleoside Reverse Transcriptase Inhibitors				
→ Restricted (RS1572)				
nitiation – Confirmed HIV Patient has confirmed HIV infection.				
nitiation – Prevention of maternal transmission				
Either:				
1 Prevention of maternal foetal transmission; or				
2 Treatment of the newborn for up to eight weeks.				
nitiation – Post-exposure prophylaxis following non-occupational Both:	exposu	re to HIV		
 Treatment course to be initiated within 72 hours post exposure; a Any of the following: 	Ind			
2.1 Patient has had unprotected receptive anal intercourse w2.2 Patient has shared intravenous injecting equipment with a2.3 Patient has had non-consensual intercourse and the clini prophylaxis is required.	a known	HIV posi	tive person;	or
nitiation – Percutaneous exposure				
Patient has percutaneous exposure to blood known to be HIV positive.				
ABACAVIR SULPHATE – Restricted see terms above				
 Tab 300 mg - 1% DV Jul-19 to 2022 Oral lig 20 mg per ml 			60 240 ml	Ziagen Ziagen
ABACAVIR SULPHATE WITH LAMIVUDINE – Restricted see terms a		-00.01	240 111	Ziagon
Tab 600 mg with lamivudine 300 mg – 1% DV Jul-19 to 2022		.63.00	30	Kivexa
EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPROXIL	- Restr	icted see	e terms abo	ve
t Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245				
(300 mg as a maleate) – 1% DV Jun-19 to 2022	1	06.88	30	Mylan
EMTRICITABINE – Restricted see terms above				
t Cap 200 mg - 1% DV Jul-19 to 2022	3	307.20	30	Emtriva
LAMIVUDINE – Restricted see terms above Tab 150 mg – 1% DV Nov-20 to 2023		01 50	60	Lamivudine
		.04.30	00	Alphapharm
STAVUDINE – Restricted see terms above				
t Cap 40 mg				
Powder for oral soln 1 mg per ml				
ZIDOVI IDINE [AZT] – Bestricted see terms above				

ZIDOVUDINE [AZT] – Restricted see terms above			
t Cap 100 mg	152.25	100	Retrovir
t Oral liq 10 mg per ml		200 ml	Retrovir
1 Inj 10 mg per ml, 20 ml vial		5	Retrovir IV
ZIDOVUDINE [AZT] WITH LAMIVUDINE - Restricted see terms above t Tab 300 mg with lamivudine 150 mg		60	Alphapharm
		00	ripriapriarii

Price Brand or (ex man. excl. GST) Generic \$ Per Manufacturer
--

Protease Inhibitors

 → Restricted (RS1573) Initiation - Confirmed HIV Patient has confirmed HIV infection. Initiation - Prevention of maternal transmission Either: Prevention of maternal foetal transmission; or Treatment of the newborn for up to eight weeks. Initiation - Post-exposure prophylaxis following non-occupational exposure to HIV Both: 		
1 Treatment course to be initiated within 72 hours post exposure; and		
 Any of the following: 2.1 Patient has had unprotected receptive anal intercourse with a known HIV pos 2.2 Patient has shared intravenous injecting equipment with a known HIV positive 2.3 Patient has had non-consensual intercourse and the clinician considers that the prophylaxis is required. 	e person; o	r
Initiation – Percutaneous exposure		
Patient has percutaneous exposure to blood known to be HIV positive.		
ATAZANAVIR SULPHATE - Restricted see terms above		
t Cap 150 mg - 1% DV Jun-19 to 2022	60 60	Teva
t Cap 200 mg - 1% DV Jun-19 to 2022	60	Teva
DARUNAVIR – Restricted see terms above	60	Prezista
Tab 400 mg 335.00 Tab 600 mg 476.00	60 60	Prezista
INDINAVIR – Restricted see terms above t Cap 200 mg t Cap 400 mg	00	11021314
LOPINAVIR WITH RITONAVIR – Restricted see terms above		
t Tab 100 mg with ritonavir 25 mg 183.75	60	Kaletra
t Tab 200 mg with ritonavir 50 mg	120	Kaletra
Cral liq 80 mg with ritonavir 20 mg per ml735.00	300 ml	Kaletra
RITONAVIR - Restricted see terms above t Tab 100 mg - 1% DV Jul-19 to 2022	30	Norvir
Strand Transfer Inhibitors		

➡ Restricted (RS1574)

Initiation – Confirmed HIV

Patient has confirmed HIV infection.

Initiation – Prevention of maternal transmission Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

Initiation – Post-exposure prophylaxis following non-occupational exposure to HIV Both:

	F (ex man.	Price excl. \$	GST)	Per	Brand or Generic Manufacturer
ontinued					
 Treatment course to be initiated within 72 hours post exposure; a Any of the following: 	and				
2.1 Patient has had unprotected receptive anal intercourse w2.2 Patient has shared intravenous injecting equipment with a2.3 Patient has had non-consensual intercourse and the clini prophylaxis is required.	a known	HIV p	ositive	person;	or
nitiation – Percutaneous exposure Patient has percutaneous exposure to blood known to be HIV positive.					
OCLUTEGRAVIR – Restricted see terms on the previous page Tab 50 mg	1,(090.00)	30	Tivicay
RALTEGRAVIR POTASSIUM - Restricted see terms on the previous	page				
Tab 400 mg				60	Isentress
Tab 600 mg	1,0)90.00)	60	Isentress HD
Antivirals					
Hepatitis B					
DEFOVIR DIPIVOXIL - Restricted see terms below					
Tab 10 mg Hepsera Tab 10 mg to be delisted 1 March 2021) → Restricted (RS1104) nitiation		570.00	J	30	Hepsera
astroenterologist or infectious disease specialist Il of the following:					
 Patient has confirmed Hepatitis B infection (HBsAg+); and Documented resistance to lamivudine defined as: Patient has raised serum ALT (> 1 × ULN); and 					
 3 Patient has HBV DNA greater than 100,000 copies per mL, or vi 4 Detection of M204I or M204V mutation; and 5 Either: 	rai load (greate	r than	or equal	to 10-fold over hadir; and
5.1 Both:					
5.1.1 Patient is cirrhotic; and 5.1.2 Adefovir dipivoxil to be used in combination with la	mivudin	0: 0r			
5.2 Both:		e, u			
5.2.1 Patient is not cirrhotic; and					
5.2.2 Adefovir dipivoxil to be used as monotherapy.					
NTECAVIR Tab 0.5 mg – 1% DV Nov-18 to 2021		.52.00)	30	Entecavir Sandoz
AMIVUDINE					
Tab 100 mg – 1% DV Nov-20 to 2023				28	Zetlam
Oral liq 5 mg per ml	2	270.00	ו	240 ml	Zeffix
ENOFOVIR DISOPROXIL Tab 245 mg (300.6 mg as a succinate) – 1% DV Sep-18 to 2021		.38.10)	30	Tenofovir Disoproxil

e.g. Brand indicates brand example only. It is not a contracted product.

	(ex man.	excl. GST) \$	Per	Generic Manufacturer
Hepatitis C				
GLECAPREVIR WITH PIBRENTASVIR Note: the supply of treatment is via PHARMAC's approved direct PHARMAC's website https://www.pharmac.govt.nz/hepatitis-c-trea	atments/.	,		
Tab 100 mg with pibrentasvir 40 mg	24,	750.00	84	Maviret
LEDIPASVIR WITH SOFOSBUVIR − Restricted see terms below Tab 90 mg with sofosbuvir 400 mg → Restricted (RS1528) Initiation	24,:	363.46	28	Harvoni
Note: Only for use in patients with approval by the Hepatitis C Treatm HepCTP at its regular meetings and approved subject to eligibility accord Pharmaceutical Schedule).				
Herpesviridae				
ACICLOVIR Tab dispersible 200 mg - 1% DV Oct-19 to 2022 Tab dispersible 400 mg - 1% DV Oct-19 to 2022 Tab dispersible 800 mg - 1% DV Oct-19 to 2022 Inj 250 mg vial - 1% DV Sep-18 to 2021		5.38 5.98	25 56 35 5	Lovir Lovir Lovir Aciclovir-Baxter Aciclovir-Claris
 (Aciclovir-Claris Inj 250 mg vial to be delisted 1 March 2021) CIDOFOVIR - Restricted see terms below Inj 75 mg per ml, 5 ml vial Restricted (RS1108) Clinical microbiologist, infectious disease specialist, otolaryngologist o FOSCARNET SODIUM - Restricted see terms below Inj 24 mg per ml, 250 ml bottle Restricted (RS1109) Clinical microbiologist or infectious disease specialist GANCICLOVIR - Restricted see terms below 	r oral surg	eon		
Inj 500 mg vial		380.00	5	Cymevene
Tab 500 mg - 1% DV Sep-18 to 2021		5.75	30 30	Vaclovir Vaclovir
VALGANCICLOVIR – Restricted see terms below			00	
↓ Tab 450 mg – 1% DV May-19 to 2021 → Restricted (RS1112) Initiation – Transplant cytomegalovirus prophylaxis Limited to 3 months treatment			60	Valganciclovir Mylan
Patient has undergone a solid organ transplant and requires valgancic Initiation – Lung transplant cytomegalovirus prophylaxis <i>Limited to 6 months</i> treatment Both:	lovir for C	MV prophyla	xis.	

Price

INFECTIONS

Brand or

	Price		Brand or
	(ex man. excl. GST) \$	Per	Generic Manufacturer
	Ŷ	1.01	Manulacturer
continued 1 Patient has undergone a lung transplant; and			
2 Either:			
2.1 The donor was cytomegalovirus positive and the p	atient is cytomegalovirus ne	egative: o	r
2.2 The recipient is cytomegalovirus positive.	allon lo cytomogalovil do hi	iganito, o	
Initiation – Cytomegalovirus in immunocompromised patien	ts		
Both:			
1 Patient is immunocompromised; and			
2 Any of the following:			
2.1 Patient has cytomegalovirus syndrome or tissue ir			
2.2 Patient has rapidly rising plasma CMV DNA in abs	ence of disease; or		
2.3 Patient has cytomegalovirus retinitis.			
HIV Prophylaxis and Treatment			
EMTRICITABINE WITH TENOFOVIR DISOPROXIL - Restricte	d see terms below		
✓ Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a			
- 1% DV Jun-19 to 2022	'	30	Teva
→ Restricted (RS1737)			
Initiation – Confirmed HIV			
Patient has confirmed HIV infection. Initiation – Prevention of maternal transmission			
Fither:			
1 Prevention of maternal foetal transmission; or			
2 Treatment of the newborn for up to eight weeks.			
Initiation – Post-exposure prophylaxis following non-occupa	tional exposure to HIV		
Both:			
1 Treatment course to be initiated within 72 hours post exp	osure; and		
2 Any of the following:			
2.1 Patient has had unprotected receptive anal interco2.2 Patient has shared intravenous injecting equipment			
2.3 Patient has had non-consensual intercourse and t			
prophylaxis is required.			
Initiation – Percutaneous exposure			
Patient has percutaneous exposure to blood known to be HIV po	sitive.		
Initiation – Pre-exposure prophylaxis			
Re-assessment required after 3 months			
All of the following:			
 Applicant has an up to date knowledge of the safety issue to local health pathways or https://ashm.org.au/HIV/PrEP 			exposure propriyiaxis (refer
2 Patient has undergone testing for HIV, syphilis and Hep E	• /·		eks: and
3 Patient has had renal function testing (creatinine, phosph			
is not contraindicated for treatment; and			
4 Patient has received advice regarding the reduction of ris	k of HIV and sexually transr	nitted infe	ctions and how to reduce
those risks; and			
5 Patient has tested HIV negative and is not at risk of HIV s	eroconversion; and		
6 Either:			

6.1 All of the following:

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 6.1.1 Patient is male or transgender; and
- 6.1.2 Patient has sex with men; and
- 6.1.3 Patient is likely to have multiple episodes of condomless anal intercourse in the next 3 months; and
- 6.1.4 Any of the following:
 - 6.1.4.1 Patient has had at least one episode of condomless receptive anal intercourse with one or more casual male partners in the last 3 months; or
 - 6.1.4.2 A diagnosis of rectal chlamydia, rectal gonorrhoea, or infectious syphilis within the last 3 months; or
 - 6.1.4.3 Patient has used methamphetamine in the last three months; or
- 6.2 All of the following:
 - 6.2.1 Patient has a regular partner who has HIV infection; and
 - 6.2.2 Partner is either not on treatment or has a detectable viral load; and
 - 6.2.3 Condoms have not been consistently used.

Continuation – Pre-exposure prophylaxis

Re-assessment required after 3 months

All of the following:

- 1 Applicant has an up to date knowledge of the safety issues and is competent to prescribe pre-exposure prophylaxis (refer to local health pathways or https://ashm.org.au/HIV/PrEP/ for training materials); and
- 2 Patient has undergone testing for HIV, syphilis and Hep B if not immune in the previous two weeks; and
- 3 Patient has had renal function testing (creatinine, phosphate and urine protein/creatinine ratio) within the last 12 months and is not contraindicated for treatment; and
- 4 Patient has received advice regarding the reduction of risk of HIV and sexually transmitted infections and how to reduce those risks; and
- 5 Patient has tested HIV negative and is not at risk of HIV seroconversion; and
- 6 Either:
 - 6.1 All of the following:
 - 6.1.1 Patient is male or transgender; and
 - 6.1.2 Patient has sex with men; and
 - 6.1.3 Patient is likely to have multiple episodes of condomless anal intercourse in the next 3 months; and
 - 6.1.4 Any of the following:
 - 6.1.4.1 Patient has had at least one episode of condomless receptive anal intercourse with one or more casual male partners in the last 3 months; or
 - 6.1.4.2 A diagnosis of rectal chlamydia, rectal gonorrhoea, or infectious syphilis within the last 3 months; or
 - 6.1.4.3 Patient has used methamphetamine in the last three months; or
 - 6.2 All of the following:
 - 6.2.1 Patient has a regular partner who has HIV infection; and
 - 6.2.2 Partner is either not on treatment or has a detectable viral load; and
 - 6.2.3 Condoms have not been consistently used.

Influenza

OSELTAMIVIR - Restricted see terms below

Note: The restriction on the use of oseltamivir to hospitalised patients means that supply into the community for a new course is not permitted. Supply of a part original pack on discharge where initiated as a hospital inpatient is permitted.

- Tab 75 mg
- Powder for oral suspension 6 mg per ml

→ Restricted (RS1307)

Initiation

Either:

- 1 Only for hospitalised patient with known or suspected influenza; or
- 2 For prophylaxis of influenza in hospitalised patients as part of a DHB hospital approved infections control plan.

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

Price			Brand or
(ex man. excl	. GST)		Generic
\$		Per	Manufacturer

ZANAMIVIR

Note: The restriction on the use of zanamivir to hospitalised patients means that supply into the community for a new course is not permitted. Supply of a part original pack on discharge where initiated as a hospital inpatient is permitted.

→ Restricted (RS1369)

Initiation

Either:

- 1 Only for hospitalised patient with known or suspected influenza; or
- 2 For prophylaxis of influenza in hospitalised patients as part of a DHB hospital approved infections control plan.

Immune Modulators

INTERFERON ALFA-2A

- Inj 3 m iu prefilled syringe
- Inj 6 m iu prefilled syringe
- Inj 9 m iu prefilled syringe

(Any Inj 3 m iu prefilled syringe to be delisted 1 December 2020) (Any Inj 6 m iu prefilled syringe to be delisted 1 December 2020) (Any Inj 9 m iu prefilled syringe to be delisted 1 December 2020)

INTERFERON ALFA-2B

- Inj 18 m iu, 1.2 ml multidose pen
- Inj 30 m iu, 1.2 ml multidose pen
- Inj 60 m iu, 1.2 ml multidose pen

INTERFERON GAMMA - Restricted see terms below

- Inj 100 mcg in 0.5 ml vial
- ➡ Restricted (RS1113)

Initiation

Patient has chronic granulomatous disease and requires interferon gamma.

PEGYLATED INTERFERON ALFA-2A - Restricted see terms below

t	Inj 180 mcg prefilled syringe500.00	4	Pegasys
---	-------------------------------------	---	---------

➡ Restricted (RS1762)

Initiation – Chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver transplant

Limited to 48 weeks treatment

Any of the following:

- 1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or
- 2 Patient has chronic hepatitis C and is co-infected with HIV; or
- 3 Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant.

Notes: Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.

Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml.

Continuation - Chronic hepatitis C - genotype 1 infection

Gastroenterologist, infectious disease specialist or general physician

Re-assessment required after 48 weeks

All of the following:

92

1 Patient has chronic hepatitis C, genotype 1; and

	(ex man. excl. \$	Per	Generic Manufacturer
continued			
2 Patient has had previous treatment with pegylated interferon3 Either:	and ribavirin; and		
3.1 Patient has responder relapsed; or3.2 Patient was a partial responder; and			
4 Patient is to be treated in combination with boceprevir.			
Initiation – Chronic Hepatitis C - genotype 1 infection treatment Gastroenterologist, infectious disease specialist or general physicial <i>Limited to 48 weeks</i> treatment All of the following:		rs prior	
 Patient has chronic hepatitis C, genotype 1; and Patient has had previous treatment with pegylated interferon Any of the following: 	and ribavirin; and		
3.1 Patient has responder relapsed; or3.2 Patient was a partial responder; or3.3 Patient received interferon treatment prior to 2004; ar	nd		
4 Patient is to be treated in combination with boceprevir. Initiation – Chronic hepatitis C - genotype 2 or 3 infection without Limited to 6 months treatment	out co-infection w	rith HIV	
Patient has chronic hepatitis C, genotype 2 or 3 infection. Initiation – Hepatitis B	_		
Gastroenterologist, infectious disease specialist or general physician <i>Limited to 48 weeks</i> treatment All of the following:	n		
 Patient has confirmed Hepatitis B infection (HBsAg positive f Patient is Hepatitis B treatment-naive; and ALT > 2 times Upper Limit of Normal; and HBV DNA < 10 log10 IU/ml; and Either: 	for more than 6 mo	onths); and	
5.1 HBeAg positive; or5.2 Serum HBV DNA greater than or equal to 2,000 units Stage F2 or moderate fibrosis); and	/ml and significant	fibrosis (grea	ater than or equal to Metavir
 6 Compensated liver disease; and 7 No continuing alcohol abuse or intravenous drug use; and 8 Not co-infected with HCV, HIV or HDV; and 9 Neither ALT nor AST > 10 times upper limit of normal; and 10 No history of hypersensitivity or contraindications to pegylate 	ed interferon.		
Notes: Approved dose is 180 mcg once weekly. The recommended dose of Pegylated Interferon alfa-2a is 180 mcg In patients with renal insufficiency (calculated creatinine clearance is be reduced to 135 mcg once weekly.	ess than 50ml/min		
In patients with neutropaenia and thrombocytopaenia, dose should Pegylated Interferon alfa-2a is not approved for use in children. Initiation – myeloproliferative disorder or cutaneous T cell lymp		ordance with t	he datasheet guidelines.
Re-assessment required after 12 months Any of the following: 1 Patient has a cutaneous T cell lymphoma*; or			
2 All of the following:			
			continued.

INFECTIONS

Brand or

Generic

Price

(ex man. excl. GST)

Price			Brand or
(ex man. exc	. GST)	Generic
\$		Per	Manufacturer

continued...

- 2.1 Patient has a myeloproliferative disorder*; and
- 2.2 Patient is intolerant of hydroxyurea; and
- 2.3 Treatment with anagrelide and busulfan is not clinically appropriate; or
- 3 Both:
 - 3.1 Patient has a myeloproliferative disorder; and
 - 3.2 Patient is pregnant, planning pregnancy or lactating.

Continuation – myeloproliferative disorder or cutaneous T cell lymphoma

Re-assessment required after 12 months

All of the following:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and patient is benefitting from treatment; and
- 3 Either:

94

- 3.1 Patient has a cutaneous T cell lymphoma*; or
- 3.2 Both:
 - 3.2.1 Patient has a myeloproliferative disorder*; and
 - 3.2.2 Either:
 - 3.2.2.1 Remains intolerant of hydroxyurea and treatment with anagrelide and busulfan remains clinically inappropriate; or
 - 3.2.2.2 Patient is pregnant, planning pregnancy or lactating.
- Note: Indications marked with * are unapproved indications

	Price		Brand or
	(ex man. excl. GST)		Generic
	\$	Per	Manufacturer
Anticholinesterases			
EDROPHONIUM CHLORIDE – Restricted see terms below			
Inj 10 mg per ml, 15 ml vial			
Inj 10 mg per ml, 1 ml ampoule			
→ Restricted (RS1015)			
Initiation			
For the diagnosis of myasthenia gravis.			
NEOSTIGMINE METILSULFATE			
Inj 2.5 mg per ml, 1 ml ampoule		50	AstraZeneca
NEOSTIGMINE METILSULFATE WITH GLYCOPYRRONIUM BROMI	DF		
Inj 2.5 mg with glycopyrronium bromide 0.5 mg per ml, 1 ml ampo		10	Max Health
PYRIDOSTIGMINE BROMIDE	20100		
Tab 60 mg – 1% DV Nov-19 to 2022	45 79	100	Mestinon
1 ab 66 mg = 1 % DV NOV-19 to 2022		100	Mestinon
Antirheumatoid Agents			
Junio			
HYDROXYCHLOROQUINE – Restricted see terms below			
↓ Tab 200 mg - 1% DV Sep-18 to 2021	7.98	100	Plaquenil
→ Restricted (RS1776)			
Initiation			
Any of the following:			
1 Rheumatoid arthritis; or			
2 Systemic or discoid lupus erythematosus; or			
3 Malaria treatment or suppression; or			
4 Relevant dermatological conditions (cutaneous forms of lupus a ulcoration); or	and lichen planus, cui	aneous	ascullutes and mucosal
ulceration); or 5 Sarcoidosis (pulmonary and non-pulmonary).			
LEFLUNOMIDE			
Tab 10 mg - 1% DV Dec-20 to 2023		30	Apo-Leflunomide
Tak 00 mm - 40/ BV Baa 00 ta 0000	6.00	00	Arava
Tab 20 mg – 1% DV Dec-20 to 2023		30	Apo-Leflunomide
(Apo-Leflunomide Tab 10 mg to be delisted 1 December 2020)	6.00		Arava
(Apo-Leflunomide Tab 20 mg to be delisted 1 December 2020)			
PENICILLAMINE			
Tab 125 mg	67.23	100	D-Penamine
Tab 250 mg		100	D-Penamine
5		100	Direnamine
SODIUM AUROTHIOMALATE			
Inj 10 mg in 0.5 ml ampoule Inj 20 mg in 0.5 ml ampoule			
Inj 50 mg in 0.5 ml ampoule			
Drugs Affecting Bone Metabolism			
Bisphosphonates			
ALENDRONATE SODIUM			
Tab 70 mg - 1% DV Apr-19 to 2022		4	Fosamax

	Price		Brand or
	(ex man. excl. GST		Generic
	\$	Per	Manufacturer
ALENDRONATE SODIUM WITH COLECALCIFEROL			
Tab 70 mg with colecalciferol 5,600 iu - 1% DV Apr-19 to 2022	1.51	4	Fosamax Plus
PAMIDRONATE DISODIUM			
Inj 3 mg per ml, 10 ml vial	5.98	1	Pamisol
Inj 6 mg per ml, 10 ml vial		1	Pamisol
Inj 9 mg per ml, 10 ml vial	17.05	1	Pamisol
RISEDRONATE SODIUM			
Tab 35 mg - 1% DV Oct-19 to 2022	3.10	4	Risedronate Sandoz
ZOLEDRONIC ACID			
Inj 5 mg per 100 ml, vial – 1% DV Oct-19 to 2022	60.00	100 ml	Aclasta
➡ Restricted (RS1663)			
Initiation – Inherited bone fragility disorders			
Any specialist			
Patient has been diagnosed with an inherited bone fragility disorder (e.g.	. osteogenesis in	perfecta).	
Initiation – Osteoporosis			
Any specialist			
Therapy limited to 3 doses			
inerapy infined to 3 doses			

Both:

- 1 Any of the following:
 - 1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note); or
 - 1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
 - 1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
 - 1.4 Documented T-Score greater than or equal to -3.0 (see Note); or
 - 1.5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
 - 1.6 Patient has had a Special Authority approval for alendronate (Underlying cause Osteoporosis) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and
- 2 The patient will not be prescribed more than 5 mg of zoledronic acid in a 12-month period.

Initiation - glucocorticosteroid therapy

Any specialist

Re-assessment required after 12 months All of the following:

- 1 The patient is receiving systemic glucocorticosteroid therapy (greater than or equal to 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
- 2 Any of the following:
 - 2.1 The patient has documented BMD greater than or equal to 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -1.5) (see Note); or
 - 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
 - 2.3 The patient has had a Special Authority approval for alendronate (Underlying cause glucocorticosteroid therapy) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and
- 3 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

|--|

continued...

Continuation - glucocorticosteroid therapy

Any specialist

Re-assessment required after 12 months Both:

- 1 The patient is continuing systemic glucocorticosteriod therapy (greater than or equal to 5 mg per day prednisone equivalents); and
- 2 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Initiation – Paget's disease

Any specialist

Re-assessment required after 12 months

All of the following:

- 1 Paget's disease; and
- 2 Any of the following:
 - 2.1 Bone or articular pain; or
 - 2.2 Bone deformity; or
 - 2.3 Bone, articular or neurological complications; or
 - 2.4 Asymptomatic disease, but risk of complications; or
 - 2.5 Preparation for orthopaedic surgery; and
- 3 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Continuation - Paget's disease

Any specialist

Re-assessment required after 12 months Both:

- 1 Any of the following:
 - 1.1 The patient has relapsed (based on increases in serum alkaline phosphatase); or
 - 1.2 The patient's serum alkaline phosphatase has not normalised following previous treatment with zoledronic acid; or
 - 1.3 Symptomatic disease (prescriber determined); and
- 2 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Notes:

- 1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- 2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.
- 3 Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- 4 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Other Drugs Affecting Bone Metabolism

DE	NOSUMAB – Restricted see terms on the next page			
t	Inj 60 mg prefilled syringe	326.00	1	Prolia

	P	rice			Brand or
(e	ex man.	excl.	GST)		Generic
		\$		Per	Manufacturer

→ Restricted (RS1665)

Initiation

All of the following:

- 1 The patient has severe, established osteoporosis; and
- 2 Either:
 - 2.1 The patient is female and postmenopausal; or
 - 2.2 The patient is male or non-binary; and
- 3 Any of the following:
 - 3.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note); or
 - 3.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons; or
 - 3.3 History of two significant osteoporotic fractures demonstrated radiologically; or
 - 3.4 Documented T-Score less than or equal to -3.0 (see Note); or
 - 3.5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
 - 3.6 Patient has had a Special Authority approval for alendronate (Underlying cause Osteoporosis) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and
- 4 Zoledronic acid is contraindicated because the patient's creatinine clearance is less than 35 mL/min; and
- 5 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes); and
- 6 The patient must not receive concomitant treatment with any other funded antiresorptive agent for this condition or teriparatide.

Notes:

- 1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- 2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for treatment with denosumab.
- 3 Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- 4 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.
- 5 Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: risedronate sodium tab 35 mg once weekly; alendronate sodium tab 70 mg or tab 70 mg with cholecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy.

RALOXIFENE - Restricted see terms below

t	Tab 60 mg	53.76	28	Evista
	Restricted (RS1666)			
Initi	iation			
Any	r of the following:			

Price		Brand or	
(ex man. excl. GST)	-	Generic	
 \$	Per	Manufacturer	

continued...

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Notes); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score greater than or equal to -3.0 (see Notes); or
- 5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Notes); or
- 6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause Osteoporosis) or has had a Special Authority approval for alendronate (Underlying cause Osteoporosis) prior to 1 February 2019.

Notes:

- 1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- 2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for raloxifene funding.
- 3 Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- 4 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

TERIPARATIDE - Restricted see terms below

t	Inj 250 mcg per ml, 2.4 ml cartridge	 1	Forteo
➡	Restricted (RS1143)		
Init	tiation		

Initiation

Limited to 18 months treatment

All of the following:

- 1 The patient has severe, established osteoporosis; and
- 2 The patient has a documented T-score less than or equal to -3.0 (see Notes); and
- 3 The patient has had two or more fractures due to minimal trauma; and
- 4 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes).

Notes:

- 1 The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable
- 2 Antiresorptive agents and their adequate doses for the purposes of this restriction are defined as: alendronate sodium tab 70 mg or tab 70 mg with colecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy.
- 3 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer	
Enzymes				

HYALURONIDASE

Inj 1,500 iu ampoule

Hyperuricaemia and Antigout			
ALLOPURINOL			
Tab 100 mg – 1% DV Nov-20 to 2023	11.47	500	DP-Allopurinol
Tab 300 mg - 1% DV Nov-20 to 2023	28.57	500	DP-Allopurinol
BENZBROMARONE - Restricted see terms below			
↓ Tab 50 mg			
↓ Tab 100 mg	45.00	100	Benzbromaron AL 100
→ Restricted (RS1489)			

Initiation

Any specialist

All of the following:

- 1 Patient has been diagnosed with gout; and
- 2 Any of the following:
 - 2.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
 - 2.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
 - 2.3 Both:
 - 2.3.1 The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note); and
 - 2.3.2 The patient has a rate of creatinine clearance greater than or equal to 20 ml/min; or
 - 2.4 All of the following:
 - 2.4.1 The patient is taking azathioprine and requires urate-lowering therapy; and
 - 2.4.2 Allopurinol is contraindicated; and
 - 2.4.3 Appropriate doses of probenecid are ineffective or probenecid cannot be used due to reduced renal function; and
- 3 The patient is receiving monthly liver function tests.

Notes: Benzbromarone has been associated with potentially fatal hepatotoxicity. In chronic renal insufficiency, particularly when the glomerular filtration rate is 30 ml/minute or less, probenecid may not be effective. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose. The New Zealand Rheumatology Association has developed information for prescribers which can be accessed from its website at www.rheumatology.org.nz/home/resources-2/

COLCHICINE Tab 500 mcg - 1% DV Jan-19 to 2021	100	Colgout
FEBUXOSTAT – Restricted see terms below		
I Tab 80 mg	28	Adenuric
I Tab 120 mg	28	Adenuric
→ Restricted (RS1760)		
Initiation		
Any specialist		
Both:		

(ex man. excl. GST) Generic \$ Per Manufacturer		Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer	
--	--	------------------------------------	-----	-------------------------------------	--

continued...

- 1 Patient has been diagnosed with gout; and
- 2 Any of the following:
 - 2.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
 - 2.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
 - 2.3 The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note); or
 - 2.4 The patient has previously had an initial Special Authority approval for benzbromarone for treatment of gout...

Note: In chronic renal insufficiency, particularly when the glomerular filtration rate is 30 ml/minute or less, probenecid may not be effective. The efficacy and safety of febuxostat have not been fully evaluated in patients with severe renal impairment (creatinine clearance less than 30 ml/minute). No dosage adjustment of febuxostat is necessary in patients with mild or moderate renal impairment. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

PROBENECID

Tab 500 mg

RASBURICASE - Restricted see terms below

Inj 1.5 mg vial

➡ Restricted (RS1016)

Haematologist

Muscle Relaxants and Related Agents

ATRACURIUM BESYLATE		
Inj 10 mg per ml, 2.5 ml ampoule - 1% DV Jun-18 to 2021) 5	Tracrium
Inj 10 mg per ml, 5 ml ampoule - 1% DV Jun-18 to 2021) 5	Tracrium
BACLOFEN		
Tab 10 mg - 1% DV Oct-18 to 2021) 100	Pacifen
Oral lig 1 mg per ml		
Inj 0.05 mg per ml, 1 ml ampoule	5 1	Lioresal Intrathecal
Inj 2 mg per ml, 5 ml ampoule - 1% DV Apr-19 to 2021		Medsurge
CLOSTRIDIUM BOTULINUM TYPE A TOXIN		-
Inj 100 u vial) 1	Botox
Inj 300 u vial		Dysport
Inj 500 u vial		Dysport
DANTROLENE		
Cap 25 mg) 100	Dantrium
Cap 50 mg77.00		Dantrium
Inj 20 mg vial		Dantrium IV
MIVACURIUM CHLORIDE		
Inj 2 mg per ml, 5 ml ampoule	2 5	Mivacron
Inj 2 mg per ml, 10 ml ampoule67.17		Mivacron
ORPHENADRINE CITRATE		
Tab 100 mg – 1% DV Jun-18 to 2021	l 100	Norflex
PANCURONIUM BROMIDE		
Inj 2 mg per ml, 2 ml ampoule		

Price			Brand or
(ex man. ex	l. GS	T)	Generic
\$		Per	Manufacturer
ROCURONIUM BROMIDE			
Inj 10 mg per ml, 5 ml ampoule - 1% DV Aug-20 to 2022	14	10	Hameln
SUXAMETHONIUM CHLORIDE			
Inj 50 mg per ml, 2 ml ampoule - 1% DV Feb-21 to 2023	00	50	AstraZeneca
23	40	10	Martindale
(AstraZeneca Inj 50 mg per ml, 2 ml ampoule to be delisted 1 February 2021)			
Inj 10 mg vial			
Reversers of Neuromuscular Blockade			
SUGAMMADEX – Restricted see terms below			
Inj 100 mg per ml, 2 ml vial	00	10	Bridion
Inj 100 mg per ml, 5 ml vial		10	Bridion
Fini Too ing per nii, 5 nii viai	00	10	DINION
nitiation			

Initiation

Any of the following:

- 1 Patient requires reversal of profound neuromuscular blockade following rapid sequence induction that has been undertaken using rocuronium (i.e. suxamethonium is contraindicated or undesirable); or
- 2 Severe neuromuscular degenerative disease where the use of neuromuscular blockade is required; or
- 3 Patient has an unexpectedly difficult airway that cannot be intubated and requires a rapid reversal of anaesthesia and neuromuscular blockade; or
- 4 The duration of the patient's surgery is unexpectedly short; or
- 5 Neostigmine or a neostigmine/anticholinergic combination is contraindicated (for example the patient has ischaemic heart disease, morbid obesity or COPD); or
- 6 Patient has a partial residual block after conventional reversal.

Non-Steroidal Anti-Inflammatory Drugs

CELECOXIB

Cap 100 mg	3.63	60	Celecoxib Pfizer
Cap 200 mg	2.30	30	Celecoxib Pfizer
DICLOFENAC SODIUM			
Tab EC 25 mg - 1% DV Oct-18 to 2021	1.23	50	Diclofenac Sandoz
Tab 50 mg dispersible	1.50	20	Voltaren D
Tab EC 50 mg - 1% DV Oct-18 to 2021	1.23	50	Diclofenac Sandoz
Tab long-acting 75 mg - 1% DV Oct-18 to 2021	22.80	500	Apo-Diclo SR
Tab long-acting 100 mg - 1% DV Oct-18 to 2021	25.15	500	Apo-Diclo SR
Inj 25 mg per ml, 3 ml ampoule	13.20	5	Voltaren
Suppos 12.5 mg		10	Voltaren
Suppos 25 mg	2.44	10	Voltaren
Suppos 50 mg	4.22	10	Voltaren
Suppos 100 mg	7.00	10	Voltaren

ETORICOXIB - Restricted see terms below

- Tab 30 mg
- ↓ Tab 60 mg
- Tab 90 mg
- Tab 120 mg
- → Restricted (RS1290)

Initiation

102

For in-vivo investigation of allergy only.

BUPROFEN	 \$.11.71	Per	Manufacturer
	 .11.71		
	 .11.71		
Tab 200 mg		1,000	Relieve
→ Tab 400 mg - Restricted: For continuation only			
→ Tab 600 mg - Restricted: For continuation only	F 00	20	Ibunratan CD DNM
Tab long-acting 800 mg – 1% DV Apr-20 to 2021 Oral lig 20 mg per ml – 1% DV May-19 to 2021		30 200 ml	Ibuprofen SR BNM Ethics
Ini 5 mg per ml, 2 ml ampoule	 1.00	200 111	Luncs
Inj 10 mg per ml, 2 ml vial			
Cap 25 mg Cap 50 mg			
Cap long-acting 75 mg			
Inj 1 mg vial			
Suppos 100 mg			
KETOPROFEN			
Cap long-acting 200 mg	12 07	28	Oruvail SR
	 . 12.07	20	
MEFENAMIC ACID - Restricted: For continuation only → Cap 250 mg			
VAPROXEN	00.00	500	N - flam 050
Tab 250 mg - 1% DV Dec-18 to 2021		500	Noflam 250 Noflam 500
Tab 500 mg – 1% DV Dec-18 to 2021 Tab long-acting 750 mg – 1% DV Oct-18 to 2021		250 28	Naprosyn SR 750
Tab long-acting 1 g – 1% DV Oct-18 to 2021		28	Naprosyn SR 1000
	 0.2 1	20	Naprosyn on 1000
PARECOXIB Inj 40 mg vial	00.00	10	Durpootot
	 100.00	10	Dynastat
SULINDAC			
Tab 100 mg			
Tab 200 mg			
TENOXICAM			
Tab 20 mg – 1% DV Oct-19 to 2022		100	Tilcotil
Inj 20 mg vial	 9.95	1	AFT
Topical Products for Joint and Muscular Pain			
Topical Products for Joint and Muscular Pall			
CAPSAICIN – Restricted see terms below	 		
Crm 0.025%	 9.95	45 g	Zostrix
→ Restricted (RS1309)			

Initiation

Patient has osteoarthritis that is not responsive to paracetamol and oral non-steroidal anti-inflammatories are contraindicated.

	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
Agents for Parkinsonism and Related Disorders	1		
Agents for Essential Tremor, Chorea and Relate	d Disorders		
 RILUZOLE - Restricted see terms below I Tab 50 mg - 1% DV Aug-18 to 2021	duration of 5 years or lea		Rilutek
 5.3 The patient is able to swallow. Continuation <i>Re-assessment required after 18 months</i> All of the following: The patient has not undergone a tracheostomy; and The patient has not experienced respiratory failure; and Any of the following: The patient is ambulatory; or The patient is able to use upper limbs; or The patient is able to swallow. 			
TETRABENAZINE Tab 25 mg – 1% DV Oct-19 to 2022	91.10	112	Motetis
Anticholinergics			
BENZATROPINE MESYLATE Tab 2 mg Inj 1 mg per ml, 2 ml ampoule – 1% DV Dec-20 to 2023 (Cogentin Inj 1 mg per ml, 2 ml ampoule to be delisted 1 Decemb PROCYCLIDINE HYDROCHLORIDE Tab 5 mg	95.00	60 5	Benztrop Cogentin Phebra
Dopamine Agonists and Related Agents			
AMANTADINE HYDROCHLORIDE Cap 100 mg APOMORPHINE HYDROCHLORIDE Inj 10 mg per ml, 2 ml ampoule – 1% DV Jan-20 to 2023 Inj 10 mg per ml, 5 ml ampoule – 1% DV Feb-20 to 2023 BROMOCRIPTINE Tab 2.5 mg		60 5 5	Symmetrel Movapo Movapo

t Item restricted (see → above); t Item restricted (see → below)

104

e.g. Brand indicates brand example only. It is not a contracted product.

NERVOUS SYSTEM

	Price		Brand or
	(ex man. excl. GST) \$	Per	Generic Manufacturer
ENTACAPONE	· ·	-	
Tab 200 mg – 1% DV Sep-18 to 2021	22.00	100	Entapone
LEVODOPA WITH BENSERAZIDE			
Tab dispersible 50 mg with benserazide 12.5 mg	13.25	100	Madopar Rapid
Cap 50 mg with benserazide 12.5 mg		100	Madopar 62.5
Cap 100 mg with benserazide 25 mg		100	Madopar 125
Cap long-acting 100 mg with benserazide 25 mg		100	Madopar HBS
Cap 200 mg with benserazide 50 mg		100	Madopar 250
EVODOPA WITH CARBIDOPA			
Tab 100 mg with carbidopa 25 mg - 1% DV Dec-20 to 2023		100	Sinemet
Tab long-acting 100 mg with carbipoda 25 mg			
Tab long-acting 200 mg with carbidopa 50 mg		100	Sinemet CR
Tab 250 mg with carbidopa 25 mg - 1% DV Dec-20 to 2023		100	Sinemet
PRAMIPEXOLE HYDROCHLORIDE			
Tab 0.25 mg – 1% DV Oct-19 to 2022	6.12	100	Ramipex
Tab 1 mg – 1% DV Oct-19 to 2022		100	Ramipex
ROPINIROLE HYDROCHLORIDE			
Tab 0.25 mg – 1% DV Mar-20 to 2022	2.85	84	Ropin
Tab 0.25 mg – 1% DV Mar-20 to 2022		84 84	Ropin
Tab 2 mg – 1% DV Mar-20 to 2022		84	Ropin
Tab 5 mg - 1% DV Mar-20 to 2022		84	Ropin
SELEGILINE HYDROCHLORIDE		•	
Tab 5 mg			
-			
TOLCAPONE Tab 100 mg	150.00	100	Tasmar
Tab 100 Hig		100	lasillai
Anaesthetics			
General Anaesthetics			
DESFLURANE	1 050 00	e	Cupropo
Soln for inhalation 100%, 240 ml bottle	1,350.00	6	Suprane
DEXMEDETOMIDINE		_	
Inj 100 mcg per ml, 2 ml vial – 1% DV Mar-21 to 2023		5	Dexmedetomidine-Teva
(Presedent lai 100 mere new mil 0 mil viel to be delicted 1 March 0001)	357.00		Precedex
(Precedex Inj 100 mcg per ml, 2 ml vial to be delisted 1 March 2021)			
ETOMIDATE			
Inj 2 mg per ml, 10 ml ampoule			
SOFLURANE			
Soln for inhalation 100%, 250 ml bottle	1,020.00	6	Aerrane
KETAMINE			
Inj 1 mg per ml, 100 ml bag - 1% DV Feb-20 to 2022		5	Biomed
Inj 10 mg per ml, 10 ml syringe - 1% DV Feb-20 to 2022	70.00	5	Biomed
Inj 100 mg per ml, 2 ml vial - 1% DV Jan-19 to 2021		5	Ketalar
	155.60		Ketamine-Baxter
			Ketamine-Claris
Ketamine-Claris Inj 100 mg per ml, 2 ml vial to be delisted 1 March 2	2021)		
METHOHEXITAL SODIUM			

Inj 10 mg per ml, 50 ml vial

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
PROPOFOL			
Inj 10 mg per ml, 20 ml ampoule - 10% DV Dec-19 to 2022	4.35	5	Fresofol 1% MCT/LCT
Inj 10 mg per ml, 50 ml vial - 10% DV Oct-19 to 2022		10	Fresofol 1% MCT/LCT
Inj 10 mg per ml, 100 ml vial – 10% DV Oct-19 to 2022		10	Fresofol 1% MCT/LCT
SEVOFLURANE			
Soln for inhalation 100%, 250 ml bottle		6	Baxter
THIOPENTAL [THIOPENTONE] SODIUM Inj 500 mg ampoule			
Local Anaesthetics			
ARTICAINE HYDROCHLORIDE Inj 1%			
ARTICAINE HYDROCHLORIDE WITH ADRENALINE Inj 4% with adrenaline 1:100,000, 1.7 ml dental cartridge Inj 4% with adrenaline 1:100,000, 2.2 ml dental cartridge Inj 4% with adrenaline 1:200,000, 1.7 ml dental cartridge Inj 4% with adrenaline 1:200,000, 2.2 ml dental cartridge			
BENZOCAINE Gel 20%			
BENZOCAINE WITH TETRACAINE HYDROCHLORIDE			
Gel 18% with tetracaine hydrochloride 2%			e.g. ZAP Topical Anaesthetic Gel
BUPIVACAINE HYDROCHLORIDE		_	
Inj 5 mg per ml, 4 ml ampoule – 1% DV Oct-20 to 2023	50.00	5	Marcain Isobaric
Inj 2.5 mg per ml, 20 ml ampoule Inj 2.5 mg per ml, 20 ml ampoule sterile pack - 1% DV Aug-20 t	• 2023 23.36	5	Marcain
Inj 5 mg per ml, 10 ml ampoule sterile pack – 1% DV Aug-20 to		5	Marcain
lnj 5 mg per ml, 20 ml ampoule		-	
Inj 5 mg per ml, 20 ml ampoule sterile pack – 1% DV Aug-20 to Inj 1.25 mg per ml, 100 ml bag Inj 1.25 mg per ml, 200 ml bag	2023 16.56	5	Marcain
Inj 1.25 mg per ml, 200 ml bag – 1% DV Oct-20 to 2023 Inj 2.5 mg per ml, 200 ml bag Inj 1.25 mg per ml, 500 ml bag	150.00	5	Marcain
BUPIVACAINE HYDROCHLORIDE WITH ADRENALINE			
Inj 2.5 mg per ml with adrenaline 1:400,000, 20 ml vial – 1% DV to 2022	•	5	Marcain with
Inj 5 mg per ml with adrenaline 1:200,000, 20 ml vial $-$ 1% DV A	•	_	Adrenaline
to 2022		5	Marcain with Adrenaline

106

NERVOUS SYSTEM

	Price		Brand or
((ex man. excl. GST \$) Per	Generic Manufacturer
	φ	Fei	Manulaciulei
BUPIVACAINE HYDROCHLORIDE WITH FENTANYL			
Inj 0.625 mg with fentanyl 2 mcg per ml, 100 ml bag	0		
Inj 0.625 mg with fentanyl 2 mcg per ml, 200 ml bag – 1% DV Apr-2 to 2022		5	Biomed
Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml syringe		5	Diomed
Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml bag – 1% DV Nov-19	a a a a a a a a a a a a a a a a a a a		
to 2022		5	Bupafen
Inj 1.25 mg with fentanyl 2 mcg per ml, 200 ml bag - 1% DV Nov-19			
to 2022	117.50	5	Bupafen
Inj 1.25 mg with fentanyl 2 mcg per ml, 50 ml syringe			
Inj 1.25 mg with fentanyl 2 mcg per ml, 15 ml syringe		5	Biomed
Inj 1.25 mg with fentanyl 2 mcg per ml, 20 ml syringe		5	Biomed
BUPIVACAINE HYDROCHLORIDE WITH GLUCOSE			
Inj 0.5% with glucose 8%, 4 ml ampoule		5	Marcain Heavy
COCAINE HYDROCHLORIDE			
Paste 5%			
Soln 15%, 2 ml syringe			
Soln 4%, 2 ml syringe	25.46	1	Biomed
COCAINE HYDROCHLORIDE WITH ADRENALINE			
Paste 15% with adrenaline 0.06%			
Paste 25% with adrenaline 0.06%			
ETHYL CHLORIDE			
Spray 100%			
LIDOCAINE [LIGNOCAINE]			
Crm 4%	5.40	5 g	LMX4
	27.00	30 g	LMX4
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE			
Gel 2% - 1% DV Nov-18 to 2021	4.87	20 g	Orion
Soln 4%			
Spray 10% - 1% DV Jul-19 to 2022		50 ml	Xylocaine
Oral (gel) soln 2%		200 ml	Mucosoothe
Inj 1%, 20 ml ampoule, sterile pack			
Inj 2%, 20 ml ampoule, sterile pack Inj 1%, 5 ml ampoule	9.75	25	Lidocaine-Claris
Inj 1%, 20 ml vial – 1% DV Jul-19 to 2022		5	Lidocaine-Claris
Inj 2%, 5 ml ampoule – 1% DV Nov-19 to 2022		25	Lidocaine-Claris
Inj 2%, 20 ml vial – 1% DV Jul-19 to 2022		5	Lidocaine-Claris
Gel 2%, 11 ml urethral syringe - 1% DV Apr-20 to 2022		10	Instillagel Lido
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE			-
Ini 1% with adrenaline 1:100.000. 5 ml ampoule – 1% DV Nov-19			
to 2022		10	Xylocaine
Inj 1% with adrenaline 1:200,000, 20 ml vial		5	Xylocaine
Inj 2% with adrenaline 1:80,000, 1.7 ml dental cartridge			
Inj 2% with adrenaline 1:80,000, 1.8 ml dental cartridge			
Inj 2% with adrenaline 1:80,000, 2.2 ml dental cartridge			
Inj 2% with adrenaline 1:200,000, 20 ml vial	60.00	5	Xylocaine
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE A	ND TETRACAINE	HYDROC	HLORIDE
Soln 4% with adrenaline 0.1% and tetracaine hydrochloride 0.5%, 5			
syringe	17.50	1	Topicaine

Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price (ex man. excl. GST		Brand or Generic
	\$	Per	Manufacturer
DOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH CHLORHEXIDI	NE		
Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringe	81.50	10	Pfizer
DOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH PHENYLEPHR	INE HYDROCHLO	RIDE	
Nasal spray 5% with phenylephrine hydrochloride 0.5%			
DOCAINE [LIGNOCAINE] WITH PRILOCAINE			
Crm 2.5% with prilocaine 2.5%	45.00	30 g	EMLA
Patch 25 mcg with prilocaine 25 mcg	115.00	20	EMLA
Crm 2.5% with prilocaine 2.5%, 5 g	45.00	5	EMLA
EPIVACAINE HYDROCHLORIDE			
Inj 3%, 1.8 ml dental cartridge		50	Scandonest 3%
Inj 3%, 2.2 ml dental cartridge	43.60	50	Scandonest 3%
RILOCAINE HYDROCHLORIDE			
Inj 0.5%, 50 ml vial		5	Citanest
Inj 2%, 5 ml ampoule			
RILOCAINE HYDROCHLORIDE WITH FELYPRESSIN			
Inj 3% with felypressin 0.03 iu per ml, 1.8 ml dental cartridge			
Inj 3% with felypressin 0.03 iu per ml, 2.2 ml dental cartridge			
OPIVACAINE HYDROCHLORIDE			
Inj 2 mg per ml, 10 ml ampoule – 1% DV Nov-20 to 2023		5	Ropivacaine Kabi
Inj 2 mg per ml, 20 ml ampoule - 1% DV Nov-20 to 2023	9.65	5	Ropivacaine Kabi
Inj 2 mg per ml, 100 ml bag - 1% DV Nov-20 to 2023		5	Ropivacaine Kabi
Inj 2 mg per ml, 200 ml bag – 1% DV Nov-20 to 2023	40.95	5	Ropivacaine Kabi
Inj 7.5 mg per ml, 10 ml ampoule - 1% DV Nov-20 to 2023		5	Ropivacaine Kabi
Inj 7.5 mg per ml, 20 ml ampoule - 1% DV Nov-20 to 2023		5	Ropivacaine Kabi
Inj 10 mg per ml, 10 ml ampoule - 1% DV Nov-20 to 2023		5	Ropivacaine Kabi
Inj 10 mg per ml, 20 ml ampoule - 1% DV Nov-20 to 2023		5	Ropivacaine Kabi
OPIVACAINE HYDROCHLORIDE WITH FENTANYL			
Inj 2 mg with fentanyl 2 mcg per ml, 100 ml bag		5	Naropin
Inj 2 mg with fentanyl 2 mcg per ml, 200 ml bag	270.00	5	Naropin
ETRACAINE [AMETHOCAINE] HYDROCHLORIDE			
Gel 4%			

Non-Opioid Analgesics

ASPIRIN			
Tab dispersible 300 mg - 1% DV Oct-19 to 2022	4.50	100	Ethics Aspirin
CAPSAICIN – Restricted see terms below			
↓ Crm 0.075%	12.50	45 g	Zostrix HP
→ Restricted (RS1145)		Ū	
Initiation			
For post-herpetic neuralgia or diabetic peripheral neuropathy.			
METHOXYFLURANE – Restricted see terms below			
Soln for inhalation 99.9%, 3 ml bottle			
➡ Restricted (RS1292)			
Initiation			
Both:			

continued...

	Price		Brand or
	(ex man. excl. GS		Generic
	\$	Per	Manufacturer
continued			
1 Patient is undergoing a painful procedure with an expected 2 Only to be used under supervision by a medical practitioner			
NEFOPAM HYDROCHLORIDE Tab 30 mg			
PARACETAMOL – Some items restricted see terms below Tab soluble 500 mg Tab 500 mg			
Oral liq 120 mg per 5 ml - 20% DV Nov-20 to 2023	5.45	1.000 ml	Paracare
Oral liq 250 mg per 5 ml - 20% DV Nov-20 to 2023		1,000 ml	Paracare Double Strength
Inj 10 mg per ml, 100 ml vial – 1% DV Nov-20 to 2023	8.90	10	Paracetamol Kabi
Suppos 25 mg - 1% DV Nov-19 to 2022		20	Biomed
Suppos 50 mg - 1% DV Nov-19 to 2022		20	Biomed
Suppos 125 mg - 1% DV Nov-18 to 2021	3.29	10	Gacet
Suppos 250 mg - 1% DV Nov-18 to 2021	3.79	10	Gacet
Suppos 500 mg – 1% DV Feb-19 to 2021	12.40	50	Gacet
→ Restricted (RS1146)			
nitiation			
ntravenous paracetamol is only to be used where other routes are absorption. The need for IV paracetamol must be re-assessed even		tical, or wher	e there is reduced
SUCROSE Oral lig 25% – 1% DV Feb-20 to 2022	10.00	25 ml	Biomed
 Oral liq 25% – 1% DV Feb-20 to 2022 Oral liq 66.7% (preservative free) 		25 [[]]	Diomed
➤ Restricted (RS1763)			
nitiation			
For use in neonatal patients only.			
Opioid Analgesics			
ALFENTANIL			
Inj 0.5 mg per ml, 2 ml ampoule - 1% DV Nov-20 to 2023	24.75	10	Hameln
CODEINE PHOSPHATE			
Tab 15 mg – 1% DV Nov-20 to 2023	6.25	100	PSM
Tab 30 mg – 1% DV Nov-20 to 2023		100	PSM
Tab 60 mg - 1% DV Nov-20 to 2023		100	PSM
Tab long-acting 60 mg – 1% DV Oct-19 to 2022	8 60	60	DHC Continus
	0.00	00	Bilo Continus

	Price (ex man. excl. GST)		Brand or Generic
	(ex man. exci. dor) \$	Per	Manufacturer
ENTANYL			
Inj 10 mcg per ml, 10 ml syringe			
Inj 50 mcg per ml, 2 ml ampoule - 1% DV Nov-18 to 2021		10	Boucher and Muir
Inj 10 mcg per ml, 50 ml bag		10	Biomed
Inj 10 mcg per ml, 50 ml syringe		10	Biomed
Inj 50 mcg per ml, 10 ml ampoule – 1% DV Nov-18 to 2021		10	Boucher and Muir
Inj 10 mcg per ml, 100 ml bag - 1% DV Nov-19 to 2022		5	Biomed
Inj 20 mcg per ml, 50 ml syringe - 1% DV Oct-18 to 2021		1	Biomed
Inj 20 mcg per ml, 100 ml bag			
Patch 12.5 mcg per hour		5	Fentanyl Sandoz
Patch 25 mcg per hour		5	Fentanyl Sandoz
Patch 50 mcg per hour		5	Fentanyl Sandoz
Patch 75 mcg per hour		5	Fentanyl Sandoz
Patch 100 mcg per hour		5	Fentanyl Sandoz
ETHADONE HYDROCHLORIDE		-	
	1 40	10	Methatabs
Tab 5 mg - 1% DV Sep-19 to 2022			Biodone
Oral liq 2 mg per ml – 1% DV Oct-18 to 2021		200 ml	Biodone Forte
Oral liq 5 mg per ml – 1% DV Oct-18 to 2021		200 ml	
Oral liq 10 mg per ml – 1% DV Oct-18 to 2021		200 ml	Biodone Extra Forte
Inj 10 mg per ml, 1 ml vial		10	AFT
ORPHINE HYDROCHLORIDE			
Oral liq 1 mg per ml - 1% DV Dec-18 to 2021		200 ml	RA-Morph
Oral liq 2 mg per ml - 1% DV Dec-18 to 2021		200 ml	RA-Morph
Oral liq 5 mg per ml - 1% DV Dec-18 to 2021		200 ml	RA-Morph
Oral liq 10 mg per ml - 1% DV Dec-18 to 2021	27.74	200 ml	RA-Morph
ORPHINE SULPHATE			
Tab immediate-release 10 mg - 1% DV Nov-20 to 2023		10	Sevredol
Tab immediate-release 20 mg - 1% DV Nov-20 to 2023		10	Sevredol
Tab long-acting 30 mg		10	Arrow-Morphine LA
Tab long-acting 60 mg		10	Arrow-Morphine LA
Cap long-acting 10 mg – 1% DV Jan-20 to 2022		10	m-Eslon
Cap long-acting 30 mg – 1% DV Jan-20 to 2022		10	m-Eslon
Cap long-acting 60 mg – 1% DV Jan-20 to 2022		10	m-Eslon
Cap long-acting 100 mg – 1% DV Jan-20 to 2022		10	m-Eslon
Inj 1 mg per ml, 100 ml bag – 1% DV Nov-20 to 2023		5	Biomed
Inj 1 mg per ml, 10 ml syringe – 1% DV Nov-20 to 2023		5	Biomed
Inj 1 mg per ml, 50 ml syringe - 1% DV Nov-20 to 2023		5	Biomed
Inj 1 mg per ml, 2 ml syringe			
Inj 2 mg per ml, 30 ml syringe	135.00	10	Biomed
Inj 5 mg per ml, 1 ml ampoule		5	DBL Morphine Sulpha
Inj 10 mg per ml, 1 ml ampoule		5	DBL Morphine Sulpha
Inj 10 mg per ml, 100 mg cassette		Ŭ	
Inj 10 mg per ml, 100 ml bag			
Inj 15 mg per ml, 1 ml ampoule	4 76	5	DBL Morphine Sulpha
Inj 30 mg per ml, 1 ml ampoule		5	DBL Morphine Sulpha
Inj 200 mcg in 0.4 ml syringe		U	
Inj 300 mcg in 0.3 ml syringe			
DRPHINE TARTRATE			

Inj 80 mg per ml, 1.5 ml ampoule

110

\$ Per Manufacturer DXYCODONE HYDROCHLORIDE Tab controlled-release 5 mg - 1% DV May-19 to 2021 2.15 20 Oxycodone Sandoz Tab controlled-release 10 mg - 1% DV May-19 to 2021 2.15 20 Oxycodone Sandoz Tab controlled-release 20 mg - 1% DV May-19 to 2021 2.15 20 Oxycodone Sandoz Tab controlled-release 20 mg - 1% DV May-19 to 2021 3.20 20 Oxycodone Sandoz Tab controlled-release 40 mg - 1% DV May-19 to 2021 3.20 20 Oxycodone Sandoz Tab controlled-release 80 mg - 1% DV May-19 to 2021 10.98 20 Oxycodone Sandoz Cap immediate-release 5 mg - 1% DV Sep-18 to 2021 188 20 OxyNorm Cap immediate-release 10 mg - 1% DV Sep-18 to 2021 3.32 20 OxyNorm Cap immediate-release 20 mg - 1% DV Sep-18 to 2021 5.81 20 OxyNorm Oral liq 5 mg per 5 ml 11.20 250 ml OxyNorm Inj 10 mg per ml, 100 ml bag 11.120 250 ml OxyNorm Inj 10 mg per ml, 2 ml ampoule - 1% DV Sep-18 to 2021 7.28 5 OxyNorm Inj 50 mg per ml, 1 ml a		Price (ex man. excl. GST)		Brand or Generic
Tab controlled-release 5 mg - 1% DV May-19 to 2021 2.15 20 Oxycodone Sandoz Tab controlled-release 10 mg - 1% DV May-19 to 2021 2.15 20 Oxycodone Sandoz Tab controlled-release 40 mg - 1% DV May-19 to 2021 3.20 20 Oxycodone Sandoz Cap immediate-release 5 mg - 1% DV May-19 to 2021 3.20 20 Oxycodone Sandoz Cap immediate-release 5 mg - 1% DV Sep-18 to 2021 1.88 20 OxyNorm Cap immediate-release 20 mg - 1% DV Sep-18 to 2021 3.32 20 OxyNorm Oral liq 5 mg per 5 ml 100 M bag 11.20 250 ml OxyNorm Oral liq 5 mg per 5 ml 100 mg per ml, 1 ml ampoule - 1% DV Sep-18 to 2021 7.28 5 OxyNorm Inj 10 mg per ml, 1 ml ampoule - 1% DV Sep-18 to 2021 4.36 5 OxyNorm Inj 10 mg per ml, 1 ml ampoule - 1% DV Sep-18 to 2021 4.36 5 OxyNorm PARACETAMOL WITH CODEINE Tab paracetamol 500 mg with codeine phosphate 8 mg 18.21 1,000 Paracetamol + Codeine (Relieve) PETHIDINE HYDROCHLORIDE Tab paracetamol 500 mg with codeine phosphate 8 mg 18.21 1,000 Paracetamol + Codeine Hydrochloride Inj 5 mg per ml, 100 ml bag In				
Tab controlled-release 5 mg - 1% DV May-19 to 2021 2.15 20 Oxycodone Sandoz Tab controlled-release 10 mg - 1% DV May-19 to 2021 2.15 20 Oxycodone Sandoz Tab controlled-release 40 mg - 1% DV May-19 to 2021 3.20 20 Oxycodone Sandoz Cap immediate-release 5 mg - 1% DV May-19 to 2021 3.20 20 Oxycodone Sandoz Cap immediate-release 5 mg - 1% DV Sep-18 to 2021 1.88 20 OxyNorm Cap immediate-release 20 mg - 1% DV Sep-18 to 2021 3.32 20 OxyNorm Oral liq 5 mg per 5 ml 100 M bag 11.20 250 ml OxyNorm Oral liq 5 mg per 5 ml 100 mg per ml, 1 ml ampoule - 1% DV Sep-18 to 2021 7.28 5 OxyNorm Inj 10 mg per ml, 1 ml ampoule - 1% DV Sep-18 to 2021 4.36 5 OxyNorm Inj 10 mg per ml, 1 ml ampoule - 1% DV Sep-18 to 2021 4.36 5 OxyNorm PARACETAMOL WITH CODEINE Tab paracetamol 500 mg with codeine phosphate 8 mg 18.21 1,000 Paracetamol + Codeine (Relieve) PETHIDINE HYDROCHLORIDE Tab paracetamol 500 mg with codeine phosphate 8 mg 18.21 1,000 Paracetamol + Codeine Hydrochloride Inj 5 mg per ml, 100 ml bag In				
Tab controlled-release 10 mg -1% DV May-19 to 2021 2.15 20 Oxycodone Sandoz Tab controlled-release 20 mg -1% DV May-19 to 2021 2.15 20 Oxycodone Sandoz Tab controlled-release 80 mg -1% DV May-19 to 2021 3.20 Oxycodone Sandoz Cap immediate-release 80 mg -1% DV May-19 to 2021 3.20 Oxycodone Sandoz Cap immediate-release 50 mg -1% DV Sep-18 to 2021 3.32 OxyNorm Cap immediate-release 20 mg -1% DV Sep-18 to 2021 3.32 OxyNorm Cap immediate-release 20 mg -1% DV Sep-18 to 2021 3.32 OxyNorm Oral liq 5 mg per 5 ml .11.20 250 ml OxyNorm Oral liq 5 mg per 5 ml .11.20 250 ml OxyNorm Inj 10 mg per ml, 10 ml appoule -1% DV Sep-18 to 2021 30.60 5 OxyNorm PARACETAMOL WITH CODEINE Tab so 0mg or ml, 10 ml appoule 1% DV Sep-18 to 2021 4.46 10 PSM Tab 50 mg or ml, 10 ml apyinge 1j 5 mg per ml, 10 ml ayninge 1j 5 mg per ml, 10 ml ayninge 1k 1k 1k 92 Trab		2 15	20	Oxycodone Sandoz
Tab controlled-release 20 mg -1% DV May-19 to 2021 .2.15 20 Oxycodone Sandoz Tab controlled-release 40 mg -1% DV May-19 to 2021 .0.98 20 Oxycodone Sandoz Cap immediate-release 5 mg -1% DV May-19 to 2021 .0.98 20 Oxycodone Sandoz Cap immediate-release 10 mg -1% DV Sep-18 to 2021 .3.32 20 OxyNorm Cap immediate-release 20 mg -1% DV Sep-18 to 2021 .5.81 20 OxyNorm Oral liq 5 mg per 5 ml .11.20 .250 ml OxyNorm OxyNorm Inj 10 mg per ml, 10 ml bag .11.20 .250 ml OxyNorm OxyNorm Inj 10 mg per ml, 1 ml ampoule -1% DV Sep-18 to 2021 .7.28 5 OxyNorm PARACETAMOL WITH CODEINE Tab controlled-release 100 mg .1% DV Sep-18 to 2021 .3.66 5 OxyNorm PETHIDINE HYDROCHLORIDE Tab 50 mg er ml, 10 ml syringe .1 .4.46 10 PSM Inj 5 mg per ml, 10 ml syringe .1 .5.12 5 DBL Pethidine Hydrochloride Hydrochloride Inj 10 mg per ml, 2 ml ampoule .5.12 5 DBL Pethidine Hydrochloride Hydrochl				
Tab controlled-release 40 mg - 1% DV May-19 to 2021 .3.20 20 Oxycodone Sandoz Tab controlled-release 80 mg - 1% DV May-19 to 2021 .10.98 20 Oxycodone Sandoz Cap immediate-release 50 mg - 1% DV Sep-18 to 2021 .3.32 20 OxyNorm Cap immediate-release 20 mg - 1% DV Sep-18 to 2021 .5.81 20 OxyNorm Oral liq 5 mg per 5 ml .11.20 250 ml OxyNorm Oral liq 5 mg per 5 ml .11.20 250 ml OxyNorm Inj 10 mg per ml, 10 ml bag .11.20 250 ml OxyNorm Inj 10 mg per ml, 2 ml ampoule - 1% DV Sep-18 to 2021 .7.28 5 OxyNorm PARACETAMOL WITH CODEINE .14.36 5 OxyNorm OxyNorm Tab 50 mg - 1% DV Sep-18 to 2021 .4.66 10 Paracetamol + Codeine (Relieve) *2FHIDINE HYDROCHLORIDE .4.46 10 PSM Inj 5 mg per ml, 10 ml syringe Inj 10 mg per ml, 2 ml ampoule - 1% DV Sep-18 to 2023 .5.12 DBL Pethidine Hydrochloride Inj 5 mg per ml, 10 ml syringe .1,50 mg per ml, 10 ml syringe .1,51 .1,95 S Remifentanil-AFT Inj 5 mg per ml, 10 ml syringe .1,1 mg vial - 1% DV Oct-20 to 2023				
Tab controlled-release 80 mg - 1% DV May-19 to 2021 10.98 20 Oxycodone Sandoz Cap immediate-release 5 mg - 1% DV Sep-18 to 2021 1.88 20 OxyNorm Cap immediate-release 20 mg - 1% DV Sep-18 to 2021 3.32 20 OxyNorm Cap immediate-release 20 mg - 1% DV Sep-18 to 2021 5.81 20 OxyNorm Oral lig 5 mg per 5 ml 11.20 250 ml OxyNorm Inj 10 mg per ml, 1 ml ampoule - 1% DV Sep-18 to 2021 7.28 5 OxyNorm Inj 10 mg per ml, 2 ml ampoule - 1% DV Sep-18 to 2021 30.60 5 OxyNorm PARACETAMOL WITH CODEINE Tab paracetamol 500 mg with codeine phosphate 8 mg 18.21 1,000 Paracetamol + Codeine (Relieve) PETHIDINE HYDROCHLORIDE Tab 50 mg per ml, 10 ml bag 1 1 95 DBL Pethidine Hydrochloride Inj 5 mg per ml, 100 ml bag 1 1 00 mg per ml, 100 ml bag 1 1 95 DBL Pethidine Hydrochloride Inj 50 mg per ml, 100 ml bag 1 1 00 mg per ml, 100 ml bag 1 1 95 DBL Pethidine Hydrochloride Inj 50 mg per ml, 100 ml bag 1 10 mg per ml, 100 ml bag 1 1				
Cap immediate-release 5 mg - 1% DV Sep-18 to 2021 1.88 20 OxyNorm Cap immediate-release 10 mg - 1% DV Sep-18 to 2021 3.32 20 OxyNorm Cap immediate-release 20 mg - 1% DV Sep-18 to 2021 5.81 20 OxyNorm Oral lig 5 mg per 5 ml 11.20 250 ml OxyNorm Inj 10 mg per ml, 100 ml bag 11.20 250 ml OxyNorm Inj 10 mg per ml, 1 ml ampoule - 1% DV Sep-18 to 2021 14.36 5 OxyNorm PARACETAMOL WITH CODEINE 30.60 5 OxyNorm PARACETAMOL WITH CODEINE 18.21 1,000 Paracetarnol + Codeine (Relieve) PETHIDINE HYDROCHLORIDE 4.46 10 PSM Tab 50 mg - 1% DV Sep-18 to 2021 4.46 10 PSM Inj 5 mg per ml, 100 ml bag 11 100 mg per ml, 100 ml bag 11 Inj 10 mg per ml, 50 ml syringe 5 DBL Pethidine Hydrochloride REMIFENTANIL Inj 1 mg vial - 1% DV Oct-20 to 2023 1.52 5 Remifentanil-AFT Inj 2 mg vial - 1% DV Oct-20 to 2023 1.52 20 Tramal SR 100 Tab sustained-release 150 mg - 1% DV Nov-20 to 2023 2.10 Tramal SR 100 </td <td></td> <td></td> <td></td> <td></td>				
Cap immediate-release 10 mg - 1% DV Sep-18 to 2021 3.32 20 OxyNorm Cap immediate-release 20 mg - 1% DV Sep-18 to 2021 5.81 20 OxyNorm Oral liq 5 mg per 5 ml 11.20 250 ml OxyNorm Inj 1 mg per ml, 10 ml bag 11.10 250 ml OxyNorm Inj 10 mg per ml, 2 ml ampoule - 1% DV Sep-18 to 2021 7.28 5 OxyNorm PARACETAMOL WITH CODEINE Tab paracetamol 500 mg with codeine phosphate 8 mg 18.21 1,000 Paracetamol + Codeine (Relieve) PETHIDINE HYDROCHLORIDE Tab 50 mg - 1% DV Sep-18 to 2021 4.46 10 PSM Inj 5 mg per ml, 100 ml bag Inj 5 0 mg per ml, 2 ml ampoule 4.98 5 DBL Pethidine Hydrochloride REMIFENTANIL Inj 1 mg vial - 1% DV Oct-20 to 2023 13.95 5 Remifentanil-AFT IRAMADOL HYDROCHLORIDE Tab sustained-release 100 mg - 1% DV Nov-20 to 2023 2.10 Tramal SR 100 Tramal SR 100 Tab sustained-release 100 mg - 1% DV Nov-20 to 2023 2.75 20				
Cap immediate-release 20 mg - 1% DV Sep-18 to 2021 5.81 20 OxyNorm Oral lig 5 mg per 5 ml 11.20 250 ml 0xyNorm Inj 10 mg per ml, 100 ml bag 7.28 5 OxyNorm Inj 10 mg per ml, 2 ml ampoule - 1% DV Sep-18 to 2021 7.28 5 OxyNorm PARACETAMOL WITH CODEINE 30.60 5 OxyNorm Tab paracetamol 500 mg with codeine phosphate 8 mg 18.21 1,000 Paracetamol + Codeine (Relieve) PETHIDINE HYDROCHLORIDE 1 100 ml bag 1 10 mg per ml, 100 ml bag 1 Inj 5 mg per ml, 100 ml bag 1 10 mg per ml, 100 ml bag 1 95 DBL Pethidine Hydrochloride PETHIDINE HYDROCHLORIDE 4.46 10 PSM 1 1000 PSM Inj 5 mg per ml, 100 ml bag 1 1 100 mg per ml, 100 ml bag 1 1 100 PSM Inj 5 0 mg per ml, 100 ml bag 1 1 10 mg per ml, 100 ml bag 1 1 10 mg per ml, 100 ml bag 1 1 10 mg per ml, 100 ml bag 1 1 1				
Oral liq 5 mg per 5 ml 11.20 250 ml OxyNorm Inj 1 mg per ml, 100 ml bag 11 mappoule – 1% DV Sep-18 to 2021 7.28 5 OxyNorm Inj 10 mg per ml, 2 ml ampoule – 1% DV Sep-18 to 2021 14.36 5 OxyNorm Inj 50 mg per ml, 2 ml ampoule – 1% DV Sep-18 to 2021 30.60 5 OxyNorm PARACETAMOL WITH CODEINE 1 10.00 Paracetamol + Codeine (Relieve) PETHIDINE HYDROCHLORIDE 1 10.00 Paracetamol + Codeine (Relieve) PETHIDINE HYDROCHLORIDE 4.46 10 PSM Inj 5 mg per ml, 100 ml bag 11.00 ml bag 11.00 ml bag 11.00 ml bag Inj 10 mg per ml, 100 ml bag 11.00 mg per ml, 100 ml bag 11.00 mg per ml, 100 ml bag 11.00 mg per ml, 100 ml bag Inj 50 mg per ml, 2 ml ampoule 5.12 5 DBL Pethidine Hydrochloride REMIFENTANIL 11 mg vial – 1% DV Oct-20 to 2023 13.95 7 Remifentanil-AFT TRAMADOL HYDROCHLORIDE 11 mg vial – 1% DV Oct-20 to 2023 2.10 20 Tramal SR 100 Tab sustained-release 100 mg – 1% DV Nov-20 to 2023 2.10 20 Tramal SR 100 Tab sustained-release 100 mg – 1% DV Nov-20 t				
Inj 1 mg per ml, 100 ml bag 7.28 5 OxyNorm Inj 10 mg per ml, 2 ml ampoule - 1% DV Sep-18 to 2021 14.36 5 OxyNorm Inj 50 mg per ml, 1 ml ampoule - 1% DV Sep-18 to 2021 30.60 5 OxyNorm PARACETAMOL WITH CODEINE 1 1,000 Paracetamol + Codeine (Relieve) PETHIDINE HYDROCHLORIDE 1,000 Paracetamol + Codeine (Relieve) PETHIDINE HYDROCHLORIDE 4.46 10 PSM Inj 5 mg per ml, 100 ml bag 11 0 ml syringe 11 0 mg per ml, 100 ml bag 11 1 0 mg per ml, 100 ml bag Inj 10 mg per ml, 50 ml syringe 11 0 mg per ml, 100 ml bag 11 1 mg yial - 1% DV Oct-20 to 2023 13.95 5 Remifentanil-AFT REMIFENTANIL Inj 1 mg vial - 1% DV Oct-20 to 2023 19.95 5 Remifentanil-AFT TAMADOL HYDROCHLORIDE 19.95 5 Remifentanil-AFT Tramal SR 100 Tab sustained-release 100 mg - 1% DV Nov-20 to 2023 2.15 20 Tramal SR 100 Tab sustained-release 150 mg - 1% DV Nov-20 to 2023 2.75 20 Tramal SR 100 Tab sustained-release 200 mg - 1% DV Nov-20 to 2023 2.80 100 Arrow-Tramadol Oral soin 10 mg p	· · · ·			
Inj 10 mg per ml, 1 ml ampoule – 1% DV Sep-18 to 2021	1 51	11.20	250 111	Oxynorm
Inj 10 mg per ml, 2 ml ampoule – 1% DV Sep-18 to 2021		7.00	-	Ormablearm
Inj 50 mg per ml, 1 ml ampoule - 1% DV Sep-18 to 202130.605OxyNormPARACETAMOL WITH CODEINE Tab paracetamol 500 mg with codeine phosphate 8 mg18.211,000Paracetamol + Codeine (Relieve)PETHIDINE HYDROCHLORIDE Tab 50 mg - 1% DV Sep-18 to 20214.4610PSMPETHIDINE HYDROCHLORIDE Inj 5 mg per ml, 10 ml syringe Inj 5 mg per ml, 100 ml bag Inj 50 mg per ml, 100 ml bag Inj 50 mg per ml, 100 ml bag Inj 50 mg per ml, 2 ml ampoule4.4610PSMREMIFENTANIL Inj 1 mg vial - 1% DV Oct-20 to 20235.125DBL Pethidine HydrochlorideRAMADOL HYDROCHLORIDE Tab sustained-release 100 mg - 1% DV Nov-20 to 20231.5220Tramal SR 100Tab sustained-release 100 mg - 1% DV Nov-20 to 20232.1020Tramal SR 100Tab sustained-release 100 mg - 1% DV Nov-20 to 20232.7520Tramal SR 100Tab sustained-release 100 mg - 1% DV Nov-20 to 20232.8000Arrow-TramadolOral soln 10 mg per ml Inj 10 mg per ml1% DV Not-20 to 20233.835Tramal S0Tab sustained-release 100 mg - 1% DV Not-20 to 20233.835Tramal S0				
PARACETAMOL WITH CODEINE 1,000 Paracetamol 500 mg with codeine phosphate 8 mg				
Tab paracetamol 500 mg with codeine phosphate 8 mg			5	OxyNorm
PETHIDINE HYDROCHLORIDE (Relieve) Tab 50 mg - 1% DV Sep-18 to 2021 446 10 PSM Inj 5 mg per ml, 10 ml syringe 10 ml bag 10 ml pag PSM Inj 5 mg per ml, 100 ml bag 11 0 mg per ml, 50 ml syringe 10 ml pag PSM Inj 50 mg per ml, 1 ml ampoule 4.98 5 DBL Pethidine Hydrochloride Inj 50 mg per ml, 2 ml ampoule 5.12 5 DBL Pethidine Hydrochloride Inj 1 mg vial - 1% DV Oct-20 to 2023 13.95 5 Remifentanil-AFT Inj 1 mg vial - 1% DV Oct-20 to 2023 13.95 5 Remifentanil-AFT Inj 2 mg vial - 1% DV Oct-20 to 2023 19.95 5 Remifentanil-AFT TRAMADOL HYDROCHLORIDE Tramal SR 100 Tramal SR 100 Tramal SR 150 Tab sustained-release 100 mg - 1% DV Nov-20 to 2023 2.10 20 Tramal SR 150 Tab sustained-release 200 mg - 1% DV Nov-20 to 2023 2.80 100 Arrow-Tramadol Oral soln 10 mg per ml 10 ml ampoule - 1% DV Oct-20 to 2023 3.83 5 Tramal 50 Inj 50 mg per ml, 2 ml ampoule - 1% DV Oct-20 to 2023 3.83 5 Tramal 100	PARACETAMOL WITH CODEINE			
Tab 50 mg - 1% DV Sep-18 to 2021 4.46 10 PSM Inj 5 mg per ml, 10 ml syringe 10 ml pag 10 ml pag 10 ml pag Inj 10 mg per ml, 100 ml bag 10 ml pag 10 ml pag 10 ml pag Inj 50 mg per ml, 100 ml bag 11 ml ampoule 4.98 5 DBL Pethidine Inj 50 mg per ml, 2 ml ampoule 5.12 5 DBL Pethidine Hydrochloride Inj 50 mg per ml, 2 ml ampoule 5.12 5 Remifentanil-AFT Hydrochloride REMIFENTANIL Inj 1 mg vial - 1% DV Oct-20 to 2023 13.95 5 Remifentanil-AFT Inj 2 mg vial - 1% DV Oct-20 to 2023 19.95 5 Remifentanil-AFT TRAMADOL HYDROCHLORIDE 100 152 20 Tramal SR 100 Tab sustained-release 100 mg - 1% DV Nov-20 to 2023 2.10 20 Tramal SR 150 Tab sustained-release 150 mg - 1% DV Nov-20 to 2023 2.75 20 Tramal SR 150 Tab sustained-release 200 mg - 1% DV Nov-20 to 2023 2.80 100 Arrow-Tramadol Oral soln 10 mg per ml nj 10 mg per ml 0 Arrow-Tramadol 0 Oral soln 10 mg per ml, 100 ml bag 10 <td< td=""><td>Tab paracetamol 500 mg with codeine phosphate 8 mg</td><td></td><td>1,000</td><td>Paracetamol + Codeine (Relieve)</td></td<>	Tab paracetamol 500 mg with codeine phosphate 8 mg		1,000	Paracetamol + Codeine (Relieve)
Inj 5 mg per ml, 10 ml syringe Inj 5 mg per ml, 100 ml bag Inj 10 mg per ml, 100 ml bag Inj 10 mg per ml, 50 ml syringe Inj 50 mg per ml, 1 ml ampoule	PETHIDINE HYDROCHLORIDE			
Inj 5 mg per ml, 100 ml bagInj 10 mg per ml, 100 ml bagInj 10 mg per ml, 50 ml syringeInj 50 mg per ml, 1 ml ampouleInj 50 mg per ml, 2 ml ampouleInj 50 mg per ml, 2 ml ampouleSo mg per ml, 2 ml ampouleInj 1 mg vial - 1% DV Oct-20 to 2023Inj 1 mg vial - 1% DV Oct-20 to 2023Inj 2 mg vial - 1% DV Oct-20 to 2023Inj 2 mg vial - 1% DV Oct-20 to 2023Inj 2 mg vial - 1% DV Oct-20 to 2023Inj 2 mg vial - 1% DV Oct-20 to 2023Inj 2 mg vial - 1% DV Oct-20 to 2023Inj 2 mg vial - 1% DV Nov-20 to 2023Inj 2 mg vial - 1% DV Nov-20 to 2023Inj 2 mg vial - 1% DV Nov-20 to 2023Inj 2 mg vial - 1% DV Nov-20 to 2023Inj 2 mg vial - 1% DV Nov-20 to 2023Inj 2 mg vial - 1% DV Nov-20 to 2023Inj 2 mg vial - 1% DV Nov-20 to 2023Inj 2 mg vial - 1% DV Nov-20 to 2023Inj 2 mg vial - 1% DV Nov-20 to 2023Inj 2 mg vial - 1% DV Nov-20 to 2023Inj 2 mg vial - 1% DV Nov-20 to 2023Inj 3 mg per mlInj 10 mg per mlInj 10 mg per mlInj 10 mg per mlInj 10 mg per mlInj 50 mg per ml, 1 ml ampoule - 1% DV Oct-20 to 2023Inj 50 mg per ml, 2 ml ampoule - 1% DV Oct-20 to 2023Inj 50 mg per ml, 2 ml ampoule - 1% DV Oct-20 to 2023Inj 50 mg per ml, 2 ml ampoule - 1% DV Oct-20 to 2023Inj 50 mg per ml, 2 ml ampoule - 1% DV Oct-20 to 2023Inj 50 mg per ml, 2 ml ampoule - 1% DV Oct-20 to 2023Inj 50 mg per ml, 2 ml ampoule - 1% DV Oct-20 to 2023Inj 50 mg per ml, 2 ml ampoule - 1% DV Oct-20 to 2023<	Tab 50 mg - 1% DV Sep-18 to 2021	4.46	10	PSM
Inj 5 mg per ml, 100 ml bagInj 10 mg per ml, 100 ml bagInj 10 mg per ml, 50 ml syringeInj 50 mg per ml, 1 ml ampouleInj 50 mg per ml, 2 ml ampouleInj 50 mg per ml, 2 ml ampouleSo mg per ml, 2 ml ampouleInj 1 mg vial - 1% DV Oct-20 to 2023Inj 1 mg vial - 1% DV Oct-20 to 2023Inj 2 mg vial - 1% DV Oct-20 to 2023Inj 2 mg vial - 1% DV Oct-20 to 2023Inj 2 mg vial - 1% DV Oct-20 to 2023Inj 2 mg vial - 1% DV Oct-20 to 2023Inj 2 mg vial - 1% DV Oct-20 to 2023Inj 2 mg vial - 1% DV Nov-20 to 2023Inj 2 mg vial - 1% DV Nov-20 to 2023Inj 2 mg vial - 1% DV Nov-20 to 2023Inj 2 mg vial - 1% DV Nov-20 to 2023Inj 2 mg vial - 1% DV Nov-20 to 2023Inj 2 mg vial - 1% DV Nov-20 to 2023Inj 2 mg vial - 1% DV Nov-20 to 2023Inj 2 mg vial - 1% DV Nov-20 to 2023Inj 2 mg vial - 1% DV Nov-20 to 2023Inj 2 mg vial - 1% DV Nov-20 to 2023Inj 2 mg vial - 1% DV Nov-20 to 2023Inj 3 mg per mlInj 10 mg per mlInj 10 mg per mlInj 10 mg per mlInj 10 mg per mlInj 50 mg per ml, 1 ml ampoule - 1% DV Oct-20 to 2023Inj 50 mg per ml, 2 ml ampoule - 1% DV Oct-20 to 2023Inj 50 mg per ml, 2 ml ampoule - 1% DV Oct-20 to 2023Inj 50 mg per ml, 2 ml ampoule - 1% DV Oct-20 to 2023Inj 50 mg per ml, 2 ml ampoule - 1% DV Oct-20 to 2023Inj 50 mg per ml, 2 ml ampoule - 1% DV Oct-20 to 2023Inj 50 mg per ml, 2 ml ampoule - 1% DV Oct-20 to 2023Inj 50 mg per ml, 2 ml ampoule - 1% DV Oct-20 to 2023<	Inj 5 mg per ml, 10 ml syringe			
Inj 10 mg per ml, 50 ml syringeInj 50 mg per ml, 1 ml ampoule4.985DBL PethidineHydrochlorideHydrochlorideHydrochlorideInj 50 mg per ml, 2 ml ampoule5.125DBL PethidineHydrochlorideHydrochlorideHydrochlorideREMIFENTANILInj 1 mg vial - 1% DV Oct-20 to 202313.955Inj 2 mg vial - 1% DV Oct-20 to 202319.955Remifentanil-AFTRAMADOL HYDROCHLORIDETab sustained-release 100 mg - 1% DV Nov-20 to 20232.1020Tramal SR 100Tab sustained-release 150 mg - 1% DV Nov-20 to 20232.1020Tramal SR 150Tab sustained-release 200 mg - 1% DV Nov-20 to 20232.7520Tramal SR 200Cap 50 mg - 1% DV Dec-20 to 20232.7520Tramal SR 200Arrow-TramadolOral soln 10 mg per mlInj 10 mg per ml100 ml bag100Arrow-TramadolInj 50 mg per ml, 2 ml ampoule - 1% DV Oct-20 to 20234.505Tramal 50Inj 50 mg per ml, 2 ml ampoule - 1% DV Oct-20 to 20233.835Tramal 100	Inj 5 mg per ml, 100 ml bag			
Inj 50 mg per ml, 1 ml ampoule4.985DBL Pethidine HydrochlorideInj 50 mg per ml, 2 ml ampoule5.125DBL Pethidine HydrochlorideInj 50 mg per ml, 2 ml ampoule5.125DBL Pethidine HydrochlorideREMIFENTANILInj 1 mg vial - 1% DV Oct-20 to 202313.955Remifentanil-AFT Remifentanil-AFTInj 2 mg vial - 1% DV Oct-20 to 202319.955Remifentanil-AFTTRAMADOL HYDROCHLORIDE Tab sustained-release 100 mg - 1% DV Nov-20 to 20232.1020Tramal SR 100 Tramal SR 150Tab sustained-release 150 mg - 1% DV Nov-20 to 20232.7520Tramal SR 150 Tramal SR 150Tab sustained-release 200 mg - 1% DV Nov-20 to 20232.7520Tramal SR 200 Arrow-TramadolOral soln 10 mg per ml Inj 10 mg per ml, 100 ml bag Inj 50 mg per ml, 1 ml ampoule - 1% DV Oct-20 to 20234.505Tramal 50 Tramal 100	Inj 10 mg per ml, 100 ml bag			
HydrochlorideInj 50 mg per ml, 2 ml ampoule5125DBL Pethidine HydrochlorideREMIFENTANILInj 1 mg vial - 1% DV Oct-20 to 202313.955Remifentanil-AFTInj 2 mg vial - 1% DV Oct-20 to 202319.955Remifentanil-AFTTRAMADOL HYDROCHLORIDETab sustained-release 100 mg - 1% DV Nov-20 to 20231.5220Tramal SR 100Tab sustained-release 150 mg - 1% DV Nov-20 to 20232.1020Tramal SR 150Tab sustained-release 200 mg - 1% DV Nov-20 to 20232.7520Tramal SR 200Cap 50 mg - 1% DV Dec-20 to 20232.7520Tramal SR 200Oral soln 10 mg per ml100 mg per ml100 mg per ml100 mg per mlInj 50 mg per ml, 100 ml bagInj 50 mg per ml, 2 ml ampoule - 1% DV Oct-20 to 20234.505Tramal 50Inj 50 mg per ml, 2 ml ampoule - 1% DV Oct-20 to 20233.835Tramal 100	Inj 10 mg per ml, 50 ml syringe			
Inj 50 mg per ml, 2 ml ampoule 5 DBL Pethidine Hight S0 mg per ml, 2 ml ampoule 5 DBL Pethidine Hydrochloride Hydrochloride Hydrochloride REMIFENTANIL 13.95 5 Remifentanil-AFT Inj 2 mg vial - 1% DV Oct-20 to 2023 13.95 5 Remifentanil-AFT RAMADOL HYDROCHLORIDE 19.95 5 Remifentanil-AFT Tab sustained-release 100 mg - 1% DV Nov-20 to 2023 2.10 20 Tramal SR 100 Tab sustained-release 150 mg - 1% DV Nov-20 to 2023 2.75 20 Tramal SR 150 Tab sustained-release 200 mg - 1% DV Nov-20 to 2023 2.75 20 Tramal SR 200 Cap 50 mg - 1% DV Dec-20 to 2023 2.80 100 Arrow-Tramadol Oral soln 10 mg per ml 0 100 ml bag 10 10 Inj 50 mg per ml, 100 ml bag 100 ml per ml 5 Tramal 50 10 Inj 50 mg per ml, 2 ml ampoule - 1% DV Oct-20 to 2023 3.83 5 Tramal 100	Inj 50 mg per ml. 1 ml ampoule	4.98	5	DBL Pethidine
Inj 50 mg per ml, 2 ml ampoule 5 DBL Pethidine Hight S0 mg per ml, 2 ml ampoule 5 DBL Pethidine Hydrochloride Hydrochloride Hydrochloride REMIFENTANIL 13.95 5 Remifentanil-AFT Inj 2 mg vial - 1% DV Oct-20 to 2023 13.95 5 Remifentanil-AFT RAMADOL HYDROCHLORIDE 19.95 5 Remifentanil-AFT Tab sustained-release 100 mg - 1% DV Nov-20 to 2023 2.10 20 Tramal SR 100 Tab sustained-release 150 mg - 1% DV Nov-20 to 2023 2.75 20 Tramal SR 150 Tab sustained-release 200 mg - 1% DV Nov-20 to 2023 2.75 20 Tramal SR 200 Cap 50 mg - 1% DV Dec-20 to 2023 2.80 100 Arrow-Tramadol Oral soln 10 mg per ml 0 100 ml bag 10 10 Inj 50 mg per ml, 100 ml bag 100 ml per ml 5 Tramal 50 10 Inj 50 mg per ml, 2 ml ampoule - 1% DV Oct-20 to 2023 3.83 5 Tramal 100				Hydrochloride
Hydrochloride REMIFENTANIL Inj 1 mg vial - 1% DV Oct-20 to 2023	Ini 50 mg per ml. 2 ml ampoule	5.12	5	
REMIFENTANIL Inj 1 mg vial – 1% DV Oct-20 to 2023	, ••••••••••••••••••••••••••••••••••			
Inj 1 mg vial - 1% DV Oct-20 to 2023				.,
Inj 2 mg vial - 1% DV Oct-20 to 2023		12.05	Б	Pomifontanil_AET
RAMADOL HYDROCHLORIDE Tab sustained-release 100 mg - 1% DV Nov-20 to 2023 1.52 20 Tramal SR 100 Tab sustained-release 150 mg - 1% DV Nov-20 to 2023 2.10 20 Tramal SR 150 Tab sustained-release 200 mg - 1% DV Nov-20 to 2023 2.75 20 Tramal SR 200 Cap 50 mg - 1% DV Dec-20 to 2023 2.80 100 Arrow-Tramadol Oral soln 10 mg per ml 101 mg per ml 100 ml bag 11 for gper ml, 100 ml bag Inj 50 mg per ml, 2 ml ampoule - 1% DV Oct-20 to 2023 4.50 5 Tramal 50 Inj 50 mg per ml, 2 ml ampoule - 1% DV Oct-20 to 2023 3.83 5 Tramal 100				
Tab sustained-release 100 mg -1% DV Nov-20 to 2023 1.52 20 Tramal SR 100 Tab sustained-release 150 mg -1% DV Nov-20 to 2023 2.10 20 Tramal SR 150 Tab sustained-release 200 mg -1% DV Nov-20 to 2023 2.75 20 Tramal SR 200 Cap 50 mg -1% DV Dec-20 to 2023 2.80 100 Arrow-Tramadol Oral soln 10 mg per ml Inj 10 mg per ml, 100 ml bag 105 mg per ml, 100 ml bag 100 S Inj 50 mg per ml, 2 ml ampoule -1% DV Oct-20 to 2023 4.50 5 Tramal 50 Inj 50 mg per ml, 2 ml ampoule -1% DV Oct-20 to 2023 3.83 5 Tramal 100			5	Remmentarin-AFT
Tab sustained-release 150 mg - 1% DV Nov-20 to 2023 2.10 20 Tramal SR 150 Tab sustained-release 200 mg - 1% DV Nov-20 to 2023 2.75 20 Tramal SR 200 Cap 50 mg - 1% DV Dec-20 to 2023 2.80 100 Arrow-Tramadol Oral soln 10 mg per ml 10 mg per ml, 100 ml bag 11 5 Tramal 50 Inj 50 mg per ml, 2 ml ampoule - 1% DV Oct-20 to 2023 3.83 5 Tramal 100				
Tab sustained-release 200 mg - 1% DV Nov-20 to 2023 2.75 20 Tramal SR 200 Cap 50 mg - 1% DV Dec-20 to 2023 2.80 100 Arrow-Tramadol Oral soln 10 mg per ml 100 mg per ml, 100 ml bag 100 mg per ml, 100 ml bag 100 Tramal S0 Inj 50 mg per ml, 2 ml ampoule - 1% DV Oct-20 to 2023 3.83 5 Tramal 100				
Cap 50 mg - 1% DV Dec-20 to 2023			20	Tramal SR 150
Oral soln 10 mg per ml Inj 10 mg per ml, 100 ml bag Inj 50 mg per ml, 1 ml ampoule – 1% DV Oct-20 to 2023	Tab sustained-release 200 mg - 1% DV Nov-20 to 2023	2.75	20	Tramal SR 200
Inj 10 mg per ml, 100 ml bag Inj 50 mg per ml, 1 ml ampoule – 1% DV Oct-20 to 2023	Cap 50 mg - 1% DV Dec-20 to 2023	2.80	100	Arrow-Tramadol
Inj 10 mg per ml, 100 ml bag Inj 50 mg per ml, 1 ml ampoule – 1% DV Oct-20 to 2023	Oral soln 10 mg per ml			
Inj 50 mg per ml, 2 ml ampoule - 1% DV Oct-20 to 2023	Inj 10 mg per ml, 100 ml bag			
Inj 50 mg per ml, 2 ml ampoule – 1% DV Oct-20 to 2023	Inj 50 mg per ml, 1 ml ampoule - 1% DV Oct-20 to 2023	4.50	5	Tramal 50
			5	Tramal 100

Cyclic and Related Agents

Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
DOSULEPIN [DOTHIEPIN] HYDROCHLORIDE – Restricted: For → Cap 25 mg		50	Dosulepin Mylan
DOXEPIN HYDROCHLORIDE - Restricted: For continuation only → Cap 10 mg → Cap 25 mg → Cap 50 mg			
IMIPRAMINE HYDROCHLORIDE			
Tab 10 mg		50	Tofranil
Tab 25 mg	6.58 8.80	60 50	Tofranil Tofranil
MAPROTILINE HYDROCHLORIDE – Restricted: For continuation → Tab 25 mg → Tab 75 mg		00	- on drim
MIANSERIN HYDROCHLORIDE – Restricted: For continuation or → Tab 30 mg	ly		
NORTRIPTYLINE HYDROCHLORIDE Tab 10 mg – 1% DV Oct-19 to 2022 Tab 25 mg – 1% DV Oct-19 to 2022		100 180	Norpress Norpress
Monoamine-Oxidase Inhibitors - Non-Selective			
PHENELZINE SULPHATE Tab 15 mg TRANYLCYPROMINE SULPHATE Tab 10 mg			
Monoamine-Oxidase Type A Inhibitors			
MOCLOBEMIDE Tab 150 mg – 1% DV Apr-19 to 2021 Tab 300 mg – 1% DV Apr-19 to 2021		60 60	Aurorix Aurorix
Other Antidepressants			
MIRTAZAPINE Tab 30 mg – 1% DV Oct-18 to 2021 Tab 45 mg – 1% DV Oct-18 to 2021		30 30	Apo-Mirtazapine Apo-Mirtazapine
VENLAFAXINE	6.00	04	Enlafov VD
Cap 37.5 mg Cap 75 mg	0.30 8 11	84 84	Enlafax XR Enlafax XR
Cap 150 mg		84	Enlafax XR
Selective Serotonin Reuptake Inhibitors			
CITALOPRAM HYDROBROMIDE			
Tab 20 mg - 1% DV Sep-18 to 2021	1.52	84	PSM Citalopram
ESCITALOPRAM		00	Facitalenvers Areter
Tab 10 mg Tab 20 mg		28 28	Escitalopram-Apotex Escitalopram-Apotex

e.g. Brand indicates brand example only. It is not a contracted product.

112

	Price		Brand or
	(ex man. excl. GST	7	Generic
	\$	Per	Manufacturer
Tab dispersible 20 mg, scored – 1% DV Feb-21 to 2022	9.93	30	Arrow-Fluoxetine
	1.98		Fluox
Cap 20 mg - 1% DV Feb-21 to 2022	7.49	90	Arrow-Fluoxetine
	2.91	84	Fluox
(Arrow-Fluoxetine Tab dispersible 20 mg, scored to be delisted 1 F		04	THUCK
(Arrow-Fluoxetine Cap 20 mg to be delisted 1 February 2021)			
(Anow-nuoxelline Cap 20 mg to be delisted 1 rebruary 2021)			
PAROXETINE			
Tab 20 mg - 1% DV Mar-20 to 2022		90	Loxamine
SERTRALINE			_
Tab 50 mg – 1% DV Mar-20 to 2022	0.92	30	Setrona
Tab 100 mg - 1% DV Mar-20 to 2022	1.61	30	Setrona
.			
Antiepilepsy Drugs			
Agents for the Control of Status Epilepticus			
• • • •			
CLONAZEPAM	01.00	-	Dissel
Inj 1 mg per ml, 1 ml ampoule	21.00	5	Rivotril
DIAZEPAM			
Inj 5 mg per ml, 2 ml ampoule	23.66	5	Hospira
		5	
Rectal tubes 5 mg			Stesolid
Rectal tubes 10 mg		5	Stesolid
(Stesolid Rectal tubes 10 mg to be delisted 1 December 2020)			
LORAZEPAM			
-			
Inj 2 mg vial			
Inj 4 mg per ml, 1 ml vial			
PARALDEHYDE			
Inj 5 ml ampoule			
inj 5 mi ampoue			
PHENYTOIN SODIUM			
Inj 50 mg per ml, 2 ml ampoule		5	Hospira
Inj 50 mg per ml, 5 ml ampoule		5	Hospira
	100.02	Ū	ricopila
Control of Epilepsy			
CARBAMAZEPINE			
Tab 200 mg	1/ 53	100	Tegretol
5			0
Tab long-acting 200 mg		100	Tegretol CR
Tab 400 mg		100	Tegretol
Tab long-acting 400 mg		100	Tegretol CR
Oral lig 20 mg per ml		250 ml	Tegretol
			0
CLOBAZAM			
Tab 10 mg			
CLONAZEPAM			
Oral drops 2.5 mg per ml			
ETHOSUXIMIDE			
Cap 250 mg		100	Zarontin
Oral lig 50 mg per ml		200 ml	Zarontin
		200 111	

	Price (ex man. excl. GST)		Brand or Generic
	`\$	Per	Manufacturer
GABAPENTIN			
Note: Gabapentin not to be given in combination with pregabalin			
Cap 100 mg - 1% DV Aug-18 to 2021	2.65	100	Apo-Gabapentin
Cap 300 mg - 1% DV Aug-18 to 2021	4.07	100	Apo-Gabapentin
Cap 400 mg – 1% DV Aug-18 to 2021		100	Apo-Gabapentin
LACOSAMIDE – Restricted see terms below			
Tab 50 mg	25.04	14	Vimpat
Tab 100 mg		14	Vimpat
•	200.24	56	Vimpat
Tab 150 mg	75.10	14	Vimpat
-	300.40	56	Vimpat
↓ Tab 200 mg		56	Vimpat

Inj 10 mg per ml, 20 ml vial

⇒ Restricted (RS1151)

Initiation

Re-assessment required after 15 months Both:

- 1 Patient has partial-onset epilepsy; and
- 2 Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note).

Note: "Optimal treatment" is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not required to have a trial of sodium valproate.

Continuation

Patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life compared with that prior to starting lacosamide treatment (see Note).

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective

LAMOTRIGINE

Tab dispersible 2 mg		30	Lamictal
Tab dispersible 5 mg		30	Lamictal
Tab dispersible 25 mg - 5% DV Oct-19 to 2022	2.76	56	Logem
Tab dispersible 50 mg - 5% DV Oct-19 to 2022		56	Logem
Tab dispersible 100 mg - 5% DV Oct-19 to 2022	4.40	56	Logem
LEVETIRACETAM			
Tab 250 mg - 1% DV Aug-19 to 2022	4.99	60	Everet
Tab 500 mg - 1% DV Aug-19 to 2022		60	Everet
Tab 750 mg - 1% DV Aug-19 to 2022	14.39	60	Everet
Tab 1,000 mg - 1% DV Aug-19 to 2022		60	Everet
Oral liq 100 mg per ml		300 ml	Levetiracetam-AFT
Inj 100 mg per ml, 5 ml vial - 1% DV Oct-19 to 2022		10	Levetiracetam-AFT
PHENOBARBITONE			
Tab 15 mg - 1% DV Oct-18 to 2021		500	PSM
Tab 30 mg - 1% DV Oct-18 to 2021		500	PSM
PHENYTOIN			
Tab 50 mg			
PHENYTOIN SODIUM			
Cap 30 mg			
Cap 100 mg			
Oral liq 6 mg per ml			

t Item restricted (see \Rightarrow above); **f** Item restricted (see \Rightarrow below)

e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST)		Brand or Generic
	(ex man. excl. GST) \$	Per	Manufacturer
PREGABALIN			
Note: Pregabalin not to be given in combination with gabaper	itin		
Cap 25 mg – 1% DV Jul-18 to 2021		56	Pregabalin Pfizer
Cap 75 mg – 1% DV Jul-18 to 2021		56	Pregabalin Pfizer
Cap 150 mg – 1% DV Jul-18 to 2021		56	Pregabalin Pfizer
Cap 300 mg - 1% DV Jul-18 to 2021		56	Pregabalin Pfizer
		00	i rogubullir i lizor
PRIMIDONE			
Tab 250 mg			
SODIUM VALPROATE			
Tab 100 mg			
Tab EC 200 mg			
Tab EC 500 mg			
Oral liq 40 mg per ml			
Inj 100 mg per ml, 4 ml vial - 1% DV Sep-18 to 2021	9.98	1	Epilim IV
STIRIPENTOL - Restricted see terms below			-
Cap 250 mg.	509 29	60	Diacomit
Powder for oral liq 250 mg sachet		60	Diacomit
→ Restricted (RS1152)		00	Diaconni
nitiation			
nitiation			
Paediatric neurologist			
Paediatric neurologist Re-assessment required after 6 months			
Paediatric neurologist Re-assessment required after 6 months Both:			
Paediatric neurologist Re-assessment required after 6 months Both: 1 Patient has confirmed diagnosis of Dravet syndrome; and	<i>.</i>		
Paediatric neurologist Re-assessment required after 6 months Both: 1 Patient has confirmed diagnosis of Dravet syndrome; and 2 Seizures have been inadequately controlled by appropriate	courses of sodium valpro	pate, clob	azam and at least two of
 Paediatric neurologist Re-assessment required after 6 months Both: Patient has confirmed diagnosis of Dravet syndrome; and Seizures have been inadequately controlled by appropriate following: topiramate, levetiracetam, ketogenic diet. 	courses of sodium valpro	pate, clob	azam and at least two of
 Paediatric neurologist Re-assessment required after 6 months Both: Patient has confirmed diagnosis of Dravet syndrome; and Seizures have been inadequately controlled by appropriate following: topiramate, levetiracetam, ketogenic diet. Continuation 	courses of sodium valpro	oate, clob	azam and at least two of
 Paediatric neurologist Re-assessment required after 6 months Both: Patient has confirmed diagnosis of Dravet syndrome; and Seizures have been inadequately controlled by appropriate following: topiramate, levetiracetam, ketogenic diet. Continuation Paediatric neurologist			
 Paediatric neurologist Re-assessment required after 6 months Both: Patient has confirmed diagnosis of Dravet syndrome; and Seizures have been inadequately controlled by appropriate following: topiramate, levetiracetam, ketogenic diet. Continuation 			
 Paediatric neurologist Re-assessment required after 6 months Both: Patient has confirmed diagnosis of Dravet syndrome; and Seizures have been inadequately controlled by appropriate following: topiramate, levetiracetam, ketogenic diet. Continuation Paediatric neurologist			
 Paediatric neurologist Re-assessment required after 6 months Both: Patient has confirmed diagnosis of Dravet syndrome; and Seizures have been inadequately controlled by appropriate following: topiramate, levetiracetam, ketogenic diet. Continuation Paediatric neurologist Patient continues to benefit from treatment as measured by reduced 	ed seizure frequency from		
 Paediatric neurologist Re-assessment required after 6 months Both: Patient has confirmed diagnosis of Dravet syndrome; and Seizures have been inadequately controlled by appropriate following: topiramate, levetiracetam, ketogenic diet. Continuation Paediatric neurologist Paediatric neurologist Patient continues to benefit from treatment as measured by reduce FOPIRAMATE 	ed seizure frequency from	baseline	Э.
 Paediatric neurologist Re-assessment required after 6 months Both: Patient has confirmed diagnosis of Dravet syndrome; and Seizures have been inadequately controlled by appropriate following: topiramate, levetiracetam, ketogenic diet. Continuation Paediatric neurologist Paediatric neurologist Patient continues to benefit from treatment as measured by reduce FOPIRAMATE 	ed seizure frequency from	baseline	e. Arrow-Topiramate
 Paediatric neurologist Re-assessment required after 6 months Both: Patient has confirmed diagnosis of Dravet syndrome; and Seizures have been inadequately controlled by appropriate following: topiramate, levetiracetam, ketogenic diet. Continuation Paediatric neurologist Paediatric neurologist Patient continues to benefit from treatment as measured by reduce FOPIRAMATE 	ed seizure frequency from 11.07 26.04 11.07	baseline	e. Arrow-Topiramate Topamax
 Paediatric neurologist Re-assessment required after 6 months Both: Patient has confirmed diagnosis of Dravet syndrome; and Seizures have been inadequately controlled by appropriate following: topiramate, levetiracetam, ketogenic diet. Continuation Paediatric neurologist Patient continues to benefit from treatment as measured by reduce TOPIRAMATE Tab 25 mg Tab 25 mg 	ed seizure frequency from 11.07 26.04 11.07	ı baseline 60	e. Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate
 Paediatric neurologist Re-assessment required after 6 months Both: Patient has confirmed diagnosis of Dravet syndrome; and Seizures have been inadequately controlled by appropriate following: topiramate, levetiracetam, ketogenic diet. Continuation Paediatric neurologist Patient continues to benefit from treatment as measured by reduce TOPIRAMATE Tab 25 mg Tab 25 mg 	ed seizure frequency from 11.07 26.04 11.07 18.81	ı baseline 60	e. Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax
 Paediatric neurologist Re-assessment required after 6 months Both: Patient has confirmed diagnosis of Dravet syndrome; and Seizures have been inadequately controlled by appropriate following: topiramate, levetiracetam, ketogenic diet. Continuation Paediatric neurologist Patient continues to benefit from treatment as measured by reduce FOPIRAMATE Tab 25 mg Tab 50 mg 	ed seizure frequency from 11.07 26.04 11.07 18.81 44.26 18.81	ı baseline 60	e. Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax Topiramate Actavis
 Paediatric neurologist Re-assessment required after 6 months Both: Patient has confirmed diagnosis of Dravet syndrome; and Seizures have been inadequately controlled by appropriate following: topiramate, levetiracetam, ketogenic diet. Continuation Paediatric neurologist Patient continues to benefit from treatment as measured by reduce TOPIRAMATE Tab 25 mg Tab 25 mg 	ed seizure frequency from 26.04 11.07 	baseline 60 60	e. Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate
 Paediatric neurologist Re-assessment required after 6 months Both: Patient has confirmed diagnosis of Dravet syndrome; and Seizures have been inadequately controlled by appropriate following: topiramate, levetiracetam, ketogenic diet. Continuation Paediatric neurologist Patient continues to benefit from treatment as measured by reduce FOPIRAMATE Tab 25 mg Tab 50 mg 	ed seizure frequency from 26.04 11.07 	baseline 60 60	e. Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax
 Paediatric neurologist Re-assessment required after 6 months Both: Patient has confirmed diagnosis of Dravet syndrome; and Seizures have been inadequately controlled by appropriate following: topiramate, levetiracetam, ketogenic diet. Continuation Patient continues to benefit from treatment as measured by reduce TOPIRAMATE Tab 25 mg Tab 50 mg Tab 100 mg 	ed seizure frequency from 26.04 11.07 18.81 44.26 18.81 31.99 75.25 31.99	baseline 60 60 60	Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax Topiramate Actavis Topiramate Actavis
 Paediatric neurologist Re-assessment required after 6 months Both: Patient has confirmed diagnosis of Dravet syndrome; and Seizures have been inadequately controlled by appropriate following: topiramate, levetiracetam, ketogenic diet. Continuation Paediatric neurologist Patient continues to benefit from treatment as measured by reduce FOPIRAMATE Tab 25 mg Tab 50 mg 	ed seizure frequency from 26.04 11.07 18.81 44.26 18.81 31.99 75.25 31.99 	baseline 60 60	Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate
 Paediatric neurologist Re-assessment required after 6 months Both: Patient has confirmed diagnosis of Dravet syndrome; and Seizures have been inadequately controlled by appropriate following: topiramate, levetiracetam, ketogenic diet. Continuation Patient continues to benefit from treatment as measured by reduce TOPIRAMATE Tab 25 mg Tab 50 mg Tab 100 mg 	ed seizure frequency from 26.04 11.07 18.81 44.26 18.81 31.99 75.25 31.99 55.19 129.85	baseline 60 60 60	Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topiramate Actavis Arrow-Topiramate Topamax
 Paediatric neurologist Re-assessment required after 6 months Both: Patient has confirmed diagnosis of Dravet syndrome; and Seizures have been inadequately controlled by appropriate following: topiramate, levetiracetam, ketogenic diet. Continuation Paediatric neurologist Paediatric neurologist Patient continues to benefit from treatment as measured by reduce TOPIRAMATE Tab 25 mg Tab 50 mg Tab 100 mg Tab 200 mg	ed seizure frequency from 26.04 11.07 26.04 11.07 18.81 44.26 18.81 31.99 75.25 31.99 55.19 129.85 55.19	60 60 60 60 60	Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax
 Paediatric neurologist Re-assessment required after 6 months Both: Patient has confirmed diagnosis of Dravet syndrome; and Seizures have been inadequately controlled by appropriate following: topiramate, levetiracetam, ketogenic diet. Continuation Patient continues to benefit from treatment as measured by reduce TOPIRAMATE Tab 25 mg Tab 50 mg Tab 100 mg 	ed seizure frequency from 26.04 11.07 26.04 11.07 18.81 44.26 18.81 31.99 75.25 31.99 55.19 129.85 55.19 129.85 55.19 20.84	baseline 60 60 60	Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topiramate Actavis Arrow-Topiramate Topamax

- → Restricted (RS1739)

Initiation

Re-assessment required after 15 months Both:

Price		Brand or	1
(ex man. excl. GST)		Generic	
 \$	Per	Manufacturer	

continued...

- 1 Either:
 - 1.1 Patient has infantile spasms; or
 - 1.2 Both:
 - 1.2.1 Patient has epilepsy; and
 - 1.2.2 Either:
 - 1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
 - 1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; and

2 Either:

- 2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or
- 2.2 It is impractical or impossible (due to comorbid conditions, or health system capacity constraints) to monitor the patient's visual fields.

Notes: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages. Continuation

Both:

- 1 The patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life; and
- 2 Either:
 - 2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin; or
 - 2.2 It is impractical or impossible (due to comorbid conditions, or health system capacity constraints) to monitor the patient's visual fields.

Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

Antimigraine Preparations

Acute Migraine Treatment

DIHYDROERGOTAMINE MESYLATE

Inj 1 mg per ml, 1 ml ampoule

METOCLOPRAMIDE HYDROCHLORIDE WITH PARACETAMOL

Tab 5 mg with paracetamol 500 mg

RIZATRIPTAN

116

Tab orodispersible 10 mg - 1% DV Oct-20 to 2023	30	Rizamelt
SUMATRIPTAN		
Tab 50 mg - 1% DV Oct-19 to 2022	100	Apo-Sumatriptan
Tab 100 mg - 1% DV Oct-19 to 2022	100	Apo-Sumatriptan
Inj 12 mg per ml, 0.5 ml prefilled pen - 1% DV Sep-20 to 2022	2	Imigran
Prophylaxis of Migraine		
PIZOTIFEN		

Tab 500 mcg	23.21	100	Sandomigran

e.g. Brand indicates brand example only. It is not a contracted product.

	Price		Brand or				
	(ex man. excl. GST) \$	Per	Generic Manufacturer				
Antinausea and Vertigo Agents							
APREPITANT - Restricted see terms below ↓ Cap 2 × 80 mg and 1 × 125 mg - 1% DV Jul-18 to 2021 → Restricted (RS1154) Initiation		3	Emend Tri-Pack				
Patient is undergoing highly emetogenic chemotherapy and/or anthr malignancy.	acycline-based chemoth	nerapy fo	r the treatment of				
BETAHISTINE DIHYDROCHLORIDE Tab 16 mg - 1% DV Nov-20 to 2023	3.88	84	Vergo 16				
CYCLIZINE HYDROCHLORIDE Tab 50 mg – 1% DV Jan-19 to 2021	0.55	10	Nausicalm				
CYCLIZINE LACTATE Inj 50 mg per ml, 1 ml ampoule	14.95	5	Nausicalm				
DOMPERIDONE Tab 10 mg - 1% DV Mar-19 to 2021	2.25	100	Pharmacy Health				
DROPERIDOL Inj 2.5 mg per ml, 1 ml ampoule - 1% DV May-20 to 2022		10	Droleptan				
GRANISETRON Inj 1 mg per ml, 3 ml ampoule – 1% DV Jan-21 to 2023	1.20	1	Deva				
HYOSCINE HYDROBROMIDE Inj 400 mcg per ml, 1 ml ampoule Patch 1.5 mg		2	Scopoderm TTS				
→ Restricted (RS1155) Initiation							
 Initiation Any of the following: Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease where the patient cannot tolerate or does not adequately respond to oral anti-nausea agents; or Control of clozapine-induced hypersalivation where trials of at least two other alternative treatments have proven ineffective; or For treatment of post-operative nausea and vomiting where cyclizine, droperidol and a 5HT3 antagonist have proven ineffective, are not tolerated or are contraindicated. 							
METOCLOPRAMIDE HYDROCHLORIDE Tab 10 mg - 1% DV Oct-20 to 2023	1.30	100	Metoclopramide Actavis 10				
Oral liq 5 mg per 5 ml Inj 5 mg per ml, 2 ml ampoule – 1% DV Jan-20 to 2022	9.50	10	Pfizer				
ONDANSETRON							
Tab 4 mg – 1% DV Apr-20 to 2022 Tab dispersible 4 mg – 1% DV Oct-20 to 2023		50 10	Onrex Ondansetron ODT-DRLA				
Tab 8 mg – 1% DV Apr-20 to 2022	4.57	50	Onrex				
Tab dispersible 8 mg - 1% DV Oct-20 to 2023		10	Ondansetron ODT-DRLA				
Inj 2 mg per ml, 2 ml ampoule		5	Ondansetron-Claris				
Inj 2 mg per ml, 4 ml ampoule	2.20	5	Ondansetron Kabi				

	Price (ex man. excl. G \$	ST) Per	Brand or Generic Manufacturer
ROCHLORPERAZINE			
Tab buccal 3 mg			
Tab 5 mg - 1% DV Dec-20 to 2023	8.00	250	Nausafix
Inj 12.5 mg per ml, 1 ml ampoule			
Suppos 25 mg			
ROPISETRON			
Inj 1 mg per ml, 2 ml ampoule - 1% DV Sep-18 to 2021	8.95	1	Tropisetron-AFT
Inj 1 mg per ml, 5 ml ampoule		1	Tropisetron-AFT
Antipsychotic Agents			
General			
MISULPRIDE			
Tab 100 mg - 1% DV Nov-19 to 2022	5.15	30	Sulprix
Tab 200 mg - 1% DV Nov-19 to 2022	14.96	60	Sulprix
Tab 400 mg - 1% DV Feb-20 to 2022	29.78	60	Sulprix
Oral liq 100 mg per ml			
RIPIPRAZOLE			
Tab 5 mg - 1% DV Aug-18 to 2021	17.50	30	Aripiprazole Sandoz
Tab 10 mg - 1% DV Aug-18 to 2021		30	Aripiprazole Sandoz
Tab 15 mg - 1% DV Aug-18 to 2021		30	Aripiprazole Sandoz
Tab 20 mg - 1% DV Aug-18 to 2021		30	Aripiprazole Sandoz
Tab 30 mg – 1% DV Aug-18 to 2021	17.50	30	Aripiprazole Sandoz
HLORPROMAZINE HYDROCHLORIDE			
Tab 10 mg - 1% DV Jan-20 to 2022		100	Largactil
Tab 25 mg - 1% DV Jan-20 to 2022		100	Largactil
Tab 100 mg – 1% DV Jan-20 to 2022		100	Largactil
Oral liq 10 mg per ml			
Oral liq 20 mg per ml	20.70	10	Largactil
Inj 25 mg per ml, 2 ml ampoule – 1% DV Jan-20 to 2022		10	Largactil
	0.00	50	Olanina
Tab 25 mg		50	Clopine Clopine
	13.37 5.69	100 50	Clozaril
	11.36	100	Clozaril
Tab 50 mg		50	Clopine
	17.33	100	Clopine
Tab 100 mg		50	Clopine
-	34.65	100	Clopine
	14.73	50	Clozaril
	29.45	100	Clozaril
		50	Clopine
Tab 200 mg	69.30	100	Clopine
-	1	100 ml	Clopine
Oral liq 50 mg per ml	17.33		
Oral liq 50 mg per ml			
Oral liq 50 mg per ml ALOPERIDOL Tab 500 mcg – 1% DV Oct-19 to 2022	6.23	100	Serenace
Oral liq 50 mg per ml ALOPERIDOL Tab 500 mcg – 1% DV Oct-19 to 2022 Tab 1.5 mg – 1% DV Oct-19 to 2022		100	Serenace
Oral liq 50 mg per ml ALOPERIDOL Tab 500 mcg – 1% DV Oct-19 to 2022			

t Item restricted (see → above); t Item restricted (see → below)

e.g. Brand indicates brand example only. It is not a contracted product.

118

	Price		Brand or
	(ex man. excl. GST) \$) Per	Generic Manufacturer
LEVOMEPROMAZINE			
Tab 25 mg - 1% DV Sep-19 to 2022		100	Nozinan
Tab 100 mg - 1% DV Sep-19 to 2022	41.75	100	Nozinan
LEVOMEPROMAZINE HYDROCHLORIDE			
Inj 25 mg per ml, 1 ml ampoule - 1% DV Apr-20 to 2022		10	Nozinan
LITHIUM CARBONATE			
Tab long-acting 400 mg			
Tab 250 mg		500	Lithicarb FC
Cap 250 mg	9.42	100	Douglas
(Lithicarb FC Tab 250 mg to be delisted 1 November 2020)			-
OLANZAPINE			
Tab 2.5 mg – 1% DV Nov-20 to 2023		28	Zypine
Tab 5 mg – 1% DV Nov-20 to 2023		28	Zypine
Tab orodispersible 5 mg - 1% DV Nov-20 to 2023	1.81	28	Zypine ODT
Tab 10 mg - 1% DV Nov-20 to 2023	2.01	28	Zypine
Tab orodispersible 10 mg - 1% DV Nov-20 to 2023	2.38	28	Zypine ODT
Inj 10 mg vial			
PERICYAZINE			
Tab 2.5 mg			
Tab 10 mg			
QUETIAPINE			
Tab 25 mg - 1% DV Nov-20 to 2023	2.15	90	Quetapel
Tab 100 mg - 1% DV Nov-20 to 2023		90	Quetapel
Tab 200 mg - 1% DV Nov-20 to 2023		90	Quetapel
Tab 300 mg - 1% DV Nov-20 to 2023		90	Quetapel
RISPERIDONE			
Tab 0.5 mg – 1% DV Dec-20 to 2023		60	Risperidone (Teva)
Tab 1 mg - 1% DV Dec-20 to 2023		60	Risperidone (Teva)
Tab 2 mg - 1% DV Dec-20 to 2023	2.29	60	Risperidone (Teva)
Tab 3 mg - 1% DV Dec-20 to 2023	2.50	60	Risperidone (Teva)
Tab 4 mg - 1% DV Dec-20 to 2023		60	Risperidone (Teva)
Oral liq 1 mg per ml – 1% DV Nov-20 to 2023	8.90	30 ml	Risperon
ZIPRASIDONE			
Cap 20 mg - 1% DV Dec-18 to 2021		60	Zusdone
Cap 40 mg - 1% DV Sep-18 to 2021		60	Zusdone
Cap 60 mg - 1% DV Sep-18 to 2021		60	Zusdone
Cap 80 mg – 1% DV Sep-18 to 2021		60	Zusdone
ZUCLOPENTHIXOL ACETATE			
Inj 50 mg per ml, 1 ml ampoule			
Inj 50 mg per ml, 2 ml ampoule			
ZUCLOPENTHIXOL HYDROCHLORIDE			
Tab 10 mg	31.45	100	Clopixol
Depot Injections			
FLUPENTHIXOL DECANOATE			
Inj 20 mg per ml, 1 ml ampoule		5	Fluanxol
Inj 20 mg per ml, 2 ml ampoule		5	Fluanxol
Inj 100 mg per ml, 1 ml ampoule		5	Fluanxol

Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

Price (ex man. excl. GS \$) Per	Brand or Generic Manufacturer
HALOPERIDOL DECANOATE			
Inj 50 mg per ml, 1 ml ampoule		5	Haldol
Inj 100 mg per ml, 1 ml ampoule	55.90	5	Haldol Concentrate
OLANZAPINE – Restricted see terms below			
Inj 210 mg vial – 1% DV Oct-18 to 2021	252.00	1	Zyprexa Relprevv
Inj 300 mg vial - 1% DV Oct-18 to 2021		1	Zyprexa Relprevv
Inj 405 mg vial − 1% DV Oct-18 to 2021		1	Zyprexa Relprevv

➡ Restricted (RS1379)

Initiation

Re-assessment required after 12 months Either:

1 The patient has had an initial Special Authority approval for risperidone depot injection or paliperidone depot injection; or

- 2 All of the following:
 - 2.1 The patient has schizophrenia; and
 - 2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

Continuation

Re-assessment required after 12 months

The initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

PALIPERIDONE - Restricted see terms below

t	Inj 25 mg syringe	 1	Invega Sustenna
	Inj 50 mg syringe	1	Invega Sustenna
	Inj 75 mg syringe	1	Invega Sustenna
	Inj 100 mg syringe	1	Invega Sustenna
	Inj 150 mg syringe	1	Invega Sustenna
	Destricted (D01001)		5

→ Restricted (RS1381)

Initiation

Re-assessment required after 12 months Either:

1 The patient has had an initial Special Authority approval for risperidone depot injection or olanzapine depot injection; or

- 2 All of the following:
 - 2.1 The patient has schizophrenia or other psychotic disorder; and
 - 2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

Continuation

120

Re-assessment required after 12 months

The initiation of paliperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

PIPOTHIAZINE PALMITATE - Restricted: For continuation only

- → Inj 50 mg per ml, 1 ml ampoule
- ➡ Inj 50 mg per ml, 2 ml ampoule

RISPERIDONE - Restricted see terms on the next page

t	Inj 25 mg vial	3 1	Risperdal Consta
t	Inj 37.5 mg vial	1	Risperdal Consta
t	Inj 50 mg vial	6 1	Risperdal Consta

Price Brand or (ex man. excl. GST) Generic \$ Per Manufacturer
--

➡ Restricted (RS1380)

Initiation

Re-assessment required after 12 months

Either:

- 1 The patient has had an initial Special Authority approval for paliperidone depot injection or olanzapine depot injection; or
- 2 All of the following:
 - 2.1 The patient has schizophrenia or other psychotic disorder; and
 - 2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

Continuation

Re-assessment required after 12 months

The initiation of risperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

ZUCLOPENTHIXOL DECANOATE

Inj 200 mg per ml, 1 ml ampoule	5	Clopixol e.g. Clopixol Conc
Anxiolytics		
BUSPIRONE HYDROCHLORIDE		
Tab 5 mg - 1% DV Sep-18 to 2021	100	Orion
Tab 10 mg - 1% DV Sep-18 to 2021	100	Orion
CLONAZEPAM		
Tab 500 mcg - 1% DV Jun-18 to 2021	100	Paxam
Tab 2 mg - 1% DV Jun-18 to 2021	100	Paxam
DIAZEPAM		
Tab 2 mg - 1% DV Dec-20 to 2023	500	Arrow-Diazepam
Tab 5 mg - 1% DV Dec-20 to 2023	500	Arrow-Diazepam
LORAZEPAM		•
Tab 1 mg - 1% DV Sep-18 to 2021	250	Ativan
Tab 2.5 mg - 1% DV Sep-18 to 2021	100	Ativan
OXAZEPAM		
Tab 10 mg	100	Ox-Pam
Tab 15 mg	100	Ox-Pam
,		
Multiple Sclerosis Treatments		
DIMETHYL FUMARATE – Restricted see terms below		
Cap 120 mg	14	Tecfidera

ŧ	Cap 120 mg		14	Tecfidera
t	Cap 240 mg	2,000.00	56	Tecfidera

→ Restricted (RS1504)

Initiation

Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).

FIN	VGOLIMOD – Restricted see terms on the next page			
t	Cap 0.5 mg2	2,200.00	28	Gilenya

	(ex man	Price . excl. \$	GST)	Per	Brand or Generic Manufacturer
Restricted (RS1433)					
itiation International in patients with approval by the Multiple Calenasis Track	mont Accor		+ 0		ICTAC) Applications will be
nly for use in patients with approval by the Multiple Sclerosis Treat onsidered by MSTAC at its regular meetings and approved subject					
ut in Section B of the Pharmaceutical Schedule).		accoi	ung to		ry and Stopping chiena (se
ATALIZUMAB – Restricted see terms below Ini 20 mg per ml. 15 ml vial	4	750.0	^	1	Tupohri
Inj 20 mg per ml, 15 ml vial • Restricted (RS1447)	I,	750.0	0	I	Tysabri
itiation					
inly for use in patients with approval by the Multiple Sclerosis Treat	Imont Accor	emon	t Comn	hittaa (M	ISTAC) Applications will be
posidered by MSTAC at its regular meetings and approved subject					, ,,
ut in Section B of the Pharmaceutical Schedule).	to ongronity	40001	ung to		y and otopping ontona (oo
CRELIZUMAB – Restricted see terms below					
Inj 30 mg per ml, 10 ml vial	9	346.0	0	1	Ocrevus
Restricted (RS1711)		010.0	•	•	0010100
litiation					
Inly for use in patients with approval by the Multiple Sclerosis Treat	tment Asses	smen	t Comn	nittee (M	ISTAC). Applications will be
onsidered by MSTAC at its regular meetings and approved subject					
ut in Section B of the Pharmaceutical Schedule).	0,		•		
ERIFLUNOMIDE - Restricted see terms below					
Tab 14 mg	1,	582.6	2	28	Aubagio
Restricted (RS1505)					-
itiation					
nly for use in patients with approval by the Multiple Sclerosis Treat	tment Asses	smen	t Comn	nittee (M	ISTAC). Applications will b

Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).

Other Multiple Sclerosis Treatments

➡ Restricted (RS1434)

Initiation

Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).

GLATIRAMER ACETATE – Restricted see terms above 1 Inj 40 mg prefilled syringe	2,275.00	12	Copaxone
INTERFERON BETA-1-ALPHA - Restricted see terms above			
t Inj 6 million iu in 0.5 ml pen injector	1,170.00	4	Avonex Pen
1 Inj 6 million iu in 0.5 ml syringe	1,170.00	4	Avonex

INTERFERON BETA-1-BETA - Restricted see terms above

1 Inj 8 million iu per ml, 1 ml vial

Sedatives and Hypnotics

CHLORAL HYDRATE

Oral liq 100 mg per ml Oral liq 200 mg per ml

LORMETAZEPAM - Restricted: For continuation only

➡ Tab 1 mg

		Price excl. GS \$	ST)	Per	Brand or Generic Manufacturer
MELATONIN – Restricted see terms below Tab modified-release 2 mg Tab 3 mg				30	Circadin
 Note: Only for use in compounding an oral liquid formulation, f Restricted (RS1576) Initiation – insomnia secondary to neurodevelopmental disorder Psychiatrist, paediatrician, neurologist or respiratory specialist <i>Re-assessment required after 12 months</i> All of the following: Patient has been diagnosed with persistent and distressing insoon (including, but not limited to, autism spectrum disorder or attentiot Behavioural and environmental approaches have been tried or a Funded modified-release melatonin is to be given at doses no gi Patient is aged 18 years or under. Continuation – insomnia secondary to neurodevelopmental disorder Psychiatrist, paediatrician, neurologist or respiratory specialist <i>Re-assessment required after 12 months</i> All of the following: Patient is aged 18 years or under; and Patient has demonstrated clinically meaningful benefit from fund Patient has had a trial of funded modified-release melatonin disc recurrence of persistent and distressing insomnia; and Funded modified-release melatonin is to be given at doses no gi Initiation – insomnia where benzodiazepines and zopiclone are con Both: Patient has insomnia and benzodiazepines and zopiclone are con 	mnia sec on deficit re inapp reater the ed modi continuat continuat reater the ntraindic	in ondary to hyperac ropriate; an 10 mg fied-relea ion withir an 10 mg cated	o a i tivity and per	neurode y disorda r day; ar melatoni e past 12	er); and d n (clinician determined); and
MIDAZOLAM Tab 7.5 mg Oral liq 2 mg per ml Inj 1 mg per ml, 5 ml ampoule – 1% DV Jan-19 to 2021 Inj 5 mg per ml, 3 ml ampoule – 1% DV Jan-19 to 2021 PHENOBARBITONE Inj 200 mg per ml, 1 ml ampoule TEMAZEPAM				10 5	Mylan Midazolam Mylan Midazolam
Tab 10 mg – 1% DV Nov-20 to 2023 TRIAZOLAM – Restricted: For continuation only → Tab 125 mcg → Tab 250 mcg ZOPICLONE Tab 7.5 mg		1.33		25	Normison

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Stimulants / ADHD Treatments			
TOMOXETINE			
Cap 10 mg – 1% DV Sep-20 to 2022	18.41	28	Generic Partners
Cap 18 mg – 1% DV Sep-20 to 2022		28	Generic Partners
Cap 25 mg – 1% DV Sep-20 to 2022		28	Generic Partners
Cap 40 mg – 1% DV Sep-20 to 2022		28	Generic Partners
Cap 60 mg – 1% DV Sep-20 to 2022		28	Generic Partners
Cap 80 mg - 1% DV Sep-20 to 2022		28	Generic Partners
Cap 100 mg - 1% DV Sep-20 to 2022		28	Generic Partners
		20	denenc Farmers
AFFEINE Tab 100 mg			
5			
EXAMFETAMINE SULFATE – Restricted see terms below		105	
Tab 5 mg - 1% DV Oct-18 to 2021	20.00	100	PSM
Restricted (RS1169)			
itiation – ADHD			
aediatrician or psychiatrist	= =		
atient has ADHD (Attention Deficit and Hyperactivity Disorder), dia	agnosed according to DS	W-IV or	ICD 10 criteria.
itiation – Narcolepsy			
eurologist or respiratory specialist			
e-assessment required after 24 months			
1 3			
ontinuation – Narcolepsy			
ontinuation – Narcolepsy eurologist or respiratory specialist			
atient suffers from narcolepsy. continuation – Narcolepsy leurologist or respiratory specialist le-assessment required after 24 months			
ontinuation – Narcolepsy eurologist or respiratory specialist	m treatment.		
ontinuation – Narcolepsy eurologist or respiratory specialist e-assessment required after 24 months			
ontinuation – Narcolepsy eurologist or respiratory specialist <i>e-assessment required after 24 months</i> ne treatment remains appropriate and the patient is benefiting from ETHYLPHENIDATE HYDROCHLORIDE – Restricted see terms	s on the next page	30	Concerta
ontinuation – Narcolepsy eurologist or respiratory specialist <i>e-assessment required after 24 months</i> ne treatment remains appropriate and the patient is benefiting from ETHYLPHENIDATE HYDROCHLORIDE – Restricted see terms	s on the next page	30	Concerta Methylphenidate ER -
ontinuation – Narcolepsy eurologist or respiratory specialist <i>e-assessment required after 24 months</i> ne treatment remains appropriate and the patient is benefiting from ETHYLPHENIDATE HYDROCHLORIDE – Restricted see terms	s on the next page 58.96	30	
ontinuation – Narcolepsy eurologist or respiratory specialist <i>e-assessment required after 24 months</i> ne treatment remains appropriate and the patient is benefiting from ETHYLPHENIDATE HYDROCHLORIDE – Restricted see terms	s on the next page 58.96 18.20	30 30	Methylphenidate ER -
ontinuation – Narcolepsy eurologist or respiratory specialist <i>e-assessment required after 24 months</i> ne treatment remains appropriate and the patient is benefiting froi ETHYLPHENIDATE HYDROCHLORIDE – Restricted see terms Tab extended-release 18 mg	s on the next page 58.96 18.20		Methylphenidate ER - Teva
ontinuation – Narcolepsy eurologist or respiratory specialist <i>e-assessment required after 24 months</i> ne treatment remains appropriate and the patient is benefiting from ETHYLPHENIDATE HYDROCHLORIDE – Restricted see terms Tab extended-release 18 mg Tab extended-release 27 mg	s on the next page 		Methylphenidate ER - Teva Concerta
ontinuation – Narcolepsy eurologist or respiratory specialist <i>e-assessment required after 24 months</i> ne treatment remains appropriate and the patient is benefiting froi ETHYLPHENIDATE HYDROCHLORIDE – Restricted see terms Tab extended-release 18 mg	s on the next page 		Methylphenidate ER - Teva Concerta Methylphenidate ER -
ontinuation – Narcolepsy eurologist or respiratory specialist <i>e-assessment required after 24 months</i> ne treatment remains appropriate and the patient is benefiting from ETHYLPHENIDATE HYDROCHLORIDE – Restricted see terms Tab extended-release 18 mg Tab extended-release 27 mg	s on the next page 	30	Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva
ontinuation – Narcolepsy eurologist or respiratory specialist <i>e-assessment required after 24 months</i> ne treatment remains appropriate and the patient is benefiting from ETHYLPHENIDATE HYDROCHLORIDE – Restricted see terms Tab extended-release 18 mg Tab extended-release 27 mg Tab extended-release 26 mg	s on the next page 58.96 18.20 	30 30	Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva
ontinuation – Narcolepsy eurologist or respiratory specialist <i>e-assessment required after 24 months</i> ne treatment remains appropriate and the patient is benefiting from ETHYLPHENIDATE HYDROCHLORIDE – Restricted see terms Tab extended-release 18 mg Tab extended-release 27 mg	s on the next page 58.96 18.20 	30	Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Concerta Methylphenidate ER -
ontinuation – Narcolepsy eurologist or respiratory specialist <i>e-assessment required after 24 months</i> ne treatment remains appropriate and the patient is benefiting from ETHYLPHENIDATE HYDROCHLORIDE – Restricted see terms Tab extended-release 18 mg Tab extended-release 27 mg Tab extended-release 26 mg	s on the next page 58.96 18.20 	30 30	Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva
Dontinuation – Narcolepsy eurologist or respiratory specialist e-assessment required after 24 months ne treatment remains appropriate and the patient is benefiting from ETHYLPHENIDATE HYDROCHLORIDE – Restricted see terms Tab extended-release 18 mg Tab extended-release 27 mg Tab extended-release 36 mg Tab extended-release 54 mg	s on the next page 58.96 18.20 	30 30 30	Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva
Dontinuation – Narcolepsy eurologist or respiratory specialist e-assessment required after 24 months ne treatment remains appropriate and the patient is benefiting from ETHYLPHENIDATE HYDROCHLORIDE – Restricted see terms Tab extended-release 18 mg Tab extended-release 27 mg Tab extended-release 36 mg Tab extended-release 54 mg Tab immediate-release 5 mg	s on the next page 58.96 18.20 	30 30 30 30	Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Rubifen
ontinuation – Narcolepsy eurologist or respiratory specialist e-assessment required after 24 months ne treatment remains appropriate and the patient is benefiting from ETHYLPHENIDATE HYDROCHLORIDE – Restricted see terms Tab extended-release 18 mg Tab extended-release 27 mg Tab extended-release 36 mg Tab extended-release 54 mg	s on the next page 58.96 18.20 	30 30 30	Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Rubifen Ritalin
Datimuation – Narcolepsy Beurologist or respiratory specialist e-assessment required after 24 months ne treatment remains appropriate and the patient is benefiting from ETHYLPHENIDATE HYDROCHLORIDE – Restricted see terms Tab extended-release 18 mg Tab extended-release 27 mg Tab extended-release 36 mg Tab extended-release 54 mg Tab immediate-release 5 mg Tab immediate-release 10 mg	s on the next page 58.96 18.20 	30 30 30 30 30	Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Rubifen Ritalin Rubifen
Dontinuation – Narcolepsy eurologist or respiratory specialist e-assessment required after 24 months ne treatment remains appropriate and the patient is benefiting from ETHYLPHENIDATE HYDROCHLORIDE – Restricted see terms Tab extended-release 18 mg Tab extended-release 27 mg Tab extended-release 36 mg Tab extended-release 54 mg Tab immediate-release 5 mg Tab immediate-release 10 mg Tab immediate-release 20 mg	s on the next page 58.96 18.20 	30 30 30 30	Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Rubifen Ritalin Rubifen Rubifen
Dontinuation – Narcolepsy eurologist or respiratory specialist e-assessment required after 24 months ne treatment remains appropriate and the patient is benefiting from ETHYLPHENIDATE HYDROCHLORIDE – Restricted see terms Tab extended-release 18 mg Tab extended-release 27 mg Tab extended-release 36 mg Tab extended-release 54 mg Tab immediate-release 5 mg Tab immediate-release 10 mg	s on the next page 58.96 18.20 	30 30 30 30 30	Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Rubifen Ritalin Rubifen
Dontinuation – Narcolepsy Beurologist or respiratory specialist Be-assessment required after 24 months ne treatment remains appropriate and the patient is benefiting from ETHYLPHENIDATE HYDROCHLORIDE – Restricted see terms Tab extended-release 18 mg Tab extended-release 27 mg Tab extended-release 36 mg Tab extended-release 54 mg Tab immediate-release 5 mg Tab immediate-release 20 mg Tab immediate-release 20 mg Tab immediate-release 20 mg	s on the next page 58.96 18.20 65.44 22.00 71.93 22.40 86.24 26.40 3.20 3.00 7.85 50.00 10.95	30 30 30 30 30 30 30	Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Rubifen Ritalin Rubifen Rubifen
Datimuation – Narcolepsy Beurologist or respiratory specialist e-assessment required after 24 months ne treatment remains appropriate and the patient is benefiting from ETHYLPHENIDATE HYDROCHLORIDE – Restricted see terms Tab extended-release 18 mg Tab extended-release 27 mg Tab extended-release 36 mg Tab extended-release 54 mg Tab immediate-release 5 mg Tab immediate-release 10 mg Tab immediate-release 20 mg	s on the next page 58.96 18.20 65.44 22.00 71.93 22.40 86.24 26.40 3.20 3.00 7.85 50.00 10.95	30 30 30 30 30 30 30 30	Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Rubifen Ritalin Rubifen Rubifen Ritalin SR
Dontinuation – Narcolepsy Beurologist or respiratory specialist e-assessment required after 24 months he treatment remains appropriate and the patient is benefiting from ETHYLPHENIDATE HYDROCHLORIDE – Restricted see terms Tab extended-release 18 mg Tab extended-release 27 mg Tab extended-release 36 mg Tab extended-release 54 mg Tab immediate-release 5 mg Tab immediate-release 20 mg Tab immediate-release 20 mg Tab immediate-release 20 mg	s on the next page 58.96 18.20 65.44 22.00 71.93 22.40 86.24 26.40 3.20 3.00 7.85 50.00 10.95 15.60	30 30 30 30 30 30 30 100 30	Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Rubifen Ritalin Rubifen Rubifen Ritalin SR Rubifen SR
ontinuation – Narcolepsy eurologist or respiratory specialist e-assessment required after 24 months ne treatment remains appropriate and the patient is benefiting from ETHYLPHENIDATE HYDROCHLORIDE – Restricted see terms Tab extended-release 18 mg Tab extended-release 27 mg Tab extended-release 36 mg Tab extended-release 54 mg Tab immediate-release 5 mg Tab immediate-release 20 mg Tab immediate-release 20 mg Tab sustained-release 20 mg Cap modified-release 10 mg	s on the next page 58.96 18.20 	30 30 30 30 30 30 30 30 30 30 30	Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Rubifen Ritalin Rubifen Ritalin SR Rubifen SR Rubifen SR Ritalin LA
ontinuation – Narcolepsy eurologist or respiratory specialist e-assessment required after 24 months ne treatment remains appropriate and the patient is benefiting from ETHYLPHENIDATE HYDROCHLORIDE – Restricted see terms Tab extended-release 18 mg Tab extended-release 27 mg Tab extended-release 36 mg Tab extended-release 54 mg Tab immediate-release 5 mg Tab immediate-release 20 mg Tab immediate-release 20 mg Tab sustained-release 20 mg Cap modified-release 10 mg Cap modified-release 20 mg	s on the next page 58.96 18.20 	30 30 30 30 30 30 30 30 30 30 30	Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Concerta Methylphenidate ER - Teva Rubifen Ritalin Rubifen Ritalin SR Rubifen SR Ritalin LA Ritalin LA

t Item restricted (see → above); ↓ Item restricted (see → below) e.g. Brand indicates brand example only. It is not a contracted product.

	(ex man.	Price . excl. \$	GST)	Per	Brand or Generic Manufacturer
 → Restricted (RS1294) Initiation – ADHD (immediate-release and sustained-release form Paediatrician or psychiatrist Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diag Initiation – Narcolepsy (immediate-release and sustained-release Neurologist or respiratory specialist Re-assessment required after 24 months Patient suffers from narcolepsy. Continuation – Narcolepsy (immediate-release and sustained-release 	nosed acco e formulati	ions)		M-IV or l	CD 10 criteria.
Neurologist or respiratory specialist <i>Re-assessment required after 24 months</i> The treatment remains appropriate and the patient is benefiting from Initiation – Extended-release and modified-release formulations Paediatrician or psychiatrist Both:	treatment.				
 Patient has ADHD (Attention Deficit and Hyperactivity Disorde 2 Either: 2.1 Patient is taking a currently listed formulation of methyl sustained-release) which has not been effective due to 2.2 There is significant concern regarding the risk of divers hydrochloride. 	phenidate significant	hydro t admi	chlorid nistrati	e (immeo on and/o	tiate-release or r compliance difficulties; or
MODAFINIL – Restricted see terms below ↓ Tab 100 mg → Restricted (RS1761) Initiation – Narcolepsy Neurologist or respiratory specialist <i>Re-assessment required after 24 months</i> All of the following:		64.0	0	60	Modavigil
 The patient has a diagnosis of narcolepsy and has excessive almost daily for three months or more; and Any of the following: The patient has a multiple sleep latency test with a memore sleep onset rapid eye movement periods; or A multiple sleep latency test is not possible due to COV The patient has at least one of: cataplexy, sleep paraly 	an sleep la /ID-19 con	tency	of less ts on th	than or the health	equal to 10 minutes and 2 or sector; or
 3.1 An effective dose of a listed formulation of methylpheni because of intolerable side effects; or 3.2 Methylphenidate and dexamphetamine are contraindic Continuation – Narcolepsy Neurologist or respiratory specialist <i>Re-assessment required after 24 months</i> The treatment remains appropriate and the patient is benefiting from 	ated.	xampl	hetamii	ne has b	een trialled and discontinued
Treatments for Dementia DONEPEZIL HYDROCHLORIDE Tab 5 mg – 1% DV Dec-20 to 2023 Tab 10 mg – 1% DV Dec-20 to 2023				90 90	Donepezil-Rex Donepezil-Rex

	F (ex man.	Price excl. \$	GST)	Per	Brand or Generic Manufacturer
RIVASTIGMINE – Restricted see terms below ↓ Patch 4.6 mg per 24 hour – 1% DV Apr-20 to 2021 ↓ Patch 9.5 mg per 24 hour – 1% DV Apr-20 to 2021				30 30	Generic Partners Generic Partners
nitiation Re-assessment required after 6 months Both:					
 The patient has been diagnosed with dementia; and The patient has experienced intolerable nausea and/or vomiting Continuation 	g from dor	nepezi	il table	IS.	
le-assessment required after 12 months oth:					
 The treatment remains appropriate; and The patient has demonstrated a significant and sustained bene 	fit from tre	atme	nt.		
Treatments for Substance Dependence					
BUPRENORPHINE WITH NALOXONE - Restricted see terms below Tab 2 mg with naloxone 0.5 mg - 1% DV Apr-20 to 2022		.18.37	7	28	Buprenorphine
Tab 8 mg with naloxone 2 mg - 1% DV Apr-20 to 2022		.53.12	2	28	Naloxone BNM Buprenorphine Naloxone BNM
 Restricted (RS1172) nitiation – Detoxification If of the following: Patient is opioid dependent; and Patient is currently engaged with an opioid treatment service ap Prescriber works in an opioid treatment service approved by the 				y of Hea	lth; and
itiation – Maintenance treatment Il of the following: 1 Patient is opioid dependent; and	,				
 Patient will not be receiving methadone; and Patient will not be receiving methadone; and Patient is currently enrolled in an opioid substitution treatment p and Prescriber works in an opioid treatment service approved by the 	Ū			oproved	by the Ministry of Health;
UPROPION HYDROCHLORIDE Tab modified-release 150 mg		.11.00)	30	Zyban
ISULFIRAM Tab 200 mg	1	153.00)	100	Antabuse
ALTREXONE HYDROCHLORIDE – Restricted see terms below Tab 50 mg – 1% DV Jan-21 to 2023 Restricted (RS1173)	1	133.33	3	30	Naltraccord
nitiation – Alcohol dependence Both:					
 Patient is currently enrolled, or is planned to be enrolled, in a re dependence; and 	cognised	comp	rehens	sive treat	tment programme for alco

2 Naltrexone is to be prescribed by, or on the recommendation of, a physician working in an Alcohol and Drug Service.

Initiation – Constipation

126

For the treatment of opioid-induced constipation.

	Price	\	Brand or Generic
	(ex man. excl. GST \$) Per	Manufacturer
NICOTINE - Some items restricted see terms below			
Patch 7 mg per 24 hours		28	Habitrol
Patch 14 mg per 24 hours		28	Habitrol
Patch 21 mg per 24 hours		28	Habitrol
Oral spray 1 mg per dose			e.g. Nicorette QuickMist Mouth Spray
Lozenge 1 mg		216	Habitrol
Lozenge 2 mg	21.02	216	Habitrol
Soln for inhalation 15 mg cartridge			e.g. Nicorette Inhalator
Gum 2 mg		384	Habitrol (Fruit)
			Habitrol (Mint)
Gum 4 mg		384	Habitrol (Fruit)
			Habitrol (Mint)
➡ Restricted (RS1310)			
Initiation			
Any of the following:			
 For perioperative use in patients who have a 'nil by mouth' instruct 	ruction; or		
2 For use within mental health inpatient units; or			
3 For acute use in agitated patients who are unable to leave the l	hospital facilities.		
VARENICLINE - Restricted see terms below			
■ Tab 0.5 mg × 11 and 1 mg × 42 - 1% DV Mar-19 to 2021		53	Varenicline Pfizer
↓ Tab 1 mg - 1% DV Mar-19 to 2021		56	Varenicline Pfizer
→ Restricted (RS1702)			

Initiation

All of the following:

- 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and

3 Either:

- 3.1 The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or
- 3.2 The patient has tried but failed to quit smoking using bupropion or nortriptyline; and
- 4 The patient has not had a Special Authority for varenicline approved in the last 6 months; and
- 5 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
- 6 The patient is not pregnant; and
- 7 The patient will not be prescribed more than 12 weeks' funded varenicline in a 12 month period.

	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
Chemotherapeutic Agents			
Alkylating Agents			
BENDAMUSTINE HYDROCHLORIDE - Restricted see terms belo ↓ Inj 25 mg vial ↓ inj 100 mg vial → Restricted (RS1578) Initiation - treatment naive CLL All of the following: 1 The patient has Binet stage B or C, or progressive stage A ch 2 The patient is chemotherapy treatment naive; and	271.35 1,085.38	1 1 kaemia re	Ribomustin Ribomustin quiring treatment; and
 3 The patient is unable to tolerate toxicity of full-dose FCR; and 4 Patient has ECOG performance status 0-2; and 5 Patient has a Cumulative Illness Rating Scale (CIRS) score of 6 Bendamustine is to be administered at a maximum dose of 11 6 cycles. Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphot to comprise a known standard therapeutic chemotherapy regimen at Initiation – Indolent, Low-grade lymphomas 	of < 6; and 00 mg/m² on days 1 a cytic lymphoma (SLL)	Chemoth	
Re-assessment required after 9 months All of the following:			
 The patient has indolent low grade NHL requiring treatment; Patient has a WHO performance status of 0-2; and Either: 	and		
 3.1 Both: 3.1.1 Patient is treatment naive; and 3.1.2 Bendamustine is to be administered for a maxi CD20+); or 	imum of 6 cycles (in c	ombination	n with rituximab when
3.2 All of the following:			
3.2.1 Patient has relapsed refractory disease followin3.2.2 The patient has not received prior bendamustin3.2.3 Either:		r; and	
3.2.3.1 Both:			and an advention of a
3.2.3.1.1 Bendamustine is to be administer combination with rituximab when		cycles in	i relapsed patients (in
3.2.3.1.2 Patient has had a rituximab treatm	<i>,</i> .	2 months of	or more; or
3.2.3.2 Bendamustine is to be administered as a refractory patients.	a monotherapy for a n	naximum o	of 6 cycles in rituximab

Continuation - Indolent, Low-grade lymphomas

Re-assessment required after 9 months

Both:

128

- 1 Patients have not received a bendamustine regimen within the last 12 months; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+); and
 - 2.1.2 Patient has had a rituximab treatment-free interval of 12 months or more; or

e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
continued			
2.2 Bendamustine is to be administered as a monotherap	y for a maximum of 6 cy	cles in r	ituximab refractory patients.
Note: 'indolent, low-grade lymphomas' includes follicular, mantle cel macroglobulinaemia.	ll, marginal zone and ly	mphoplas	smacytic/ Waldenström's
0			
BUSULFAN Tab 2 mg	90.05	100	Mularan
Inj 6 mg per ml, 10 ml ampoule		100	Myleran
CARMUSTINE	1 207 00	1	BiCNU
Inj 100 mg vial	1,307.00	1	Bichu Heritage
CHLORAMBUCIL			Diena Hernage
Tab 2 mg			
5			
CYCLOPHOSPHAMIDE	70.00	50	F order on
Tab 50 mg		50	Endoxan
Inj 1 g vial - 1% DV Oct-18 to 2021	158.00	100 1	Procytox Endoxan
Inj 2 g vial – 1% DV Oct-18 to 2021		1	Endoxan
		1	Enuoxan
IFOSFAMIDE	00.00		11.1
Inj 1 g vial Inj 2 g vial		1 1	Holoxan Holoxan
		1	ΠΟΙΟΧάΠ
LOMUSTINE	100.50		•
Cap 10 mg		20	Ceenu
Cap 40 mg		20	Ceenu
MELPHALAN			
Tab 2 mg			
Inj 50 mg vial			
THIOTEPA			
Inj 15 mg vial			
Inj 100 mg vial			
Anthracyclines and Other Cytotoxic Antibiotics			
BLEOMYCIN SULPHATE			
Inj 15,000 iu vial – 1% DV Dec-18 to 2021	161.01	1	DBL Bleomycin Sulfate
DACTINOMYCIN [ACTINOMYCIN D]			
Inj 0.5 mg vial	255.00	1	Cosmegen
DAUNORUBICIN			
Inj 2 mg per ml, 10 ml vial	149.50	1	Pfizer
DOXORUBICIN HYDROCHLORIDE			
Inj 2 mg per ml, 5 ml vial			
Inj 2 mg per ml, 25 ml vial	11.50	1	Doxorubicin Ebewe
Note: DV limit applies to all 50 mg presentations of doxorul	bicin hydrochloride.		
Inj 50 mg vial			
Inj 2 mg per ml, 50 ml vial		1	Doxorubicin Ebewe
Inj 2 mg per ml, 100 ml vial – 1% DV Jan-19 to 2021	56.15	1	Doxorubicin Ebewe
EPIRUBICIN HYDROCHLORIDE			
	25.00	1	Epirubicin Ebewe
EPIRUBICIN HYDROCHLORIDE		1 1 1	Epirubicin Ebewe Epirubicin Ebewe Epirubicin Ebewe

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price		Brand or
	(ex man. excl. GST)		Generic
	\$	Per	Manufacturer
IDARUBICIN HYDROCHLORIDE			
Inj 5 mg vial – 1% DV Sep-18 to 2021	93.00	1	Zavedos
Inj 10 mg vial – 1% DV Sep-18 to 2021		1	Zavedos
MITOMYCIN C			
Inj 5 mg vial		1	Teva
Inj 20 mg vial	816.32	1	Omegapharm
(Omegapharm Inj 20 mg vial to be delisted 1 November 2020)			
MITOZANTRONE			· · · · · ·
Inj 2 mg per ml, 10 ml vial		1	Mitozantrone Ebewe
Antimetabolites			
AZACITIDINE – Restricted see terms below			
Inj 100 mg vial - 1% DV Dec-18 to 2021		1	Azacitidine Dr Reddy's
→ Restricted (RS1418)			
Initiation			
Haematologist			
Re-assessment required after 12 months All of the following:			
1 Any of the following:			
1.1 The patient has International Prognostic Scoring Sys	tem (IPSS) intermediate	-2 or high	risk myelodysplastic
syndrome; or		, 2 or nigi	riokinyolodyopidolio
1.2 The patient has chronic myelomonocytic leukaemia	10%-29% marrow blast	s without	myeloproliferative disorder);
or	•		
 The patient has acute myeloid leukaemia with 20-30 Health Organisation Classification (WHO); and 	% blasts and multi-linea	ge dyspla	sia, according to World
 The patient has performance status (WHO/ECOG) grade 0- The patient does not have secondary myelodysplastic syndi 		nical iniur	v or prior treatment with
chemotherapy and/or radiation for other diseases; and	0	,	, ,
4 The patient has an estimated life expectancy of at least 3 m	onths.		
Continuation			
Haematologist			
Re-assessment required after 12 months Both:			
1 No evidence of disease progression, and; and			
2 The treatment remains appropriate and patient is benefitting	from treatment.		
CAPECITABINE			
Tab 150 mg - 1% DV Jul-20 to 2022	10.00	60	Capercit
Tab 500 mg - 1% DV Jul-20 to 2022		120	Capercit
CLADRIBINE			•
Inj 2 mg per ml, 5 ml vial			
Inj 1 mg per ml, 10 ml vial	749.96	1	Leustatin
CYTARABINE			
Inj 20 mg per ml, 5 ml vial		5	Pfizer
Inj 100 mg per ml, 20 ml vial - 1% DV Dec-18 to 2021	41.36	1	Pfizer
FLUDARABINE PHOSPHATE			
Tab 10 mg – 1% DV Sep-18 to 2021		20	Fludara Oral
Inj 50 mg vial – 1% DV Nov-19 to 2022	576.45	5	Fludarabine Ebewe

130

	Price (ex man. excl. GS [*] \$	T) Per	Brand or Generic Manufacturer
FLUOROURACIL			
Inj 50 mg per ml, 20 ml vial – 1% DV Oct-18 to 2021		1	Fluorouracil Ebewe
Inj 50 mg per ml, 100 ml vial - 1% DV Oct-18 to 2021		1	Fluorouracil Ebewe
GEMCITABINE			
Inj 10 mg per ml, 100 ml vial - 1% DV Jul-20 to 2023		1	Gemcitabine Ebewe
MERCAPTOPURINE			
Tab 50 mg - 1% DV Jul-19 to 2022	37.00	25	Puri-nethol
Oral suspension 20 mg per ml		100 ml	Allmercap
→ Restricted (RS1635)			
Initiation			
Paediatric haematologist or paediatric oncologist			
Re-assessment required after 12 months			
The patient requires a total dose of less than one full 50 mg tablet p	er day.		
Continuation			
Paediatric haematologist or paediatric oncologist			
Re-assessment required after 12 months			
The patient requires a total dose of less than one full 50 mg tablet p	er day.		
METHOTREXATE			
Tab 2.5 mg - 1% DV Jan-19 to 2021	8.05	90	Trexate
Tab 10 mg - 1% DV Jan-19 to 2021		90	Trexate
Inj 2.5 mg per ml, 2 ml vial			
Inj 7.5 mg prefilled syringe	14.61	1	Methotrexate Sandoz
Inj 10 mg prefilled syringe		1	Methotrexate Sandoz
Inj 15 mg prefilled syringe	14.77	1	Methotrexate Sandoz
Inj 20 mg prefilled syringe		1	Methotrexate Sandoz
Inj 25 mg prefilled syringe	14.99	1	Methotrexate Sandoz
Inj 30 mg prefilled syringe		1	Methotrexate Sandoz
Inj 25 mg per ml, 2 ml vial		5	DBL Methotrexate
	45.00		Onco-Vial
Inj 25 mg per ml, 20 ml vial	45.00	1	DBL Methotrexate
Inj 100 mg per ml, 10 ml vial	25.00	1	Onco-Vial Methotrexate Ebewe
Inj 100 mg per ml, 50 ml vial – 1% DV Oct-20 to 2023		1	Methotrexate Ebewe
		I	
PEMETREXED – Restricted see terms below			
Inj 100 mg vial		1	Juno Pemetrexed
Inj 500 mg vial	217.77	1	Juno Pemetrexed
→ Restricted (RS1596)			
nitiation – Mesothelioma			

Re-assessment required after 8 months

Both:

- 1 Patient has been diagnosed with mesothelioma; and
- 2 Pemetrexed to be administered at a dose of 500 mg/m² every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles.

Continuation – Mesothelioma

Re-assessment required after 8 months

All of the following:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefitting from treatment; and

(ex man. exci. \$	Price (ex man. excl. GST)		
Ŷ	Per	Generic Manufacturer	
continued			
3 Pemetrexed to be administered at a dose of 500mg/m ² every 21 days for a max	kimum of 6 cy	cles.	
nitiation – Non small cell lung cancer			
Re-assessment required after 8 months Both:			
 Patient has locally advanced or metastatic non-squamous non-small cell lung of 2 Either: 	arcinoma; and	b	
2.1 Both:			
 2.1.1 Patient has chemotherapy-naïve disease; and 2.1.2 Pemetrexed is to be administered at a dose of 500 mg/m² every carboplatin for a maximum of 6 cycles; or 	21 days in co	mbination with cisplatin or	
2.2 All of the following:			
2.2.1 Patient has had first-line treatment with platinum based chemoth			
2.2.2 Patient has not received prior funded treatment with pemetrexed2.2.3 Pemetrexed is to be administered at a dose of 500 mg/m² every		maximum of 6 avalas	
Continuation – Non small cell lung cancer	21 uays 101 a	maximum of o cycles.	
Re-assessment required after 8 months			
All of the following:			
1 No evidence of disease progression; and 2. The treatment remains appropriate and the potient is benefitting from treatment	- ond		
 The treatment remains appropriate and the patient is benefitting from treatmen Pemetrexed is to be administered at a dose of 500mg/m² every 21 days. 	l, anu		
THIOGUANINE			
Tab 40 mg			
Other Cytotoxic Agents			
AMSACRINE Inj 50 mg per ml, 1.5 ml ampoule			
Inj 75 mg ANAGRELIDE HYDROCHLORIDE Cap 0.5 mg			
Inj 75 mg ANAGRELIDE HYDROCHLORIDE Cap 0.5 mg) 10	Phenasen	
Inj 75 mg ANAGRELIDE HYDROCHLORIDE Cap 0.5 mg ARSENIC TRIOXIDE Inj 1 mg per ml, 10 ml vial			
Inj 75 mg ANAGRELIDE HYDROCHLORIDE Cap 0.5 mg ARSENIC TRIOXIDE Inj 1 mg per ml, 10 ml vial		Phenasen Bortezomib Dr-Reddy'	
Inj 75 mg ANAGRELIDE HYDROCHLORIDE Cap 0.5 mg ARSENIC TRIOXIDE Inj 1 mg per ml, 10 ml vial			
Inj 75 mg ANAGRELIDE HYDROCHLORIDE Cap 0.5 mg ARSENIC TRIOXIDE Inj 1 mg per ml, 10 ml vial) 1		
Inj 75 mg ANAGRELIDE HYDROCHLORIDE Cap 0.5 mg ARSENIC TRIOXIDE Inj 1 mg per ml, 10 ml vial) 1	Bortezomib Dr-Reddy	
Inj 75 mg ANAGRELIDE HYDROCHLORIDE Cap 0.5 mg ARSENIC TRIOXIDE Inj 1 mg per ml, 10 ml vial) 1 ! 1	Bortezomib Dr-Reddy	

TOPOSIDE			
Cap 50 mg – 1% DV Jul-19 to 2022	340.73	20	Vepesid
Cap 100 mg - 1% DV Jul-19 to 2022	340.73	10	Vepesid
Inj 20 mg per ml, 5 ml vial	7.90	1	Rex Medical

t Item restricted (see → above); t Item restricted (see → below)

e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ETOPOSIDE (AS PHOSPHATE) Inj 100 mg vial		1	Etopophos
HYDROXYUREA [HYDROXYCARBAMIDE] Cap 500 mg - 1% DV Feb-21 to 2023	23.82 31.76	100	Devatis Hydrea
(Hydrea Cap 500 mg to be delisted 1 February 2021) IRINOTECAN HYDROCHLORIDE Inj 20 mg per ml, 5 ml vial – 1% DV Apr-19 to 2021		1	Irinotecan Actavis 100
LENALIDOMIDE – Restricted see terms below	5,122.76	28	Revlimid
Cap 10 mg	6,207.00	21 28	Revlimid Revlimid
Cap 15 mg	7,239.18	21 28	Revlimid Revlimid
 ↓ Cap 25 mg		21	Revlimid

Initiation – Relapsed/refractory disease Haematologist

Re-assessment required after 6 months All of the following:

1 Patient has relapsed or refractory multiple myeloma with progressive disease; and

- 2 Patient has not previously been treated with lenalidomide; and
- 3 Either:

3.1 Lenalidomide to be used as third line* treatment for multiple myeloma; or

- 3.2 Both:
 - 3.2.1 Lenalidomide to be used as second line treatment for multiple myeloma; and
 - 3.2.2 The patient has experienced severe (grade 3 or higher), dose limiting, peripheral neuropathy with either bortezomib or thalidomide that precludes further treatment with either of these treatments; and
- 4 Lenalidomide to be administered at a maximum dose of 25 mg/day in combination with dexamethasone.

Continuation - Relapsed/refractory disease

Haematologist

Re-assessment required after 6 months

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and patient is benefitting from treatment.

Initiation - Maintenance following first-line autologous stem cell transplant (SCT)

Haematologist

Re-assessment required after 6 months All of the following:

- 1 Patient has newly diagnosed symptomatic multiple myeloma and has undergone first-line treatment that included an autologous stem cell transplantation; and
- 2 Patient has at least a stable disease response in the first 100 days after transplantation; and
- 3 Lenalidomide maintenance is to be commenced within 6 months of transplantation; and
- 4 The patient has ECOG performance score of 0-1; and
- 5 Lenalidomide to be administered at a maximum dose of 15 mg/day.

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

Continuation – Maintenance following first-line autologous stem cell transplant (SCT)

Haematologist

Re-assessment required after 6 months

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and patient is benefitting from treatment.

Note: Indication marked with * is an unapproved indication. A line of treatment is considered to comprise either: a) a known therapeutic chemotherapy regimen and supportive treatments or b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments. Prescriptions must be written by a registered prescriber in the lenalidomide risk management programme operated by the supplier.

OLAPARIB	-	Restricted	see	terms	be	low
----------	---	------------	-----	-------	----	-----

t	Tab 100 mg	56	Lynparza
	Tab 150 mg		Lynparza
	Cap 50 mg		Lynparza

➡ Restricted (RS1722)

Initiation

Medical oncologist Re-assessment required after 12 months

All of the following:

- 1 Patient has a high-grade serous* epithelial ovarian, fallopian tube, or primary peritoneal cancer; and
- 2 There is documentation confirming pathogenic germline BRCA1 or BRCA2 gene mutation; and
- 3 Patient has received at least two lines of previous treatment with platinum-based chemotherapy; and
- 4 Patient has platinum sensitive disease defined as disease progression occurring at least 6 months after the last dose of the penultimate line of platinum-based chemotherapy; and
- 5 Patient's disease must have achieved partial or complete response to treatment with the immediately preceding platinum-based regimen; and
- 6 Patient's disease has not progressed following prior treatment with olaparib; and
- 7 Treatment will be commenced within 8 weeks of the patient's last dose of the immediately preceding platinum-based regimen; and
- 8 Treatment to be administered as maintenance treatment; and
- 9 Treatment not to be administered in combination with other chemotherapy.

Continuation

Medical oncologist

Re-assessment required after 12 months

All of the following:

- 1 Treatment remains clinically appropriate and patient is benefitting from treatment; and
- 2 No evidence of progressive disease; and
- 3 Treatment to be administered as maintenance treatment; and
- 4 Treatment not to be administered in combination with other chemotherapy.
- Note: *Note "high-grade serous" includes tumours with high-grade serous features or a high-grade serous component.

PEGASPARGASE - Restricted see terms below

→ Restricted (RS1190)

Initiation – Newly diagnosed ALL

Limited to 12 months treatment

All of the following:

1 The patient has newly diagnosed acute lymphoblastic leukaemia; and

	<u> </u>			
1	Price ex man. exc			Brand or Generic
(ex man. exc \$. (131)	Per	Manufacturer
continued				
2 Pegaspargase to be used with a contemporary intensive multi-age	ent chemoth	nerapy tr	reatment	t protocol; and
3 Treatment is with curative intent.				
Initiation – Relapsed ALL				
Limited to 12 months treatment				
All of the following:				
1 The patient has relapsed acute lymphoblastic leukaemia; and				
2 Pegaspargase to be used with a contemporary intensive multi-age	ent chemoth	nerapy tr	reatment	t protocol; and
3 Treatment is with curative intent.				
PENTOSTATIN [DEOXYCOFORMYCIN]				
Inj 10 mg vial				
PROCARBAZINE HYDROCHLORIDE				
Cap 50 mg		00	50	Natulan
TEMOZOLOMIDE – Restricted see terms below				
↓ Cap 5 mg - 1% DV May-20 to 2022	9.	13	5	Temaccord
↓ Cap 20 mg - 1% DV May-20 to 2022	16.	38	5	Temaccord
Cap 100 mg – 1% DV May-20 to 2022		98	5	Temaccord
Cap 140 mg – 1% DV May-20 to 2022			5	Temaccord
↓ Cap 250 mg - 1% DV May-20 to 2022		34	5	Temaccord
→ Restricted (RS1645)				
Initiation – High grade gliomas				
Re-assessment required after 12 months				
All of the following:				
1 Either:				
1.1 Patient has newly diagnosed glioblastoma multiforme; or	1			
1.2 Patient has newly diagnosed anaplastic astrocytoma*; and				
2 Temozolomide is to be (or has been) given concomitantly with rad	1.27		o troot-	ont nor avala at a maximum
3 Following concomitant treatment temozolomide is to be used for a	maximum	u b day	sireatm	ient per cycle at a maximum

dose of 200 mg/m² per day.

Continuation - High grade gliomas

Re-assessment required after 12 months Fither:

- 1 Both:
 - 1.1 Patient has glioblastoma multiforme; and
 - 1.2 The treatment remains appropriate and the patient is benefitting from treatment; or
- 2 All of the following:
 - 2.1 Patient has anaplastic astrocytoma*; and
 - 2.2 The treatment remains appropriate and the patient is benefitting from treatment; and
 - 2.3 Adjuvant temozolomide is to be used for a maximum of 24 months.

Initiation - Neuroendocrine tumours

Re-assessment required after 9 months All of the following:

- 1 Patient has been diagnosed with metastatic or unresectable well-differentiated neuroendocrine tumour*; and
- 2 Temozolomide is to be given in combination with capecitabine; and
- 3 Temozolomide is to be used in 28 day treatment cycles for a maximum of 5 days treatment per cycle at a maximum dose of 200 mg/m² per day; and
- 4 Temozolomide to be discontinued at disease progression.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
continued			
Continuation – Neuroendocrine tumours			
Re-assessment required after 6 months			
Both:			
1 No evidence of disease progression; and			
2 The treatment remains appropriate and the patient is benef	itting from treatment.		
nitiation – ewing's sarcoma			
Re-assessment required after 9 months			
Patient has relapse or refractory Ewing's sarcoma.			
Continuation – ewing's sarcoma			
Re-assessment required after 6 months			
Both:			
1 No evidence of disease progression; and			
2 The treatment remains appropriate and the patient is benef	itting from treatment.		
Note: Indication marked with a * is an unapproved indication. Ter	nozolomide is not funded	for the tr	reatment of relapsed high
jrade glioma.			
HALIDOMIDE – Restricted see terms below			
Cap 50 mg		28	Thalomid
Cap 100 mg	756.00	28	Thalomid
→ Restricted (RS1192)			
nitiation			
Re-assessment required after 12 months			
Any of the following:			
 The patient has multiple myeloma; or 			
2 The patient has systemic AL amyloidosis*; or			
3 The patient has erythema nodosum leprosum.			
Continuation			
Patient has obtained a response from treatment during the initial a			
Notes: Prescription must be written by a registered prescriber in th	he thalidomide risk manag	ement p	rogramme operated by the
upplier			
Maximum dose of 400 mg daily as monotherapy or in a combinatic	on therapy regimen		
ndication marked with * is an unapproved indication			
RETINOIN	170 50	100	Managerial
Cap 10 mg		100	Vesanoid
/ENETOCLAX – Restricted see terms below			
Tab 14 × 10 mg, 7 × 50 mg, 21 × 100 mg		42	Venclexta
Tab 10 mg		14	Venclexta
Tab 50 mg		7	Venclexta
Tab 100 mg		120	Venclexta
→ Restricted (RS1713)			
nitiation – relapsed/refractory chronic lymphocytic leukaemia	l		
laematologist			
Re-assessment required after 7 menths			
Re-assessment required after 7 months All of the following:			

- 2 Patient has received at least one prior therapy for chronic lymphocytic leukaemia; and
- 3 Patient has not previously received funded venetoclax; and

136

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 4 The patient's disease has relapsed within 36 months of previous treatment; and
- 5 Venetoclax to be used in combination with six 28-day cycles of rituximab commencing after the 5-week dose titration schedule with venetoclax; and
- 6 Patient has an ECOG performance status of 0-2.

Continuation - relapsed/refractory chronic lymphocytic leukaemia

Haematologist

Re-assessment required after 6 months

Both:

- 1 Treatment remains clinically appropriate and the patient is benefitting from and tolerating treatment; and
- 2 Venetoclax is to be discontinued after a maximum of 24 months of treatment following the titration schedule unless earlier discontinuation is required due to disease progression or unacceptable toxicity.

Initiation - previously untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation*

Haematologist

Re-assessment required after 6 months

All of the following:

- 1 Patient has previously untreated chronic lymphocytic leukaemia; and
- 2 There is documentation confirming that patient has 17p deletion by FISH testing or TP53 mutation by sequencing; and
- 3 Patient has an ECOG performance status of 0-2.

Continuation – previously untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation* Haematologist

Re-assessment required after 6 months

The treatment remains clinically appropriate and the patient is benefitting from and tolerating treatment.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma (SLL)* and B-cell prolymphocytic leukaemia (B-PLL)*. Indications marked with * are unapproved indications.

Platinum Compounds

CARBOPLATIN Inj 10 mg per ml, 45 ml vial – 1% DV Jun-19 to 2021	1	Carboplatin Ebewe
CISPLATIN		
Inj 1 mg per ml, 50 ml vial12.29	1	DBL Cisplatin
Inj 1 mg per ml, 100 ml vial – 1% DV Sep-18 to 2021 19.70	1	DBL Cisplatin
OXALIPLATIN		
Inj 5 mg per ml, 20 ml vial – 1% DV Feb-20 to 2021	1	Oxaliplatin Accord
		•

Protein-Tyrosine Kinase Inhibitors

ALECTINIB - Restricted see terms below

➡ Restricted (RS1712)

Initiation

Re-assessment required after 6 months All of the following:

- 1 Patient has locally advanced, or metastatic, unresectable, non-small cell lung cancer; and
- 2 There is documentation confirming that the patient has an ALK tyrosine kinase gene rearrangement using an appropriate ALK test; and
- 3 Patient has an ECOG performance score of 0-2.

	Price (ex man. excl \$. GST)	Per	Brand or Generic Manufacturer
ontinued				
continuation				
Re-assessment required after 6 months				
oth:				
 No evidence of progressive disease according to RECIST The patient is benefitting from and tolerating treatment. 	criteria; and			
ASATINIB – Restricted see terms below				
Tab 20 mg)6	60	Sprycel
Tab 50 mg	,		60	Sprycel
Tab 70 mg	7,692.5	68	60	Sprycel
 Restricted (RS1685) 				
itiation				
aematologist or any relevant practitioner on the recommendation	n of a haematologis	t		
Re-assessment required after 6 months				
ny of the following:				
1 Both:				
1.1 The patient has a diagnosis of chronic myeloid leu	kaemia (CML) in bla	st crisis	or acce	elerated phase; and
1.2 Maximum dose of 140 mg/day; or				
2 Both:				
2.1 The patient has a diagnosis of Philadelphia chrom	osome-positive acut	e lymph	old leuk	aemia (Ph+ ALL); and
2.2 Maximum dose of 140 mg/day; or				
3 All of the following:				
3.1 The patient has a diagnosis of CML in chronic pha	se; and			
3.2 Maximum dose of 100 mg/day; and				
3.3 Any of the following:				
3.3.1 Patient has documented treatment failure*				
3.3.2 Patient has experienced treatment-limiting				
3.3.3 Patient has high-risk chronic-phase CML de				
3.3.4 Patients is enrolled in the KISS study** and	requires dasatinib t	reatmer	it accor	aing to the study protocol.
continuation				
laematologist or any relevant practitioner on the recommendatic Re-assessment required after 6 months	n of a naematologis	l		
Il of the following:				
 Lack of treatment failure while on dasatinib*; and 				
 2 Dasatinib treatment remains appropriate and the patient is 	bonofiting from tro	otmont:	and	
3 Maximum dasatinib dose of 140 mg/day for accelerated o				nd 100 mg/day for chronic
phase CML.			/ LE, ai	a roo mg/day for onromo
lote: *treatment failure for CML as defined by Leukaemia Net G	uidelines **Kinasa	-Inhihiti	on Stud	with Sprycel Start-up
ttps://www.cancertrialsnz.ac.nz/kiss/			on Olud	, mai opiyooi otari'up
•				
				_
RLOTINIB – Restricted see terms below	764 0	0	30	Tarcova
Tab 100 mg Tab 150 mg			30 30	Tarceva Tarceva

Initiation

Re-assessment required after 4 months

All of the following:

1 Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and

	Price (ex man. excl. GST \$	Г) Per	Brand or Generic Manufacturer	
continued				
 2 There is documentation confirming that the disease expresse 3 Either: 3.1 Patient is treatment naive; or 	es activating mutations	of EGFR	tyrosine kinase; and	
3.2 Both:				
3.2.1 The patient has discontinued getitinib due to in 3.2.2 The cancer did not progress while on gefitinib;				
4 Erlotinib is to be given for a maximum of 3 months.				
Continuation Re-assessment required after 6 months Both:				
1 Radiological assessment (preferably including CT scan) india 2 Erlotinib is to be given for a maximum of 3 months.	cates NSCLC has not p	progressed	1; and	
Continuation – pandemic circumstances Re-assessment required after 6 months All of the following:				
 The patient is clinically benefiting from treatment and continu Erlotinib to be discontinued at progression; and 				
3 The regular renewal requirements cannot be met due to COV	✓ID-19 constraints on t	the health	sector.	
GEFITINIB – Restricted see terms below Tab 250 mg	1,700.00	30	Iressa	
→ Restricted (RS1748) Initiation				
<i>Re-assessment required after 4 months</i> All of the following:				
 Patient has locally advanced, or metastatic, unresectable, no Either: 	on-squamous Non Sma	all Cell Lun	ig Cancer (NSCLC); a	and

- 2.1 Patient is treatment naive; or
- 2.2 Both:
 - 2.2.1 The patient has discontinued erlotinib due to intolerance; and
 - 2.2.2 The cancer did not progress whilst on erlotinib; and
- 3 There is documentation confirming that disease expresses activating mutations of EGFR tyrosine kinase; and
- 4 Gefitinib is to be given for a maximum of 3 months.

Continuation

Re-assessment required after 6 months

Both:

- 1 Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed; and
- 2 Gefitinib is to be given for a maximum of 3 months.

Continuation – pandemic circumstances

Re-assessment required after 6 months

All of the following:

- 1 The patient is clinically benefiting from treatment and continued treatment remains; and
- 2 Gefitinib to be discontinued at progression; and
- 3 The regular renewal requirements cannot be met due to COVID-19 constraints on the health sector.

		Price		Brand or
		excl. GST)	Per	Generic Manufacturer
IMATINIB MESILATE				
Imatinib-AFT is not a registered for the treatment of Gastro Intermesilate (supplied by Novartis) remains fully subsidised under setting metastatic malignant GIST, see SA1460 in Section B of the Pha	Special Auth	ority for patie		
Tab 100 mg	2,	400.00	60	Glivec
→ Restricted (RS1402) Initiation				
Re-assessment required after 12 months Both:				
 Patient has diagnosis (confirmed by an oncologist) of unrese tumour (GIST); and Maximum dose of 400 mg/day. 	ctable and/o	or metastatic	malignar	t gastrointestinal stromal
Continuation				
Re-assessment required after 12 months				
Adequate clinical response to treatment with imatinib (prescriber del Note: The Glivec brand of imatinib mesilate (supplied by Novartis) r with unresectable and/or metastatic malignant GIST, see SA1460 in	emains fully			
Cap 100 mg		98.00	60	Imatinib-AFT
Cap 400 mg		197.50	30	Imatinib-AFT
LAPATINIB – Restricted see terms below				
Tab 250 mg	1,	899.00	70	Tykerb
(Tykerb Tab 250 mg to be delisted 1 June 2021) → Restricted (RS1197)				
Initiation				
Re-assessment required after 12 months Either:				
1 All of the following:				
 The patient has metastatic breast cancer expressing technology); and 	HER-2 IHC	3+ or ISH+ (i	ncluding	FISH or other current
 The patient has not previously received trastuzumab Lapatinib not to be given in combination with trastuzu Lapatinib to be discontinued at disease progression; 	mab; and	r HER 2 posi	tive meta	static breast cancer; and
2 All of the following:				
2.1 The patient has metastatic breast cancer expressing technology); and	HER-2 IHC	3+ or ISH+ (i	ncluding	FISH or other current
2.2 The patient started trastuzumab for metastatic breast starting treatment due to intolerance; and		discontinued	trastuzur	mab within 3 months of
2.3 The cancer did not progress whilst on trastuzumab; a2.4 Lapatinib not to be given in combination with trastuzu				
2.5 Lapatinib to be discontinued at disease progression.				
Continuation				
Re-assessment required after 12 months All of the following:				
1 The patient has metastatic breast cancer expressing HER-2 and			-	
 The cancer has not progressed at any time point during the p Lapatinib not to be given in combination with trastuzumab; at Lapatinib to be discontinued at disease progression. 		months whils	t on lapa	tinib; and
NILOTINIB – Restricted see terms on the next page				
 Cap 150 mg Cap 200 mg 			120 120	Tasigna Tasigna

t Item restricted (see → above); t Item restricted (see → below)

140

e.g. Brand indicates brand example only. It is not a contracted product.

Price		Brand or
(ex man. excl. GS		Generic
\$	Per	Manufacturer

➡ Restricted (RS1437)

Initiation

Haematologist

Re-assessment required after 6 months

All of the following:

1 Patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase; and 2 Either:

- 2.1 Patient has documented CML treatment failure* with imatinib; or
- 2.2 Patient has experienced treatment limiting toxicity with imatinib precluding further treatment with imatinib; and
- 3 Maximum nilotinib dose of 800 mg/day; and
- 4 Subsidised for use as monotherapy only.

Note: *treatment failure as defined by Leukaemia Net Guidelines.

Continuation

Haematologist

Re-assessment required after 6 months

All of the following:

- 1 Lack of treatment failure while on nilotinib as defined by Leukaemia Net Guidelines; and
- 2 Nilotinib treatment remains appropriate and the patient is benefiting from treatment; and
- 3 Maximum nilotinib dose of 800 mg/day; and
- 4 Subsidised for use as monotherapy only.

PALBOCICLIB - Restricted see terms below

t	Cap 75 mg4,000.00	21	Ibrance
		21	Ibrance
t	Cap 125 mg	21	Ibrance
-	Postrieted (PC1721)		

➡ Restricted (RS1731)

Initiation

Medical oncologist

Re-assessment required after 6 months All of the following:

All of the following:

- 1 Patient has unresectable locally advanced or metastatic breast cancer; and
- 2 There is documentation confirming disease is hormone-receptor positive and HER2-negative; and
- 3 Patient has an ECOG performance score of 0-2; and
- 4 Either:

second or subsequent line setting

- 4.1 Disease has relapsed or progressed during prior endocrine therapy; or
- 4.2 Both:

first line setting

4.2.1 Patient is amenorrhoeic, either naturally or induced, with endocrine levels consistent with a postmenopausal state; and

4.2.2 Either:

- 4.2.2.1 Patient has not received prior systemic treatment for metastatic disease; or
- 4.2.2.2 All of the following:
 - 4.2.2.2.1 Patient commenced treatment with palbociclib in combination with an endocrine agent prior to 1 April 2020; and
 - 4.2.2.2.2 Patient has not received prior systemic endocrine treatment for metastatic disease; and
 - 4.2.2.2.3 There is no evidence of progressive disease; and
- 5 Treatment must be used in combination with an endocrine partner.

		Price . excl. GST) \$	Per	Brand or Generic Manufacturer
a su tino sa l		Ψ	1.01	Manufacturer
continued Continuation				
Medical oncologist				
Re-assessment required after 12 months				
All of the following:				
1 Treatment must be used in combination with an endocrine pa	artner: and			
2 No evidence of progressive disease; and				
3 The treatment remains appropriate and the patient is benefit	ting from tre	atment.		
PAZOPANIB – Restricted see terms below				
Tab 200 mg	1.	334.70	30	Votrient
↓ Tab 400 mg			30	Votrient
→ Restricted (RS1198)				
nitiation				
Re-assessment required after 3 months				
All of the following:				
 The patient has metastatic renal cell carcinoma; and 				
2 Any of the following:				
2.1 The patient is treatment naive; or				
2.2 The patient has only received prior cytokine treatmen	t; or			
2.3 Both:				
2.3.1 The patient has discontinued sunitinib within 3		starting treatr	nent due	to intolerance; and
2.3.2 The cancer did not progress whilst on sunitinit				
3 The patient has good performance status (WHO/ECOG grad	e 0-2); and			
4 The disease is of predominant clear cell histology; and				
5 All of the following:				
5.1 Lactate dehydrogenase level > 1.5 times upper limit of	or normal; ar	10		
 5.2 Haemoglobin level < lower limit of normal; and 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol 	/l.): and			
5.4 Interval of < 1 year from original diagnosis to the start	<i>,</i> · ·	therany: and	4	
5.5 Karnofsky performance score of less than or equal to		, morapy, and		
5.6 2 or more sites of organ metastasis.	ro, and			
Continuation				
Re-assessment required after 3 months				
, Both:				
1 No evidence of disease progression; and				
2 The treatment remains appropriate and the patient is benefit	ng from trea	atment.		
Notes: Pazopanib treatment should be stopped if disease progress	es.			
Poor prognosis patients are defined as having at least 3 of criteria 5	.1-5.6. Inte	rmediate prog	gnosis pa	atients are defined as havir
1 or 2 of criteria 5.1-5.6.				
RUXOLITINIB – Restricted see terms below				
Tab 5 mg			56	Jakavi
Tab 15 mg			56	Jakavi
Tab 20 mg	5,	000.00	56	Jakavi
→ Restricted (RS1726)				
nitiation Haematologist				

Haematologist *Re-assessment required after 12 months* All of the following:

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 1 The patient has primary myelofibrosis or post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis; and
- 2 Either:
 - 2.1 A classification of risk of intermediate-2 or high-risk myelofibrosis according to either the International Prognostic Scoring System (IPSS), Dynamic International Prognostic Scoring System (DIPSS), or the Age-Adjusted DIPSS; or
 - 2.2 Both:
 - 2.2.1 A classification of risk of intermediate-1 myelofibrosis according to either the International Prognostic Scoring System (IPSS), Dynamic International Prognostic Scoring System (DIPSS), or the Age-Adjusted DIPSS; and
 - 2.2.2 Patient has severe disease-related symptoms that are resistant, refractory or intolerant to available therapy; and
- 3 A maximum dose of 20 mg twice daily is to be given.

Continuation

Relevant specialist or medical practitioner on the recommendation of a Relevant specialist *Re-assessment required after 12 months* Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 A maximum dose of 20 mg twice daily is to be given.

SUNITINIB - Restricted see terms below

t	Cap 12.5 mg2,315.38	28	Sutent
	Cap 25 mg		Sutent
	Cap 50 mg		Sutent
⇒	Restricted (RS1749)		

Initiation – RCC

Re-assessment required after 3 months

All of the following:

- 1 The patient has metastatic renal cell carcinoma; and
- 2 Any of the following:
 - 2.1 The patient is treatment naive; or
 - 2.2 The patient has only received prior cytokine treatment; or
 - 2.3 The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval; or
 - 2.4 Both:
 - 2.4.1 The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance; and
 - 2.4.2 The cancer did not progress whilst on pazopanib; and
- 3 The patient has good performance status (WHO/ECOG grade 0-2); and
- 4 The disease is of predominant clear cell histology; and
- 5 All of the following:
 - 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; and
 - 5.2 Haemoglobin level < lower limit of normal; and
 - 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); and
 - 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; and
 - 5.5 Karnofsky performance score of less than or equal to 70; and
 - 5.6 2 or more sites of organ metastasis; and

6 Sunitinib to be used for a maximum of 2 cycles.

Notes: RCC - Sunitinib treatment should be stopped if disease progresses.

continued...

Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

Price		Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

continued...

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

Continuation – RCC

Re-assessment required after 3 months

- Both:
 - 1 No evidence of disease progression; and
 - 2 The treatment remains appropriate and the patient is benefiting from treatment.

Initiation – GIST

Re-assessment required after 3 months

Both:

1 The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and

2 Either:

- 2.1 The patient's disease has progressed following treatment with imatinib; or
- 2.2 The patient has documented treatment-limiting intolerance, or toxicity to, imatinib.

Continuation – GIST

Re-assessment required after 6 months

Both:

The patient has responded to treatment or has stable disease as determined by Choi's modified CT response evaluation criteria as follows:

- 1 Any of the following:
 - 1.1 The patient has had a complete response (disappearance of all lesions and no new lesions); or
 - 1.2 The patient has had a partial response (a decrease in size of 10% or more or decrease in tumour density in Hounsfield Units (HU) of 15% or more on CT and no new lesions and no obvious progression of non-measurable disease); or
 - 1.3 The patient has stable disease (does not meet criteria the two above) and does not have progressive disease and no symptomatic deterioration attributed to tumour progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Continuation – GIST pandemic circumstances

Re-assessment required after 6 months

All of the following:

- 1 The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and
- 2 The patient is clinically benefiting from treatment and continued treatment remains appropriate; and
- 3 Sunitinib is to be discontinued at progression; and
- 4 The regular renewal requirements cannot be met due to COVID-19 constraints on the health sector.

Note: GIST - It is recommended that response to treatment be assessed using Choi's modified CT response evaluation criteria (J Clin Oncol, 2007, 25:1753-1759). Progressive disease is defined as either: an increase in tumour size of 10% or more and not meeting criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or new intratumoral nodules, or increase in the size of the existing intratumoral nodules.

Taxanes

DOCETAXEL

Inj 10 mg per ml, 2 ml vial		1	DBL Docetaxel
Inj 10 mg per ml, 8 ml vial	26.95	1	DBL Docetaxel
PACLITAXEL			
Inj 6 mg per ml, 5 ml vial	47.30	5	Paclitaxel Ebewe
Inj 6 mg per ml, 16.7 ml vial - 1% DV Nov-20 to 2023	24.00	1	Paclitaxel Ebewe
Inj 6 mg per ml, 25 ml vial	26.69	1	Paclitaxel Ebewe
Inj 6 mg per ml, 50 ml vial - 1% DV Nov-20 to 2023	44.00	1	Paclitaxel Ebewe

e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Treatment of Cytotoxic-Induced Side Effects			
CALCIUM FOLINATE Tab 15 mg Inj 3 mg per ml, 1 ml ampoule		10	DBL Leucovorin Calcium
Inj 10 mg per ml, 5 ml ampoule Inj 10 mg per ml, 5 ml vial – 1% DV Jan-20 to 2022		5 1	Calcium Folinate Ebewe Calcium Folinate Sandoz
Inj 10 mg per ml, 10 ml vial – 1% DV Jan-20 to 2022	9.49	1	Calcium Folinate Sandoz
Inj 10 mg per ml, 30 ml vial Inj 10 mg per ml, 35 ml vial – 1% DV Nov-19 to 2022		1 1	Calcium Folinate Ebewe Calcium Folinate Sandoz
Inj 10 mg per ml, 100 ml vial – 1% DV Mar-20 to 2022		1	Calcium Folinate Sandoz
DEXRAZOXANE - Restricted see terms below ↓ Inj 500 mg → Restricted (RS1695) Initiation Medical oncologist, paediatric oncologist, haematologist or paediatric	hoomotologist		e.g. Cardioxane
 All of the following: 1 Patient is to receive treatment with high dose anthracycline gi 2 Based on current treatment plan, patient's cumulative lifetime equivalent or greater; and 3 Dexrazoxane to be administered only whilst on anthracycline i 4 Either: 4.1 Treatment to be used as a cardioprotectant for a child 4.2 Treatment to be used as a cardioprotectant for second 	ven with curative inten dose of anthracycline treatment; and or young adult; or		d 250mg/m2 doxorubicin
MESNA Tab 400 mg – 1% DV Nov-19 to 2022 Tab 600 mg – 1% DV Nov-19 to 2022 Inj 100 mg per ml, 4 ml ampoule – 1% DV Nov-19 to 2022 Inj 100 mg per ml, 10 ml ampoule – 1% DV Nov-19 to 2022	448.50 177.45	50 50 15 15	Uromitexan Uromitexan Uromitexan Uromitexan
Vinca Alkaloids			
VINBLASTINE SULPHATE Inj 1 mg per ml, 10 ml vial VINCRISTINE SULPHATE	270.37	5	Hospira
Inj 1 mg per ml, 1 ml vial Inj 1 mg per ml, 2 ml vial		5 5	DBL Vincristine Sulfate DBL Vincristine Sulfate
VINORELBINE Inj 10 mg per ml, 1 ml vial Inj 10 mg per ml, 5 ml vial		1 1	Navelbine Navelbine
Endocrine Therapy			
ABIRATERONE ACETATE - Restricted see terms on the next page Tab 250 mg		120	Zytiga

Pric	ce			Brand or
(ex man. e	xcl.	GST)		Generic
\$			Per	Manufacturer

→ Restricted (RS1746)

Initiation

Medical oncologist, radiation oncologist or urologist *Re-assessment required after 6 months* All of the following:

- 1 Patient has prostate cancer; and
- 2 Patient has metastases; and
- 3 Patient's disease is castration resistant; and
- 4 Either:

4.1 All of the following:

- 4.1.1 Patient is symptomatic; and
- 4.1.2 Patient has disease progression (rising serum PSA) after second line anti-androgen therapy; and
- 4.1.3 Patient has ECOG performance score of 0-1; and
- 4.1.4 Patient has not had prior treatment with taxane chemotherapy; or
- 4.2 All of the following:
 - 4.2.1 Patient's disease has progressed following prior chemotherapy containing a taxane; and
 - 4.2.2 Patient has ECOG performance score of 0-2; and
 - 4.2.3 Patient has not had prior treatment with abiraterone.

Continuation

Medical oncologist, radiation oncologist or urologist

Re-assessment required after 6 months

All of the following:

- 1 No evidence of clinical disease progression; and
- 2 No initiation of taxane chemotherapy with abiraterone; and
- 3 The treatment remains appropriate and the patient is benefiting from treatment.

BICALUTAMIDE

Tab 50 mg		28	Binarex
FLUTAMIDE			
Tab 250 mg		100	Flutamin
FULVESTRANT - Restricted see terms below			
Inj 50 mg per ml, 5 ml prefilled syringe	1,068.00	2	Faslodex
>> Destricted (DC1700)			

⇒ Restricted (RS1732)

Initiation

Medical oncologist

Re-assessment required after 6 months

All of the following:

- 1 Patient has oestrogen-receptor positive locally advanced or metastatic breast cancer; and
- 2 Patient has disease progression following prior treatment with an aromatase inhibitor or tamoxifen for their locally advanced or metastatic disease; and
- 3 Treatment to be given at a dose of 500 mg monthly following loading doses; and
- 4 Treatment to be discontinued at disease progression.

Continuation

146

Medical oncologist

Re-assessment required after 6 months

All of the following:

- 1 Treatment remains appropriate and patient is benefitting from treatment; and
- 2 Treatment to be given at a dose of 500 mg monthly; and
- 3 No evidence of disease progression.

	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
MEGESTROL ACETATE			
Tab 160 mg - 1% DV Oct-18 to 2021	63.53	30	Apo-Megestrol
OCTREOTIDE - Restricted see terms below			
Inj 50 mcg per ml, 1 ml ampoule		5	DBL Octreotide
Inj 100 mcg per ml, 1 ml ampoule		5	DBL Octreotide
Inj 500 mcg per ml, 1 ml ampoule	72.50	5	DBL Octreotide
Inj 10 mg vial	1,772.50	1	Sandostatin LAR
Inj 20 mg vial	2,358.75	1	Sandostatin LAR
Inj 30 mg vial	2,951.25	1	Sandostatin LAR
Bestricted (PS1744)			

➡ Restricted (RS1744)

Initiation - Malignant bowel obstruction

All of the following:

- 1 The patient has nausea* and vomiting* due to malignant bowel obstruction*; and
- 2 Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has failed; and
- 3 Octreotide to be given at a maximum dose 1500 mcg daily for up to 4 weeks.
- Note: Indications marked with * are unapproved indications

Initiation – acromegaly

Re-assessment required after 3 months

Both:

- 1 The patient has acromegaly; and
- 2 Any of the following:
 - 2.1 Treatment with surgery, radiotherapy and a dopamine agonist has failed; or
 - 2.2 Treatment with octreotide is for an interim period while awaiting the effects of radiotherapy and a dopamine agonist has failed; or
 - 2.3 The patient is unwilling, or unable, to undergo surgery and/or radiotherapy.

Continuation - acromegaly

Both:

- 1 IGF1 levels have decreased since starting octreotide; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Note: In patients with acromegaly octreotide treatment should be discontinued if IGF1 levels have not decreased after 3 months treatment. In patients treated with radiotherapy octreotide treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Octreotide treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following octreotide treatment withdrawal for at least 4 weeks.

Initiation - Other indications

Any of the following:

- 1 VIPomas and glucagonomas for patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or
- 2 Both:
 - 2.1 Gastrinoma; and
 - 2.2 Either:
 - 2.2.1 Patient has failed surgery; or
 - 2.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or
- 3 Both:
 - 3.1 Insulinomas; and
 - 3.2 Surgery is contraindicated or has failed; or
- 4 For pre-operative control of hypoglycaemia and for maintenance therapy; or

5 Both:

			Brand or Generic
	\$	Per	Manufacturer
	y 5hiaa	analysis); a	nd
therapy.			
d treatmen	t remain	s appropriat	e: and
D-19 const	raints or	the health	sector.
	15.00	60	Tamoxifen Sandoz
	6.65	60	Tamoxifen Sandoz
	5.04	30	Rolin
	14.50	30	Pfizer Exemestane
	4.68	30	Letrole
e heleuu			
		1	Gliolan
		-	Gliolan
,.			Girolan
ection; and			
	44 62	50	Neoral
			Neoral
1	77.81	50	Neoral
1	98.13	50 ml	Neoral
		10	Sandimmun
		100	Tacrolimus Sandoz
		100	To see l'anna O an daoin
		100	Tacrolimus Sandoz
		100 100	Tacrolimus Sandoz Tacrolimus Sandoz Tacrolimus Sandoz
	(ex man. ad/or urinary I therapy. d treatmen D-19 const btide us below 4,4,0 me; and ection; and	(ex man. excl. G3 s ad/or urinary 5HIAA I therapy. d treatment remain D-19 constraints or tide 	(ex man. excl. GST) Per ad/or urinary 5HIAA analysis); a hterapy. ad treatment remains appropriat b D-19 constraints on the health hterapy. ad treatment remains appropriat b

e.g. Brand indicates brand example only. It is not a contracted product.

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer	

➡ Restricted (RS1651) Initiation – organ transplant recipients

Any specialist

For use in organ transplant recipients.

Initiation - non-transplant indications*

Any specialist

Both:

- 1 Patient requires long-term systemic immunosuppression; and
- 2 Ciclosportin has been trialled and discontinued treatment because of unacceptable side effects or inadequate clinical response.

Note: Indications marked with * are unapproved indications

Fusion Proteins

ETANERCEPT - Restricted see terms below

t	Inj 25 mg vial - 5% DV Sep-19 to 2024	4	Enbrel
t	Inj 50 mg autoinjector - 5% DV Sep-19 to 2024	4	Enbrel
t	Inj 50 mg syringe - 5% DV Sep-19 to 20241,050.00	4	Enbrel

→ Restricted (RS1770)

Initiation - juvenile idiopathic arthritis

Rheumatologist or named specialist

Re-assessment required after 6 months Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for juvenile idiopathic arthritis (JIA); and 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for JIA; or
- 2 All of the following:
 - 2.1 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
 - 2.2 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
 - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and
 - 2.5 Both:
 - 2.5.1 Either:
 - 2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
 - 2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
 - 2.5.2 Physician's global assessment indicating severe disease.

Continuation - juvenile idiopathic arthritis

Rheumatologist or named specialist

Re-assessment required after 6 months

Both:

1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

toxicity or intolerance; and

- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initiation - rheumatoid arthritis

Rheumatologist

Re-assessment required after 6 months Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
 - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
 - 2.5 Any of the following:
 - 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or
 - 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
 - 2.6 Either:
 - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
 - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.7 Either:
 - 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation - rheumatoid arthritis

Rheumatologist

Re-assessment required after 6 months

All of the following:

1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by

150

Price		Brand or	
(ex man. excl. GST)		Generic	
 \$	Per	Manufacturer	

continued...

toxicity or intolerance; and

- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation - ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis; and

1.2 Either:

- 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
- 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for ankylosing spondylitis; or
- 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
 - 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of a regular exercise regimen for ankylosing spondylitis; and
 - 2.5 Either:
 - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
 - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and
 - 2.6 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of starting treatment. Average normal chest expansion corrected for age and gender:

Age	Male	Female
18-24	7.0 cm	5.5 cm
25-34	7.5 cm	5.5 cm
35-44	6.5 cm	4.5 cm
45-54	6.0 cm	5.0 cm
55-64	5.5 cm	4.0 cm
65-74	4.0 cm	4.0 cm
75+	3.0 cm	2.5 cm

Price		Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

Continuation - ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Following 12 weeks' initial treatment and for subsequent renewals, treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less; and
- 2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation - psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for psoriatic arthritis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
 - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation - psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months Both:

1 Either:

152

- 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and
- 2 Etanercept to be administered at doses no greater than 50 mg every 7 days.

e.g. Brand indicates brand example only. It is not a contracted product.

Price	Brand or
(ex man. excl. GST)	Generic
 \$ Per	Manufacturer

Initiation - severe chronic plaque psoriasis, prior TNF use

Dermatologist

Limited to 4 months treatment

All of the following:

- 1 The patient has had an initial Special Authority approval for adalimumab for severe chronic plaque psoriasis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe chronic plaque psoriasis; and
- 3 Patient must be reassessed for continuation after 3 doses.

Initiation - severe chronic plaque psoriasis, treatment-naive

Dermatologist

Limited to 4 months treatment

All of the following:

1 Either:

- 1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
- 1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- 2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
- 3 A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 4 The most recent PASI or DLQI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment. **Continuation – severe chronic plaque psoriasis**

Dermatologist

Re-assessment required after 6 months Both:

1 Either:

1.1 Both:

- 1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
- 1.1.2 Either:
 - 1.1.2.1 Following each prior etanercept treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-etanercept treatment baseline value; or
 - 1.1.2.2 Following each prior etanercept treatment course the patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, when compared with the pre-treatment baseline value; or

1.2 Both:

1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and

Pi	rice		Brand or	
(ex man.	excl. (GST)	Generic	
	\$	Per	Manufacturer	

- 1.2.2 Either:
 - 1.2.2.1 Following each prior etanercept treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 1.2.2.2 Following each prior etanercept treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-etanercept treatment baseline value; and
- 2 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation – pyoderma gangrenosum

Dermatologist

All of the following:

- 1 Patient has pyoderma gangrenosum*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 8 doses.
- Note: Indications marked with * are unapproved indications.

Continuation – pyoderma gangrenosum

Dermatologist

All of the following:

- 1 Patient has shown clinical improvement; and
- 2 Patient continues to require treatment; and
- 3 A maximum of 8 doses.

Initiation - adult-onset Still's disease

Rheumatologist

Re-assessment required after 6 months Either:

1 Both:

- 1.1 Either:
 - 1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still's disease (AOSD); or
 - 1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the Section H rules; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept and/or tocilizumab; or
 - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or
- 2 All of the following:
 - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
 - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
 - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Continuation - adult-onset Still's disease

Rheumatologist

154

Re-assessment required after 6 months

The patient has a sustained improvement in inflammatory markers and functional status.

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

Initiation - undifferentiated spondyloarthritis

Rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Patient has undifferentiated peripheral spondyloarthritis* with active peripheral joint arthritis in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day (or maximum tolerated dose); and
- 4 Patient has tried and not responded to at least three months of leflunomide at a dose of up to 20 mg daily (or maximum tolerated dose); and
- 5 Any of the following:
 - 5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour measured no more than one month prior to the date of this application; or
 - 5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Note: Indications marked with * are unapproved indications.

Continuation - undifferentiated spondyloarthritis

Rheumatologist or medical practitioner on the recommendation of a Rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and
- 3 Etanercept to be administered at doses no greater than 50 mg dose every 7 days.

Monoclonal Antibodies

ABCIXIMAB – Restricted see terms below			
Inj 2 mg per ml, 5 ml vial	579.53	1	ReoPro
(ReoPro Inj 2 mg per ml, 5 ml vial to be delisted 1 January 2021)			
→ Restricted (RS1202)			
Initiation			
Either:			
1 For use in patients with acute coronary syndromes undergoing	percutaneous corona	ary interv	ention; or
2 For use in patients undergoing intra-cranial intervention.			
ADALIMUMAB – Restricted see terms on the next page			
Inj 20 mg per 0.4 ml syringe		2	Humira
Inj 40 mg per 0.8 ml pen		2	HumiraPen
Inj 40 mg per 0.8 ml syringe		2	Humira

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

Price		Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

⇒ Restricted (RS1771)

Initiation - juvenile idiopathic arthritis

Rheumatologist or named specialist *Re-assessment required after 6 months* Either:

1 Either:

- 1.1 Both:
 - 1.1.1 The patient has had an initial Special Authority approval for etanercept for juvenile idiopathic arthritis (JIA); and
 - 1.1.2 Either:
 - 1.1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for JIA; or
- 2 All of the following:
 - 2.1 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
 - 2.2 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
 - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and
 - 2.5 Both:
 - 2.5.1 Either:
 - 2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
 - 2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
 - 2.5.2 Physician's global assessment indicating severe disease.

Continuation - juvenile idiopathic arthritis

Rheumatologist or named specialist

Re-assessment required after 6 months

Both:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initiation - fistulising Crohn's disease

Gastroenterologist

Re-assessment required after 4 months

All of the following:

- 1 Patient has confirmed Crohn's disease; and
- 2 Either:

156

- 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
- 2.2 Patient has one or more rectovaginal fistula(e); and

e.g. Brand indicates brand example only. It is not a contracted product.

Price		Brand or
(ex man. excl. GST		Generic
\$	Per	Manufacturer

3 A Baseline Fistula Assessment (a copy of which is available at

www.pharmac.govt.nz/latest/BaselineFistulaAssessment.pdf) has been completed and is no more than 1 month old at the time of application.

Continuation - fistulising Crohn's disease

Gastroenterologist

Re-assessment required after 6 months

Either:

- 1 The number of open draining fistulae have decreased from baseline by at least 50%; or
- 2 There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain.

Initiation - Crohn's disease - adults

Gastroenterologist

Re-assessment required after 3 months

All of the following:

- 1 Patient has severe active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or
 - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
 - 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
 - 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

Continuation - Crohn's disease - adults

Gastroenterologist

Re-assessment required after 3 months

Both:

- 1 Either:
 - 1.1 Either:
 - 1.1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or
 - 1.1.2 CDAI score is 150 or less; or
 - 1.2 Both:
 - 1.2.1 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
 - 1.2.2 Applicant to indicate the reason that CDAI score cannot be assessed; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation - Crohn's disease - children

Gastroenterologist

Re-assessment required after 3 months

All of the following:

- 1 Paediatric patient has severe active Crohn's disease; and
- 2 Either:
 - 2.1 Patient has a Paediatric Crohn's Disease Activity Index (PCDAI) score of greater than or equal to 30; or
 - 2.2 Patient has extensive small intestine disease; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and

Price		Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

4 Surgery (or further surgery) is considered to be clinically inappropriate.

Continuation – Crohn's disease - children

Gastroenterologist

Re-assessment required after 3 months Both:

- 1 Any of the following:
 - 1.1 PCDAI score has reduced by 100 points from the PCDAI score when the patient was initiated on adalimumab; or
 - 1.2 PCDAI score is 150 or less; or
 - 1.3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation - rheumatoid arthritis

Rheumatologist

Re-assessment required after 6 months Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
 - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
 - 2.5 Any of the following:
 - 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or
 - 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
 - 2.6 Either:
 - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
 - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.7 Either:

158

- 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
- 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

e.g. Brand indicates brand example only. It is not a contracted product.

	Price		Brand or
(ex mar	. excl. GST) \$	Per	Generic Manufacturer

continued...

Continuation - rheumatoid arthritis

Rheumatologist *Re-assessment required after 6 months* All of the following:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation - ankylosing spondylitis

Rheumatologist *Re-assessment required after 6 months* Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for ankylosing spondylitis; or
- 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
 - 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of a regular exercise regimen for ankylosing spondylitis; and
 - 2.5 Either:
 - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
 - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and
 - 2.6 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of starting treatment. Average normal chest expansion corrected for age and gender:

Price		Brand or
(ex man. excl. GST)	1	Generic
 \$	Per	Manufacturer

continue		
Age	Male	Female
18-24	7.0 cm	5.5 cm
25-34	7.5 cm	5.5 cm
35-44	6.5 cm	4.5 cm
45-54	6.0 cm	5.0 cm
55-64	5.5 cm	4.0 cm
65-74	4.0 cm	4.0 cm
75+	3.0 cm	2.5 cm

Continuation – ankylosing spondylitis

Rheumatologist

continued

Re-assessment required after 6 months

All of the following:

- 1 Following 12 weeks' initial treatment and subsequent renewals, treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less; and
- 2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation - psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for psoriatic arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
 - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

Continuation - psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months Both:

1 Either:

- 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation - plaque psoriasis, prior TNF use

Dermatologist

Limited to 4 months treatment Both:

- 1 The patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from etanercept; or
 - 2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for severe chronic plaque psoriasis.

Initiation - plaque psoriasis, treatment-naive

Dermatologist

Limited to 4 months treatment

- All of the following:
 - 1 Either:
 - 1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
 - 2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
 - 3 A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
 - 4 The most recent PASI or DLQI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment. **Continuation – plaque psoriasis**

Dermatologist

Re-assessment required after 6 months Both:

1 Either:

- 1.1 Both:
 - 1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and

Price		Brand or
(ex man. excl. GST)	Generic
 \$	Per	Manufacturer

- 1.1.2 Either:
 - 1.1.2.1 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or
 - 1.1.2.2 Following each prior adalimumab treatment course the patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, when compared with the pre-treatment baseline value; or

1.2 Both:

- 1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
- 1.2.2 Either:
 - 1.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 1.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-etanercept treatment baseline value; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation – pyoderma gangrenosum

Dermatologist

All of the following:

- 1 Patient has pyoderma gangrenosum*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 8 doses.

Note: Indications marked with * are unapproved indications.

Continuation – pyoderma gangrenosum

Dermatologist

All of the following:

- 1 Patient has shown clinical improvement; and
- 2 Patient continues to require treatment; and
- 3 A maximum of 8 doses.

Initiation - adult-onset Still's disease

Rheumatologist

Re-assessment required after 6 months Either:

1 Both:

162

- 1.1 Either:
 - 1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still's disease (AOSD); or
 - 1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the Section H rules; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept and/or tocilizumab; or
 - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of etanercept and/or
 - tocilizumab such that they do not meet the renewal criteria for AOSD; or
- 2 All of the following:
 - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and

e.g. Brand indicates brand example only. It is not a contracted product.

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
- 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Continuation - adult-onset Still's disease

Rheumatologist

Re-assessment required after 6 months

The patient has a sustained improvement in inflammatory markers and functional status.

Initiation - severe Behcet's disease

Any relevant practitioner

Re-assessment required after 3 months

All of the following:

- 1 The patient has severe Behcet's disease that is significantly impacting the patient's quality of life (see Notes); and
- 2 Either:
 - 2.1 The patient has severe ocular, neurological, gastrointestinal, rheumatological, mucocutaneous and/or vasculitic symptoms and has not responded adequately to treatment with infliximab (see Notes); or
 - 2.2 The patient has severe ocular, neurological, gastrointestinal, rheumatological, mucocutaneous and/or vasculitic symptoms and has experienced intolerable side effects from treatment with infliximab; and
- 3 The patient is experiencing significant loss of quality of life; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Note: Behcet's disease diagnosed according to the International Study Group for Behcet's disease. Lancet 1990;335(8697):1078-80. Quality of life measured using an appropriate quality of life scale such as that published in Gilworth et al, J Rheumatol. 2004;31:931-7.

Continuation - severe Behcet's disease

Any relevant practitioner

Re-assessment required after 6 months

Both:

- 1 Patient has had a good clinical response to initial treatment with measurably improved quality of life; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation - severe ocular inflammation

Re-assessment required after 4 months Fither:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for infliximab for severe ocular inflammation; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from infliximab; or
 - 1.2.2 The patient has received insufficient benefit from infliximab to meet the renewal criteria for infliximab for severe ocular inflammation; or

2 Both:

- 2.1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and
- 2.2 Any of the following:
 - 2.2.1 Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms; or
 - 2.2.2 Patient developed new inflammatory symptoms while receiving high dose steroids; or
 - 2.2.3 Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms.

Price		Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

Continuation - severe ocular inflammation

Re-assessment required after 12 months

Both:

- 1 Any of the following:
 - 1.1 The patient has had a good clinical response following 3 initial doses; or
 - 1.2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
 - 1.3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old; and</p>
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if adalimumab is withdrawn.

Initiation - chronic ocular inflammation

Re-assessment required after 4 months

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for infliximab for chronic ocular inflammation; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from infliximab; or
 - 1.2.2 The patient has received insufficient benefit from infliximab to meet the renewal criteria for infliximab for chronic ocular inflammation; or
- 2 Both:
 - 2.1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and
 - 2.2 Any of the following:
 - 2.2.1 Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective; or
 - 2.2.2 Patient is under 18 years and treatment with methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or
 - 2.2.3 Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or disease requires control to prevent irreversible vision loss prior to achieving a therapeutic dose of methotrexate.

Continuation - chronic ocular inflammation

Re-assessment required after 12 months Both:

- 1 Any of the following:
 - 1.1 The patient has had a good clinical response following 12 weeks' initial treatment; or
 - 1.2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
 - 1.3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if adalimumab is withdrawn.

	Price	Brand or	
(ex	man. excl. GS	ST)	Generic
	\$	Per	Manufacturer

continued...

Initiation - hidradenitis suppurativa

Dermatologist

Re-assessment required after 4 months

All of the following:

- 1 Patient has hidradenitis suppurativa Hurley Stage II or Hurley Stage III lesions in distinct anatomic areas; and
- 2 Patient has tried, but had an inadequate response to at least a 90 day trial of systemic antibiotics or patient has demonstrated intolerance to or has contraindications for systemic antibiotics; and
- 3 The patient has 3 or more active lesions (e.g. inflammatory nodules, abscesses, draining fistulae); and
- 4 The patient has a Dermatology Quality of Life Index of 10 or more and the assessment is no more than 1 month old at time of application; and
- 5 Following the initial loading doses, adalimumab is to be administered at doses no greater than 40mg every 7 days.

Continuation - hidradenitis suppurativa

Dermatologist

Re-assessment required after 6 months

All of the following:

- 1 The patient has a reduction in active lesions (e.g. inflammatory nodules, abscesses, draining fistulae) of 25% or more from baseline; and
- 2 The patient has a Dermatology Quality of Life Index improvement of 4 or more from baseline; and
- 3 Adalimumab is to be administered at doses no greater than 40mg every 7 days. Fortnightly dosing has been considered.

AFLIBERCEPT - Restricted see terms below

Inj 40 mg per ml, 0.1 ml vial1,250.00	1	Eylea
---------------------------------------	---	-------

➡ Restricted (RS1659)

Initiation – Wet Age Related Macular Degeneration

Ophthalmologist

Re-assessment required after 3 months Either:

1 All of the following:

- 1.1 Any of the following:
 - 1.1.1 Wet age-related macular degeneration (wet AMD); or
 - 1.1.2 Polypoidal choroidal vasculopathy; or
 - 1.1.3 Choroidal neovascular membrane from causes other than wet AMD; and
- 1.2 Either:
 - 1.2.1 The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab; or
 - 1.2.2 There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart; and
- 1.3 There is no structural damage to the central fovea of the treated eye; and
- 1.4 Patient has not previously been treated with ranibizumab for longer than 3 months; or
- 2 Either:
 - 2.1 Patient has current approval to use ranibizumab for treatment of wAMD and was found to be intolerant to ranibizumab within 3 months; or
 - 2.2 Patient has previously* (*before June 2018) received treatment with ranibizumab for wAMD and disease was stable while on treatment.

Continuation – Wet Age Related Macular Degeneration

Ophthalmologist *Re-assessment required after 12 months* All of the following:

Price		Brand or
(ex man. excl. GST		Generic
 \$	Per	Manufacturer

continued...

- 1 Documented benefit must be demonstrated to continue; and
- 2 Patient's vision is 6/36 or better on the Snellen visual acuity score; and
- 3 There is no structural damage to the central fovea of the treated eye.

Initiation – Diabetic Macular Oedema

Ophthalmologist

Re-assessment required after 4 months

All of the following:

- 1 Patient has centre involving diabetic macular oedema (DMO); and
- 2 Patient's disease is non responsive to 4 doses of intravitreal bevacizumab when administered 4-6 weekly; and
- 3 Patient has reduced visual acuity between 6/9 6/36 with functional awareness of reduction in vision; and
- 4 Patient has DMO within central OCT (ocular coherence tomography) subfield > 350 micrometers; and
- 5 There is no centre-involving sub-retinal fibrosis or foveal atrophy.

Continuation – Diabetic Macular Oedema

Ophthalmologist

Re-assessment required after 12 months All of the following:

- 1 There is stability or two lines of Snellen visual acuity gain; and
- 2 There is structural improvement on OCT scan (with reduction in intra-retinal cysts, central retinal thickness, and sub-retinal fluid); and
- 3 Patient's vision is 6/36 or better on the Snellen visual acuity score; and
- 4 There is no centre-involving sub-retinal fibrosis or foveal atrophy; and
- 5 After each consecutive 12 months treatment with aflibercept, patient has retrialled with at least one injection of bevacizumab and had no response.

BASILIXIMAB - Restricted see terms below

➡ Restricted (RS1203)

Initiation

For use in solid organ transplants.

BEVACIZUMAB - Restricted see terms below

- Inj 25 mg per ml, 4 ml vial
- Inj 25 mg per ml, 16 ml vial

➡ Restricted (RS1691)

Initiation – Recurrent Respiratory Papillomatosis

Otolaryngologist

Re-assessment required after 12 months All of the following:

- If of the following:
 - 1 Maximum of 6 doses; and
 - 2 The patient has recurrent respiratory papillomatosis; and
 - 3 The treatment is for intra-lesional administration.

Continuation – Recurrent Respiratory Papillomatosis

Otolaryngologist

Re-assessment required after 12 months All of the following:

- 1 Maximum of 6 doses; and
- 2 The treatment is for intra-lesional administration; and
- 3 There has been a reduction in surgical treatments or disease regrowth as a result of treatment.

	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
continued Initiation – ocular conditions Either: 1 Ocular neovascularisation; or 2 Exudative ocular angiopathy.			
CETUXIMAB - Restricted see terms below ↓ Inj 5 mg per ml, 20 ml vial	1,820.00	1 1 d neck; and	Erbitux Erbitux
INFLIXIMAB – Restricted see terms below ↓ Inj 100 mg		1	Remicade
1 The patient has had an initial Special Authority approval for a	dalimumab and/or eta	nercept for	rheumatoid arthritis; and

- 2 Fither:
 - ither:
 - 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept; and
- 3 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance.

Continuation - rheumatoid arthritis

Rheumatologist *Re-assessment required after 6 months* All of the following:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 3 Infliximab to be administered at doses no greater than 3 mg/kg every 8 weeks.

Price		Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

Initiation - ankylosing spondylitis

Rheumatologist

Re-assessment required after 3 months

Both:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for ankylosing spondylitis; and 2 Either:
 - 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 2.2 Following 12 weeks of adalimumab and/or etanercept treatment, the patient did not meet the renewal criteria for adalimumab and/or etanercept for ankylosing spondylitis.

Continuation – ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Following 12 weeks of infliximab treatment, BASDAI has improved by 4 or more points from pre-infliximab baseline on a 10 point scale, or by 50%, whichever is less; and
- 2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 3 Infliximab to be administered at doses no greater than 5 mg/kg every 6-8 weeks.

Initiation - psoriatic arthritis

Rheumatologist

Re-assessment required after 4 months

Both:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for psoriatic arthritis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 2.2 Following 3-4 months' initial treatment with adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for psoriatic arthritis.

Continuation - psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months Both:

1 Either:

- 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior infliximab treatment in the opinion of the treating physician; and
- 2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

Initiation - severe ocular inflammation

Re-assessment required after 4 months Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for severe ocular inflammation; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe ocular inflammation; or

2 Both:

2.1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and

168

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 2.2 Any of the following:
 - 2.2.1 Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms; or
 - 2.2.2 Patient developed new inflammatory symptoms while receiving high dose steroids; or
 - 2.2.3 Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms.

Continuation - severe ocular inflammation

Re-assessment required after 12 months

Any of the following:

- 1 The patient has had a good clinical response following 3 initial doses; or
- 2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
- 3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

Initiation - chronic ocular inflammation

Re-assessment required after 4 months

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for chronic ocular inflammation; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for chronic ocular inflammation; or

2 Both:

- 2.1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and
- 2.2 Any of the following:
 - 2.2.1 Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective; or
 - 2.2.2 Patient is under 18 years and treatment with methotrexate has proven ineffective or is not tolerated at therapeutic dose; or
 - 2.2.3 Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or disease requires control to prevent irreversible vision loss prior to achieving a therapeutic dose of methotrexate.

Continuation - chronic ocular inflammation

Re-assessment required after 12 months

Any of the following:

- 1 The patient has had a good clinical response following 3 initial doses; or
- 2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
- 3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.
- Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

high risk of irreversible vision loss if infliximab is withdrawn.

Initiation – Pulmonary sarcoidosis

Both:

- 1 Patient has life-threatening pulmonary sarcoidosis that is refractory to other treatments; and
- 2 Treatment is to be prescribed by, or has been recommended by, a physician with expertise in the treatment of pulmonary sarcoidosis.

Initiation - Crohn's disease (adults)

Gastroenterologist

Re-assessment required after 3 months All of the following:

- 1 Patient has severe active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or
 - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
 - 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
 - 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate; and
- 5 Patient must be reassessed for continuation after 3 months of therapy.

Continuation – Crohn's disease (adults)

Gastroenterologist

Re-assessment required after 6 months Both:

- 1 Any of the following:
 - 1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on infliximab; or
 - 1.2 CDAI score is 150 or less; or
 - 1.3 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation - Crohn's disease (children)

Gastroenterologist

Re-assessment required after 3 months All of the following:

- 1 Paediatric patient has severe active Crohn's disease; and
- 2 Either:

2.1 Patient has a Paediatric Crohn's Disease Activity Index (PCDAI) score of greater than or equal to 30; or

- 2.2 Patient has extensive small intestine disease; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate; and
- 5 Patient must be reassessed for continuation after 3 months of therapy.

	P	rice			Brand or
(e)	ex man.	excl.	GST)		Generic
		\$		Per	Manufacturer

continued...

Continuation - Crohn's disease (children)

Gastroenterologist

Re-assessment required after 6 months Both:

- 1 Any of the following:
 - 1.1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on infliximab; or
 - 1.2 PCDAI score is 15 or less; or
 - 1.3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation - fistulising Crohn's disease

Gastroenterologist

Re-assessment required after 4 months Both:

- 1 Patient has confirmed Crohn's disease; and
- 2 Either:
 - 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
 - 2.2 Patient has one or more rectovaginal fistula(e).

Continuation – fistulising Crohn's disease

Gastroenterologist

Re-assessment required after 6 months

1 Fither:

- 1.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
- 1.2 There has been a marked reduction in drainage of all fistula(e) from baseline (in the case of adult patients, as demonstrated by a reduction in the Fistula Assessment score), together with less induration and patient reported pain; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation - acute severe fulminant ulcerative colitis

Gastroenterologist *Limited to 6 weeks* treatment Both:

- 1 Patient has acute, severe fulminant ulcerative colitis; and
- 2 Treatment with intravenous or high dose oral corticosteroids has not been successful.

Continuation - severe fulminant ulcerative colitis

Gastroenterologist

Re-assessment required after 6 months Both:

- 1 Where maintenance treatment is considered appropriate, infliximab should be used in combination with immunomodulators and reassessed every 6 months; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Price			Brand or
(ex man. exc	I. GST)		Generic
\$		Per	Manufacturer

continued

Initiation - severe ulcerative colitis

Gastroenterologist

Re-assessment required after 3 months

All of the following:

- 1 Patient has histologically confirmed ulcerative colitis: and
- 2 Either:
 - 2.1 Patient is 18 years or older and the Simple Clinical Colitis Activity Index (SCCAI) is greater than or equal to 4; or
 - 2.2 Patient is under 18 years and the Paediatric Ulcerative Colitis Activity Index (PUCAI) score is greater than or equal to 65: and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses for an adequate duration (unless contraindicated) and corticosteroids: and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

Continuation - severe ulcerative colitis

Gastroenterologist

Re-assessment required after 6 months

All of the following:

- 1 Patient is continuing to maintain remission and the benefit of continuing infliximab outweighs the risks; and
- 2 Either:
 - 2.1 Patient is 18 years or older and the SCCAI score has reduced by 2 points or more from the SCCAI score when the patient was initiated on infliximab: or
 - 2.2 Patient is under 18 years and the PUCAI score has reduced by 30 points or more from the PUCAI score when the patient was initiated on infliximab: and
- 3 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation - plaque psoriasis

Dermatologist

Re-assessment required after 3 doses Fither:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab or etanercept for severe chronic plaque psoriasis: and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab or etanercept; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab or etanercept to meet the renewal criteria for adalimumab or etanercept for severe chronic plague psoriasis; or
- 2 All of the following:
 - 2.1 Either:
 - 2.1.1 Patient has "whole body" severe chronic plague psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis: or
 - 2.1.2 Patient has severe chronic plague psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
 - 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cvclosporin. or acitretin: and

Price		Brand or	_
(ex man. excl. GST)		Generic	
 \$	Per	Manufacturer	

continued...

- 2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 2.4 The most recent PASI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Continuation – plaque psoriasis

Dermatologist

Re-assessment required after 3 doses Both:

1 Either:

- 1.1 Both:
 - 1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 1.1.2 Following each prior infliximab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-infliximab treatment baseline value; or
- 1.2 Both:
 - 1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 1.2.2 Either:
 - 1.2.2.1 Following each prior infliximab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 1.2.2.2 Following each prior infliximab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-infliximab treatment baseline value; and
- 2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

Initiation – neurosarcoidosis

Neurologist

Re-assessment required after 18 months

All of the following:

- 1 Biopsy consistent with diagnosis of neurosarcoidosis; and
- 2 Patient has CNS involvement; and
- 3 Patient has steroid-refractory disease; and
- 4 Either:
 - 4.1 IV cyclophosphamide has been tried; or
 - 4.2 Treatment with IV cyclophosphamide is clinically inappropriate.

Continuation - neurosarcoidosis

Neurologist

Re-assessment required after 18 months Either:

- 1 A withdrawal period has been tried and the patient has relapsed; or
- 2 All of the following:
 - 2.1 A withdrawal period has been considered but would not be clinically appropriate; and
 - 2.2 There has been a marked reduction in prednisone dose; and

Pr	rice			Brand or
(ex man.)	excl.	GST)		Generic
:	\$		Per	Manufacturer

- 2.3 Either:
 - 2.3.1 There has been an improvement in MRI appearances; or
 - 2.3.2 Marked improvement in other symptomology.

Initiation - severe Behcet's disease

Re-assessment required after 4 months

All of the following:

- 1 The patient has severe Behcet's disease which is significantly impacting the patient's quality of life (see Notes); and
- 2 Either:
 - 2.1 The patient has severe ocular, neurological and/or vasculitic symptoms and has not responded adequately to one or more treatment(s) appropriate for the particular symptom(s) (see Notes); or
 - 2.2 The patient has severe gastrointestinal, rheumatologic and/or mucocutaneous symptoms and has not responded adequately to two or more treatment appropriate for the particular symptom(s) (see Notes); and
- 3 The patient is experiencing significant loss of quality of life.

Notes:

- 1 Behcet's disease diagnosed according to the International Study Group for Behcet's Disease. Lancet 1990;335(8697):1078-80. Quality of life measured using an appropriate quality of life scale such as that published in Gilworth et al J Rheumatol. 2004;31:931-7.
- 2 Treatments appropriate for the particular symptoms are those that are considered standard conventional treatments for these symptoms, for example intravenous/oral steroids and other immunosuppressants for ocular symptoms; azathioprine, steroids, thalidomide, interferon alpha and ciclosporin for mucocutaneous symptoms; and colchicine, steroids and methotrexate for rheumatological symptoms.

Continuation - severe Behcet's disease

Re-assessment required after 6 months

Both:

- 1 Patient has had a good clinical response to initial treatment with measurably improved quality of life; and
- 2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

Initiation – pyoderma gangrenosum

Dermatologist

All of the following:

- 1 Patient has pyoderma gangrenosum*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 8 doses.

Note: Indications marked with * are unapproved indications.

Continuation – pyoderma gangrenosum

Dermatologist

All of the following:

- 1 Patient has shown clinical improvement; and
- 2 Patient continues to require treatment; and
- 3 A maximum of 8 doses.

MEPOLIZUMAB - Restricted see terms below

Inj 100 mg vial	1,638.00	1	Nucala
➡ Restricted (RS1733)			
Initiation – Severe eosinophilic asthma			
Respiratory physician or clinical immunologist			
Re-assessment required after 12 months			
All of the following:			

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 1 Patient must be aged 12 years or older; and
- 2 Patient must have a diagnosis of severe eosinophilic asthma documented by a respiratory physician or clinical immunologist; and
- 3 Conditions that mimic asthma eg. vocal cord dysfunction, central airway obstruction, bronchiolitis etc. have been excluded; and
- 4 Patient has a blood eosinophil count of greater than 0.5 × 10⁹ cells/L in the last 12 months; and
- 5 Patient must be adherent to optimised asthma therapy including inhaled corticosteroids (equivalent to at least 1000 mcg per day of fluticasone propionate) plus long acting beta-2 agonist, or budesonide/formoterol as part of the single maintenance and reliever therapy regimen, unless contraindicated or not tolerated; and
- 6 Either:
 - 6.1 Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral corticosteroids; or
 - 6.2 Patient has received continuous oral corticosteroids of at least the equivalent of 10 mg per day over the previous 3 months; and
- 7 Patient has an Asthma Control Test (ACT) score of 10 or less. Baseline measurements of the patient's asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 52 weeks after the first dose to assess response to treatment.

Continuation – Severe eosinophilic asthma

Respiratory physician or clinical immunologist *Re-assessment required after 2 years* Both:

- 1 An increase in the Asthma Control Test (ACT) score of at least 5 from baseline; and
- 2 Either:
 - 2.1 Exacerbations have been reduced from baseline by 50% as a result of treatment with mepolizumab; or
 - 2.2 Reduction in continuous oral corticosteroid use by 50% or by 10 mg/day while maintaining or improving asthma control.

OBINUTUZUMAB - Restricted see terms below

t	Inj 25 mg per ml, 40 ml vial	5,910.00	1	Gazyva
⇒	Restricted (RS1550)			

Initiation

Haematologist

Limited to 6 months treatment

All of the following:

- 1 The patient has progressive Binet stage A, B or C CD20+ chronic lymphocytic leukaemia requiring treatment; and
- 2 The patient is obinutuzumab treatment naive; and
- 3 The patient is not eligible for full dose FCR due to comorbidities with a score > 6 on the Cumulative Illness Rating Scale (CIRS) or reduced renal function (creatinine clearance < 70mL/min); and
- 4 Patient has adequate neutrophil and platelet counts* unless the cytopenias are a consequence of marrow infiltration by CLL; and
- 5 Patient has good performance status; and
- 6 Obinutuzumab to be administered at a maximum cumulative dose of 8,000 mg and in combination with chlorambucil for a maximum of 6 cycles.

Notes: Chronic lymphocytic leukaemia includes small lymphocytic lymphoma. Comorbidity refers only to illness/impairment other than CLL induced illness/impairment in the patient. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with obinutuzumab is expected to improve symptoms and improve ECOG score to < 2.

* greater than or equal to 1.5×10^{9} /L and platelets greater than or equal to 75×10^{9} /L

(ex m	Price an. excl. GST) \$	Per	Brand or Generic Manufacturer
OMALIZUMAB – Restricted see terms below			
Inj 150 mg prefilled syringe	450.00	1	Xolair
↓ Inj 150 mg vial	450.00	1	Xolair

➡ Restricted (RS1652)

Initiation – severe asthma

Clinical immunologist or respiratory specialist

Re-assessment required after 6 months

All of the following:

- 1 Patient must be aged 6 years or older ; and
- 2 Patient has a diagnosis of severe asthma; and
- 3 Past or current evidence of atopy, documented by skin prick testing or RAST; and
- 4 Total serum human immunoglobulin E (IgE) between 76 IU/mL and 1300 IU/ml at baseline; and
- 5 Proven adherence with optimal inhaled therapy including high dose inhaled corticosteroid (budesonide 1,600 mcg per day or fluticasone propionate 1,000 mcg per day or equivalent), plus long-acting beta-2 agonist therapy (at least salmeterol 50 mcg bd or eformoterol 12 mcg bd) for at least 12 months, unless contraindicated or not tolerated; and
- 6 Either:
 - 6.1 Patient has received courses of systemic corticosteroids equivalent to at least 28 days treatment in the past 12 months, unless contraindicated or not tolerated; or
 - 6.2 Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral steroids; and
- 7 Patient has an Asthma Control Test (ACT) score of 10 or less; and
- 8 Baseline measurements of the patient's asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 26 weeks after the first dose to assess response to treatment.

Continuation - severe asthma

Respiratory specialist

Re-assessment required after 6 months

Both:

- 1 An increase in the Asthma Control Test (ACT) score of at least 5 from baseline; and
- 2 A reduction in the maintenance oral corticosteroid dose or number of exacerbations of at least 50% from baseline.

Initiation – severe chronic spontaneous urticaria

Clinical immunologist or dermatologist

Re-assessment required after 6 months

All of the following:

- 1 Patient must be aged 12 years or older; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Patient is symptomatic with Urticaria Activity Score 7 (UAS7) of 20 or above; and
 - 2.1.2 Patient has a Dermatology life quality index (DLQI) of 10 or greater; and
- 3 Any of the following:
 - 3.1 Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and ciclosporin (> 3 mg/kg day) for at least 6 weeks; or
 - 3.2 Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and at least 3 courses of systemic corticosteroids (> 20 mg prednisone per day for at least 5 days) in the previous 6 months; or
 - 3.3 Patient has developed significant adverse effects whilst on corticosteroids or ciclosporin; and
- 4 Either:
 - 4.1 Treatment to be stopped if inadequate response* following 4 doses; or
 - 4.2 Complete response* to 6 doses of omalizumab.

continued...

176

e.g. Brand indicates brand example only. It is not a contracted product.

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

Continuation - severe chronic spontaneous urticaria

Clinical immunologist or dermatologist

Re-assessment required after 6 months

Either:

1 Patient has previously had a complete response* to 6 doses of omalizumab; or

2 Both:

- 2.1 Patient has previously had a complete response* to 6 doses of omalizumab; and
- 2.2 Patient has relapsed after cessation of omalizumab therapy.

Note: *Inadequate response defined as less than 50% reduction in baseline UAS7 and DLQI score, or an increase in Urticaria Control Test (UCT) score of less than 4 from baseline. Patient is to be reassessed for response after 4 doses of omalizumab. Complete response is defined as UAS7 less than or equal to 6 and DLQI less than or equal to 5; or UCT of 16. Relapse of chronic urticaria on stopping prednisone/ciclosporin does not justify the funding of omalizumab.

PERTUZUMAB - Restricted see terms below

➡ Restricted (RS1551)

Initiation

Re-assessment required after 12 months All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Either:
 - 2.1 Patient is chemotherapy treatment naive; or
 - 2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
- 3 The patient has good performance status (ECOG grade 0-1); and
- 4 Pertuzumab to be administered in combination with trastuzumab; and
- 5 Pertuzumab maximum first dose of 840 mg, followed by maximum of 420 mg every 3 weeks; and
- 6 Pertuzumab to be discontinued at disease progression.

Continuation

Re-assessment required after 12 months

Both:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The cancer has not progressed at any time point during the previous 12 months whilst on pertuzumab and trastuzumab.

RANIBIZUMAB - Restricted see terms below

- Inj 10 mg per ml, 0.23 ml vial
- Inj 10 mg per ml, 0.3 ml vial

⇒ Restricted (RS1637)

Initiation - Wet Age Related Macular Degeneration

Ophthalmologist

Re-assessment required after 3 months Fither:

Either:

- 1 All of the following:
 - 1.1 Any of the following:
 - 1.1.1 Wet age-related macular degeneration (wet AMD); or
 - 1.1.2 Polypoidal choroidal vasculopathy; or

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

- 1.1.3 Choroidal neovascular membrane from causes other than wet AMD; and
- 1.2 Either:
 - 1.2.1 The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab; or
 - 1.2.2 There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart; and
- 1.3 There is no structural damage to the central fovea of the treated eye; and
- 1.4 Patient has not previously been treated with aflibercept for longer than 3 months; or
- 2 Patient has current approval to use aflibercept for treatment of wAMD and was found to be intolerant to aflibercept within 3 months.

Continuation - Wet Age Related Macular Degeneration

Ophthalmologist

Re-assessment required after 12 months

All of the following:

- 1 Documented benefit must be demonstrated to continue; and
- 2 Patient's vision is 6/36 or better on the Snellen visual acuity score; and
- 3 There is no structural damage to the central fovea of the treated eye.

RITUXIMAB (MABTHERA) - Restricted see terms below

t	Inj 10 mg per ml, 10 ml vial1,075.50	2	Mabthera
t	Inj 10 mg per ml, 50 ml vial2,688.30	1	Mabthera

→ Restricted (RS1734)

Initiation - haemophilia with inhibitors

No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

Continuation – haemophilia with inhibitors

Haematologist

All of the following:

- 1 Patient was previously treated with rituximab for haemophilia with inhibitors; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Patient now requires repeat treatment.

Initiation - post-transplant

No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

Continuation – post-transplant

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 3 To be used for no more than 6 treatment cycles.

Note: Indications marked with * are unapproved indications.

Initiation – indolent, low-grade lymphomas or hairy cell leukaemia*

No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

Continuation - indolent, low-grade lymphomas or hairy cell leukaemia*

Re-assessment required after 9 months

All of the following:

178

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has indolent, low-grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy; and
- 3 To be used for no more than 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom

Price		Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

continued...

macroglobulinaemia. *Unapproved indication. 'Hairy cell leukaemia' also includes hairy cell leukaemia variant. Initiation - aggressive CD20 positive NHL

No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

Continuation – aggressive CD20 positive NHL

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has relapsed refractory/aggressive CD20 positive NHL; and
- 3 To be used with a multi-agent chemotherapy regimen given with curative intent; and
- 4 To be used for a maximum of 4 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

Initiation – Chronic lymphocytic leukaemia

No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

Continuation – Chronic lymphocytic leukaemia

Re-assessment required after 12 months

Both:

1 Either:

- 1.1 The patient's disease has relapsed within 36 months of previous treatment and rituximab treatment is to be used in combination with funded venetoclax; or
- 1.2 All of the following:
 - 1.2.1 The patient's disease has relapsed following no more than one prior line of treatment with rituximab for CLL; and
 - 1.2.2 The patient has had an interval of 36 months or more since commencement of initial rituximab treatment; and
 - 1.2.3 The patient does not have chromosome 17p deletion CLL; and
 - 1.2.4 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration) or bendamustin; and
- 2 Rituximab to be administered in combination with fludarabine and cyclophosphamide, bendamustine or venetoclax for a maximum of 6 treatment cycles.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

Initiation - rheumatoid arthritis - prior TNF inhibitor use

Rheumatologist

Limited to 4 months treatment

All of the following:

- 1 Both:
 - 1.1 The patient has had an initial community Special Authority approval for at least one of etanercept and/or adalimumab for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 1.2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for rheumatoid arthritis; and
- 2 Either:
 - 2.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
 - 2.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 3 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Price		Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

Initiation - rheumatoid arthritis - TNF inhibitors contraindicated

Rheumatologist

Limited to 4 months treatment

All of the following:

- 1 Treatment with a Tumour Necrosis Factor alpha inhibitor is contraindicated; and
- 2 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
- 3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
- 5 Any of the following:
 - 5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or
 - 5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
- 6 Either:
 - 6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
 - 6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 7 Either:
 - 7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months; and
- 8 Either:
 - 8.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
 - 8.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 9 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Continuation - rheumatoid arthritis - re-treatment in 'partial responders' to rituximab

Rheumatologist

Re-assessment required after 4 months

All of the following:

- 1 Any of the following:
 - 1.1 At 4 months following the initial course of rituximab infusions the patient had between a 30% and 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.2 At 4 months following the second course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.3 At 4 months following the third and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and
- 3 Either:
 - 3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
 - 3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and

Price	Brand or
(ex man. excl. GST)	Generic
 \$ P	er Manufacturer

continued...

4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Continuation - rheumatoid arthritis - re-treatment in 'responders' to rituximab

Rheumatologist

Re-assessment required after 4 months All of the following:

1 Either:

- 1.1 At 4 months following the initial course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 1.2 At 4 months following the second and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and

2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and

3 Either:

- 3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
- 3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Initiation - severe cold haemagglutinin disease (CHAD)

No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

Continuation - severe cold haemagglutinin disease (CHAD)

Haematologist

Re-assessment required after 8 weeks

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for severe cold haemagglutinin disease*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

Initiation - warm autoimmune haemolytic anaemia (warm AIHA)

No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

Continuation - warm autoimmune haemolytic anaemia (warm AIHA)

Haematologist

Re-assessment required after 8 weeks Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for warm autoimmune haemolytic anaemia*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

Initiation – immune thrombocytopenic purpura (ITP)

No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

	Price			Brand or
(e	ex man. exc	I. GST)		Generic
	\$		Per	Manufacturer

continued...

Continuation – immune thrombocytopenic purpura (ITP)

Haematologist

Re-assessment required after 8 weeks

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for immune thrombocytopenic purpura*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

Initiation – thrombotic thrombocytopenic purpura (TTP)

No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

Continuation - thrombotic thrombocytopenic purpura (TTP)

Haematologist

Re-assessment required after 8 weeks

All of the following:

- 1 Patient was previously treated with rituximab for thrombotic thrombocytopenic purpura*; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Patient now requires repeat treatment; and
- 4 The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Initiation – pure red cell aplasia (PRCA)

No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

Continuation – pure red cell aplasia (PRCA)

Haematologist

Re-assessment required after 6 weeks

Patient was previously treated with rituximab for pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder and demonstrated an initial response lasting at least 12 months.

Note: Indications marked with * are unapproved indications.

Initiation – ANCA associated vasculitis

No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

Continuation - ANCA associated vasculitis

Re-assessment required after 8 weeks

All of the following:

- 1 Patient has been diagnosed with ANCA associated vasculitis*; and
- 2 Patient has previously responded to treatment with rituximab but is now experiencing an acute flare of vasculitis; and
- 3 The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Initiation – treatment refractory systemic lupus erythematosus (SLE)

No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

Continuation - treatment refractory systemic lupus erythematosus (SLE)

Rheumatologist or nephrologist

All of the following:

182

- 1 Patient's SLE* achieved at least a partial response to the previous round of prior rituximab treatment; and
- 2 The disease has subsequently relapsed; and

	Price		Brand or
(ex	man. excl. (Generic
	\$	Per	Manufacturer

continued...

3 Maximum of two 1000 mg infusions of rituximab.

Note: Indications marked with * are unapproved indications.

Initiation – Antibody-mediated renal transplant rejection

No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

Initiation – ABO-incompatible renal transplant

No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

Initiation – Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS) No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

Continuation – Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS) Nephrologist

Re-assessment required after 8 weeks

All of the following:

- 1 Patient who was previously treated with rituximab for nephrotic syndrome*; and
- 2 Treatment with rituximab was previously successful and has demonstrated sustained response for > 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with a * are unapproved indications.

Initiation - Steroid resistant nephrotic syndrome (SRNS)

No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

Continuation – Steroid resistant nephrotic syndrome (SRNS)

Nephrologist

Re-assessment required after 8 weeks

All of the following:

- 1 Patient who was previously treated with rituximab for nephrotic syndrome*; and
- 2 Treatment with rituximab was previously successful and has demonstrated sustained response for greater than 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.
- Note: Indications marked with a * are unapproved indications.

Initiation – Neuromyelitis Optica Spectrum Disorder (NMOSD)

No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

Continuation - Neuromyelitis Optica Spectrum Disorder (NMOSD)

Relevant specialist or medical practitioner on the recommendation of a Relevant specialist

Re-assessment required after 2 years

All of the following:

- 1 One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m2 administered weekly for four weeks; and
- 2 The patients has responded to the most recent course of rituximab; and
- 3 The patient has not received rituximab in the previous 6 months.

Initiation – Severe Refractory Myasthenia Gravis

No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

Continuation – Severe Refractory Myasthenia Gravis

Neurologist or medical practitioner on the recommendation of a Neurologist

Re-assessment required after 2 years

All of the following:

1 One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and

	Price (ex man. ex \$		Per	Brand or Generic Manufacturer
continued				
2 An initial response lasting at least 12 months was demon	strated; and			
3 Either:				
3.1 The patient has relapsed despite treatment with concerning period of at least 12 months; or	orticosteroids and a	it least o	ne other	immunosuppressant for a
3.2 Both:	ad doopito troatmo	nt with a	t looot or	a immunacunnracant for
3.2.1 The patient's myasthenia gravis has relaps period of at least 12 months; and	eu despile llealine	ni wili a	i least of	ie initiutiosuppressant for a
3.2.2 Corticosteroids have been trialed for at lea side effects.	st 12 months and h	ave bee	n discont	inued due to unacceptable
RITUXIMAB (RIXIMYO) – Restricted see terms below				
Inj 10 mg per ml, 10 ml vial	275	.33	2	Riximyo
 Inj 10 mg per ml, 50 ml vial → Restricted (RS1764) 	688	.20	1	Riximyo
Initiation – haemophilia with inhibitors				
Haematologist				
Any of the following:				
1 Patient has mild congenital haemophilia complicated by in				
2 Patient has severe congenital haemophilia complicated b	y inhibitors and has	s failed ir	nmune to	plerance therapy; or
3 Patient has acquired haemophilia.				
Continuation – haemophilia with inhibitors				
Haematologist All of the following:				
 Patient was previously treated with rituximab for haemople 	hilia with inhihitors:	and		
2 An initial response lasting at least 12 months was demon		unu		
3 Patient now requires repeat treatment.				
Initiation – post-transplant				
Both:				
1 The patient has B-cell post-transplant lymphoproliferative	disorder*; and			
2 To be used for a maximum of 8 treatment cycles.				
Note: Indications marked with * are unapproved indications.				
Continuation – post-transplant All of the following:				
 The patient has had a rituximab treatment-free interval of 	12 months or more	o and		
2 The patient has B-cell post-transplant lymphoproliferative		, anu		
3 To be used for no more than 6 treatment cycles.				
Note: Indications marked with * are unapproved indications.				
Initiation - indolent, low-grade lymphomas or hairy cell leuk	aemia*			
Re-assessment required after 9 months				
Either:				
1 Both:				
 The patient has indolent low grade NHL or hairy c abarratherapius and 	ell leukaemia* with	relapsed	disease	tollowing prior
chemotherapy; and				

- 1.2 To be used for a maximum of 6 treatment cycles; or
- 2 Both:

184

- 2.1 The patient has indolent, low grade lymphoma or hairy cell leukaemia* requiring first-line systemic chemotherapy; and
- 2.2 To be used for a maximum of 6 treatment cycles.

e.g. Brand indicates brand example only. It is not a contracted product.

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. 'Hairy cell leukaemia' also includes hairy cell leukaemia variant.

Continuation - indolent, low-grade lymphomas or hairy cell leukaemia*

Re-assessment required after 12 months

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has indolent, low-grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy; and
- 3 To be used for no more than 6 treatment cycles.

Note: 'Indolent, Iow-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. 'Hairy cell leukaemia' also includes hairy cell leukaemia variant. **Initiation – aggressive CD20 positive NHL**

Either:

- 1 All of the following:
 - 1.1 The patient has treatment naive aggressive CD20 positive NHL; and
 - 1.2 To be used with a multi-agent chemotherapy regimen given with curative intent; and
 - 1.3 To be used for a maximum of 8 treatment cycles; or
- 2 Both:
 - 2.1 The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.
- Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

Continuation - aggressive CD20 positive NHL

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has relapsed refractory/aggressive CD20 positive NHL; and
- 3 To be used with a multi-agent chemotherapy regimen given with curative intent; and
- 4 To be used for a maximum of 4 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

Initiation – Chronic lymphocytic leukaemia

Re-assessment required after 12 months

All of the following:

- 1 The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment; and
- 2 Any of the following:
 - 2.1 The patient is rituximab treatment naive; or
 - 2.2 Either:
 - 2.2.1 The patient is chemotherapy treatment naive; or

2.2.2 Both:

- 2.2.2.1 The patient's disease has relapsed following no more than three prior lines of chemotherapy treatment; and
- 2.2.2.2 The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy; or
- 2.3 The patient's disease has relapsed within 36 months of previous treatment and rituximab treatment is to be used in combination with funded venetoclax; and
- 3 The patient has good performance status; and
- 4 Either:
 - 4.1 The patient does not have chromosome 17p deletion CLL; or
 - 4.2 Rituximab treatment is to be used in combination with funded venetoclax for relapsed/refractory chronic lymphocytic leukaemia; and

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 5 Rituximab to be administered in combination with fludarabine and cyclophosphamide, bendamustine or venetoclax for a maximum of 6 treatment cycles; and
- 6 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration), bendamustine or venetoclax.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to < 2.

Continuation – Chronic lymphocytic leukaemia

Re-assessment required after 12 months Both:

- 1 Either:
 - 1.1 The patient's disease has relapsed within 36 months of previous treatment and rituximab treatment is to be used in combination with funded venetoclax; or
 - 1.2 All of the following:
 - 1.2.1 The patient's disease has relapsed following no more than one prior line of treatment with rituximab for CLL; and
 - 1.2.2 The patient has had an interval of 36 months or more since commencement of initial rituximab treatment; and
 - 1.2.3 The patient does not have chromosome 17p deletion CLL; and
 - 1.2.4 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration) or bendamustin; and
- 2 Rituximab to be administered in combination with fludarabine and cyclophosphamide, bendamustine or venetoclax for a maximum of 6 treatment cycles.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

Initiation - severe cold haemagglutinin disease (CHAD)

Haematologist

Re-assessment required after 8 weeks

All of the following:

- 1 Patient has cold haemagglutinin disease*; and
- 2 Patient has severe disease which is characterized by symptomatic anaemia, transfusion dependence or disabling circulatory symptoms; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Continuation - severe cold haemagglutinin disease (CHAD)

Haematologist

Re-assessment required after 8 weeks

Either:

186

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for severe cold haemagglutinin disease*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

e.g. Brand indicates brand example only. It is not a contracted product.

Price		Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

continued...

Initiation – warm autoimmune haemolytic anaemia (warm AIHA)

Haematologist

Re-assessment required after 8 weeks

All of the following:

- 1 Patient has warm autoimmune haemolytic anaemia*; and
- 2 One of the following treatments has been ineffective: steroids (including if patient requires ongoing steroids at doses equivalent to > 5 mg prednisone daily), cytotoxic agents (e.g. cyclophosphamide monotherapy or in combination), intravenous immunoglobulin; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Continuation - warm autoimmune haemolytic anaemia (warm AIHA)

Haematologist

Re-assessment required after 8 weeks

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for warm autoimmune haemolytic anaemia*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.
- Note: Indications marked with * are unapproved indications.

Initiation – immune thrombocytopenic purpura (ITP)

Haematologist

Re-assessment required after 8 weeks

- All of the following:
 - 1 Either:
 - 1.1 Patient has immune thrombocytopenic purpura* with a platelet count of less than or equal to 20,000 platelets per microlitre; or
 - 1.2 Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding; and
 - 2 Any of the following:
 - 2.1 Treatment with steroids and splenectomy have been ineffective; or
 - 2.2 Treatment with steroids has been ineffective and splenectomy is an absolute contraindication; or
 - 2.3 Other treatments including steroids have been ineffective and patient is being prepared for elective surgery (e.g. splenectomy); and
 - 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Continuation - immune thrombocytopenic purpura (ITP)

Haematologist

Re-assessment required after 8 weeks Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for immune thrombocytopenic purpura*; and

Price		Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

continued...

- 2.2 An initial response lasting at least 12 months was demonstrated; and
- 2.3 Patient now requires repeat treatment.
- Note: Indications marked with * are unapproved indications.

Initiation – thrombotic thrombocytopenic purpura (TTP)

Haematologist

Re-assessment required after 8 weeks

Both:

- 1 The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks; and
- 2 Either:
 - 2.1 Patient has thrombotic thrombocytopenic purpura* and has experienced progression of clinical symptoms or persistent thrombocytopenia despite plasma exchange; or
 - 2.2 Patient has acute idiopathic thrombotic thrombocytopenic purpura* with neurological or cardiovascular pathology.

Note: Indications marked with * are unapproved indications.

Continuation – thrombotic thrombocytopenic purpura (TTP)

Haematologist

Re-assessment required after 8 weeks All of the following:

- 1 Patient was previously treated with rituximab for thrombotic thrombocytopenic purpura*; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Patient now requires repeat treatment; and
- 4 The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Initiation – pure red cell aplasia (PRCA)

Haematologist

Re-assessment required after 6 weeks

Patient has autoimmune pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder.

Note: Indications marked with * are unapproved indications.

Continuation - pure red cell aplasia (PRCA)

Haematologist

Re-assessment required after 6 weeks

Patient was previously treated with rituximab for pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder and demonstrated an initial response lasting at least 12 months.

Note: Indications marked with * are unapproved indications.

Initiation – ANCA associated vasculitis

Re-assessment required after 8 weeks

All of the following:

- 1 Patient has been diagnosed with ANCA associated vasculitis*; and
- 2 The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks; and
- 3 Any of the following:
 - 3.1 Induction therapy with daily oral or pulse intravenous cyclophosphamide has failed to achieve significant improvement of disease after at least 3 months; or
 - 3.2 Patient has previously had a cumulative dose of cyclophosphamide > 15 g or a further repeat 3 month induction course of cyclophosphamide would result in a cumulative dose > 15 g; or
 - 3.3 Cyclophosphamide and methotrexate are contraindicated; or

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 3.4 Patient is a female of child-bearing potential; or
- 3.5 Patient has a previous history of haemorrhagic cystitis, urological malignancy or haematological malignancy.

Note: Indications marked with * are unapproved indications.

Continuation – ANCA associated vasculitis

Re-assessment required after 8 weeks

All of the following:

- 1 Patient has been diagnosed with ANCA associated vasculitis*; and
- 2 Patient has previously responded to treatment with rituximab but is now experiencing an acute flare of vasculitis; and
- 3 The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Initiation - treatment refractory systemic lupus erythematosus (SLE)

Rheumatologist or nephrologist

All of the following:

- 1 The patient has severe, immediately life- or organ-threatening SLE*; and
- 2 The disease has proved refractory to treatment with steroids at a dose of at least 1 mg/kg; and
- 3 The disease has relapsed following prior treatment for at least 6 months with maximal tolerated doses of azathioprine, mycophenolate mofetil and high dose cyclophosphamide, or cyclophosphamide is contraindicated; and
- 4 Maximum of four 1000 mg infusions of rituximab.

Note: Indications marked with * are unapproved indications.

Continuation - treatment refractory systemic lupus erythematosus (SLE)

Rheumatologist or nephrologist

All of the following:

- 1 Patient's SLE* achieved at least a partial response to the previous round of prior rituximab treatment; and
- 2 The disease has subsequently relapsed; and
- 3 Maximum of two 1000 mg infusions of rituximab.

Note: Indications marked with * are unapproved indications.

Initiation - Antibody-mediated organ transplant rejection

Patient has been diagnosed with antibody-mediated organ transplant rejection*.

Note: Indications marked with * are unapproved indications.

Initiation – ABO-incompatible organ transplant

Patient is to undergo an ABO-incompatible solid organ transplant*.

Note: Indications marked with * are unapproved indications.

Initiation – Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS) Nephrologist

Re-assessment required after 8 weeks

All of the following:

- 1 Patient is a child with SDNS* or FRNS*; and
- 2 Treatment with steroids for at least a period of 3 months has been ineffective or associated with evidence of steroid toxicity; and
- 3 Treatment with ciclosporin for at least a period of 3 months has been ineffective and/or discontinued due to unacceptable side effects; and
- 4 Treatment with mycophenolate for at least a period of 3 months with no reduction in disease relapses; and
- 5 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with a * are unapproved indications.

Pri	ice			Brand or
(ex man. e	excl.	GST)		Generic
 9	\$	F	Per	Manufacturer

continued...

Continuation – Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS) Nephrologist

Re-assessment required after 8 weeks

All of the following:

- 1 Patient who was previously treated with rituximab for nephrotic syndrome*; and
- 2 Treatment with rituximab was previously successful and has demonstrated sustained response for > 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with a * are unapproved indications.

Initiation – Steroid resistant nephrotic syndrome (SRNS)

Nephrologist

Re-assessment required after 8 weeks

All of the following:

- 1 Patient is a child with SRNS* where treatment with steroids and ciclosporin for at least 3 months have been ineffective; and
- 2 Treatment with tacrolimus for at least 3 months has been ineffective; and
- 3 Genetic causes of nephrotic syndrome have been excluded; and
- 4 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with a * are unapproved indications.

Continuation – Steroid resistant nephrotic syndrome (SRNS)

Nephrologist

Re-assessment required after 8 weeks

All of the following:

- 1 Patient who was previously treated with rituximab for nephrotic syndrome*; and
- 2 Treatment with rituximab was previously successful and has demonstrated sustained response for greater than 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.
- Note: Indications marked with a * are unapproved indications.

Initiation – Neuromyelitis Optica Spectrum Disorder (NMOSD)

Re-assessment required after 6 months

Both:

- 1 One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m2 administered weekly for four weeks; and
- 2 Either:
 - 2.1 The patient has experienced a severe episode or attack of NMOSD (rapidly progressing symptoms and clinical investigations supportive of a severe attack of NMOSD); or
 - 2.2 All of the following:
 - 2.2.1 The patient has experienced a breakthrough attack of NMOSD; and
 - 2.2.2 The patient is receiving treatment with mycophenolate; and
 - 2.2.3 The patients is receiving treatment with corticosteroids.

Continuation - Neuromyelitis Optica Spectrum Disorder (NMOSD)

Re-assessment required after 2 years

All of the following:

1 One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 375 mg/m2 administered weekly for four weeks; and
- 2 The patients has responded to the most recent course of rituximab; and
- 3 The patient has not received rituximab in the previous 6 months.

Initiation - Severe Refractory Myasthenia Gravis

Neurologist

Re-assessment required after 2 years Both:

- 1 One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and
- 2 Either:
 - 2.1 Treatment with corticosteroids and at least one other immunosuppressant for at least a period of 12 months has been ineffective; or
 - 2.2 Both:
 - 2.2.1 Treatment with at least one other immunosuppressant for a period of at least 12 months; and
 - 2.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

Continuation - Severe Refractory Myasthenia Gravis

Neurologist

Re-assessment required after 2 years

All of the following:

- 1 One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Either:
 - 3.1 The patient has relapsed despite treatment with corticosteroids and at least one other immunosuppressant for a period of at least 12 months; or
 - 3.2 Both:
 - 3.2.1 The patient's myasthenia gravis has relapsed despite treatment with at least one immunosuppressant for a period of at least 12 months; and
 - 3.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

Initiation – Severe antisynthetase syndrome

Re-assessment required after 12 months

All of the following:

- 1 Patient has confirmed antisynthetase syndrome; and
- 2 Patient has severe, immediately life or organ threatening disease, including interstitial lung disease; and
- 3 Either:
 - 3.1 Treatment with at least 3 immunosuppressants (oral steroids, cyclophosphamide, methotrexate, mycophenolate, ciclosporin, azathioprine) has not be effective at controlling active disease; or
 - 3.2 Rapid treatment is required due to life threatening complications; and

4 Maximum of four 1,000 mg infusions of rituximab.

Continuation - Severe antisynthetase syndrome

Re-assessment required after 12 months

All of the following:

- 1 Patient's disease has responded to the previous rituximab treatment with demonstrated improvement in inflammatory markers, muscle strength and pulmonary function; and
- 2 The patient has not received rituximab in the previous 6 months; and

Price		Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

continued...

3 Maximum of two cycles of 2 × 1,000 mg infusions of rituximab given two weeks apart.

Initiation – graft versus host disease

All of the following:

- 1 Patient has refractory graft versus host disease following transplant; and
- 2 Treatment with at least 3 immunosuppressants (oral steroids, ciclosporin, tacrolimus, mycophenolate, sirolimus) has not be effective at controlling active disease; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Initiation - severe chronic inflammatory demyelinating polyneuropathy

Neurologist

Re-assessment required after 6 months

All of the following:

1 Patient has severe chronic inflammatory demyelinating polyneuropathy (CIPD); and

2 Either:

- 2.1 Both:
 - 2.1.1 Treatment with steroids and intravenous immunoglobulin and/or plasma exchange has not been effective at controlling active disease; and
 - 2.1.2 At least one other immunosuppressant (cyclophosphamide, ciclosporin, tacrolimus, mycophenolate) has not been effective at controlling active disease; or
- 2.2 Rapid treatment is required due to life threatening complications; and
- 3 One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

Continuation - severe chronic inflammatory demyelinating polyneuropathy

Neurologist or medical practitioner on the recommendation of a Neurologist

Re-assessment required after 6 months

All of the following:

- 1 Patient's disease has responded to the previous rituximab treatment with demonstrated improvement in neurological function compared to baseline; and
- 2 The patient has not received rituximab in the previous 6 months; and
- 3 One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

Initiation – anti-NMDA receptor autoimmune encephalitis

Neurologist

Re-assessment required after 6 months All of the following:

- 1 Patient has severe anti-NMDA receptor autoimmune encephalitis; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Treatment with steroids and intravenous immunoglobulin and/or plasma exchange has not been effective at controlling active disease; and
 - 2.1.2 At least one other immunosuppressant (cyclophosphamide, ciclosporin, tacrolimus, mycophenolate) has not been effective at controlling active disease; or
 - 2.2 Rapid treatment is required due to life threatening complications; and
- 3 One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

Price (ex man. excl. GST) \$ Per	Brand or Generic Manufacturer
 ¢ 101	Manalaotaroi

continued...

Continuation - anti-NMDA receptor autoimmune encephalitis

Neurologist

Re-assessment required after 6 months

All of the following:

- 1 Patient's disease has responded to the previous rituximab treatment with demonstrated improvement in neurological function; and
- 2 The patient has not received rituximab in the previous 6 months; and
- 3 The patient has experienced a relapse and now requires further treatment; and
- 4 One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

Initiation - CD20+ low grade or follicular B-cell NHL

Re-assessment required after 9 months

Either:

1 Both:

- 1.1 The patient has CD20+ low grade or follicular B-cell NHL with relapsed disease following prior chemotherapy; and
- 1.2 To be used for a maximum of 6 treatment cycles; or
- 2 Both:
 - 2.1 The patient has CD20+ low grade or follicular B-cell NHL requiring first-line systemic chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.

Continuation - CD20+ low grade or follicular B-cell NHL

Re-assessment required after 24 months

Both:

ſ

- 1 Rituximab is to be used for maintenance in CD20+ low grade or follicular B-cell NHL following induction with first-line systemic chemotherapy; and
- 2 Patient is intended to receive rituximab maintenance therapy for 2 years at a dose of 375 mg/m2 every 8 weeks (maximum of 12 cycles).

SECUKINUMAB - Restricted see terms below

	Inj 150 mg per ml,	1 ml prefilled syringe		2	Cosentyx
--	--------------------	------------------------	--	---	----------

→ Restricted (RS1653)

Initiation – severe chronic plaque psoriasis, second-line biologic

Dermatologist

Re-assessment required after 4 months

All of the following:

- 1 The patient has had an initial Special Authority approval for adalimumab or etanercept, or has trialled infliximab in a DHB hospital in accordance with the General Rules of the Pharmaceutical Schedule, for severe chronic plaque psoriasis; and 2 Either.
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from adalimumab, etanercept or infliximab; or
 - 2.2 The patient has received insufficient benefit from adalimumab, etanercept or infliximab; and
- 3 A Psoriasis Area and Severity Index (PASI) assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 4 The most recent PASI or DQLI assessment is no more than 1 month old at the time of application.

Continuation - severe chronic plaque psoriasis, second-line biologic

Dermatologist *Re-assessment required after 6 months* Both:

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

1 Either:

- 1.1 Patient's PASI score has reduced by 75% or more (PASI 75) as compared to baseline PASI prior to commencing secukinumab; or
- 1.2 Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing secukinumab; and
- 2 Secukinumab to be administered at a maximum dose of 300 mg monthly.

Initiation - severe chronic plaque psoriasis, first-line biologic

Dermatologist

Re-assessment required after 4 months

All of the following:

1 Either:

- 1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
- 1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- 2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
- 3 A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 4 The most recent PASI or DQLI assessment is no more than 1 month old at the time of application.

Note: A treatment course is defined as a minimum of 12 weeks of treatment. "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom sub scores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Continuation - severe chronic plaque psoriasis, first-line biologic

Dermatologist

Re-assessment required after 6 months

Both:

1 Either:

- 1.1 Patient's PASI score has reduced by 75% or more (PASI 75) as compared to baseline PASI prior to commencing secukinumab; or
- 1.2 Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing secukinumab; and
- 2 Secukinumab to be administered at a maximum dose of 300 mg monthly.

SILTUXIMAB - Restricted see terms below

t	Inj 100 mg vial770.57	' 1	Sylvant
t	Inj 400 mg vial	8 1	Sylvant

→ Restricted (RS1525)

Initiation Haematologist or rheumatologist

Re-assessment required after 6 months All of the following:

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 1 Patient has severe HHV-8 negative idiopathic multicentric Castleman's Disease; and
- 2 Treatment with an adequate trial of corticosteroids has proven ineffective; and
- 3 Siltuximab is to be administered at doses no greater than 11 mg/kg every 3 weeks.

Continuation

Haematologist or rheumatologist

Re-assessment required after 12 months

The treatment remains appropriate and the patient has sustained improvement in inflammatory markers and functional status.

TOCILIZUMAB - Restricted see terms below

t	Inj 20 mg per ml, 4 ml vial220.00	1	Actemra
t	Inj 20 mg per ml, 10 ml vial550.00	1	Actemra
t	Inj 20 mg per ml, 20 ml vial1,100.00	1	Actemra

→ Restricted (RS1710)

Initiation - cytokine release syndrome

Therapy limited to 3 doses

Either:

- 1 All of the following:
 - 1.1 The patient is enrolled in the Children's Oncology Group AALL1731 trial; and
 - 1.2 The patient has developed grade 3 or 4 cytokine release syndrome associated with the administration of blinatumomab for the treatment of acute lymphoblastic leukaemia; and
 - Tocilizumab is to be administered at doses no greater than 8 mg/kg IV for a maximum of 3 doses (if less than 30kg, maximum of 12 mg/kg); or
- 2 All of the following:
 - 2.1 The patient is enrolled in the Malaghan Institute of Medical Research Phase I ENABLE trial; and
 - 2.2 The patient has developed CRS or CAR T-Cell Related Encephalopathy Syndrome (CRES) associated with the administration of CAR T-cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma; and
 - 2.3 Tocilizumab is to be administered according to the consensus guidelines for CRS and CRES for CAR T-cell therapy (Neelapu et al. Nat Rev Clin Oncol 2018;15:47-62) at doses no greater than 8 mg/kg IV for a maximum of 3 doses.

Initiation - previous use

Any relevant practitioner

Limited to 6 months treatment

Both:

- 1 Patient was being treated with tocilizumab prior to 1 February 2019; and
- 2 Any of the following:
 - 2.1 rheumatoid arthritis; or
 - 2.2 systemic juvenile idiopathic arthritis; or
 - 2.3 adult-onset Still's disease; or
 - 2.4 polyarticular juvenile idiopathic arthritis; or
 - 2.5 idiopathic multicentric Castleman's disease.

Initiation - Rheumatoid Arthritis (patients previously treated with adalimumab or etanercept)

Rheumatologist or Practitioner on the recommendation of a rheumatologist

Limited to 6 months treatment

All of the following:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and 2 Either:
 - 2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
 - 2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for rheumatoid arthritis; and

Price		Brand or
(ex man. excl. GS		Generic
 \$	Per	Manufacturer

continued...

- 3 Either:
 - 3.1 The patient is seronegative for both anti-cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor; or 3.2 Both:
 - 3.2.1 The patient has been started on rituximab for rheumatoid arthritis in a DHB hospital in accordance with the Section H rules; and
 - 3.2.2 Either:
 - 3.2.2.1 The patient has experienced intolerable side effects from rituximab; or
 - 3.2.2.2 At four months following the initial course of rituximab the patient has received insufficient benefit such that they do not meet the renewal criteria for rheumatoid arthritis.

Initiation - Rheumatoid Arthritis

Rheumatologist or Practitioner on the recommendation of a rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
- 2 Tocilizumab is to be used as monotherapy; and
- 3 Either:
 - 3.1 Treatment with methotrexate is contraindicated; or
 - 3.2 Patient has tried and did not tolerate oral and/or parenteral methotrexate; and
- 4 Either:
 - 4.1 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of ciclosporin alone or in combination with another agent; or
 - 4.2 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of leflunomide alone or in combination with another agent; and
- 5 Either:
 - 5.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 active, swollen, tender joints; or
 - 5.2 Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 6 Either:
 - 6.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 6.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initiation - systemic juvenile idiopathic arthritis

Rheumatologist or Practitioner on the recommendation of a rheumatologist

Re-assessment required after 6 months

Both:

- 1 Patient diagnosed with systemic juvenile idiopathic arthritis; and
- 2 Patient has tried and not responded to a reasonable trial of all of the following, either alone or in combination: oral or parenteral methotrexate; non-steroidal anti-inflammatory drugs (NSAIDs); and systemic corticosteroids.

Initiation - adult-onset Still's disease

Rheumatologist or Practitioner on the recommendation of a rheumatologist

Re-assessment required after 6 months

Either:

196

1 Both:

1.1 Either:

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 1.1.1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for adult-onset Still's disease (AOSD); or
- 1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the General Rules of the Pharmaceutical Schedule; and

1.2 Either:

- 1.2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
- 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for AOSD; or
- 2 All of the following:
 - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
 - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
 - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Initiation - polyarticular juvenile idiopathic arthritis

Rheumatologist or Practitioner on the recommendation of a rheumatologist *Re-assessment required after 4 months* Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for both etanercept and adalimumab for juvenile idiopathic arthritis (JIA); and
 - 1.2 The patient has experienced intolerable side effects, or has received insufficient benefit from, both etanercept and adalimumab; or
- 2 All of the following:
 - 2.1 Treatment with a tumour necrosis factor alpha inhibitor is contraindicated; and
 - 2.2 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
 - 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and
 - 2.4 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.5 Both:
 - 2.5.1 Either:
 - 2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
 - 2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
 - 2.5.2 Physician's global assessment indicating severe disease.

Initiation - idiopathic multicentric Castleman's disease

Haematologist, rheumatologist or Practitioner on the recommendation of a haematologist or rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Patient has severe HHV-8 negative idiopathic multicentric Castleman's disease; and
- 2 Treatment with an adequate trial of corticosteroids has proven ineffective; and
- 3 Tocilizumab to be administered at doses no greater than 8 mg/kg IV every 3-4 weeks.

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

Continuation – Rheumatoid Arthritis

Rheumatologist or Practitioner on the recommendation of a rheumatologist *Re-assessment required after 6 months*

Either:

- 1 Following 6 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.

Continuation - systemic juvenile idiopathic arthritis

Rheumatologist or Practitioner on the recommendation of a rheumatologist

Re-assessment required after 6 months

Either:

- 1 Following up to 6 months' initial treatment, the patient has achieved at least an American College of Rheumatology paediatric 30% improvement criteria (ACR Pedi 30) response from baseline; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing ACR Pedi 30 response from baseline.

Continuation - adult-onset Still's disease

Rheumatologist or Practitioner on the recommendation of a rheumatologist

Re-assessment required after 6 months

the patient has a sustained improvement in inflammatory markers and functional status.

Continuation - polyarticular juvenile idiopathic arthritis

Rheumatologist or Practitioner on the recommendation of a rheumatologist

Re-assessment required after 6 months

Both:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Continuation - idiopathic multicentric Castleman's disease

Haematologist, rheumatologist or Practitioner on the recommendation of a haematologist or rheumatologist

Re-assessment required after 12 months

the treatment remains appropriate and the patient has a sustained improvement in inflammatory markers and functional status.

TRASTUZUMAB – Restricted see terms below		
Inj 150 mg vial	1	Herceptin
Ini 440 mg vial 3875.00	1	Herceptin

→ Restricted (RS1554)

Initiation - Early breast cancer

Limited to 12 months treatment

All of the following:

198

- 1 The patient has early breast cancer expressing HER 2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Maximum cumulative dose of 106 mg/kg (12 months' treatment); and
- 3 Any of the following:
 - 3.1 9 weeks' concurrent treatment with adjuvant chemotherapy is planned; or
 - 3.2 12 months' concurrent treatment with adjuvant chemotherapy is planned; or
 - 3.3 12 months' sequential treatment following adjuvant chemotherapy is planned; or

e.g. Brand indicates brand example only. It is not a contracted product.

	Price		Brand or
()	ex man. excl. GST)		Generic
	\$	Per	Manufacturer

continued...

- 3.4 12 months' treatment with neoadjuvant and adjuvant chemotherapy is planned; or
- 3.5 Other treatment regimen, in association with adjuvant chemotherapy, is planned.

Initiation - metastatic breast cancer (trastuzumab-naive patients)

Limited to 12 months treatment

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Either:
 - 2.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
 - 2.2 Both:
 - 2.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
 - 2.2.2 The cancer did not progress whilst on lapatinib; and
- 3 Either:
 - 3.1 Trastuzumab will not be given in combination with pertuzumab; or
 - 3.2 All of the following:
 - 3.2.1 Trastuzumab to be administered in combination with pertuzumab; and
 - 3.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
 - 3.2.3 The patient has good performance status (ECOG grade 0-1); and
- 4 Trastuzumab not to be given in combination with lapatinib; and
- 5 Trastuzumab to be discontinued at disease progression.

Initiation - metastatic breast cancer (patients previously treated with trastuzumab)

Limited to 12 months treatment

All of the following:

- The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Either:
 - 2.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
 - 2.2 Both:
 - 2.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
 - 2.2.2 The cancer did not progress whilst on lapatinib; and
- 3 Either:
 - 3.1 Trastuzumab will not be given in combination with pertuzumab; or
 - 3.2 All of the following:
 - 3.2.1 Trastuzumab to be administered in combination with pertuzumab; and
 - 3.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
 - 3.2.3 The patient has good performance status (ECOG grade 0-1); and
- 4 Trastuzumab not to be given in combination with lapatinib; and
- 5 Trastuzumab to be discontinued at disease progression.

Continuation - metastatic breast cancer

Re-assessment required after 12 months All of the following:

Price		Brand or
(ex man. excl. GST		Generic
 \$	Per	Manufacturer

continued...

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
- 3 Trastuzumab not to be given in combination with lapatinib; and
- 4 Trastuzumab to be discontinued at disease progression.

TRASTUZUMAB EMTANSINE - Restricted see terms below

t	Inj 100 mg vial2,320	.00	1	Kadcyla
t	Inj 160 mg vial	.00	1	Kadcyla

→ Restricted (RS1715)

Initiation

Re-assessment required after 6 months

All of the following:

- 1 Patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Patient has previously received trastuzumab and chemotherapy, separately or in combination; and
- 3 Either:
 - 3.1 The patient has received prior therapy for metastatic disease*; or
 - 3.2 The patient developed disease recurrence during, or within six months of completing adjuvant therapy*; and
- 4 Patient has a good performance status (ECOG 0-1); and
- 5 Either:
 - 5.1 Patient does not have symptomatic brain metastases; or
 - 5.2 Patient has brain metastases and has received prior local CNS therapy; and
- 6 Treatment to be discontinued at disease progression.

Continuation

Re-assessment required after 6 months

Both:

- 1 The cancer has not progressed at any time point during the previous approval period whilst on trastuzumab emtansine; and
- 2 Treatment to be discontinued at disease progression.

Note: *Note: Prior or adjuvant therapy includes anthracycline, other chemotherapy, biological drugs, or endocrine therapy.

Programmed Cell Death-1 (PD-1) Inhibitors

NIVOLUMAB – Restricted see terms below			
Inj 10 mg per ml, 4 ml vial	1,051.98	1	Opdivo
Inj 10 mg per ml, 10 ml vial		1	Opdivo
→ Restricted (RS1742)			
Initiation			

Medical oncologist Re-assessment required after 4 months

All of the following:

- 1 Patient has metastatic or unresectable melanoma (excluding uveal) stage III or IV; and
- 2 Patient has measurable disease as defined by RECIST version 1.1; and
- 3 The patient has ECOG performance score of 0-2; and
- 4 Either:
 - 4.1 Patient has not received funded pembrolizumab; or

4.2 Both:

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 4.2.1 Patient has received an initial Special Authority approval for pembrolizumab and has discontinued pembrolizumab within 12 weeks of starting treatment due to intolerance; and
- 4.2.2 The cancer did not progress while the patient was on pembrolizumab; and
- 5 Baseline measurement of overall tumour burden is documented (see Note); and
- 6 Documentation confirming that the patient has been informed and acknowledges that funded treatment with nivolumab will not be continued if their disease progresses.

Continuation

Medical oncologist

Re-assessment required after 4 months Either:

- 1 All of the following:
 - 1.1 Any of the following:
 - 1.1.1 Patient's disease has had a complete response to treatment according to RECIST criteria (see Note); or
 - 1.1.2 Patient's disease has had a partial response to treatment according to RECIST criteria (see Note); or
 - 1.1.3 Patient has stable disease according to RECIST criteria (see Note); and
 - 1.2 Patient's disease has not progressed clinically and disease response to treatment has been clearly documented in patient notes; and
 - 1.3 No evidence of progressive disease according to RECIST criteria (see Note); and
 - 1.4 The treatment remains clinically appropriate and the patient is benefitting from the treatment; or

2 All of the following:

- 2.1 Patient has previously discontinued treatment with nivolumab for reasons other than severe toxicity or disease progression; and
- 2.2 Patient has signs of disease progression; and
- 2.3 Disease has not progressed during previous treatment with nivolumab.

Notes: Baseline assessment and disease responses to be assessed according to the Response Evaluation Criteria in Solid Turnours (RECIST) version 1.1 (Eisenhauer EA, et al. Eur J Cancer 2009;45:228-47). Assessments of overall turnour burden and measurable disease to be undertaken on a minimum of one lesion and maximum of 5 target lesions (maximum two lesions per organ). Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, and suitable for reproducible repeated measurements. Measurable disease includes by CT or MRI imaging or caliper measurement by clinical exam. Target lesion measurements should be assessed using the same method of assessment and the same technique used to characterise each identified and reported lesion at baseline and every 12 weeks. Response definitions as follows:

- Complete Response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.
- Partial Response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
- Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
- Stable Disease: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.

PEMBROLIZUMAB - Restricted see terms below

Inj 25 mg per ml, 4 ml vial	 1	Keytruda
→ Restricted (RS1741)		-
Initiation		
Medical oncologist		
Re-assessment required after 4 months		
All of the following:		

	P	rice			Brand or
(ex	man.	excl.	GST)		Generic
		\$		Per	Manufacturer

continued...

- 1 Patient has metastatic or unresectable melanoma (excluding uveal) stage III or IV; and
- 2 Patient has measurable disease as defined by RECIST version 1.1; and
- 3 The patient has ECOG performance score of 0-2; and
- 4 Either:
 - 4.1 Patient has not received funded nivolumab; or
 - 4.2 Both:
 - 4.2.1 Patient has received an initial Special Authority approval for nivolumab and has discontinued nivolumab within 12 weeks of starting treatment due to intolerance; and
 - 4.2.2 The cancer did not progress while the patient was on nivolumab; and
- 5 Baseline measurement of overall tumour burden is documented (see Note); and
- 6 Documentation confirming that the patient has been informed and acknowledges that funded treatment with pembrolizumab will not be continued if their disease progresses.

Continuation

Medical oncologist

Re-assessment required after 4 months Either:

- 1 All of the following:
 - 1.1 Any of the following:
 - 1.1.1 Patient's disease has had a complete response to treatment according to RECIST criteria (see Note); or
 - 1.1.2 Patient's disease has had a partial response to treatment according to RECIST criteria (see Note); or
 - 1.1.3 Patient has stable disease according to RECIST criteria (see Note); and
 - 1.2 Patient's disease has not progressed clinically and disease response to treatment has been clearly documented in patient notes; and
 - 1.3 No evidence of progressive disease according to RECIST criteria (see Note); and
 - 1.4 The treatment remains clinically appropriate and the patient is benefitting from the treatment; or
- 2 All of the following:
 - 2.1 Patient has previously discontinued treatment with pembrolizumab for reasons other than severe toxicity or disease progression; and
 - 2.2 Patient has signs of disease progression; and
 - 2.3 Disease has not progressed during previous treatment with pembrolizumab.

Notes: Baseline assessment and disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer EA, et al. Eur J Cancer 2009;45:228-47). Assessments of overall tumour burden and measurable disease to be undertaken on a minimum of one lesion and maximum of 5 target lesions (maximum two lesions per organ). Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, and suitable for reproducible repeated measurements. Measurable disease includes by CT or MRI imaging or caliper measurement by clinical exam. Target lesion measurements should be assessed using the same method of assessment and the same technique used to characterise each identified and reported lesion at baseline and every 12 weeks. Response definitions as follows:

- Complete Response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.
- Partial Response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
- Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
- Stable Disease: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive

	Price (ex man. excl. GST)		Brand or Generic
	\$	Per	Manufacturer
continued disease.			
Other Immunosuppressants			
ANTITHYMOCYTE GLOBULIN (EQUINE) Inj 50 mg per ml, 5 ml ampoule ANTITHYMOCYTE GLOBULIN (RABBIT)	2,351.25	5	ATGAM
Inj 25 mg vial AZATHIOPRINE			
Tab 25 mg - 1% DV Jan-20 to 2022	7.35	60	Azamun
Tab 50 mg - 1% DV Jan-20 to 2022		100	Azamun
Inj 50 mg vial – 1% DV Nov-19 to 2022		1	Imuran
BACILLUS CALMETTE-GUERIN (BCG) - Restricted see terms be			
Inj 2-8 × 10 [°] 8 CFU vial	149.37	1	OncoTICE
→ Restricted (RS1206) Initiation			
For use in bladder cancer.			
EVEROLIMUS – Restricted see terms below			
↓ Tab 5 mg	4,555.76	30	Afinitor
↓ Tab 10 mg	6,512.29	30	Afinitor
Restricted (RS1745)			
Initiation Neurologist or oncologist			
Re-assessment required after 3 months			
Both:			
 Patient has tuberous sclerosis; and Patient has progressively enlarging sub-ependymal giant cel 	l astrocytomas (SEGAs) that req	uire treatment.
Continuation – pandemic circumstances			
Re-assessment required after 6 months			
All of the following:			
 The patient is clinically benefiting from treatment and continu Everolimus to be discontinued at progression of SEGAs; and 		ippropriat	e; and
3 The regular renewal requirements cannot be met due to CO		ne health :	sector.
Note: MRI should be performed at minimum once every 12 months			
of symptoms such as headaches, visual complaints, nausea or vom		0	•
Continuation			
Neurologist or oncologist			
Re-assessment required after 12 months			
All of the following: 1 Documented evidence of SEGA reduction or stabilisation by	MDI within the last 2 m	onthe: on	4
2 The treatment remains appropriate and the patient is benefit			u
3 Everolimus to be discontinued at progression of SEGAs.	ing nom routhont, and		
Note: MRI should be performed at minimum once every 12 months	, more frequent scannir	ng should	be performed with new onset
of symptoms such as headaches, visual complaints, nausea or vom			
MYCOPHENOLATE MOFETIL			
T 500	05.00	= 0	0.00

Tab 500 mg	50	CellCept
Cap 250 mg	100	CellCept
Powder for oral liq 1 g per 5 ml	165 ml	CellCept
Inj 500 mg vial	4	CellCept

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
PICIBANIL Inj 100 mg vial			
SIROLIMUS – Restricted see terms below			
I Tab 1 mg	749.99	100	Rapamune
↓ Tab 2 mg	1,499.99	100	Rapamune
Oral liq 1 mg per ml		60 ml	Rapamune
➡ Restricted (RS1208)			
Initiation			

For rescue therapy for an organ transplant recipient.

Notes: Rescue therapy defined as unresponsive to calcineurin inhibitor treatment as defined by refractory rejection; or intolerant to calcineurin inhibitor treatment due to any of the following:

- GFR < 30 ml/min; or
- · Rapidly progressive transplant vasculopathy; or
- · Rapidly progressive obstructive bronchiolitis; or
- HUS or TTP; or
- Leukoencepthalopathy; or
- Significant malignant disease

	Price (ex man. excl. GS \$	T) Per	Brand or Generic Manufacturer
Antiallergy Preparations			
Allergic Emergencies			
ICATIBANT - Restricted see terms below ↓ Inj 10 mg per ml, 3 ml prefilled syringe	haryngeal or severe -esterase inhibitor c bon an action plan fo	deficiency; an	ıd
Allergy Desensitisation			
BEE VENOM - Restricted see terms below ↓ Maintenance kit - 6 vials 120 mcg freeze dried venom, with diluer ↓ Inj 550 mcg vial with diluent → Restricted (RS1117) Initiation Both: 1 RAST or skin test positive; and 2 Patient has had severe generalised reaction to the sensitising PAPER WASP VENOM - Restricted see terms below ↓ Treatment kit - 6 vials 120 mcg freeze dried venom, with diluent ↓ Inj 550 mcg vial with diluent → Restricted (RS1118) Initiation Both: 1 RAST or skin test positive; and			
 2 Patient has had severe generalised reaction to the sensitising 2 Patient has had severe generalised reaction to the sensitising YELLOW JACKET WASP VENOM – Restricted see terms below I Treatment kit - 6 vials 120 mcg freeze dried venom, with diluent Inj 550 mcg vial with diluent Restricted (RS1119) Initiation Both: RAST or skin test positive; and 2 Patient has had severe generalised reaction to the sensitising 	-		
Allergy Prophylactics			
BUDESONIDE Nasal spray 50 mcg per dose – 1% DV Oct-20 to 2023 Nasal spray 100 mcg per dose – 1% DV Oct-20 to 2023		200 dose 200 dose	SteroClear SteroClear

Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price (ex man. excl. GS \$	ST) Per	Brand or Generic Manufacturer
LUTICASONE PROPIONATE			
Nasal spray 50 mcg per dose – 1% DV Nov-18 to 2021	1.98	120 dose	Flixonase Hayfever & Allergy
PRATROPIUM BROMIDE Aqueous nasal spray 0.03%	4.61	15 ml	Univent
SODIUM CROMOGLICATE Nasal spray 4%			
Antihistamines			
CETIRIZINE HYDROCHLORIDE Tab 10 mg – 1% DV Nov-19 to 2022 Oral liq 1 mg per ml CHLORPHENIRAMINE MALEATE Oral liq 0.4 mg per ml		100 200 ml	Zista Histaclear
Inj 10 mg per ml, 1 ml ampoule YPROHEPTADINE HYDROCHLORIDE Tab 4 mg			
EXOFENADINE HYDROCHLORIDE Tab 60 mg Tab 120 mg Tab 180 mg			
ORATADINE Tab 10 mg - 1% DV Feb-20 to 2022	1.69	100	Lorafix
Oral liq 1 mg per ml		120 ml	Lorfast
POMETHAZINE HYDROCHLORIDE Tab 10 mg – 1% DV Sep-18 to 2021		50	Allersoothe
Tab 25 mg – 1% DV Sep-18 to 2021		50	Allersoothe
Oral liq 1 mg per ml – 1% DV Sep-18 to 2021 Inj 25 mg per ml, 2 ml ampoule		100 ml 5	Allersoothe Hospira
Anticholinergic Agents			
PRATROPIUM BROMIDE			
Aerosol inhaler 20 mcg per dose Nebuliser soln 250 mcg per ml, 1 ml ampoule	3 35	20	Univent
Nebuliser soln 250 mcg per ml, 2 ml ampoule – 1% DV Jan-20 Univent Nebuliser soln 250 mcg per ml, 1 ml ampoule to be deliste	0 to 2022 11.73	20	Univent
Anticholinergic Agents with Beta-Adrenoceptor A	• •		
	igeniete		
Aerosol inhaler 100 mcg with ipratropium bromide 20 mcg per Nebuliser soln 2.5 mg with ipratropium bromide 0.5 mg per 2.5 ampoule – 1% DV Oct-18 to 2021	ml	20	Duolin
Long-Acting Muscarinic Agents			
GLYCOPYRRONIUM			
Note: inhaled glycopyrronium treatment must not be used if th or umeclidinium. Powder for inhalation 50 mcg per dose		ving treatmen 30 dose	t with subsidised tiotropi Seebri Breezhaler

t Item restricted (see → above); t Item restricted (see → below)

206

e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GS \$	ST) Per	Brand or Generic Manufacturer
TIOTROPIUM BROMIDE			
Note: tiotropium treatment must not be used if the patient is also or umeclidinium.	receiving treatment	with subsidi	sed inhaled glycopyrronium
Soln for inhalation 2.5 mcg per dose		60 dose	Spiriva Respimat
Powder for inhalation 18 mcg per dose	50.37	30 dose	Spiriva
UMECLIDINIUM Note: Umeclidinium must not be used if the patient is also receive tiotropium bromide. Powder for inhalation 62.5 mcg per dose	0	ubsidised inł 30 dose	naled glycopyrronium or Incruse Ellipta

Long-Acting Muscarinic Antagonists with Long-Acting Beta-Adrenoceptor Agonists

→ Restricted (RS1518)

Initiation

Re-assessment required after 2 years Both:

- 1 Patient has been stabilised on a long acting muscarinic antagonist; and
- 2 The prescriber considers that the patient would receive additional benefit from switching to a combination product.

Continuation

Re-assessment required after 2 years Both:

- 1 Patient is compliant with the medication; and
- 2 Patient has experienced improved COPD symptom control (prescriber determined).

Note: Combination long acting muscarinic antagonist and long acting beta-2 agonist must not be used if the patient is also receiving treatment with a combination inhaled corticosteroid and long acting beta-2 agonist.

GLYCOPYRRONIUM WITH INDACATEROL – Restricted see terms above		
Powder for Inhalation 50 mcg with indacaterol 110 mcg81.00	30 dose	Ultibro Breezhaler
TIOTROPIUM BROMIDE WITH OLODATEROL – Restricted see terms above		
t Soln for inhalation 2.5 mcg with olodaterol 2.5 mcg	60 dose	Spiolto Respimat
UMECLIDINIUM WITH VILANTEROL - Restricted see terms above		
t Powder for inhalation 62.5 mcg with vilanterol 25 mcg77.00	30 dose	Anoro Ellipta

Antifibrotics

NI	NTEDANIB – Restricted see terms below		
t	Cap 100 mg2,554.00	60	Ofev
	Cap 150 mg		Ofev

➡ Restricted (RS1756)

Initiation – idiopathic pulmonary fibrosis

Respiratory specialist

Re-assessment required after 12 months

All of the following:

- 1 Patient has been diagnosed with idiopathic pulmonary fibrosis; and
- 2 Forced vital capacity is between 50% and 90% predicted; and
- 3 Nintedanib is to be discontinued at disease progression (See Note); and
- 4 Nintedanib is not to be used in combination with subsidised pirfenidone; and
- 5 Any of the following:

Price			Brand or
(ex man. excl.	GST)		Generic
\$		Per	Manufacturer

continued...

- 5.1 The patient has not previously received treatment with pirfenidone; or
- 5.2 Patient has previously received pirfenidone, but discontinued pirfenidone within 12 weeks due to intolerance; or
- 5.3 Patient has previously received pirfenidone, but the patient's disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with pirfenidone).

Continuation – idiopathic pulmonary fibrosis

Re-assessment required after 12 months

All of the following:

- 1 Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment; and
- 2 Nintedanib is not to be used in combination with subsidised pirfenidone; and
- 3 Nintedanib is to be discontinued at disease progression (See Note).

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

PIRFENIDONE - Restricted see terms below

t	Tab 801 mg3,645.00	90	Esbriet
t	Cap 267 mg3,645.00	270	Esbriet

➡ Restricted (RS1757)

Initiation - idiopathic pulmonary fibrosis

Respiratory specialist

Re-assessment required after 12 months

All of the following:

- 1 Patient has been diagnosed with idiopathic pulmonary fibrosis; and
- 2 Forced vital capacity is between 50% and 90% predicted; and
- 3 Pirfenidone is to be discontinued at disease progression (See Notes); and
- 4 Pirfenidone is not to be used in combination with subsidised nintedanib; and
- 5 Any of the following:
 - 5.1 The patient has not previously received treatment with nintedanib; or
 - 5.2 Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance; or
 - 5.3 Patient has previously received nintedanib, but the patient's disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with nintedanib).

Continuation - idiopathic pulmonary fibrosis

Re-assessment required after 12 months

All of the following:

- 1 Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment; and
- 2 Pirfenidone is not to be used in combination with subsidised nintedanib; and
- 3 Pirfenidone is to be discontinued at disease progression (See Note).

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

Beta-Adrenoceptor Agonists

SALBUTAMOL

208

Oral liq 400 mcg per ml – 1% DV Nov-18 to 2021	150 ml	Ventolin
Inj 500 mcg per ml, 1 ml ampoule		
Inj 1 mg per ml, 5 ml ampoule		
Aerosol inhaler, 100 mcg per dose	200 dose	SalAir
6.00		Ventolin
Nebuliser soln 1 mg per ml, 2.5 ml ampoule - 1% DV Oct-18 to 2021	20	Asthalin
Nebuliser soln 2 mg per ml, 2.5 ml ampoule - 1% DV Oct-18 to 20214.03	20	Asthalin

	P (ex man.	Price excl. \$	GST) Per	Brand or Generic Manufacturer
ERBUTALINE SULPHATE				
Powder for inhalation 250 mcg per dose				
Inj 0.5 mg per ml, 1 ml ampoule				
Powder for inhalation, 200 mcg per dose (equivalent to 250 mcg metered dose), breath activated		22.20	120 dose	Bricanyl Turbuhaler
Cough Suppressants				
HOLCODINE				
Oral liq 1 mg per ml – 1% DV Jun-20 to 2022		3.09	200 ml	AFT Pholcodine Linctus BP
Decongestants				
XYMETAZOLINE HYDROCHLORIDE				
Aqueous nasal spray 0.25 mg per ml				
Aqueous nasal spray 0.5 mg per ml				
SEUDOEPHEDRINE HYDROCHLORIDE Tab 60 mg				
ODIUM CHLORIDE				
Aqueous nasal spray isotonic				
DDIUM CHLORIDE WITH SODIUM BICARBONATE Soln for nasal irrigation				
YLOMETAZOLINE HYDROCHLORIDE				
Aqueous nasal spray 0.05%				
Aqueous nasal spray 0.1%				
Nasal drops 0.05% Nasal drops 0.1%				
nhaled Corticosteroids				
ECLOMETHASONE DIPROPIONATE		0 5 4	000 -1	Declarate 50
Aerosol inhaler 50 mcg per dose		8.54 9.30		Beclazone 50 Qvar
Aerosol inhaler 100 mcg per dose				Beclazone 100
		15.50		Qvar
Aerosol inhaler 250 mcg per dose		22.67	200 dose	Beclazone 250
JDESONIDE				
Nebuliser soln 250 mcg per ml, 2 ml ampoule				
Nebuliser soln 500 mcg per ml, 2 ml ampoule				
Powder for inhalation 100 mcg per dose				
Powder for inhalation 200 mcg per dose Powder for inhalation 400 mcg per dose				
UTICASONE				
Aerosol inhaler 50 mcg per dose – 1% DV Sep-20 to 2023		7 19	120 dose	Flixotide
Powder for inhalation 50 mcg per dose				Flixotide Accuhaler
Powder for inhalation 100 mcg per dose				Flixotide Accuhaler
Aerosol inhaler 125 mcg per dose - 1% DV Sep-20 to 2023				Flixotide
Aerosol inhaler 250 mcg per dose - 1% DV Sep-20 to 2023				Flixotide
Powder for inhalation 250 mcg per dose		24.51	60 dose	Flixotide Accuhaler

	Price (ex man. excl. GS \$	T) Per	Brand or Generic Manufacturer
Leukotriene Receptor Antagonists			
MONTELUKAST Tab 4 mg – 1% DV Jan-20 to 2022 Tab 5 mg – 1% DV Jan-20 to 2022 Tab 10 mg – 1% DV Jan-20 to 2022	4.25	28 28 28	Montelukast Mylan Montelukast Mylan Montelukast Mylan
Long-Acting Beta-Adrenoceptor Agonists			
EFORMOTEROL FUMARATE Powder for inhalation 12 mcg per dose			
EFORMOTEROL FUMARATE DIHYDRATE Powder for inhalation 4.5 mcg per dose, breath activated (equiv eformoterol fumarate 6 mcg metered dose)	alent to		
INDACATEROL Powder for inhalation 150 mcg per dose Powder for inhalation 300 mcg per dose		30 dose 30 dose	Onbrez Breezhaler Onbrez Breezhaler
SALMETEROL Aerosol inhaler 25 mcg per dose		120 dose	Meterol Serevent
Powder for inhalation 50 mcg per dose (Meterol Aerosol inhaler 25 mcg per dose to be delisted 1 January 2		60 dose	Serevent Accuhaler

Inhaled Corticosteroids with Long-Acting Beta-Adrenoceptor Agonists

BUDESONIDE WITH EFORMOTEROL Powder for inhalation 100 mcg with eformoterol fumarate 6 mcg Powder for inhalation 200 mcg with eformoterol fumarate 6 mcg Powder for inhalation 400 mcg with eformoterol fumarate 12 mcg Aerosol inhaler 100 mcg with eformoterol fumarate 6 mcg Aerosol inhaler 200 mcg with eformoterol fumarate 6 mcg Powder for inhalation 160 mcg with 4.5 mcg eformoterol fumarate per			
dose (equivalent to 200 mcg budesonide with 6 mcg eformoterol fumarate metered dose)	41.50	120 dose	DuoResp Spiromax
Powder for inhalation 320 mcg with 9 mcg eformoterol fumarate per dose (equivalent to 400 mcg budesonide with 12 mcg eformoterol fumarate metered dose)		120 dose	DuoResp Spiromax
FLUTICASONE FUROATE WITH VILANTEROL		0000	2 aon cop opromax
Powder for inhalation 100 mcg with vilanterol 25 mcg	44.08	30 dose	Breo Ellipta
FLUTICASONE WITH SALMETEROL	0E 70	100 dooo	Seretide
Aerosol inhaler 50 mcg with salmeterol 25 mcg – 1% DV Sep-20 to 2023		120 dose 60 dose	Seretide Accuhaler
Powder for inhalation 100 mcg with salmeterol 50 mcg Aerosol inhaler 125 mcg with salmeterol 25 mcg – 1% DV Sep-20		00 0058	Sereliue Accuridier
to 2023	32.60	120 dose	Seretide
Powder for inhalation 250 mcg with salmeterol 50 mcg		60 dose	Seretide Accuhaler

Mast Cell Stabilisers

NEDOCROMIL

210

Aerosol inhaler 2 mg per dose

(Any Aerosol inhaler 2 mg per dose to be delisted 1 February 2021)

t Item restricted (see \Rightarrow above); **t** Item restricted (see \Rightarrow below)

e.g. Brand indicates brand example only. It is not a contracted product.

		D '		
		Price excl. GST \$) Per	Brand or Generic Manufacturer
SODIUM CROMOGLICATE				
Aerosol inhaler 5 mg per dose				
(Any Aerosol inhaler 5 mg per dose to be delisted 1 May 2021)				
Methylxanthines				
AMINOPHYLLINE				
Inj 25 mg per ml, 10 ml ampoule		124.37	5	DBL Aminophylline
CAFFEINE CITRATE				
Oral liq 20 mg per ml (caffeine 10 mg per ml) – 1% DV Nov-19 Inj 20 mg per ml (caffeine 10 mg per ml), 2.5 ml ampoule – 1%		.15.10	25 ml	Biomed
Nov-19 to 2022		.63.25	5	Biomed
THEOPHYLLINE				
Tab long-acting 250 mg – 1% DV Jan-20 to 2022			100	Nuelin-SR Nuelin
Oral liq 80 mg per 15 ml - 1% DV Jan-20 to 2022		. 10.00	500 ml	Nueim
Mucolytics and Expectorants				
DORNASE ALFA – Restricted see terms below				
Vebuliser soln 2.5 mg per 2.5 ml ampoule		250.00	6	Pulmozyme
→ Restricted (RS1352)				
Initiation – cystic fibrosis The patient has cystic fibrosis and has been approved by the Cystic	: Fibrosis Pa	nel.		
nitiation – significant mucus production				
<i>Limited to 4 weeks</i> treatment Both:				
1 Patient is an in-patient; and				
2 The mucus production cannot be cleared by first line chest to	echniques.			
nitiation – pleural emphyema				
Limited to 3 days treatment				
Both: 1 Patient is an in-patient; and				
2 Patient diagnoses with pleural emphyema.				
SODIUM CHLORIDE				
Nebuliser soln 7%, 90 ml bottle - 1% DV Nov-19 to 2022		.24.50	90 ml	Biomed
Pulmonary Surfactants				
BERACTANT				
Soln 200 mg per 8 ml vial				
PORACTANT ALFA Soln 120 mg per 1.5 ml vial		425.00	1	Curosurf
Soln 240 mg per 3 ml vial			1	Curosurf
Despiratory Stimulants				
Respiratory Stimulants				
DOXAPRAM				

Inj 20 mg per ml, 5 ml vial

Price		Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

Sclerosing Agents

TALC

Powder Soln (slurry) 100 mg per ml, 50 ml

SENSORY ORGANS

	Price (ex man. excl. GST \$	Per	Brand or Generic Manufacturer
Anti-Infective Preparations			
Antibacterials			
CHLORAMPHENICOL Eye oint 1% – 1% DV May-20 to 2022 Ear drops 0.5%		5 g	Devatis
Eye drops 0.5% - 1% DV Nov-19 to 2022 Eye drops 0.5%, single dose	1.54	10 ml	Chlorafast
CIPROFLOXACIN Eye drops 0.3% FRAMYCETIN SULPHATE Ear/eye drops 0.5%	9.99	5 ml	Ciprofloxacin Teva
GENTAMICIN SULPHATE Eye drops 0.3% PROPAMIDINE ISETHIONATE	11.40	5 ml	Genoptic
Eye drops 0.1% SODIUM FUSIDATE [FUSIDIC ACID] Eye drops 1% SULPHACETAMIDE SODIUM Eye drops 10%	5.29	5 g	Fucithalmic
TOBRAMYCIN Eye oint 0.3% Eye drops 0.3%		3.5 g 5 ml	Tobrex Tobrex
Antifungals			
NATAMYCIN Eye drops 5%			
Antivirals			
ACICLOVIR Eye oint 3%		4.5 g	ViruPOS
Combination Preparations			
CIPROFLOXACIN WITH HYDROCORTISONE Ear drops ciprofloxacin 0.2% with 1% hydrocortisone DEXAMETHASONE WITH FRAMYCETIN AND GRAMICIDIN Ear/eye drops 500 mcg with framycetin sulphate 5 mg and grar 50 mcg per ml		10 ml	Ciproxin HC Otic
DEXAMETHASONE WITH NEOMYCIN SULPHATE AND POLYMY Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin b 6,000 u per g	sulphate	3.5 g	Maxitrol
Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin sulphate 6,000 u per ml		5 ml	Maxitrol
DEXAMETHASONE WITH TOBRAMYCIN Eye drops 0.1% with tobramycin 0.3%		5 ml	Tobradex

Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

		Price excl. GST; \$) Per	Brand or Generic Manufacturer
FLUMETASONE PIVALATE WITH CLIOQUINOL Ear drops 0.02% with clioquinol 1%				
TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN / Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 gramicidin 250 mcg per g	mg and		7.5 ml	Kenacomb
Anti-Inflammatory Preparations				
Corticosteroids				
DEXAMETHASONE Eye oint 0.1% Eye drops 0.1% ¶ Ocular implant 700 mcg.		4.50	3.5 g 5 ml 1	Maxidex Maxidex Ozurdex
 → Restricted (RS1606) Initiation – Diabetic macular oedema Ophthalmologist <i>Re-assessment required after 12 months</i> All of the following: Patients have diabetic macular oedema with pseudophakic le Patients have diabetic macular oedema with pseudophakic le Patient has reduced visual acuity of between 6/9 – 6/48 with Either: 	functional a with bevaci	zumab; or		n in vision; and
 3.2 Patient is unsuitable or contraindicated to treatment w 4 Dexamethasone implants are to be administered not more from maximum of 3 implants per every per year. 				is into each eye, and up to a
Continuation – Diabetic macular oedema Ophthalmologist <i>Re-assessment required after 12 months</i> Both:				
 Patient's vision is stable or has improved (prescriber determi Dexamethasone implants are to be administered not more from maximum of 3 implants per eye per year. 		n once eve	ery 4 month	is into each eye, and up to a
Initiation – Women of child bearing age with diabetic macular o Ophthalmologist <i>Re-assessment required after 12 months</i> All of the following:	edema			
 Patients have diabetic macular oedema; and Patient has reduced visual acuity of between 6/9 – 6/48 with Patient is of child bearing potential and has not yet complete Dexamethasone implants are to be administered not more from maximum of 3 implants per eye per year. 	d a family; a equently tha	nd		
Continuation – Women of child bearing age with diabetic macul Onbthalmologist	lar oedema			

Ophthalmologist *Re-assessment required after 12 months*

All of the following:

214

- 1 Patient's vision is stable or has improved (prescriber determined); and
- 2 Patient is of child bearing potential and has not yet completed a family; and
- 3 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

SENSORY ORGANS

	Price (ex man. excl. GS \$	Г) Per	Brand or Generic Manufacturer
FLUOROMETHOLONE Eye drops 0.1% PREDNISOLONE ACETATE		5 ml	FML
Eye drops 0.12% Eye drops 1%	7.00 5.93	5 ml 10 ml	Pred Forte Prednisolone- AFT
PREDNISOLONE SODIUM PHOSPHATE Eye drops 0.5%, single dose (preservative free)		20 dose	Minims Prednisolone
Non-Steroidal Anti-Inflammatory Drugs			
DICLOFENAC SODIUM Eye drops 0.1% KETOROLAC TROMETAMOL Eye drops 0.5%		5 ml	Voltaren Ophtha
Decongestants and Antiallergics			
Antiallergic Preparations			
LEVOCABASTINE Eye drops 0.05% LODOXAMIDE			
Eye drops 0.1% OLOPATADINE	8.71	10 ml	Lomide
Eye drops 0.1% – 1% DV Oct-20 to 2022 SODIUM CROMOGLICATE Eye drops 2% – 1% DV Jan-20 to 2022		5 ml 5 ml	Olopatadine Teva Rexacrom
Decongestants			
NAPHAZOLINE HYDROCHLORIDE Eye drops 0.1%	4.15	15 ml	Naphcon Forte
Diagnostic and Surgical Preparations			
Diagnostic Dyes			
FLUORESCEIN SODIUM Eye drops 2%, single dose Inj 10%, 5 ml vial Ophthalmic strips 1 mg FLUORESCEIN SODIUM WITH LIGNOCAINE HYDROCHLORID Eye drops 0.25% with lignocaine hydrochloride 4%, single dos	E	12	Fluorescite
LISSAMINE GREEN Ophthalmic strips 1.5 mg ROSE BENGAL SODIUM Ophthalmic strips 1%			

		Price excl. GST) \$	Per	Brand or Generic Manufacturer
Irrigation Solutions				
 MIXED SALT SOLUTION FOR EYE IRRIGATION Eye irrigation solution calcium chloride 0.048% with magnesium of 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, so chloride 0.64% and sodium citrate 0.17%, 15 ml dropper bott Eye irrigation solution calcium chloride 0.048% with magnesium of 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, so chloride 0.64% and sodium citrate 0.17%, 250 ml Eye irrigation solution calcium chloride 0.048% with magnesium of 0.04% 	sodium tle chloride sodium	5.00	15 ml	Balanced Salt Solution e.g. Balanced Salt Solution
0.03%, potassium chloride 0.075%, sodium acetate 0.39%, s chloride 0.64% and sodium citrate 0.17%, 500 ml bottle		. 10.50	500 ml	Balanced Salt Solution
Ocular Anaesthetics				
OXYBUPROCAINE HYDROCHLORIDE Eye drops 0.4%, single dose PROXYMETACAINE HYDROCHLORIDE Eye drops 0.5% TETRACAINE [AMETHOCAINE] HYDROCHLORIDE Eye drops 0.5%, single dose Eye drops 1%, single dose				
Viscoelastic Substances				
HYPROMELLOSE Inj 2%, 1 ml syringe Inj 2%, 2 ml syringe SODIUM HYALURONATE [HYALURONIC ACID] Inj 14 mg per ml, 0.85 ml syringe – 1% DV Oct-19 to 2022		.50.00	1	Healon GV
Inj 14 mg per ml, 0.55 ml syringe – 1% DV Oct-19 to 2022 Inj 23 mg per ml, 0.6 ml syringe – 1% DV Oct-19 to 2022 Inj 10 mg per ml, 0.85 ml syringe – 1% DV Oct-19 to 2022		.60.00	1 1 1	Healon GV Healon 5 Healon
SODIUM HYALURONATE [HYALURONIC ACID] WITH CHONDROI Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.35 ml and inj 10 mg sodium hyaluronate [hyaluronic acid] per ml, 0	TIN SULPH syringe .4 ml	IATE		
syringe Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.5 ml s and inj 10 mg sodium hyaluronate [hyaluronic acid] per ml, 0	yringe	.64.00	1	Duovisc
syringe Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.75 ml			1 1	Duovisc Viscoat

Other

216

DISODIUM EDETATE

Inj 150 mg per ml, 20 ml ampoule

Inj 150 mg per ml, 20 ml vial

Inj 150 mg per ml, 100 ml vial

		5LI	
	Price excl. GS \$	T) Per	Brand or Generic Manufacturer
RIBOFLAVIN 5-PHOSPHATE Soln trans epithelial riboflavin Inj 0.1% Inj 0.1% plus 20% dextran T500			
Glaucoma Preparations			
Beta Blockers			
BETAXOLOL Eye drops 0.25% Eye drops 0.5% TIMOLOL		5 ml 5 ml	Betoptic S Betoptic
Eye drops 0.25% – 1% DV Dec-20 to 2023 Eye drops 0.5% – 1% DV Dec-20 to 2023 Eye drops 0.5%, gel forming	 2.04	5 ml 5 ml 2.5 ml	Arrow-Timolol Arrow-Timolol Timoptol XE
Carbonic Anhydrase Inhibitors			
ACETAZOLAMIDE Tab 250 mg Inj 500 mg BRINZOLAMIDE Eye drops 1% DORZOLAMIDE Eye drops 2% DORZOLAMIDE WITH TIMOLOL Eye drops 2% with timolol 0.5% – 1% DV Jan-19 to 2021		100 5 ml	Diamox Dortimopt
Miotics			
ACETYLCHOLINE CHLORIDE Inj 20 mg vial with diluent CARBACHOL Inj 150 mcg vial PILOCARPINE HYDROCHLORIDE Eye drops 1%	4.26	15 ml	Isopto Carpine
Eye drops 2% Eye drops 2%, single dose		15 ml	Isopto Carpine
Eye drops 4%	7.99	15 ml	Isopto Carpine
Prostaglandin Analogues			
BIMATOPROST Eye drops 0.03% – 1% DV Feb-19 to 2021 ATANOPROST	 3.30	3 ml	Bimatoprost Multichen
Eye drops 0.005% - 1% DV Apr-19 to 2021	 1.57	2.5 ml	Teva
TRAVOPROST Eye drops 0.004%	 7.30	5 ml	Travopt

SENSORY ORGANS

SENSORY ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Sympathomimetics			
APRACLONIDINE Eye drops 0.5% BRIMONIDINE TARTRATE Eye drops 0.2% BRIMONIDINE TARTRATE WITH TIMOLOL Eye drops 0.2% with timolol 0.5%		5 ml 5 ml	lopidine Arrow-Brimonidine
Mydriatics and Cycloplegics			
Anticholinergic Agents			
ATROPINE SULPHATE Eye drops 0.5% Eye drops 1%, single dose Eye drops 1% – 1% DV Oct-20 to 2023 CYCLOPENTOLATE HYDROCHLORIDE Eye drops 0.5%, single dose Eye drops 1%, single dose TROPICAMIDE Eye drops 0.5% Eye drops 0.5%, single dose Eye drops 0.5%, single dose Eye drops 1% Eye drops 1%, single dose	8.76	15 ml 15 ml 15 ml 15 ml	Atropt Cyclogyl Mydriacyl Mydriacyl
Sympathomimetics			
PHENYLEPHRINE HYDROCHLORIDE Eye drops 2.5%, single dose Eye drops 10%, single dose			
Ocular Lubricants			
CARBOMER Ophthalmic gel 0.3%, single dose Ophthalmic gel 0.2% CARMELLOSE SODIUM WITH PECTIN AND GELATINE Eye drops 0.5%, single dose Eye drops 1% Eye drops 1%	8.25	30	Poly Gel
Eye drops 1%, single dose HYPROMELLOSE			
Eye drops 0.5%	3.92	15 ml	Methopt
HYPROMELLOSE WITH DEXTRAN Eye drops 0.3% with dextran 0.1% Eye drops 0.3% with dextran 0.1%, single dose	2.30	15 ml	Poly-Tears
MACROGOL 400 AND PROPYLENE GLYCOL Eye drops 0.4% with propylene glycol 0.3% preservative free, s	single dose4.30	24	Systane Unit Dose

t Item restricted (see → above); t Item restricted (see → below)

e.g. Brand indicates brand example only. It is not a contracted product.

SENSORY ORGANS

Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
3.63	3.5 g	Poly-Visc
3.80	5 g	VitA-POS
22.00	10 ml	Hylo-Fresh
	(ex man. excl. GST \$ 	(ex man. excl. GST) \$ Per

Other Otological Preparations

ACETIC ACID WITH PROPYLENE GLYCOL

Ear drops 2.3% with propylene glycol 2.8%

DOCUSATE SODIUM

Ear drops 0.5%

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Agents Used in the Treatment of Poisonings			
Antidotes			
ACETYLCYSTEINE Tab eff 200 mg Inj 200 mg per ml, 10 ml ampoule – 1% DV Sep-18 to 2021 AMYL NITRITE Liq 98% in 3 ml capsule DIGOXIN IMMUNE FAB Inj 38 mg vial Inj 40 mg vial	58.76	10	DBL Acetylcysteine
ETHANOL Liq 96%			
ETHANOL WITH GLUCOSE Inj 10% with glucose 5%, 500 ml bottle			
ETHANOL, DEHYDRATED Inj 100%, 5 ml ampoule Inj 96%			
FLUMAZENIL Inj 0.1 mg per ml, 5 ml ampoule – 1% DV Dec-18 to 2021		10	HameIn
HYDROXOCOBALAMIN Inj 5 g vial Inj 2.5 g vial			
NALOXONE HYDROCHLORIDE Inj 400 mcg per ml, 1 ml ampoule – 1% DV Aug-18 to 2021		5	DBL Naloxone Hydrochloride
PRALIDOXIME IODIDE Inj 25 mg per ml, 20 ml ampoule			·
SODIUM NITRITE Inj 30 mg per ml, 10 ml ampoule			
SODIUM THIOSULFATE Inj 250 mg per ml, 10 ml vial Inj 250 mg per ml. 50 ml vial Inj 500 mg per ml, 10 ml vial Inj 500 mg per ml, 20 ml ampoule			
SOYA OIL Inj 20%, 500 ml bag Inj 20%, 500 ml bottle			
Antitoxins			
BOTULISM ANTITOXIN			

- Inj 250 ml vial DIPHTHERIA ANTITOXIN
 - lnj 10,000 iu vial

Price			Brand or
(ex man. excl.	GST)		Generic
\$		Per	Manufacturer

Antivenoms

RED BACK SPIDER ANTIVENOM Inj 500 u vial

SNAKE ANTIVENOM

Ini 50 ml vial

Removal and Elimination

CHARCOAL			
Oral liq 200 mg per ml	43.50	250 ml	Carbasorb-X
DEFERASIROX – Restricted see terms below			
Tab 125 mg dispersible		28	Exjade
Tab 250 mg dispersible		28	Exjade
Tab 500 mg dispersible		28	Exjade
- Destricted (DS1////)			•

➡ Restricted (RS1444)

Initiation

Haematologist Re-assessment required after 2 years

All of the following:

1 The patient has been diagnosed with chronic iron overload due to congenital inherited anaemia; and

2 Deferasirox is to be given at a daily dose not exceeding 40 mg/kg/day; and

- 3 Any of the following:
 - 3.1 Treatment with maximum tolerated doses of deferiprone monotherapy or deferiprone and desferrioxamine combination therapy have proven ineffective as measured by serum ferritin levels, liver or cardiac MRI T2*; or
 - 3.2 Treatment with deferiprone has resulted in severe persistent vomiting or diarrhoea; or
 - 3.3 Treatment with deferiprone has resulted in arthritis: or
 - 3.4 Treatment with deferiprone is contraindicated due to a history of agranulocytosis (defined as an absolute neutrophil count (ANC) of < 0.5 cells per µL) or recurrent episodes (greater than 2 episodes) of moderate neutropenia (ANC 0.5 - 1.0 cells per uL).

Continuation

Haematologist

Re-assessment required after 2 years Either:

- 1 For the first renewal following 2 years of therapy, the treatment has been tolerated and has resulted in clinical improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels; or
- 2 For subsequent renewals, the treatment has been tolerated and has resulted in clinical stability or continued improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels.

DEFERIPRONE - Restricted see terms below

t	Tab 500 mg	533.17	100	Ferriprox
	Oral lig 100 mg per ml		250 ml	Ferriprox
⇒	Restricted (RS1445)			•

Initiation

Patient has been diagnosed with chronic iron overload due to congenital inherited anaemia or acquired red cell aplasia.

DESFERBIOXAMINE MESILATE

Inj 500 mg vial - 1% DV Mar-19 to 202184.53	3 10	DBL Desferrioxamine
		Mesylate for Inj
		BP

DICOBAL T EDETATE

Inj 15 mg per ml, 20 ml ampoule

VARIOUS

	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
DIMERCAPROL			
Inj 50 mg per ml, 2 ml ampoule			
DIMERCAPTOSUCCINIC ACID			
Cap 100 mg			e.g. PCNZ, Optimus
			Healthcare,
Cap 200 mg			Chemet e.g. PCNZ, Optimus
Cap 200 mg			Healthcare.
			Chemet
SODIUM CALCIUM EDETATE			
Inj 200 mg per ml, 2.5 ml ampoule			
Inj 200 mg per ml, 5 ml ampoule			
Antiseptics and Disinfectants			
CHLORHEXIDINE			
Soln 4% Soln 4%,	1.96	50 ml	healthE
Soin 5%		500 ml	healthE
(healthE Soln 4%, to be delisted 1 November 2020)		500 m	neanne
CHLORHEXIDINE WITH CETRIMIDE			
Crm 0.1% with cetrimide 0.5%			
Foaming soln 0.5% with cetrimide 0.5%			
CHLORHEXIDINE WITH ETHANOL			
Soln 0.5% with ethanol 70%			
Soln 2% with ethanol 70%			
Soln 0.5% with ethanol 70%, non-staining (pink) 100 ml	2.65	1	healthE
Soln 2% with ethanol 70%, non-staining (pink) 100 ml	3.54	1	healthE
Soln 0.5% with ethanol 70%, non-staining (pink) 25 ml	1.55	1	healthE
Soln 0.5% with ethanol 70%, staining (red) 100 ml	2.90	1	healthE
Soln 2% with ethanol 70%, staining (red) 100 ml		1	healthE
Soln 0.5% with ethanol 70%, non-staining (pink) 500 ml		1	healthE
Soln 0.5% with ethanol 70%, staining (red) 500 ml		1	healthE
Soln 2% with ethanol 70%, staining (red) 500 ml		1	healthE
(healthE Soln 0.5% with ethanol 70%, non-staining (pink) 100 ml to be of (healthE Soln 2% with ethanol 70%, non-staining (pink) 100 ml to be de		,	
(healthE Soln 2% with ethanol 70%, staining (pink) 100 mit to be delisted (healthE Soln 0.5% with ethanol 70%, staining (red) 100 mit to be delisted		,	
(healthE Soln 2% with ethanol 70%, staining (red) 100 ml to be delisted		,	
(healthE Soln 0.5% with ethanol 70%, starting (rea) 100 million be delised			
(healthE Soln 0.5% with ethanol 70%, staining (red) 500 ml to be delisted			
(healthE Soln 2% with ethanol 70%, staining (red) 500 ml to be delisted		,	
IODINE WITH ETHANOL		, ,	
Soln 1% with ethanol 70%			
Soln 1% with ethanol 70%, 100 ml	9.30	1	healthE
(healthE Soln 1% with ethanol 70%, 100 ml to be delisted 1 November			
ISOPROPYL ALCOHOL			
Soln 70%, 500 ml		1	healthE
		1	nouttie

VARIOUS

	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
POVIDONE-IODINE			
Vaginal tab 200 mg			
→ Restricted (RS1354)			
nitiation			
Rectal administration pre-prostate biopsy.			
Oint 10% - 1% DV Oct-20 to 2023	7.40	65 g	Betadine
Soln 10% - 1% DV Nov-19 to 2021	2.55	100 ml	Riodine
Soln 5%			
Soln 7.5%			
Soln 10%, -1% DV Dec-19 to 2022		15 ml	Riodine
Pad 10%	5.40	500 ml	Riodine
Swab set 10%			
POVIDONE-IODINE WITH ETHANOL			
Soln 10% with ethanol 30% Soln 10% with ethanol 70%			
SODIUM HYPOCHLORITE			
Soln			
Contrast Media			
Iodinated X-ray Contrast Media			
DIATRIZOATE MEGLUMINE WITH SODIUM AMIDOTRIZOATE			
Oral liq 660 mg per ml with sodium amidotrizoate 100 mg per ml, 10	0 ml		
bottle		100 ml	Gastrografin
Inj 260 mg with sodium amidotrizoate 40 mg per ml, 250 ml bottle		1	Urografin
DIATRIZOATE SODIUM			
Oral liq 370 mg per ml, 10 ml sachet		50	loscan
ODISED OIL			
Inj 38% w/w (480 mg per ml), 10 ml ampoule	410.00	1	Lipiodol Ultra Fluid
ODIXANOL		·	
Inj 270 mg per ml (iodine equivalent), 50 ml bottle	220.00	10	Visipague
Inj 270 mg per ml (iodine equivalent), 30 ml bottle		10	Visipaque
Inj 270 mg per ml (iodine equivalent), 100 ml bottle		10	Visipaque

Inj 270 mg per ml (iodine equivalent), 100 ml bottle		10	Visipaque	
Inj 320 mg per ml (iodine equivalent), 50 ml bottle		10	Visipaque	
Inj 320 mg per ml (iodine equivalent), 100 ml bottle		10	Visipaque	
Inj 320 mg per ml (iodine equivalent), 200 ml bottle		10	Visipaque	
IOHEXOL				
Inj 240 mg per ml (iodine equivalent), 50 ml bottle	75.00	10	Omnipaque	
Inj 300 mg per ml (iodine equivalent), 20 ml bottle	57.00	10	Omnipaque	
Inj 300 mg per ml (iodine equivalent), 50 ml bottle	75.00	10	Omnipaque	
Inj 300 mg per ml (iodine equivalent), 100 ml bottle	150.00	10	Omnipaque	
Inj 350 mg per ml (iodine equivalent), 20 ml bottle		10	Omnipaque	
Inj 350 mg per ml (iodine equivalent), 50 ml bottle	75.00	10	Omnipaque	
Inj 350 mg per ml (iodine equivalent), 75 ml bottle	114.00	10	Omnipaque	
Inj 350 mg per ml (iodine equivalent), 100 ml bottle	150.00	10	Omnipaque	
Inj 350 mg per ml (iodine equivalent), 200 ml bottle		10	Omnipaque	

	Price (ex man. excl. GST \$	⁻⁾ Per	Brand or Generic Manufacturer
Non-iodinated X-ray Contrast Media			
BARIUM SULPHATE			
Powder for oral liq 20 mg per g (2% w/w), 22.1 g sachet		50	E-Z-Cat Dry
Oral liq 400 mg per ml (40% w/v, 30% w/w), bottle		148 g	Varibar - Thin Liquid
Oral liq 600 mg per g (60% w/w), tube		454 g	E-Z-Paste
Oral liq 400 mg per ml (40% w/v), bottle		250 ml	Varibar - Honey
	38.40	240 ml 230 ml	Varibar - Nectar
Enema 1,250 mg per ml (125% w/v), 500 ml bag	145.04	230 mi 12	Varibar - Pudding Liquibar
Oral lig 22 mg per g (2.2% w/w), 250 ml bottle		24	CT Plus+
Oral lig 22 mg per g (2.2% w/w), 250 ml bottle		24	CT Plus+
Oral liq 1 mg per ml (0.1% w/v, 0.1% w/w), 450 ml bottle		24	VoLumen
Oral liq 20.9 mg per ml (2.1% w/v, 2% w/w), 250 ml bottle		24	Readi-CAT 2
Powder for oral soln 97.65% w/w, 300 g bottle		24	X-Opaque-HD
Oral liq 400 mg per ml (40% w/v, 30% w/w), 20 ml bottle		3	Tagitol V
Oral liq 1,250 mg per ml (125% w/v), 2,000 ml bottle		1	Liquibar
BARIUM SULPHATE WITH SODIUM BICARBONATE			4
	10		
Grans eff 382.2 mg per g with sodium bicarbonate 551.3 mg per g sachet		50	E-Z-Gas II
CITRIC ACID WITH SODIUM BICARBONATE		50	L-2-0d3 II
Powder 382.2 mg per g with sodium bicarbonate 551.3 mg per g, 4	1 a		
sachet	+ y		e.g. E-Z-GAS II
Sacher			0.9. L Z 0A0 II
Paramagnetic Contrast Media			
GADOBENIC ACID			
Inj 334 mg per ml, 10 ml vial		10	Multihance
Inj 334 mg per ml, 20 ml vial	636.28	10	Multihance
GADOBUTROL			
Inj 1 mmol per ml, 15 ml vial			
Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 5 ml prefilled			
syringe		5	Gadovist 1.0
Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 7.5 ml prefilled			
syringe		5	Gadovist 1.0
Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 15 ml prefilled			
syringe	700.00	10	Gadovist 1.0
GADODIAMIDE			
Inj 287 mg per ml, 10 ml prefilled syringe		10	Omniscan
Inj 287 mg per ml, 10 ml vial		10	Omniscan
Inj 287 mg per ml, 5 ml vial		10	Omniscan
Inj 287 mg per ml, 15 ml prefilled syringe		10	Omniscan
GADOTERIC ACID			
Inj 279.32 mg per ml (0.5 mmol per ml), 10 ml prefilled syringe	24.50	1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 15 ml bottle		1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 15 ml prefilled syringe		1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 20 ml prefilled syringe		1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 10 ml bottle		1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 20 ml bottle		1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 5 ml bottle	12.30	1	Dotarem

e.g. Brand indicates brand example only. It is not a contracted product.

VARIOUS

	Price (ex man. excl. GST \$	⁻) Per	Brand or Generic Manufacturer
GADOXETATE DISODIUM			
Inj 181.43 mg per ml (equivalent to 0.25 mmol per ml), 10 ml p			
		1	Primovist
MEGLUMINE GADOPENTETATE Inj 469 mg per ml, 10 ml prefilled syringe	95.00	5	Magnevist
Inj 469 mg per ml, 10 ml vial		10	Magnevist
MEGLUMINE IOTROXATE			
Inj 105 mg per ml, 100 ml bottle		100 ml	Biliscopin
Ultrasound Contrast Media			
PERFLUTREN			
Inj 1.1 mg per ml, 1.5 ml vial		1	Definity
	720.00	4	Definity
Diagnostic Agents			
ARGININE			
Inj 50 mg per ml, 500 ml bottle			
Inj 100 mg per ml, 300 ml bottle			
HISTAMINE ACID PHOSPHATE Nebuliser soln 0.6%, 10 ml vial			
Nebuliser soln 2.5%, 10 ml vial			
Nebuliser soln 5%, 10 ml vial			
MANNITOL			
Powder for inhalation			e.g. Aridol
METHACHOLINE CHLORIDE			
Powder 100 mg			
SECRETIN PENTAHYDROCHLORIDE Inj 100 u ampoule			
SINCALIDE			
Inj 5 mcg per vial			
Diagnostic Dyes			
BONNEY'S BLUE DYE			
Soln			
Inj 4 mg per ml, 5 ml ampoule Inj 8 mg per ml, 5 ml ampoule			
INDOCYANINE GREEN			
Inj 25 mg vial			
METHYLTHIONINIUM CHLORIDE [METHYLENE BLUE]			
Inj 5 mg per ml, 10 ml ampoule	240.35	5	Proveblue
PATENT BLUE V			
Inj 2.5%, 2 ml ampoule		5	Obex Medical
Inj 2.5%, 5 ml prefilled syringe		5	InterPharma

Price			Brand or
(ex man. excl.	GST)		Generic
\$		Per	Manufacturer

Irrigation Solutions

CHLORHEXIDINE WITH CETRIMIDE

Irrigation soln 0.015% with cetrimide 0.15%, 500 ml bottle

→ Restricted (RS1683)

Initiation

Re-assessment required after 3 months All of the following:

- 1 Patient has burns that are greater than 30% of total body surface area (BSA); and
- 2 For use in the perioperative preparation and cleansing of large burn areas requiring debridement/skin grafting; and
- 3 The use of 30 ml ampoules is impractical due to the size of the area to be covered.

Continuation

Re-assessment required after 3 months

The treatment remains appropriate for the patient and the patient is benefiting from the treatment.

Irrigation soln 0.015% with cetrimide 0.15%, 30 ml ampoule - 1% DV Aug-18 to 2021	29.76	30	Pfizer
GLYCINE			
Irrigation soln 1.5%, 3,000 ml bag - 1% DV Sep-18 to 2021	31.20	4	B Braun
SODIUM CHLORIDE			
Irrigation soln 0.9%, 3,000 ml bag - 1% DV Sep-18 to 2021	26.80	4	B Braun
Irrigation soln 0.9%, 30 ml ampoule - 1% DV Sep-18 to 2021	7.00	20	Interpharma
Irrigation soln 0.9%, 1,000 ml bottle - 1% DV Jun-18 to 2021	14.90	10	Baxter Sodium Chloride 0.9%
Irrigation soln 0.9%, 250 ml bottle - 1% DV Aug-18 to 2021	17.64	12	Fresenius Kabi
WATER			
Irrigation soln, 3,000 ml bag – 1% DV Sep-18 to 2021	28.80	4	B Braun
Irrigation soln, 1,000 ml bottle - 1% DV Jun-18 to 2021	17.30	10	Baxter Water for Irrigation
Irrigation soln, 250 ml bottle - 1% DV Aug-18 to 2021	17.64	12	Fresenius Kabi

Surgical Preparations

BISMUTH SUBNITRATE AND IODOFORM PARAFFIN

Paste

DIMETHYL SULFOXIDE Soln 50% Soln 99%

PHENOL

Inj 6%, 10 ml ampoule

PHENOL WITH IOXAGLIC ACID

Inj 12%, 10 ml ampoule

TROMETAMOL

Inj 36 mg per ml, 500 ml bottle

VARIOUS

	l (ex man.	Price excl. \$	GST)	Per	Brand Gene Manu	
Cardioplegia Solutions						
ELECTROLYTES						
Inj 15 mmol/l sodium chloride, 9 mmol/l potassium chloride, 1 potassium hydrogen 2-ketoglutarate, 4 mmol/l magnesiu 18 mmol/l histidine hydrochloride, 180 mmol/l histidine, 2 tryptophan, 30 mmol/l mannitol, 0.015 mmol/l calcium ch 1,000 ml bag Inj aspartic acid 10.43 mg per ml, citric acid 0.22476 mg per acid 11.53 mg per ml, sodium phosphate 0.1725 mg per	m chloride, mmol/l loride, ml, glutamic ml,				e.g.	Custodiol-HTK
potassium chloride 2.15211 mg per ml, sodium citrate 1. per ml, sodium hydroxide 6.31 mg per ml and trometamo 11.2369 mg per ml, 364 ml bag					e.g.	Cardioplegia Enriched Paed. Soln.
Inj aspartic acid 8.481 mg per ml, citric acid 0.8188 mg per m acid 9.375 mg per ml, sodium phosphate 0.6285 mg per potassium chloride 2.5 mg per ml, sodium citrate 6.585 r sodium hydroxide 5.133 mg per ml and trometamol 9.09 ml, 527 ml bag	ml, ng per ml,				e.g.	Cardioplegia
Inj citric acid 0.07973 mg per ml, sodium phosphate 0.06119 potassium chloride 2.181 mg per ml, sodium chloride 1.7 sodium citrate 0.6412 mg per ml and trometamol 5.9 mg	'88 mg ml,					Enriched Solution
523 ml bag					e.g.	Cardioplegia Base Solution
Inj 110 mmol/l sodium, 16 mmol/l potassium, 1.2 mmol/l calc 16 mmol/l magnesium and 160 mmol/l chloride, 1,000 m	bag				e.g.	Cardioplegia Solution AHB7832
Inj 143 mmol/l sodium, 16 mmol/l potassium, 16 mmol/l magi 1.2 mmol/l calcium, 1,000 ml bag	nesium and				e.g.	Cardioplegia Electrolyte Solutio
MONOSODIUM GLUTAMATE WITH SODIUM ASPARTATE Inj 42.68 mg with sodium aspartate 39.48 mg per ml, 250 ml MONOSODIUM L-ASPARTATE Inj 14 mmol per 10 ml, 10 ml	bottle					·

Cold Storage Solutions

SODIUM WITH POTASSIUM Inj 29 mmol/l with potassium 125 mmol/l, 1,000 ml bag

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS

	Price ex man. excl. GS \$	T) Per	Brand or Generic Manufacturer
Extemporaneously Compounded Preparations			
ACETIC ACID			
Liq			
ALUM			
Powder BP			
ARACHIS OIL [PEANUT OIL] Lig			
ASCORBIC ACID			
Powder			
BENZOIN			
Tincture compound BP			
BISMUTH SUBGALLATE Powder			
BORIC ACID			
Powder			
CARBOXYMETHYLCELLULOSE Soln 1.5%			
CETRIMIDE			
Soln 40%			
CHLORHEXIDINE GLUCONATE Soln 20 %			
CHLOROFORM			
Liq BP			
CITRIC ACID Powder BP			
CLOVE OIL			
Liq			
COAL TAR			
Soln BP - 1% DV Nov-19 to 2022		200 ml	Midwest
CODEINE PHOSPHATE Powder			
COLLODION FLEXIBLE			
Liq			
COMPOUND HYDROXYBENZOATE			•••••
Soln – 1% DV Aug-19 to 2022		100 ml	Midwest
CYSTEAMINE HYDROCHLORIDE Powder			
DISODIUM HYDROGEN PHOSPHATE WITH SODIUM DIHYDROGEN	PHOSPHATE		
Inj 37.46 mg with sodium dihydrogen phosphate 47.7 mg in 1.5 ml			
ampoule			
DITHRANOL			
GLUCOSE [DEXTROSE] Powder			

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS

	Price		Brand or
	(ex man. excl. GS	T)	Generic
	\$	Per	Manufacturer
GLYCERIN WITH SODIUM SACCHARIN			
Suspension – 1% DV Jul-19 to 2022		473 ml	Ora-Sweet SF
GLYCERIN WITH SUCROSE			
Suspension – 1% DV Jul-19 to 2022	30.95	473 ml	Ora-Sweet
GLYCEROL			
Liq – 1% DV Oct-20 to 2023	3 23	500 ml	healthE Glycerol BP
		000 111	Liquid
HYDROCORTISONE			
Powder		25 g	ABM
LACTOSE		- 5	
Powder			
MAGNESIUM HYDROXIDE			
Paste			
Suspension			
MENTHOL			
Crystals			
METHADONE HYDROCHLORIDE			
Powder			
METHYL HYDROXYBENZOATE			
Powder – 1% DV Jul-19 to 2022	8 98	25 g	Midwest
METHYLCELLULOSE		20 g	interrest
Powder – 1% DV Jul-19 to 2022	36.95	100 g	Midwest
Suspension – 1% DV Jul-19 to 2022		473 ml	Ora-Plus
METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHARIN			
Suspension – 1% DV Jul-19 to 2022		473 ml	Ora-Blend SF
METHYLCELLULOSE WITH GLYCERIN AND SUCROSE			
Suspension - 1% DV Jul-19 to 2022		473 ml	Ora-Blend
OLIVE OIL			
Liq			
PARAFFIN			
Liq			
PHENOBARBITONE SODIUM			
Powder			
PHENOL			
Liq			
PILOCARPINE NITRATE			
Powder			
POLYHEXAMETHYLENE BIGUANIDE			
Liq			
POVIDONE K30			
Powder			
SALICYLIC ACID			
Powder			
SILVER NITRATE			
Crystals			
SODIUM BICARBONATE			
Powder BP - 1% DV Jan-20 to 2022		500 g	Midwest
		9	

Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS

	Price (ex man. excl. G \$	ST) Per	Brand or Generic Manufacturer
SODIUM CITRATE Powder			
SODIUM METABISULFITE Powder			
STARCH Powder			
SULPHUR Precipitated Sublimed			
SYRUP Liq (pharmaceutical grade) – 1% DV Jan-20 to 2022		500 ml	Midwest
THEOBROMA OIL Oint			
TRI-SODIUM CITRATE Crystals			
TRICHLORACETIC ACID Grans			
UREA Powder BP			
WOOL FAT Oint, anhydrous			
XANTHAN Gum 1%			
ZINC OXIDE Powder			

SPECIAL FOODS

Price (ex man. excl. GST) \$ Per Brand or Generic Manufacturer

Food Modules

Carbohydrate

➡ Restricted (RS1467)

Initiation – Use as an additive

Any of the following:

- 1 Cystic fibrosis; or
- 2 Chronic kidney disease; or
- 3 Cancer in children; or
- 4 Cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
- 5 Faltering growth in an infant/child; or
- 6 Bronchopulmonary dysplasia; or
- 7 Premature and post premature infant; or
- 8 Inborn errors of metabolism.

Initiation – Use as a module

For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

CARBOHYDRATE SUPPLEMENT - Restricted see terms above

- t Powder 95 g carbohydrate per 100 g, 368 g can
- Powder 96 g carbohydrate per 100 g, 400 g can

e.g. Polycal

Fat

➡ Restricted (RS1468)

Initiation – Use as an additive

Any of the following:

- 1 Patient has inborn errors of metabolism; or
- 2 Faltering growth in an infant/child; or
- 3 Bronchopulmonary dysplasia; or
- 4 Fat malabsorption; or
- 5 Lymphangiectasia; or
- 6 Short bowel syndrome; or
- 7 Infants with necrotising enterocolitis; or
- 8 Biliary atresia; or
- 9 For use in a ketogenic diet; or
- 10 Chyle leak; or
- 11 Ascites; or
- 12 Patient has increased energy requirements, and for whom dietary measures have not been successful.

Initiation – Use as a module

For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

LONG-CHAIN TRIGLYCERIDE SUPPLEMENT - Restricted see terms above

- 1 Liquid 50 g fat per 100 ml, 200 ml bottle
- Liquid 50 g fat per 100 ml, 500 ml bottle

	f (ex man.	Price excl. \$	GST)	Per	Bran Gen Man	
MEDIUM-CHAIN TRIGLYCERIDE SUPPLEMENT - Restricted a Liquid 50 g fat per 100 ml, 250 ml bottle Liquid 95 g fat per 100 ml, 500 ml bottle MALNUT OIL - Restricted see terms on the previous page Liq	see terms on t	ne pre	evious	page	•	Liquigen MCT Oil
Protein						
 → Restricted (RS1469) nitiation – Use as an additive Either: Protein losing enteropathy; or High protein needs. initiation – Use as a module For use as a component in a modular formula made from at least Section D of the Pharmaceutical Schedule or breast milk Note: Patients are required to meet any Special Authority criteria PROTEIN SUPPLEMENT – Restricted see terms above Powder 5 g protein, 0.67 g carbohydrate and 0.6 g fat per 6.6 can Powder 6 g protein per 7 g, can Powder 89 g protein, < 1.5 g carbohydrate and 2 g fat per 100 can 	associated wit g, 275 g	h all c	of the p		used ir Res	
Other Supplements						
 BREAST MILK FORTIFIER Powder 0.2 g protein, 0.7 g carbohydrate and 0.02 g fat per 1 Powder 0.5 g protein, 1.2 g carbohydrate and 0.08 g fat per 2 Powder 0.6 g protein and 1.4 g carbohydrate per 2.2 g sache CARBOHYDRATE AND FAT SUPPLEMENT - Restricted see te Powder 72.7 g carbohydrate and 22.3 g fat per 100 g, 400 g d Restricted (RS1212) nitiation Both: Infant or child aged four years or under; and Any of the following: Cystic fibrosis; or Cancer in children; or S faltering growth; or S premature and post premature infants. 	g sachet t erms below				e.g. e.g.	FM 85 S26 Human Milk Fortifier Nutricia Breast Milk Fortifer Super Soluble Duocal

Price (ex man. excl. GST) \$

Per

Brand or Generic Manufacturer

Food/Fluid Thickeners

NOTE:

While pre-thickened drinks and supplements have not been included in Section H, DHB hospitals may continue to use such products for patients with dysphagia, provided that:

- use was established prior to 1 July 2013; and
- the product has not been specifically considered and excluded by PHARMAC; and
- use of the product conforms to any applicable indication restrictions for similar products that are listed in Section H (for example, use of thickened high protein products should be in line with the restriction for high protein oral feed in Section H).

PHARMAC intends to make a further decision in relation to pre-thickened drinks and supplements in the future, and will notify of any change to this situation.

CAROB BEAN GUM WITH MAIZE STARCH AND MALTODEXTRIN

Powder	e.g. Feed Thickener Karicare Aptamil
GUAR GUM Powder	e.g. Guarcol
MAIZE STARCH Powder	e.g. Resource Thicken Up; Nutilis
MALTODEXTRIN WITH XANTHAN GUM Powder	e.g. Instant Thick
MALTODEXTRIN WITH XANTHAN GUM AND ASCORBIC ACID Powder	e.g. Easy Thick

Metabolic Products

➡ Restricted (RS1232)

Initiation

Any of the following:

- 1 For the dietary management of homocystinuria, maple syrup urine disease, phenylketonuria (PKU), glutaric aciduria, isovaleric acidaemia, propionic acidaemia, methylmalonic acidaemia, tyrosinaemia or urea cycle disorders; or
- 2 Patient has adrenoleukodystrophy; or
- 3 For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

Glutaric Aciduria Type 1 Products

AMINO ACID FORMULA (WITHOUT LYSINE AND LOW TRYPTOPHAN) - Restricted see terms above

- Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can
- Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can

- e.g. GA1 Anamix Infant
- e.g. XLYS Low TRY Maxamaid

_		F (ex man.	Price excl. \$	GST)	Per	Bran Gene Man	
ŀ	Iomocystinuria Products						
	 NO ACID FORMULA (WITHOUT METHIONINE) – Restricted see Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre 100 g, 400 g can Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle 		n the I	oreviou	s page	e.g. e.g.	HCU Anamix Infant XMET Maxamaid XMET Maxamum HCU Anamix Junior LQ
k	sovaleric Acidaemia Products						
t	 IINO ACID FORMULA (WITHOUT LEUCINE) – Restricted see term Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre 100 g, 400 g can Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can 		previ	ous pa	ge	e.g.	IVA Anamix Infant XLEU Maxamaid XLEU Maxamum
N	laple Syrup Urine Disease Products						
AN t	IINO ACID FORMULA (WITHOUT ISOLEUCINE, LEUCINE AND VA Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre 100 g, 400 g can	'	Rest	ricted	see terms		e previous page MSUD Anamix
t t	Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle					e.g.	Infant MSUD Maxamum MSUD Anamix Junior LQ

SPECIAL FOODS

	Price (ex man. excl. GS \$	T) Per	Brand or Generic Manufacturer
Phenylketonuria Products			
MINO ACID FORMULA (WITHOUT PHENYLALANINE) - Restric	ted see terms on pag	je 233	
Tab 8.33 mg			e.g. Phlexy-10
Powder 20 g protein, 2.5 g carbohydrate and 0.22 g fibre per 27	7.8 g		BKUL LI
sachet			e.g. PKU Lophlex Powder
			(unflavoured)
Powder 20 g protein, 3.8 g carbohydrate and 0.23 g fibre per 28	3 g sachet		e.g. PKU Lophlex
	0		Powder
			(unflavoured)
Powder 36 g protein, 32 g carbohydrate and 12.5 g fat per 100	g, 36 g		DKU Anaria Ini
sachet			e.g. PKU Anamix Junio (van/choc/unfl)
Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g	fibre per		(vaii/choc/unii)
100 g, 400 g can			e.g. PKU Anamix Infan
Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g ca	an		e.g. XP Maxamum
Powder 8.33 g protein and 8.8 g carbohydrate per 20 g sachet			e.g. Phlexy-10
Liquid 10 g protein, 4.4 g carbohydrate and 0.25 g fibre per 100) ml,		
62.5 ml bottle l iguid 20 g protein, 8.8 g carbohydrate and 0.34 g fibre per 100	i mi		e.g. PKU Lophlex LQ 1
Liquid 20 g protein, 8.8 g carbohydrate and 0.34 g fibre per 100 125 ml bottle	, mi,		e.g. PKU Lophlex LQ 2
Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre p	er		e.g. The Lophick EQ L
100 ml, bottle		125 ml	PKU Anamix Junior LQ
			(Berry)
			PKU Anamix Junior LQ (Orange)
			PKU Anamix Junior LQ
			(Unflavoured)
Liquid 16 g protein, 7 g carbohydrate and 0.27 g fibre per 100 n	nl, 125 ml		
bottle	.1		e.g. PKU Lophlex LQ 2
Liquid 16 g protein, 7 g carbohydrate and 0.27 g fibre per 100 n 62.5 ml bottle	nı,		e.g. PKU Lophlex LQ 1
Liquid 16 g protein, 7 g carbohydrate and 0.4 g fibre per 100 ml	. 125 ml		e.g. The Lopinex Let I
bottle	,		e.g. PKU Lophlex LQ 2
Liquid 16 g protein, 7 g carbohydrate and 0.4 g fibre per 100 ml	, 62.5 ml		
bottle			e.g. PKU Lophlex LQ 1
Liquid 6.7 g protein, 5.1 g carbohydrate and 2 g fat per 100 ml,	250 ml		a a Fasishan
carton Semi-solid 18.3 g protein, 18.5 g carbohydrate and 0.92 g fibre	por		e.g. Easiphen
100 g, 109 g pot	hei		e.g. PKU Lophlex
			Sensations
			20 (berries)
e.g. PKU Lophlex Powder (unflavoured) Powder 20 g protein, 2.5	g carbohydrate and 0.	22 g fibre p	er 27.8 g sachet to be

delisted 1 March 2021)

		Price			Bran	
	(ex man.	excl. \$	GST)	Per	Gene Manu	eric ufacturer
Propionic Acidaemia and Methylmalonic Acidaemia	a Produ	cts				
MINO ACID FORMULA (WITHOUT ISOLEUCINE, METHIONINE, T age 233	HREONIN	IE AN	D VALI	NE) -	Restrict	ed see terms on
Powder 13.1 g protein, 50.1 g carbohydrate, 23 g fat and 5.3 g fit 100 g, 400 g can	ore per				e.g.	MMA/PA Anamix Infant
Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fib 100 g, 400 g can	ore per				e.g.	MMA/PA Anamix
Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can e.g. MMA/PA Anamix Infant Powder 13.1 g protein, 49.5 g carbohyd elisted 1 March 2021)		fat an	d 5.3 g	fibre (e.g.	Infant XMTVI Maxamaid XMTVI Maxamum , 400 g can to be
Protein Free Supplements						
ROTEIN FREE SUPPLEMENT – Restricted see terms on page 23 Powder nil added protein and 67 g carbohydrate per 100 g, 400 g					e.g.i	Energivit
Tyrosinaemia Products						
MINO ACID FORMULA (WITHOUT PHENYLALANINE AND TYROS Powder 36 g protein, 32 g carbohydrate and 12.5 g fat per 100 g,	,	estric	ted se	e term	s on page	9 233
sachet Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fil	•				e.g.	TYR Anamix Junior
100 g, 400 g can Powder 25 g protein and 51 g carbohydrate per 100 g, 400 g can						TYR Anamix Infant XPHEN, TYR Maxamaid
Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle	ŕ				e.g.	TYR Anamix Junior LQ
Urea Cycle Disorders Products						
MINO ACID SUPPLEMENT – Restricted see terms on page 233 Powder 25 g protein and 65 g carbohydrate per 100 g, 200 g can Powder 79 g protein per 100 g, 200 g can					0	Dialamine Essential Amino Acid Mix

X-Linked Adrenoleukodystrophy Products

GLYCEROL TRIERUCATE - Restricted see terms on page 233

Liquid, 1,000 ml bottle

GLYCEROL TRIOLEATE - Restricted see terms on page 233

1 Liquid, 500 ml bottle

Price (ex man. excl. GST) \$

Per

Brand or Generic Manufacturer

Specialised Formulas

Diabetic Products

→ Restricted (RS1215) Initiation

Any of the following:

- 1 For patients with type I or type II diabetes suffering weight loss and malnutrition that requires nutritional support; or
- 2 For patients with pancreatic insufficiency; or
- 3 For patients who have, or are expected to, eat little or nothing for 5 days; or
- 4 For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or
- 5 For use pre- and post-surgery; or
- 6 For patients being tube-fed; or
- 7 For tube-feeding as a transition from intravenous nutrition.

LOW-GI ENTERAL FEED 1 KCAL/ML - Restricted see terms above

t	Liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 1,000 ml			
	bottle	7.50	1,000 ml	Glucerna Select RTH (Vanilla)
t	Liquid 4.3 g protein, 11.3 g carbohydrate and 4.2 g fat per 100 ml,			
	1,000 ml bag			e.g. Nutrison Advanced Diason
LO	W-GI ORAL FEED 1 KCAL/ML – Restricted see terms above			
t	Liquid 4.5 g protein, 9.8 g carbohydrate, 4.4 g fat and 1.9 g fibre per			
	100 ml, can	2.10	237 ml	Sustagen Diabetic (Vanilla)
t	Liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 250 ml			
	bottle	1.88	250 ml	Glucerna Select (Vanilla)
t	Liquid 6 g protein, 9.5 g carbohydrate, 4.7 g fat and 2.6 g fibre per			
	100 ml, can	2.10	237 ml	Resource Diabetic (Vanilla)
t	Liquid 4.9 g protein, 11.7 g carbohydrate, 3.8 g fat and 2 g fibre per			
	100 ml, 200 ml bottle			e.g. Diasip

Elemental and Semi-Elemental Products

➡ Restricted (RS1216)

Initiation

Any of the following:

- 1 Malabsorption: or
 - 2 Short bowel syndrome; or
 - 3 Enterocutaneous fistulas; or
 - 4 Eosinophilic enteritis (including oesophagitis); or
 - 5 Inflammatory bowel disease; or
 - 6 Acute pancreatitis where standard feeds are not tolerated; or
 - 7 Patients with multiple food allergies requiring enteral feeding.

AMINO ACID ORAL FEED - Restricted see terms above

t Powder 11 g protein, 62 g carbohydrate and 1 g fat per sachet......4.50 80 g Vivonex TEN

	Price (ex man. excl. GST \$) Per	Bran Gen Man	
AN	IINO ACID ORAL FEED 0.8 KCAL/ML - Restricted see terms on the previous page			
t	Liquid 2.5 g protein, 11 g carbohydrate and 3.5 g fat per 100 ml, 250 ml			
	carton		e.g.	Elemental 028 Extra
	PTIDE-BASED ENTERAL FEED 1 KCAL/ML - Restricted see terms on the previous p	bage		
L	Liquid 4 g protein, 17.6 g carbohydrate and 1.7 g fat per 100 ml,			Nutrican Advanced
	1,000 ml bag		e.y.	Nutrison Advanced Peptisorb
t	Liquid 4 g protein, 17.7 g carbohydrate and 1.7 g fat per 100 ml,			r oplicere
	1,000 ml bag		e.g.	Nutrison Advanced Peptisorb
_ `	g. Nutrison Advanced Peptisorb Liquid 4 g protein, 17.6 g carbohydrate and 1.7 g fat po bruary 2021)	er 100 ml, 1	,000 i	ml bag to be delisted
PE t	PTIDE-BASED ENTERAL FEED 1.5 KCAL/ML – Restricted see terms on the previous Liquid 6.75 g protein, 18.4 g carbohydrate and 5.5 g fat per 100 ml, bottle18.06	<mark>s page</mark> 1,000 ml	Vita	I
۶E	PTIDE-BASED ORAL FEED - Restricted see terms on the previous page			
	Powder 13.7 g protein, 62.9 g carbohydrate and 17.5 g fat per 100 g,			
	400 g can		e.g.	Peptamen Junior
	Powder 13.8 g protein, 59 g carbohydrate and 18 g fat per 100 g, 400 g can		e.g.	MCT Pepdite; MCT Pepdite 1+
ᄃ	PTIDE-BASED ORAL FEED 1 KCAL/ML - Restricted see terms on the previous page			r epune r+
	Liquid 5 g protein, 16 g carbohydrate and 1.69 g fat per 100 ml, carton	237 ml	Рер	tamen OS 1.0 (Vanilla)
F	at Modified Products			
=A'	T-MODIFIED FEED – Restricted see terms below			
-	Powder 12.9 g protein, 69.1 g carbohydrate and 12.9 g fat per 100 g,			
	400 g can		e.g.	Monogen
	Restricted (RS1470)			
	tiation y of the following:			
ι.	1 Patient has metabolic disorders of fat metabolism; or			
	2 Patient has a chyle leak; or			
	3 Modified as a modular feed, made from at least one nutrient module and at least or	e further p	roduct	listed in Section D o
	the Pharmaceutical Schedule, for adults.			
10	te: Patients are required to meet any Special Authority criteria associated with all of the	products u	ised ir	the modular formula
Н	lepatic Products			
-	Restricted (RS1217)			
	tiation			
Foi	r children (up to 18 years) who require a liver transplant.			
	PATIC ORAL FEED – Restricted see terms above			
t	Powder 11 g protein, 64 g carbohydrate and 20 g fat per 100 g, can	400 a	Her	aron Junior

	F (ex man.	Price excl. G \$	GST) Per	Brand or Generic Manufacturer
High Calorie Products				
 Restricted (RS1317) nitiation ny of the following: Patient is fluid volume or rate restricted; or	oottle	5.50	500 ml	Nutrison Concentrated
Liquid 8.4 g protein, 21.9 g carbohydrate, 9.1 g fat and 0.5 g fibre 100 ml, bottle	•	. 11.00	1,000 ml	TwoCal HN RTH (Vanilla)
 RAL FEED 2 KCAL/ML – Restricted see terms above Liquid 8.4 g protein, 22.4 g carbohydrate, 8.9 g fat and 0.8 g fibre 100 ml, bottle 	•	1.90	200 ml	Two Cal HN
High Protein Products				
 IIGH PROTEIN ENTERAL FEED 1.25 KCAL/ML - Restricted see t Liquid 6.3 g protein, 14.2 g carbohydrate and 4.9 g fat per 100 m 1,000 ml bottle Restricted (RS1327) hitiation oth: 		v		e.g. Nutrison Protein Plus
 The patient has a high protein requirement; and Any of the following: Patient has liver disease; or Patient has liver disease; or Patient is obese (BMI > 30) and is undergoing surgery; Patient is fluid restricted; or Patient's needs cannot be more appropriately met usin IIGH PROTEIN ENTERAL FEED 1.28 KCAL/ML - Restricted see t Liquid 6.3 g protein, 14.1 g carbohydrate, 4.9 g fat and 1.5 g fibre 100 ml, 1,000 ml bag Restricted (RS1327) nitiation to have a high protein requirement; and Any of the following: 	g high calo erms <mark>belov</mark>		luct.	e.g. Nutrison Protein Plus Multi Fibre

SPECIAL FOODS

Price (ex man. excl. GS \$	ST) Per	Brand or Generic Manufacturer
ontinued		
 2.1 Patient has liver disease; or 2.2 Patient is obese (BMI > 30) and is undergoing surgery; or 2.3 Patient is fluid restricted; or 2.4 Patient's needs cannot be more appropriately met using high calorie produced 	ict.	
Infant Formulas		
MINO ACID FORMULA - Restricted see terms below		
Powder 1.95 g protein, 8.1 g carbohydrate and 3.5 g fat per 100 ml,		
400 g can		e.g. Neocate
Powder 13 g protein, 49 g carbohydrate and 23 g fat per 100 g, 400 g can		e.g. Neocate SYNEO
Call		unflavoured
Powder 13.3 g protein, 56 g carbohydrate and 22 g fat per 100 g, 400 g		
can		e.g. Neocate Junior
Powder 13.5 g protein, 52 g carbohydrate and 24.5 g fat per 100 g, can53.00	400 g	Unflavoured Neocate Gold (Unflavoured)
Powder 14.8 g protein, 51.4 g carbohydrate and 23 g fat per 100 g, can53.00	400 g	Neocate Junior Vanilla
Powder 15 g protein, 56 g carbohydrate and 20 g fat per 100 g, can	400 g	Alfamino Junior
Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can53.00	400 g	Elecare LCP (Unflavoured)
Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can53.00	400 g	Elecare (Unflavoured) Elecare (Vanilla)
Restricted (RS1765)		. ,
nitiation		

Any of the following:

- 1 Extensively hydrolysed formula has been reasonably trialled for 2-4 weeks and is inappropriate due to documented severe intolerance or allergy or malabsorption; or
- 2 History of anaphylaxis to cows' milk protein formula or dairy products; or
- 3 Eosinophilic oesophagitis; or
- 4 Ultra-short gut; or
- 5 Severe Immune deficiency.

Continuation

All of the following:

- 1 An assessment as to whether the infant can be transitioned to a cows' milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and
- 2 The outcome of the assessment is that the infant continues to require an amino acid infant formula; and
- 3 Amino acid formula is required for a nutritional deficit.

ENTERAL LIQUID PEPTIDE FORMULA - Restricted see terms below

- Liquid 2.75 g protein, 13.7 g carbohydrate and 3.89 g fat per 100 ml 10.45 500 ml Nutrini Peptisorb
- Liquid 4.2 g protein, 18.6 g carbohydrate and 6.58 g fat per 100 ml15.68 500 ml Nutrini Peptisorb Energy

→ Restricted (RS1775)

Initiation

All of the following:

1 Patient has impaired gastrointestinal function and either cannot tolerate polymeric feeds, or polymeric feeds are unsuitable; and

 Price	Brand or	
(ex man. excl. GST)	Generic
 \$	Per	Manufacturer

continued...

- 2 Any of the following:
 - 2.1 Severe malabsorption; or
 - 2.2 Short bowel syndrome; or
 - 2.3 Intractable diarrhoea; or
 - 2.4 Biliary atresia; or
 - 2.5 Cholestatic liver diseases causing malabsorption; or
 - 2.6 Cystic fibrosis; or
 - 2.7 Proven fat malabsorption; or
 - 2.8 Severe intestinal motility disorders causing significant malabsorption; or
 - 2.9 Intestinal failure; or
 - 2.10 Both:
 - 2.10.1 The patient is currently receiving funded amino acid formula; and
 - 2.10.2 The patient is to be trialled on, or transitioned to, an enteral liquid peptide formula; and
- 3 Either:
 - 3.1 A semi-elemental or partially hydrolysed powdered feed has been reasonably trialled and considered unsuitable; or
 - 3.2 For step down from intravenous nutrition.
- Note: A reasonable trial is defined as a 2-4 week trial.

Continuation

Both:

- 1 An assessment as to whether the patient can be transitioned to a cows milk protein or soy infant formula or extensively hydrolysed formula has been undertaken; and
- 2 The outcome of the assessment is that the patient continues to require an enteral liquid peptide formula.

EXTENSIVELY HYDROLYSED FORMULA - Restricted see terms below

t	Powder 1.6 g protein, 7.5 g carbohydrate and 3.1 g fat per 100 ml, 900 g			
	can	30.42	900 g	Allerpro 1
t	Powder 1.6 g protein, 7.8 g carbohydrate and 3.2 g fat per 100 ml, 900 g		•	
	can	30.42	900 g	Allerpro 2
t	Powder 14 g protein, 53.4 g carbohydrate and 27.3 g fat per 100 g,		•	
	450 g can			e.g. Aptamil Gold+ Pepti Junior

⇒ Restricted (RS1502)

Initiation

Any of the following:

- 1 Both:
 - 1.1 Cows' milk formula is inappropriate due to severe intolerance or allergy to its protein content; and 1.2 Either:
 - 1.2.1 Soy milk formula has been reasonably trialled without resolution of symptoms; or
 - 1.2.2 Soy milk formula is considered clinically inappropriate or contraindicated; or
- 2 Severe malabsorption; or
- 3 Short bowel syndrome; or
- 4 Intractable diarrhoea; or
- 5 Biliary atresia; or
- 6 Cholestatic liver diseases causing malsorption; or
- 7 Cystic fibrosis; or
- 8 Proven fat malabsorption; or
- 9 Severe intestinal motility disorders causing significant malabsorption; or
- 10 Intestinal failure; or

continued...

	f (ex man.	Price excl. \$	GST)	Per	Brar Gen Man	
continued						
11 For step down from Amino Acid Formula.						
Note: A reasonable trial is defined as a 2-4 week trial, or signs of an Continuation Both:	immediate	lgE m	nediate	ed allergi	c react	ion.
 An assessment as to whether the infant can be transitioned to undertaken; and 	o a cows' m	ilk pro	otein o	r soy infa	nt form	ula has been
2 The outcome of the assessment is that the infant continues to	o require an	exter	sively	hydrolys	ed infa	nt formula.
FRUCTOSE-BASED FORMULA						
Powder 14.6 g protein, 49.7 g carbohydrate and 30.8 g fat per 1 400 g can	00 g,				e.g.	Galactomin 19
LACTOSE-FREE FORMULA						
Powder 1.3 g protein, 7.3 g carbohydrate and 3.5 g fat per 100 r	nl, 900 g					
can Powder 1.5 g protein, 7.2 g carbohydrate and 3.6 g fat per 100 r	nl 900 a				e.g.	Karicare Aptamil Gold De-Lact
can	m, 000 g				e.g.	S26 Lactose Free
LOW-CALCIUM FORMULA					-	
Powder 14.6 g protein, 53.7 g carbohydrate and 26.1 g fat per 1 400 g can	00 g,				e.g.	Locasol
PAEDIATRIC ORAL/ENTERAL FEED 1 KCAL/ML - Restricted see	e terms <mark>belo</mark>	W				
Liquid 2.6 g protein, 10.3 g carbohydrate, 5.4 g fat and 0.6 g fibr 100 ml, bottle		2.3	5	125 ml	Infa	trini
➡ Restricted (RS1614) Initiation – Fluid restricted or volume intolerance with faltering g	arowth					
Both:	giowai					
1 Either:						
1.1 The patient is fluid restricted or volume intolerant; or						
1.2 The patient has increased nutritional requirements due	e to faltering	g grow	rth; an	d		
2 Patient is under 18 months old and weighs less than 8kg.	to on odea	to .	ماريم	ofinfant	formu	la ta abhiana annaata
Note: 'Volume intolerant' patients are those who are unable to tolera growth rate. These patients should have first trialled appropriate clir and adjusting the frequency of feeding.						
PRETERM FORMULA - Restricted see terms below						
Liquid 2.2 g protein, 8.4 g carbohydrate and 4.4 g fat per 100 ml		0.7	5	100 ml	S26	LBW Gold RTF
Liquid 2.3 g protein, 8.6 g carbohydrate and 4.2 g fat per 100 ml hamle	, 90 ml					Dra Nan Cald DTE
bottle Liquid 2.6 g protein, 8.4 g carbohydrate and 3.9 g fat per 100 ml	70 ml				e.g.	Pre Nan Gold RTF
bottle	, 70 m				e.g.	Karicare Aptamil Gold+Preterm
→ Restricted (RS1224)						
Initiation For infants born before 33 weeks' gestation or weighing less than 1.	5 ka at hirth					
THICKENED FORMULA		•				
Powder 1.8 g protein, 8.1 g carbohydrate and 3.3 g fat per 100 r	nl, 900 g					
can					e.g.	Karicare Aptamil Thickened AR

SPECIAL FOODS

(ex man. e	ice excl. GST) \$	Per	Brand or Generic Manufacturer
Ketogenic Diet Products			
HIGH FAT FORMULA – Restricted see terms below ↓ Powder 14.4 g protein, 2.9 g carbohydrate and 69.2 g fat per 100 g, can3	35.50	300 g	Ketocal 4:1 (Unflavoured) Ketocal 4:1 (Vanilla)
Powder 15.3 g protein, 7.2 g carbohydrate and 67.7 g fat per 100 g, can3	35.50	300 g	Ketocal 3:1 (Unflavoured)
→ Restricted (RS1225) Initiation For patients with intractable epilepsy, pyruvate dehydrogenase deficiency or gluco conditions requiring a ketogenic diet.	ose transpo	orted type-	1 deficiency and other
Paediatric Products			
 → Restricted (RS1473) Initiation Both: Child is aged one to ten years; and Any of the following: The child is being fed via a tube or a tube is to be inserted for the provide the condition causing malabsorption; or Any condition causing malabsorption; or Faltering growth in an infant/child; or Increased nutritional requirements; or The child is being transitioned from TPN or tube feeding to oral feed 2.6 The child has eaten, or is expected to eat, little or nothing for 3 days 	ding; or	feeding; o	r
 PAEDIATRIC ENTERAL FEED 0.76 KCAL/ML – Restricted see terms above Liquid 2.5 g protein, 12.5 g carbohydrate, 3.3 g fat and 0.7 g fibre per 100 ml, bag 	4.00	500 ml	Nutrini Low Energy Multifibre RTH
 PAEDIATRIC ENTERAL FEED 1 KCAL/ML - Restricted see terms above Liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, bag Liquid 2.8 g protein, 12.3 g carbohydrate and 4.4 g fat per 100 ml, 500 ml bag PAEDIATRIC ENTERAL FEED 1.5 KCAL/ML - Restricted see terms above Liquid 4.1 g protein 12.5 g carbohydrate 6.7 g fat and 0.9 g films apprendix 	.2.68	500 ml	Pediasure RTH e.g. Nutrini RTH
Liquid 4.1 g protein, 18.5 g carbohydrate, 6.7 g fat and 0.8 g fibre per 100 ml, bag	6.00	500 ml	Nutrini Energy Multi Fibre
Liquid 4.1 g protein, 18.5 g carbohydrate and 6.7 g fat per 100 ml, 500 ml bag			e.g. Nutrini Energy RTH
PAEDIATRIC ORAL FEED 1 KCAL/ML – Restricted see terms above Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, bottle		200 ml	Pediasure (Chocolate) Pediasure (Strawberry) Pediasure (Vanilla)
Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, can PAEDIATRIC ORAL FEED 1.5 KCAL/ML – Restricted see terms above	.1.34	250 ml	Pediasure (Vanilla)
Liquid 3.4 g protein, 18.8 g carbohydrate and 6.8 g fat per 100 ml,			
200 ml bottle Liquid 4.0 g protein, 18.8 g carbohydrate, 6.8 g fat and 1.5 g fibre per			e.g. Fortini
100 ml, 200 ml bottle			e.g. Fortini Multifibre

Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

		Price . excl. GST) \$	Per	Brand or Generic Manufacturer
Renal Products				
LOW ELECTROLYTE ENTERAL FEED 1.8 KCAL/ML - Restricted set ↓ Liquid 8.1 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fit per 100 ml, bottle	ore		500 ml	Nepro HP RTH
For patients with acute or chronic kidney disease. LOW ELECTROLYTE ORAL FEED - Restricted see terms below ↓ Powder 7.5 g protein, 59 g carbohydrate and 26.3 g fat per 100 g, can → Restricted (RS1227) Initiation For children (up to 18 years) with acute or chronic kidney disease. LOW ELECTROLYTE ORAL FEED 1.8 KCAL/ML	400 g			e.g. Kindergen
 ↓ Liquid 8 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre 100 ml, carton		2.67	220 ml	Nepro HP (Strawberry) Nepro HP (Vanilla)
Initiation For patients with acute or chronic kidney disease.				
LOW ELECTROLYTE ORAL FEED 2 KCAL/ML – Restricted see term Liquid 9.1 g protein, 19 g carbohydrate and 10 g fat per 100 ml, car Liquid 3 g protein, 25.5 g carbohydrate and 9.6 g fat per 100 ml, 23 bottle	rton	3.31	237 ml	Novasource Renal (Vanilla)
 ↓ Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, 12 carton → Restricted (RS1228) Initiation For patients with acute or chronic kidney disease. 	5 ml			e.g. Renilon 7.5
Surgical Products				
HIGH ARGININE ORAL FEED 1.4 KCAL/ML – Restricted see terms to Liquid 10.1 g protein, 15 g carbonhydrate, 4.5 g fat and 0 g fibre per 100 ml, carton	er	4.00	178 ml	Impact Advanced
 → Restricted (RS1231) Initiation Three packs per day for 5 to 7 days prior to major gastrointestinal, head PREOPERATIVE CARBOHYDRATE FEED 0.5 KCAL/ML - Restricted I Oral lig 0 g protein, 12.6 g carbohydrate and 0 g fat per 100 ml, 200 	d see ter	• •		Recovery
 Restricted (RS1415) Initiation Maximum of 400 ml as part of an Enhanced Recovery After Surgery (E surgery. 			4 hours befo	preOp re major abdominal

Price (ex man. excl. GST)

\$

Per

Brand or Generic Manufacturer

Standard Feeds

➡ Restricted (RS1214)

Initiation

Any of the following:

- For patients with malnutrition, defined as any of the following:
- 1 Any of the following:
 - 1.1 BMI < 18.5; or
 - 1.2 Greater than 10% weight loss in the last 3-6 months; or
 - 1.3 BMI < 20 with greater than 5% weight loss in the last 3-6 months; or
- 2 For patients who have, or are expected to, eat little or nothing for 5 days; or
- 3 For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or
- 4 For use pre- and post-surgery; or
- 5 For patients being tube-fed; or
- 6 For tube-feeding as a transition from intravenous nutrition; or
- 7 For any other condition that meets the community Special Authority criteria.

ENTERAL FEED 1.5 KCAL/ML - Restricted see terms above

 ♠			
t t	Liquid 6 g protein, 18.3 g carbohydrate and 5.8 g fat per 100 ml, bag7.00	1,000 ml	Nutrison Energy
t	Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 1.5 g fibre per		o a Nutricon Energy
	100 ml, 1,000 ml bag		e.g. Nutrison Energy Multi Fibre
t	Liquid 6.25 g protein, 20 g carbohydrate and 5 g fat per 100 ml, can	250 ml	Ensure Plus HN
t	Liquid 6.27 g protein, 20.4 g carbohydrate and 4.9 g fat per 100 ml, bag7.00	1,000 ml	Ensure Plus HN RTH
t	Liquid 6.38 g protein, 21.1 g carbohydrate, 4.9 g fat and 1.2 g fibre per	,	
	100 ml, bag	1.000 ml	Jevity HiCal RTH
Eľ	ITERAL FEED 1 KCAL/ML - Restricted see terms above		,
t	Liquid 4 g protein, 13.6 g carbohydrate and 3.4 g fat per 100 ml, bottle	1.000 ml	Osmolite RTH
t	Liquid 4 g protein, 14.1 g carbohydrate, 3.47 g fat and 1.76 g fibre per		
	100 ml, bottle	1,000 ml	Jevity RTH
t	Liquid 4 g protein, 12.3 g carbohydrate and 3.9 g fat per 100 ml,		
	1,000 ml bag		e.g. NutrisonStdRTH;
			NutrisonLowSodium
t	Liquid 4 g protein, 12.3 g carbohydrate and 3.9 g fat per 100 ml,		
٩	1.000 ml bottle		e.g. Nutrison Low
			Sodium
t	Liquid 4 g protein, 12.3 g carbohydrate, 3.9 g fat and 1.5 g fibre per		oodiani
	100 ml, 1000 ml bag		e.g. Nutrison Multi Fibre
Eľ	ITERAL FEED 1.2 KCAL/ML - Restricted see terms above		-
t	Liquid 5.55 g protein, 15.1 g carbohydrate, 3.93 g fat and 2 g fibre per		
	100 ml, 1,000 ml bag		e.g. Jevity Plus RTH
Eľ	TERAL FEED WITH FIBRE 0.83 KCAL/ML - Restricted see terms above		
t	Liquid 5.5 g protein, 8.8 g carbohydrate, 2.5 g fat and 1.5 g fibre per		
	100 ml, bottle	1,000 ml	Nutrison 800 Complete Multi Fibre

Price (ex man. excl. GS	T)	Brand or Generic
\$	Per	Manufacturer
ORAL FEED – Restricted see terms on the previous page		
t Powder 15.9 g protein, 57.4 g carbohydrate and 14 g fat per 100 g, can26.00	850 g	Ensure (Chocolate) Ensure (Vanilla)
t Powder 20.8 g protein, 61 g carbohydrate and 9.4 g fat per 100 g, can	857 g	Fortisip (Vanilla)
t Powder 23 g protein, 65 g carbohydrate and 2.5 g fat per 100 g, can26.00	840 g	Sustagen Hospital Formula Active (Choc) Sustagen Hospital Formula Active (Van)
Note: Community subsidy of Sustagen Hospital Formula is subject to both Spec manufacturer's surcharge. Higher subsidy by endorsement is available for patien criteria; fat malabsorption, fat intolerance or chyle leak.		criteria and a
ORAL FEED 1 KCAL/ML - Restricted see terms on the previous page		
Liquid 3.8 g protein, 23 g carbohydrate and 12.7 g fibre per 100 ml,		
237 ml carton		e.g. Resource Fruit Beverage
ORAL FEED 1.5 KCAL/ML - Restricted see terms on the previous page		
 Liquid 5.5 g protein, 21.1 g carbohydrate and 4.81 g fat per 100 ml, can	237 ml	Ensure Plus (Vanilla)
carton	200 ml	Ensure Plus (Banana) Ensure Plus (Chocolate) Ensure Plus (Fruit of the Forest) Ensure Plus (Vanilla)
 Liquid 4 g protein and 33.5 g carbohydrate per 100 ml, 200 ml bottle Liquid 6 g protein, 18.4 g carbohydrate and 5.8 g fat per 100 ml, 200 ml 		e.g. Fortijuice
bottle		e.g. Fortisip
 Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 2.3 g fibre per 100 ml, 200 ml bottle 		e.g. Fortisip Multi Fibre

VACCINES

	Price (ex man. excl. \$	GST)	Per	Brand or Generic Manufacturer
Bacterial and Viral Vaccines				
DIPHTHERIA, TETANUS, PERTUSSIS AND POLIO VACCINE - R	Restricted see tern	ns <mark>belo</mark>	w	
 Inj 30 IU diphtheria toxoid with 30IU tetanus toxoid, 25 mcg pertoxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mc pertactin and 80 D-antigen units poliomyelitis virus in 0.5 m - 0% DV Oct-20 to 2024. 	g Il syringe)	10	Infanrix IPV
→ Restricted (RS1387) Initiation				
Any of the following:				
 A single dose for children up to the age of 7 who have compled A course of up to four vaccines is funded for catch up prograprimary immunisation; or An additional four doses (as appropriate) are funded for (re-) or post splenectomy; pre- or post solid organ transplant, renarror 	mmes for children immunisation for p al dialysis and othe	(to the atients	age of 10	CT, or chemotherapy; pre-
4 Five doses will be funded for children requiring solid organ tr	•			
Note: Please refer to the Immunisation Handbook for appropriate s				
 DIPHTHERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS B AND Restricted see terms below Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg per toxoid, 25 mcg per toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mc pertactin, 80 D-antigen units poliomyelitis virus, 10 mcg hep - 0% DV Oct-20 to 2024	rtussis g patitis B		10	Infanrix-hexa
Initiation				
 Any of the following: 1 Up to four doses for children up to and under the age of 10 for 2 An additional four doses (as appropriate) are funded for (re-) are patients post haematopoietic stem cell transplantation, o organ transplant, renal dialysis and other severely immunose 3 Up to five doses for children up to and under the age of 10 for Note: A course of up-to four vaccines is funded for catch up program 	immunisation for c r chemotherapy; pr uppressive regimer eceiving solid organ	hildren re or po ns; or n trans	up to and ost splene plantation	ectomy; pre- or post solid
complete full primary immunisation. Please refer to the Immunisation programmes.				
Bacterial Vaccines				
BACILLUS CALMETTE-GUERIN VACCINE – Restricted see term				

1331, live attenuated, vial Danish strain 1331, live attenuated, vial

Initiation

All of the following:

- For infants at increased risk of tuberculosis defined as:
- 1 Living in a house or family with a person with current or past history of TB; and
- 2 Having one or more household members or carers who within the last 5 years lived in a country with a rate of TB > or equal to 40 per 100,000 for 6 months or longer; and

10

BCG Vaccine

3 During their first 5 years will be living 3 months or longer in a country with a rate of TB > or equal to 40 per 100,000.

Note: A list of countries with high rates of TB are available at http://www.health.govt.nz/tuberculosis (Search for Downloads) or www.bcgatlas.org/index.php

(Price ex man. excl. GST \$	Per	Brand or Generic Manufacturer
DIPHTHERIA, TETANUS AND PERTUSSIS VACCINE - Restricted see	e terms below		
Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pertussis toxoid, 8 mcg pertussis filamentous haemagglutinin and 2.5 mcg			
pertactin in 0.5 ml syringe – 0% DV Oct-20 to 2024		1	Boostrix
		10	Boostrix

→ Restricted (RS1766)

Initiation

- Any of the following:
 - 1 A single dose for pregnant women in the second or third trimester of each pregnancy; or; or
 - 2 A single dose for parents or primary caregivers of infants admitted to a Neonatal Intensive Care Unit or Specialist Care Baby Unit for more than 3 days, who had not been exposed to maternal vaccination at least 14 days prior to birth; or; or
 - 3 A course of up to four doses is funded for children from age 7 up the age of 18 years inclusive to complete full primary immunisation; or
 - 4 An additional four doses (as appropriate) are funded for (re-)immunisation for patients post haematopoietic stem cell transplantation or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
 - 5 A single dose for vaccination of patients aged 65 years old; or
 - 6 A single dose for vaccination of patients aged 45 years old who have not had 4 previous tetanus doses; or
 - 7 For vaccination of previously unimmunised or partially immunised patients; or
 - 8 For revaccination following immunosuppression; or
 - 9 For boosting of patients with tetanus-prone wounds.

Note: Tdap is not registered for patients aged less than 10 years. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

1

1

Hiberix

Menactra

HAEMOPHILUS INFLUENZAE TYPE B VACCINE - Restricted see terms below

 Haemophilus Influenzae type B polysaccharide 10 mcg conjugated to tetanus toxoid as carrier protein 20-40 mcg; prefilled syringe plus vial 0.5 ml......0.00

→ Restricted (RS1520) Initiation

Initiation

Therapy limited to 1 dose Any of the following:

- 1 For primary vaccination in children; or
- 2 An additional dose (as appropriate) is funded for (re-)immunisation for patients post haematopoietic stem cell transplantation, or chemotherapy; functional asplenic; pre or post splenectomy; pre- or post solid organ transplant, pre- or post cochlear implants, renal dialysis and other severely immunosuppressive regimens; or
- 3 For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

MENINGOCOCCAL (A, C, Y AND W-135) CONJUGATE VACCINE - Restricted see terms below

→ Restricted (RS1719) Initiation

Lithor

Either:

- 1 Any of the following:
 - 1.1 Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with HIV, complement deficiency (acquired or inherited), functional or anatomic asplenia or pre or post solid organ transplant; or

VAC	CINES
-----	-------

 Price (ex man. excl. GST)		Brand or Generic
 (ex man. excl. GST) \$	Per	Manufacturer

continued...

- 1.2 One dose for close contacts of meningococcal cases; or
- 1.3 A maximum of two doses for bone marrow transplant patients; or
- 1.4 A maximum of two doses for patients following immunosuppression*; or

2 Both:

2.1 Person is aged between 13 and 25 years, inclusive; and

2.2 Either:

- 2.2.1 One dose for individuals who are entering within the next three months, or in their first year of living in boarding school hostels, tertiary education halls of residence, military barracks, or prisons; or
- 2.2.2 One dose for individuals who are currently living in boarding school hostels, tertiary education halls of residence, military barracks, or prisons, from 1 December 2019 to 30 November 2020.

Notes: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly.

*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

MENINGOCOCCAL C CONJUGATE VACCINE - Restricted see terms below

Inj 10 mcg in 0.5 ml syringe......0.00 1 Neisvac-C

➡ Restricted (RS1767)

Initiation - Children under 9 months of age

Any of the following:

- 1 Up to three doses for patients pre- and post splenectomy and for patients with HIV, complement deficiency (acquired or inherited), functional or anatomic asplenia or pre or post solid organ transplant; or
- 2 Two doses for close contacts of meningococcal cases; or
- 3 A maximum of two doses for bone marrow transplant patients; or
- 4 A maximum of two doses for patients pre- and post-immunosuppression*.

Notes: children under nine months of age require two doses 8 weeks apart. Refer to the Immunisation Handbook for booster schedules with meningococcal ACWY vaccine.

*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

PNEUMOCOCCAL (PCV10) CONJUGATE VACCINE - Restricted see terms below

I mcg of pneumococcal polysaccharide serotypes 1, 5, 6B, 7F, 9V,

14 and 23F; 3 mcg of pneumococcal polysaccharide serotypes 4,

18C and 19F in 0.5 ml prefilled syringe - 0% DV Oct-20 to 20240.00 10 Synflorix → Restricted (RS1768)

Initiation

A primary course of three doses for previously unvaccinated individuals up to the age of 59 months inclusive.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes

PNEUMOCOCCAL (PCV13) CONJUGATE VACCINE - Restricted see terms below

 Inj 30.8 mcg of pneumococcal polysaccharide serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in 0.5 ml syringe......0.00
 Prevenar 13

10 Prevenar 13

→ Restricted (RS1769)

Initiation – High risk children who have received PCV10

Therapy limited to 1 dose

Two doses are funded for high risk children (over the age of 12 months and under 18 years) who have previously received two doses of the primary course of PCV10.

Initiation - High risk children aged under 5 years

Therapy limited to 4 doses Both:

Price			Brand or
(ex man. exc	. GST)	_	Generic
\$		Per	Manufacturer

continued...

- 1 Up to an additional four doses (as appropriate) are funded for children aged under 5 years for (re-)immunisation; and
- 2 Any of the following:
 - 2.1 On immunosuppressive therapy or radiation therapy, vaccinate when there is expected to be a sufficient immune response; or
 - 2.2 With primary immune deficiencies; or
 - 2.3 With HIV infection; or
 - 2.4 With renal failure, or nephrotic syndrome; or
 - 2.5 Who are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant); or
 - 2.6 With cochlear implants or intracranial shunts; or
 - 2.7 With cerebrospinal fluid leaks; or
 - 2.8 Receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; or
 - 2.9 With chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy); or
 - 2.10 Pre term infants, born before 28 weeks gestation; or
 - 2.11 With cardiac disease, with cyanosis or failure; or
 - 2.12 With diabetes; or
 - 2.13 With Down syndrome; or
 - 2.14 Who are pre-or post-splenectomy, or with functional asplenia.

Initiation - High risk adults and children 5 years and over

Therapy limited to 4 doses

Up to an additional four doses (as appropriate) are funded for (re-)immunisation of patients 5 years and over with HIV, for patients pre or post haematopoietic stem cell transplantation, or chemotherapy; pre- or post splenectomy; functional asplenia, pre- or post-solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, or primary immunodeficiency.

Initiation – Testing for primary immunodeficiency diseases

For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes

PNEUMOCOCCAL (PPV23) POLYSACCHARIDE VACCINE - Restricted see terms below

Inj 575 mcg in 0.5 ml prefilled syringe (25 mcg of each 23 pneumococcal

serotype) - 0% DV Oct-20 to 2024	0.00	1	Pneumovax 23
➡ Restricted (BS1587)			

Initiation – High risk patients

Therapy limited to 3 doses

For patients with HIV, for patients post haematopoietic stem cell transplant, or chemotherapy; pre- or post-splenectomy; or with functional asplenia, pre- or post-solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, or primary immunodeficiency.

Initiation - High risk children

Therapy limited to 2 doses Both:

- 1 Patient is a child under 18 years for (re-)immunisation; and
- 2 Any of the following:
 - 2.1 On immunosuppressive therapy or radiation therapy, vaccinate when there is expected to be a sufficient immune response; or
 - 2.2 With primary immune deficiencies; or
 - 2.3 With HIV infection; or

e.g. Brand indicates brand example only. It is not a contracted product.

VACCINES

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 2.4 With renal failure, or nephrotic syndrome; or
- 2.5 Who are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant); or
- 2.6 With cochlear implants or intracranial shunts; or
- 2.7 With cerebrospinal fluid leaks; or
- 2.8 Receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; or
- 2.9 With chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy); or
- 2.10 Pre term infants, born before 28 weeks gestation; or
- 2.11 With cardiac disease, with cyanosis or failure; or
- 2.12 With diabetes; or
- 2.13 With Down syndrome; or
- 2.14 Who are pre-or post-splenectomy, or with functional asplenia.

Initiation - Testing for primary immunodeficiency diseases

For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

SALMONELLA TYPHI VACCINE - Restricted see terms below

- ↓ Inj 25 mcg in 0.5 ml syringe
- → Restricted (RS1243)

Initiation

For use during typhoid fever outbreaks.

Viral Vaccines

HEPATITIS A VACCINE - Restricted see terms below		
Inj 720 ELISA units in 0.5 ml syringe – 0% DV Oct-20 to 20240.00	1	Havrix Junior
Inj 1440 ELISA units in 1 ml syringe – 0% DV Oct-20 to 20240.00	1	Havrix
➡ Restricted (RS1638)		
Initiation		
Any of the following:		
 Two vaccinations for use in transplant patients; or Two vaccinations for use in children with chronic liver disease; or One dose of vaccine for close contacts of known hepatitis A cases. 		
HEPATITIS B RECOMBINANT VACCINE ↓ Inj 20 mcg per 1 ml prefilled syringe – 0% DV Oct-20 to 20240.00 → Restricted (RS1671) Initiation Any of the following:	1	Engerix-B
 For household or sexual contacts of known acute hepatitis B patients or hepatitis B For children born to mothers who are hepatitis B surface antigen (HBsAg) positive; For children up to and under the age of 18 years inclusive who are considered not t and require additional vaccination or require a primary course of vaccination; or For HIV positive patients; or For hepatitis C positive patients; or 	or	

- 6 for patients following non-consensual sexual intercourse; or
- 7 For patients following immunosuppression; or
- 8 For solid organ transplant patients; or

continued...

	Price (ex man. excl. 0 \$	GST)	Per	Brand or Generic Manufacturer
continued				
9 For post-haematopoietic stem cell transplant (HSCT) patients; o	r			
10 Following needle stick injury; or				
 For dialysis patients; or For liver or kidney transplant patients. 				
HUMAN PAPILLOMAVIRUS (6, 11, 16, 18, 31, 33, 45, 52 AND 58) VA	CCINE [HPV] -	Rest	ri cted se	e terms below
Inj 270 mcg in 0.5 ml syringe - 0% DV Oct-20 to 2024			10	Gardasil 9
→ Restricted (RS1693)				
nitiation – Children aged 14 years and under				
<i>Therapy limited to 2 doses</i> Children aged 14 years and under.				
nitiation – other conditions				
ither:				
1 Up to 3 doses for people aged 15 to 26 years inclusive; or				
2 Both:				
2.1 People aged 9 to 26 years inclusive; and				
2.2 Any of the following: 2.2.1 Up to 3 doses for confirmed HIV infection; or				
2.2.2 Up to 3 doses for transplant (including stem cell) p	patients: or			
2.2.3 Up to 4 doses for Post chemotherapy.				
nitiation – Recurrent Respiratory Papillomatosis				
Il of the following:				
1 Either:				
1.1 Maximum of two doses for children aged 14 years and ur				
 1.2 Maximum of three doses for people aged 15 years and o 2 The patient has recurrent respiratory papillomatosis; and 	ver, and			
3 The patient has not previously had an HPV vaccine.				
NFLUENZA VACCINE				
Inj 30 mcg in 0.25 ml syringe (paediatric quadrivalent vaccine)	9.00		1	Afluria Quad Junior
				(2020 Formulation
→ Restricted (RS1675)				
nitiation – cardiovascular disease for patients aged 6 months to 3 Any of the following:	5 months			
1 Ischaemic heart disease: or				

- 1 Ischaemic heart disease; or
- 2 Congestive heart failure; or
- 3 Rheumatic heart disease; or
- 4 Congenital heart disease; or
- 5 Cerebro-vascular disease.

Note: hypertension and/or dyslipidaemia without evidence of end-organ disease is excluded from funding. Initiation – chronic respiratory disease for patients aged 6 months to 35 months Either:

- 1 Asthma, if on a regular preventative therapy; or
- 2 Other chronic respiratory disease with impaired lung function.

Note: asthma not requiring regular preventative therapy is excluded from funding.

Initiation – Other conditions for patients aged 6 months to 35 months Any of the following:

	Price (ex man. excl. GS \$	T) Per	Brand or Generic Manufacturer
continued			
1 Diabetes; or			
2 Chronic renal disease; or			
 3 Any cancer, excluding basal and squamous skin cancers if 4 Autoimmune disease; or 	not invasive; or		
5 Immune suppression or immune deficiency; or			
6 HIV; or			
7 Transplant recipient; or			
 8 Neuromuscular and CNS diseases/ disorders; or 9 Haemoglobinopathies; or 			
10 Is a child on long term aspirin; or			
11 Has a cochlear implant; or			
12 Errors of metabolism at risk of major metabolic decompensation	ation; or		
13 Pre and post splenectomy; or14 Down syndrome; or			
15 Child who has been hospitalised for respiratory illness or ha	s a history of significar	t respirato	ry illness.
Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine)		10	Afluria Quad
	9.00	1	(2020 Formualtion Influvac Tetra
			(2020 formulation)
→ Restricted (RS1674)			
nitiation – People over 65 The patient is 65 years of age or over.			
nitiation – cardiovascular disease for patients 3 years and over	er		
Any of the following:			
1 Ischaemic heart disease; or			
2 Congestive heart failure; or			
2 Congestive heart failure; or3 Rheumatic heart disease; or			
 Congestive heart failure; or Rheumatic heart disease; or Congenital heart disease; or 			
 Congestive heart failure; or Rheumatic heart disease; or Congenital heart disease; or Cerebro-vascular disease. 	organ disease is exclud	led from fu	ndina.
 2 Congestive heart failure; or 3 Rheumatic heart disease; or 4 Congenital heart disease; or 5 Cerebro-vascular disease. Note: hypertension and/or dyslipidaemia without evidence of end-initiation – chronic respiratory disease for patients 3 years and 		led from fu	nding.
 2 Congestive heart failure; or 3 Rheumatic heart disease; or 4 Congenital heart disease; or 5 Cerebro-vascular disease. Note: hypertension and/or dyslipidaemia without evidence of end-initiation – chronic respiratory disease for patients 3 years and 		led from fu	nding.
 2 Congestive heart failure; or 3 Rheumatic heart disease; or 4 Congenital heart disease; or 5 Cerebro-vascular disease. Note: hypertension and/or dyslipidaemia without evidence of end- nitiation – chronic respiratory disease for patients 3 years and Either: 	d over	led from fu	nding.
 2 Congestive heart failure; or 3 Rheumatic heart disease; or 4 Congenital heart disease; or 5 Cerebro-vascular disease. Note: hypertension and/or dyslipidaemia without evidence of end-tilitation – chronic respiratory disease for patients 3 years and Either: 1 Asthma, if on a regular preventative therapy; or 2 Other chronic respiratory disease with impaired lung functio Note: asthma not requiring regular preventative therapy is exclude 	n.	led from fu	nding.
 2 Congestive heart failure; or 3 Rheumatic heart disease; or 4 Congenital heart disease; or 5 Cerebro-vascular disease. Note: hypertension and/or dyslipidaemia without evidence of end-initiation – chronic respiratory disease for patients 3 years and Either: 1 Asthma, if on a regular preventative therapy; or 2 Other chronic respiratory disease with impaired lung function Note: asthma not requiring regular preventative therapy is exclude nitiation – Other conditions for patients 3 years and over 	n.	led from fu	nding.
 2 Congestive heart failure; or 3 Rheumatic heart disease; or 4 Congenital heart disease; or 5 Cerebro-vascular disease. Note: hypertension and/or dyslipidaemia without evidence of end- nitiation – chronic respiratory disease for patients 3 years and Either: Asthma, if on a regular preventative therapy; or Other chronic respiratory disease with impaired lung function Note: asthma not requiring regular preventative therapy is excluden nitiation – Other conditions for patients 3 years and over Either: 	n.	led from fu	nding.
 2 Congestive heart failure; or 3 Rheumatic heart disease; or 4 Congenital heart disease; or 5 Cerebro-vascular disease. Note: hypertension and/or dyslipidaemia without evidence of end- nitiation – chronic respiratory disease for patients 3 years and Either: Asthma, if on a regular preventative therapy; or Other chronic respiratory disease with impaired lung function Note: asthma not requiring regular preventative therapy is excluden nitiation – Other conditions for patients 3 years and over Either: Any of the following: 	n.	led from fu	nding.
 2 Congestive heart failure; or 3 Rheumatic heart disease; or 4 Congenital heart disease; or 5 Cerebro-vascular disease. Note: hypertension and/or dyslipidaemia without evidence of end- nitiation – chronic respiratory disease for patients 3 years and Either: Asthma, if on a regular preventative therapy; or Other chronic respiratory disease with impaired lung function Note: asthma not requiring regular preventative therapy is excluden nitiation – Other conditions for patients 3 years and over Either: Any of the following: Diabetes; or 	n.	led from fu	nding.
 2 Congestive heart failure; or 3 Rheumatic heart disease; or 4 Congenital heart disease; or 5 Cerebro-vascular disease. Note: hypertension and/or dyslipidaemia without evidence of end- nitiation – chronic respiratory disease for patients 3 years and Either: Asthma, if on a regular preventative therapy; or Other chronic respiratory disease with impaired lung function Note: asthma not requiring regular preventative therapy is excluden nitiation – Other conditions for patients 3 years and over Either: Any of the following: 	d over n. d from funding.	led from fu	nding.
 2 Congestive heart failure; or 3 Rheumatic heart disease; or 4 Congenital heart disease; or 5 Cerebro-vascular disease. Note: hypertension and/or dyslipidaemia without evidence of end-initiation – chronic respiratory disease for patients 3 years and cither: 1 Asthma, if on a regular preventative therapy; or 2 Other chronic respiratory disease with impaired lung function lote: asthma not requiring regular preventative therapy is exclude initiation – Other conditions for patients 3 years and over Either: 1 Any of the following: 1 Diabetes; or 2 chronic renal disease; or 3 Any cancer, excluding basal and squamous skin car 4 Autoimmune disease; or 	d over n. d from funding.	led from fu	nding.
 2 Congestive heart failure; or 3 Rheumatic heart disease; or 4 Congenital heart disease; or 5 Cerebro-vascular disease. Jote: hypertension and/or dyslipidaemia without evidence of end-initiation – chronic respiratory disease for patients 3 years and either: 1 Asthma, if on a regular preventative therapy; or 2 Other chronic respiratory disease with impaired lung function lote: asthma not requiring regular preventative therapy is exclude initiation – Other conditions for patients 3 years and over Either: 1 Any of the following: 1.1 Diabetes; or 2 chronic renal disease; or 3 Any cancer, excluding basal and squamous skin can 1.4 Autoimmune disease; or 	d over n. d from funding.	led from fu	nding.
 2 Congestive heart failure; or 3 Rheumatic heart disease; or 4 Congenital heart disease; or 5 Cerebro-vascular disease. Note: hypertension and/or dyslipidaemia without evidence of end-initiation – chronic respiratory disease for patients 3 years and Either: 1 Asthma, if on a regular preventative therapy; or 2 Other chronic respiratory disease with impaired lung function vote: asthma not requiring regular preventative therapy is exclude initiation – Other conditions for patients 3 years and over Either: 1 Any of the following: 1.1 Diabetes; or 2 chronic renal disease; or 3 Any cancer, excluding basal and squamous skin canal. 4 Autoimmune disease; or 1.5 Immune suppression or immune deficiency; or 16 HIV; or 	d over n. d from funding.	led from fu	nding.
 2 Congestive heart failure; or 3 Rheumatic heart disease; or 4 Congenital heart disease; or 5 Cerebro-vascular disease. Note: hypertension and/or dyslipidaemia without evidence of end-initiation – chronic respiratory disease for patients 3 years and Either: 1 Asthma, if on a regular preventative therapy; or 2 Other chronic respiratory disease with impaired lung function vote: asthma not requiring regular preventative therapy is exclude initiation – Other conditions for patients 3 years and over Either: 1 Any of the following: 1.1 Diabetes; or 2 chronic renal disease; or 3 Any cancer, excluding basal and squamous skin carr 1.4 Autoimmune disease; or 	d over n. d from funding.	led from fu	nding.

VACCINES

ontinued		\$	GST)	Per	Generic Manufacturer
1.10 Is a child on long term aspirin; or					
1.11 Has a cochlear implant; or					
1.12 Errors of metabolism at risk of major metabolic decorr	npensation;	or			
1.13 Pre and post splenectomy; or1.14 Down syndrome; or					
1.15 Is pregnant; or					
1.16 Is a child aged four and under who has been hospitali	ised for resp	irator	v illnes	s or has	a history of significant
respiratory illness; or			,		
2 Patients in a long-stay inpatient mental health care unit or wh	no are comp	ulsori	y detai	ned long	-term in a forensic unit with
a DHB hospital.					
EASLES, MUMPS AND RUBELLA VACCINE - Restricted see to					
Injection, measles virus 1,000 CCID50, mumps virus 5,012 CCI Rubella virus 1,000 CCID50; prefilled syringe/ampoule of di					
0.5 ml – 0% DV Oct-20 to 2024		0.0	n	10	Priorix
Restricted (RS1487)		0.0	•	10	
itiation – first dose prior to 12 months					
herapy limited to 3 doses					
ny of the following:					
 For primary vaccination in children; or For revaccination following immunosuppression; or 					
3 For any individual susceptible to measles, mumps or rubella.					
itiation – first dose after 12 months					
herapy limited to 2 doses					
ny of the following:					
1 For primary vaccination in children; or					
2 For revaccination following immunosuppression; or					
3 For any individual susceptible to measles, mumps or rubella.					
ote: Please refer to the Immunisation Handbook for appropriate so	chedule for o	catch	up prog	grammes	í.
OLIOMYELITIS VACCINE – Restricted see terms below			•		
Inj 80 D-antigen units in 0.5 ml syringe – 0% DV Oct-20 to 202 Restricted (RS1398)	4	0.0	0	1	IPOL
itiation					
herapy limited to 3 doses					
ther:					
1 For partially vaccinated or previously unvaccinated individual	s; or				
2 For revaccination following immunosuppression.					
ote: Please refer to the Immunisation Handbook for the appropriat	te schedule	for ca	tch up	program	mes.
ABIES VACCINE					
Inj 2.5 IU vial with diluent					
OTAVIRUS ORAL VACCINE - Restricted see terms below					
Oral susp live attenuated human rotavirus 1,000,000 CCID50 pe prefilled oral applicator - 0% DV Oct-20 to 2024		0.0	n	10	Rotarix
▶ Restricted (RS1590)		0.0	-		
itiation					
herapy limited to 2 doses					
oth: 					
 First dose to be administered in infants aged under 14 weeks No vaccination being administered to children aged 24 weeks 		1			

Price Brand or (ex man. excl. GST) Generic Per Manufacturer S VARICELLA VACCINE [CHICKENPOX VACCINE] Inj 1350 PFU prefiiled syringe – 0% DV Oct-20 to 2024......0.00 Varivax 1 10 Varivax → Restricted (RS1591) Initiation - primary vaccinations Therapy limited to 1 dose Either:

- 1 Any infant born on or after 1 April 2016; or
- 2 For previously unvaccinated children turning 11 years old on or after 1 July 2017, who have not previously had a varicella infection (chickenpox).

Initiation - other conditions

Therapy limited to 2 doses

Any of the following:

- 1 Any of the following:
 - for non-immune patients:
 - 1.1 With chronic liver disease who may in future be candidates for transplantation; or
 - 1.2 With deteriorating renal function before transplantation; or
 - 1.3 Prior to solid organ transplant; or
 - 1.4 Prior to any elective immunosuppression*; or
 - 1.5 For post exposure prophylaxis who are immune competent inpatients; or
- 2 For patients at least 2 years after bone marrow transplantation, on advice of their specialist; or
- 3 For patients at least 6 months after completion of chemotherapy, on advice of their specialist; or
- 4 For HIV positive patients non immune to varicella with mild or moderate immunosuppression on advice of HIV specialist; or
- 5 For patients with inborn errors of metabolism at risk of major metabolic decompensation, with no clinical history of varicella; or
- 6 For household contacts of paediatric patients who are immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella; or
- 7 For household contacts of adult patients who have no clinical history of varicella and who are severely immunocompromised or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella.

Note: * immunosuppression due to steroid or other immunosuppressive therapy must be for a treatment period of greater than 28 days

Inj 2000 PFU prefilled syringe plus vial

➡ Restricted (RS1777)

Initiation - infants between 9 and 12 months of age

Therapy limited to 2 doses

Any of the following:

- 1 Any of the following:
 - for non-immune patients:
 - 1.1 With chronic liver disease who may in future be candidates for transplantation; or
 - 1.2 With deteriorating renal function before transplantation; or
 - 1.3 Prior to solid organ transplant; or
 - 1.4 Prior to any elective immunosuppression*; or
 - 1.5 For post exposure prophylaxis who are immune competent inpatients; or
- 2 For patients at least 2 years after bone marrow transplantation, on advice of their specialist; or
- 3 For patients at least 6 months after completion of chemotherapy, on advice of their specialist; or
- 4 For HIV positive patients non immune to varicella with mild or moderate immunosuppression on advice of HIV specialist; or
- 5 For patients with inborn errors of metabolism at risk of major metabolic decompensation, with no clinical history of varicella; or

continued...

VACCINES

VACCINES

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 6 For household contacts of paediatric patients who are immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella; or
- 7 For household contacts of adult patients who have no clinical history of varicella and who are severely immunocompromised or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella.

Note: * immunosuppression due to steroid or other immunosuppressive therapy must be for a treatment period of greater than 28 days

VARICELLA ZOSTER VACCINE [SHINGLES VACCINE] - Restricted see terms below

Varicella zoster virus (Oka strain) live attenuated vaccine [shingles		
vaccine] 0.00	1	Zostavax
	10	Zostavax
➡ Restricted (RS1720)		
Initiation – people aged 65 years		
Therapy limited to 1 dose		
One dose for all people aged 65 years.		
Initiation – people aged between 66 and 80 years		
Therapy limited to 1 dose		
One dose for all people aged between 66 and 80 years inclusive from 1 April 2018 and 31	Decembe	r 2020.
Discussion America		

Diagnostic Agents

TUBERCULIN PPD [MANTOUX] TEST		
Inj 5 TU per 0.1 ml, 1 ml vial – 0% DV Oct-20 to 20240.00	1	Tubersol

PART III: OPTIONAL PHARMACEUTICALS

(ex man. excl. GST) Generic \$ Per Manufacturer	

Optional Pharmaceuticals

NOTE:

In addition to the products expressly listed here in Part III: Optional Pharmaceuticals, a range of hospital medical devices are listed in an addendum to Part III which is available at <u>schedule.pharmac.govt.nz</u>. The Optional Pharmaceuticals listed in the addendum are deemed to be listed in Part III, and the Rules of the Pharmaceutical Schedule applying to products listed in Part III apply to them.

BLOOD GLUCOSE DIAGNOSTIC TEST METER		
1 meter with 50 lancets, a lancing device, and 10 diagnostic test strips20.00 10.00	1	CareSens N Premier Caresens N Caresens N POP
BLOOD GLUCOSE DIAGNOSTIC TEST STRIP		
Blood glucose test strips10.56	50 test	CareSens N
Test strips 10.56	50 test	CareSens PRO
BLOOD KETONE DIAGNOSTIC TEST STRIP		
Test strips	10 strip	KetoSens
DUAL BLOOD GLUCOSE AND BLOOD KETONE DIAGNOSTIC TEST METER		
Meter with 50 lancets, a lancing device, and 10 blood glucose diagnostic		
test strips	1	CareSens Dual
MASK FOR SPACER DEVICE		
Small	1	e-chamber Mask
PEAK FLOW METER	•	
Low Range	1	Mini-Wright AFS Low
Low Hange	I	Range
Normal Range9.54	1	Mini-Wright Standard
PREGNANCY TEST - HCG URINE		inin Might Clandard
Cassette	40 test	Smith BioMed Rapid
Casselle	40 1851	Pregnancy Test
		Tregnancy rest
SODIUM NITROPRUSSIDE	EQ atria	Kataatiw
Test strip22.00	50 strip	Ketostix
SPACER DEVICE		
220 ml (single patient)	1	e-chamber Turbo
510 ml (single patient)	1	e-chamber La Grande
800 ml	1	Volumatic

Symbols -

8-methoxypsoralen
- A -
A-Scabies
Abacavir sulphate
Abacavir sulphate with
lamivudine
Abciximab
Abiraterone acetate
Acarbose
Accuretic 10
Accuretic 20
Acetazolamide
Acetec
Acetic acid
Extemporaneously Compounded
Preparations
Genito-Urinary
Acetic acid with hydroxyquinoline,
glycerol and ricinoleic acid
Acetic acid with propylene
glycol 219
Acetylcholine chloride
Acetylcysteine
Aciclovir
Infections
Sensory213
Aciclovir-Claris
Acid Citrate Dextrose A
Acidex
Acitretin
Aclasta
Actemra
Actinomycin D
Adalat 10
Adalat Oros
Adalimumab
Adapalene
Adenocor
Adenosine
Adenuric
Adrenaline
Advate
Adynovate
Aerrane
Afinitor
Aflibercept
Afluria Quad (2020 Formualtion)
Afluria Quad Junior (2020 Formulation)
(2020 FOIIIIUIalion)

AFT Pholcodine Linctus BP209
Agents Affecting the
Renin-Angiotensin System
Agents for Parkinsonism and Related
Disorders 104
Agents Used in the Treatment of
Poisonings 220
Ajmaline40
Albendazole83
Aldurazyme16
Alecensa137
Alectinib137
Alendronate sodium95
Alendronate sodium with
colecalciferol96
Alfacalcidol22
Alfamino Junior240
Alfentanil109
Alglucosidase alfa13
Alinia84
Allerpro 1241
Allerpro 2
Allersoothe
Allmercap131
Allopurinol100
Alpha tocopheryl22
Alpha tocopheryl acetate23
Alpha-Adrenoceptor Blockers
Alphamox76
Alaham 405
Alphamox 12576
Alphamox 25076
Alphamox 25076 Alprolix
Alphamox 250

hydrochloride	
Aminophylline	211
Amiodarone hydrochloride	
Amisulpride	118
Amitriptyline	
Amlodipine	42
Amorolfine	52
Amoxicillin	
Amoxicillin with clavulanic acid	76
Amphotericin B	
Alimentary	19
Infections	80
Amsacrine	132
Amyl nitrite	
Anabolic Agents	62
Anaesthetics	
Anagrelide hydrochloride	
Analgesics	108
Anastrozole	148
Andriol Testocaps	
Androderm	
Androgen Agonists and	
Antagonists	
Anoro Ellipta	
Antabuse	
Antacids and Antiflatulents	5
Anti-Infective Agents	
Anti-Infective Preparations	
Dermatological	52
Sensory	213
Anti-Inflammatory Preparations	214
Antiacne Preparations	
Antiallergy Preparations	205
Antianaemics	
Antiarrhythmics	
Antibacterials	
Anticholinergic Agents	206
Anticholinesterases	
Antidepressants	111
Antidiarrhoeals and Intestinal	
Anti-Inflammatory Agents	5
Antiepilepsy Drugs	113
Antifibrinolytics, Haemostatics and	
Local Sclerosants	26
Antifibrotics	
Antifungals	
Antihypotensives	
Antimigraine Preparations	
Antimycobacterials	
Antinausea and Vertigo Agents	02 117
Antiparasitics	
Antipruritic Preparations	
Antipsychotic Agents	
Antiretrovirals	
/ u u ou ovi ulo	00

Antirheumatoid Agents
Antiseptics and Disinfectants
Antispasmodics and Other Agents
Altering Gut Motility
Antithrombotics
Antithymocyte globulin
(equine) 203
Antithymocyte globulin (rabbit)
Antiulcerants
Antivirals
Anxiolytics
Apidra
Apidra Solostar
Apo-Amlodipine
Apo-Azithromycin
Apo-Ciclopirox
Apo-Cilazapril/ Hydrochlorothiazide
Apo-Clarithromycin
Apo-Clomipramine
Apo-Diclo SR
Apo-Diltiazem CD
Apo-Folic Acid
Apo-Gabapentin
Apo-Leflunomide
Apo-Megestrol
Apo-Metoprolol
Apo-Mirtazapine
Apo-Nadolol
Apo-Nicotinic Acid
Apo-Oxybutynin
Apo-Perindopril
Apo-Pindolol
Apo-Pravastatin
Apo-Prazosin
Apo-Prednisone
Apo-Propranolol
Apo-Pyridoxine
Apo-Sumatriptan116
Apo-Terazosin
Apomorphine hydrochloride104
Apraclonidine
Aprepitant 117
Apresoline48
Aprotinin26
Aqueous cream54
Arachis oil [Peanut oil]228
Aratac 40
Arava95
Arginine
Alimentary 14
Various225
Argipressin [Vasopressin]71
Aripiprazole118

=

Aripiprazole Sandoz	
Aristocort	
Arrow-Amitriptyline	. 111
Arrow-Bendrofluazide	44
Arrow-Brimonidine	
Arrow-Calcium	
Arrow-Diazepam	. 121
Arrow-Fluoxetine	. 113
Arrow-Losartan &	
Hydrochlorothiazide	39
Arrow-Morphine LA	. 110
Arrow-Norfloxacin	77
Arrow-Ornidazole	
Arrow-Quinapril 10	38
Arrow-Quinapril 20	38
Arrow-Quinapril 5	38
Arrow-Roxithromycin	
Arrow-Timolol	.217
Arrow-Topiramate	. 115
Arrow-Tramadol	. 111
Arsenic trioxide	. 132
Artemether with lumefantrine	
Artesunate	84
Articaine hydrochloride	. 106
Articaine hydrochloride with	
adrenaline	
Asacol	
Asamax	6
Ascorbic acid	
Alimentary	22
Alimentary Extemporaneously Compounded	<mark>22</mark>
Alimentary Extemporaneously Compounded Preparations	22 228
Alimentary Extemporaneously Compounded Preparations Aspen Adrenaline	22 228
Alimentary Extemporaneously Compounded Preparations Aspen Adrenaline Aspirin	22 228 47
Alimentary Extemporaneously Compounded Preparations Aspen Adrenaline Aspirin Blood	22
Alimentary Extemporaneously Compounded Preparations Aspen Adrenaline Aspirin Blood Nervous	22 228 47 31 108
Alimentary Extemporaneously Compounded Preparations Aspen Adrenaline Aspirin Blood Nervous Asthalin	228 47 31 108 208
Alimentary Extemporaneously Compounded Preparations Aspen Adrenaline Aspirin Blood Nervous Asthalin Atazanavir sulphate	22 228 47 31 108 208 87
Alimentary Extemporaneously Compounded Preparations Aspen Adrenaline Aspirin Blood Nervous Asthalin Atazanavir sulphate Atenolol	22 228 47 31 31 31 31 31 31 31 47
Alimentary Extemporaneously Compounded Preparations Aspen Adrenaline Aspirin Blood Nervous Asthalin Atazanavir sulphate Atenolol. Atenolol.AFT	22 228 47 31 108 208 87 41
Alimentary Extemporaneously Compounded Preparations Aspen Adrenaline Aspirin Blood Asthalin Atazanavir sulphate Atenolol ATGAM	22 228 47 31 31 31 31 31 47 41 41 203
Alimentary Extemporaneously Compounded Preparations Aspen Adrenaline Aspirin Blood Asthalin Atazanavir sulphate Atenolol Atenolol.AFT ATGAM Ativan	228 47 31 87 87 41 41 41 203 121
Alimentary Extemporaneously Compounded Preparations Aspen Adrenaline Aspirin Blood Nervous Asthalin Atazanavir sulphate Atazanavir sulphate Atenolol-AFT ATGAM Ativan Atomoxetine	228 228 47 31 208 87 41 41 41 203 121 124
Alimentary Extemporaneously Compounded Preparations Aspen Adrenaline Aspirin Blood Nervous Asthalin Atazanavir sulphate Atazanavir sulphate Atenolol-AFT ATGAM Ativan Atomoxetine Atorvastatin	228 228 47 31 208 87 41 41 41 203 121 124
Alimentary Extemporaneously Compounded Preparations Aspen Adrenaline Aspirin Blood Asthalin Asthalin Atanolol Atenolol Atenolol Atenolol Atomoxetine Atorvastatin Atovaquone with proguanil	22
Alimentary Extemporaneously Compounded Preparations Aspen Adrenaline Aspirin Blood Asthalin Atanolol Atenolol Atenolol Atenolol Atomoxetine Atovastatin Atovaquone with proguanil hydrochloride	228 47 31 108 87 41 41 41 41 41 45 45 84
Alimentary Extemporaneously Compounded Preparations Aspen Adrenaline Aspirin Blood Asthalin Atarouol Atenolol Atenolol Atenolol Atomoxetine Atovastatin Atovaquone with proguanil hydrochloride Atracurium besylate	228
Alimentary Extemporaneously Compounded Preparations Aspen Adrenaline Aspirin Blood Asthalin Atazanavir sulphate Atazanavir sulphate Atazolol Atenolol Atenolol Atenolol Atomoxetine Atomoxetine Atovaquone with proguanil hydrochloride Atropine sulphate	228
Alimentary Extemporaneously Compounded Preparations Aspen Adrenaline Aspirin Blood Asthalin Atazanavir sulphate Atazanavir sulphate AtazonolAFT Atenolol-AFT Atomoxetine Atomoxetine Atovastatin Atovaquone with proguanil hydrochloride Atracurium besylate Atoropine sulphate Cardiovascular	228
Alimentary Extemporaneously Compounded Preparations Aspen Adrenaline Aspirin Blood Asthalin Atazanavir sulphate Atazanavir sulphate Atacolol Atenolol Atenolol Atenolol Atorvastatin Atorvastatin Atovaquone with proguanil hydrochloride Atropine sulphate Cardiovascular Sensory	228
Alimentary Extemporaneously Compounded Preparations Aspen Adrenaline Aspirin Blood Asthalin Atazanavir sulphate Atazanavir sulphate Atanolol Atenolol Atenolol Atenolol Atovastine Atovastine Atovaquone with proguanil hydrochloride Atroyine sulphate Cardiovascular Sensory Atropt	22 I
Alimentary Extemporaneously Compounded Preparations Aspen Adrenaline Aspirin Blood Asthalin Atazanavir sulphate Atazanavir sulphate Atanolol Atanolol Atanolol Atarolol Atomoxetine Atowaquone with proguanil hydrochloride Atrovastatin Atovaquone with proguanil hydrochloride Atropine sulphate Cardiovascular Sensory Atapajo	22 I
Alimentary Extemporaneously Compounded Preparations Aspen Adrenaline Aspirin Blood Asthalin Atazanavir sulphate Atatanavir sulphate Atanolol Atanolol AtanololAFT ATGAM Atomoxetine Atovaquone with proguanil hydrochloride Atovaquone with proguanil hydrochloride Atropine sulphate Cardiovascular Sensory Atopt Auggio	22
Alimentary Extemporaneously Compounded Preparations Aspen Adrenaline Aspirin Blood Asthalin Atazanavir sulphate Atazanavir sulphate Atanolol Atanolol AtanololAFT ATGAM Atovastine Atovastine Atovastatin Atovaquone with proguanil hydrochloride Atrozine sulphate Cardiovascular Sensory Atropt Augenetin Augenetin	22 I
Alimentary Extemporaneously Compounded Preparations Aspen Adrenaline Aspirin Blood Asthalin Atazanavir sulphate Atatanavir sulphate Atanolol Atanolol AtanololAFT ATGAM Atomoxetine Atovaquone with proguanil hydrochloride Atovaquone with proguanil hydrochloride Atropine sulphate Cardiovascular Sensory Atopt Auggio	22

Avonex Pen 122
Azacitidine 130
Azacitidine Dr Reddy's130
Azactam
Azamun
Azathioprine
Azithromycin74
Azol
AZT86
Aztreonam
- B -
Bacillus calmette-guerin (BCG) 203
Bacillus calmette-guerin
vaccine 247
Baclofen101
Bacterial and Viral Vaccines247
Bacterial Vaccines
Balanced Salt Solution216
Barium sulphate224
Barium sulphate with sodium
bicarbonate 224
Barrier Creams and Emollients53
Basiliximab166
BCG Vaccine
BD PosiFlush36
Beclazone 100209
Beclazone 250209
Beclazone 50209
Beclomethasone dipropionate 209
Bee venom
Bendrofluazide44
Bendroflumethiazide
[Bendrofluazide] 44
Benzathine benzylpenicillin76
Benzatropine mesylate 104
Benzbromaron AL 100100
Benzbromarone100
Benzocaine106
Benzocaine with tetracaine
hydrochloride 106
Benzoin
Benzoyl peroxide
Benztrop 104
Benzydamine hydrochloride 19
Benzydamine hydrochloride with
cetylpyridinium chloride
Benzylpenicillin sodium [Penicillin
G]
Beractant
Beta Cream
Beta Ointment
Beta Scalp
Beta-Adrenoceptor Agonists
Betadine

Betahistine dihydrochloride 117
Betaine14
Betaloc CR41
Betamethasone63
Betamethasone dipropionate55
Betamethasone dipropionate with
calcipotriol
Betamethasone sodium phosphate
with betamethasone acetate
Betamethasone valerate
Betamethasone valerate with
clioquinol
Betamethasone valerate with sodium
fusidate [Fusidic acid]
Betaxolol
Betravoloi
Betoptic
Detoplic
Betoptic S 217
Bevacizumab166
Bezafibrate
Bezalip
Bezalip Retard
Bicalutamide
Bicillin LA76
BiCNU129
Bicnu Heritage 129
Bile and Liver Therapy9
Biliscopin
Bimatoprost217
Bimatoprost Multichem217
Binarex 146
Binocrit24
Biodone 110
Biodone Extra Forte110
Biodone Forte 110
Biotin15
Bisacodyl13
Bismuth subgallate
Bismuth subnitrate and iodoform
paraffin226
Bisoprolol fumarate41
Bivalirudin
Bleomycin sulphate 129
Blood glucose diagnostic test
meter
Blood glucose diagnostic test
strip
Blood ketone diagnostic test
strip
Bonney's blue dye
Boostrix
Boric acid
Bortezomib
Bortezomib Dr-Reddy's
Bosentan
Bosentan Dr Reddy's48

Bosvate41
Botox
Botulism antitoxin
Bplex
Breo Ellipta
Brevinor 1/28 58
Bricanyl Turbuhaler209
Bridion 102
Brilinta32
Brimonidine tartrate218
Brimonidine tartrate with
timolol 218
Brinzolamide217
Bromocriptine 104
Budesonide
Alimentary5
Respiratory
Budesonide with eformoterol
Bumetanide
Bupafen
Bupivacaine hydrochloride106
Bupivacaine hydrochloride with
adrenaline 106
Bupivacaine hydrochloride with
fentanyl 107
Bupivacaine hydrochloride with
glucose
Buprenorphine Naloxone BNM 126
Buprenorphine with naloxone
Bupropion hydrochloride
Burinex
Buscopan
Buserelin
Buspirone hydrochloride
Busulfan 129 - C -
Cabergoline65
Caffeine
Caffeine citrate
Calamine53
Calcipotriol56
Calcitonin62
Calcitriol22
Calcitriol-AFT22
Calcium carbonate5, 17
Calcium Channel Blockers42
Calcium chloride
Calcium folinate 145
Calcium Folinate Ebewe
Calcium Folinate Sandoz
Calcium gluconate
Blood
Dermatological
Calaium Hamaaataala
Calcium Homeostasis
Calcium polystyrene sulphonate
Calcium Resonium

Candesartan cilexetil	- 20
Candestar	
Capecitabine	130
Capercit	130
Capoten	38
Capsaicin	
Musculoskeletal	103
Nervous	108
Captopril	
Carbachol	
Carbamazepine	
Carbasorb-X	
Carbimazole	221
Carbomer	218
Carboplatin	137
Carboplatin Ebewe	
Carboprost trometamol	59
Carboxymethylcellulose	
Alimentary	19
Extemporaneously Compounded	
Preparations	228
Cardinol LA	. 42
CareSens Dual	257
Caresens N	
Caresens N POP	257
CareSens N Premier	257
CareSens PRO	
Carmellose sodium with pectin and	201
adatina	
gelatine	40
Alimentary	. 19
Alimentary Sensory	218
Alimentary Sensory Carmustine	218 129
Älimentary Sensory Carmustine Carvedilol	218 129 41
Alimentary Sensory Carmustine	218 129 41
Älimentary Sensory Carmustine Carvedilol Carvedilol Sandoz	218 129 41 41
Älimentary Sensory Carmustine Carvedilol Carvedilol Sandoz Caspofungin	218 129 41 41 81
Älimentary Sensory Carmustine Carvedilol Carvedilol Sandoz Caspofungin Catapres	218 129 41 41 81 43
Alimentary Sensory Carmustine Carvedilol Carvedilol Sandoz Caspofungin Catapres Ceenu	218 129 41 41 81 43 129
Älimentary Sensory Carmustine Carvedilol Carvedilol Sandoz Caspofungin Catapres Ceenu Cefaclor	218 129 41 41 81 43 129 73
Alimentary	218 129 41 41 81 43 129 73 73
Alimentary Sensory Carmustine Carvedilol. Carvedilol Sandoz Caspofungin Catapres Ceenu Cefalor Cefalexin Sandoz	218 129 41 41 43 129 73 73 73
Alimentary Sensory Carmustine Carvedilol Carvedilol Sandoz Caspofungin Catapres Ceenu Cefaclor Cefalexin Cefalexin Cefalexin Cefalexin	218 129 41 41 43 129 73 73 73 73
Alimentary Sensory Carmustine Carvedilol Carvedilol Sandoz Caspofungin Catapres Ceenu Cefaclor Cefalexin Cefalexin Cefalezolin Cefapime	218 129 41 41 43 129 73 73 73 73 73
Alimentary Sensory Carmustine Carvedilol Carvedilol Sandoz Caspofungin Catapres Cefaclor Cefalexin Cefazolin Cefepime Cefepime-AFT	218 129 41 41 43 129 73 73 73 73 73 73
Alimentary	218 129 41 43 129 73 73 73 73 73 73 73 73
Alimentary	218 129 41 41 43 129 73 73 73 73 73 73 73
Alimentary	218 129 41 41 43 129 73 73 73 73 73 73 73 73 73
Alimentary	218 129 41 41 43 129 73 73 73 73 73 73 73 73 73 73 73
Alimentary	218 129 41 43 129 73 73 73 73 73 73 73 73 73 73 73 73 73 73 73
Alimentary	218 129 41 41 81 129 73
Alimentary Sensory Carmustine Carvedilol Carvedilol Sandoz Caspofungin Catapres Ceenu Cefaclor Cefalexin Cefalexin Sandoz Cefaclor Cefalexin Sandoz Cefapime Cefepime Cefotaxime Cefotaxime Cefotaxime Cefotaxine Sandoz Cefotaxime Cefotaxime Cefotaxime Cefotaxime Cefotaxime Ceftaroline fosamil. Ceftaroline fosamil. Ceftaroline Mylan	218 129 41 41 81 129 73
Alimentary Sensory Carmustine Carvedilol Carvedilol Sandoz Caspofungin Catapres Ceenu Cefaclor Cefalexin Cefalexin Cefalexin Cefapime Cefotaxime Ceftazidime Ceftazidime Ceftazidime Ceftazidime Ceftazidime Ceftazidime Ceftazidime Ceftazidime Ceftazidime	218 129 41 41 81 73
Alimentary Sensory Carmustine Carvedilol Carvedilol Sandoz Caspofungin Catapres Ceenu Cefaclor Cefalexin Cefalexin Cefepime Cefepime Cefotaxime Ceftazidime	218 129 41 41 43 129 73
Alimentary Sensory Carmustine Carvedilol Carvedilol Sandoz Caspofungin Catapres Ceenu Cefaclor Cefalexin Cefalexin Cefepime Cefepime Cefotaxime Ceftaxidime Ceftaxidime Ceftaxidime Ceftaxidime Ceftaxidime Ceftaxione	218 129 41 41 43 129 73
Alimentary	218 129 41 41 43 129 73
Alimentary Sensory Carmustine Carvedilol Carvedilol Sandoz Caspofungin Catapres Ceenu Cefaclor Cefalexin Cefalexin Cefepime Cefepime Cefotaxime Ceftaxidime Ceftaxidime Ceftaxidime Ceftaxidime Ceftaxidime Ceftaxione	218 129 41 41 43 129 73

Celecoxib Pfizer10)2
Celiprolol	1
CellCept20)3
Celol	
Centrally-Acting Agents	3
Cephalexin ABM	′ 3
Cetirizine hydrochloride)6
Cetomacrogol	54
Cetomacrogol with glycerol	54
Cetrimide	
Cetuximab16	
Charcoal	21
Chemotherapeutic Agents 12	28
Chickenpox vaccine	
Chlorafast21	3
Chloral hydrate 12	
Chlorambucil12	
Chloramphenicol	
Infections	78
Sensory21	
Chlorhexidine	
Chlorhexidine gluconate	
Alimentary1	9
Extemporaneously Compounded	Č
Preparations	8
Genito-Urinary	
Chlorhexidine with	
cetrimide	6
Chlorhexidine with ethanol	
Chloroform	
Chloroquine phosphate	34
Chlorothiazide	14
Chlorpheniramine maleate	
Chlorpromazine hydrochloride	
Chlortalidone [Chlorthalidone]	14
Chlorthalidone	
Choice Load 375	
Choice TT380 Short	39
Choice TT380 Standard	
Cholestyramine	
Choline salicylate with cetalkonium	
chloride 1	q
Choriogonadotropin alfa	
Ciclopirox olamine	
Ciclosporin14	
Cidofovir	20
Cilazapril	50
0112220111	28
Cilazanril with	38
Cilazapril with	
hydrochlorothiazide	38
hydrochlorothiazide	38 76
hydrochlorothiazide	38 76 76
hydrochlorothiazide	38 76 76 .8 52 7

Ciprofloxacin
Infections77
Sensory213
Ciprofloxacin Teva213
Ciprofloxacin with
hydrocortisone 213
Ciproxin HC Otic213
Circadin
Cisplatin137
Citalopram hydrobromide 112
Citanest
Citrate sodium
Citric acid
Citric acid with magnesium oxide and
sodium picosulfate 12
Citric acid with sodium
bicarbonate
Cladribine
Clarithromycin
Clexane
Clexane Forte
Clindamycin
Clinect
Clinicians Multivit & Mineral
Boost
Clinicians Renal Vit
Clobazam
Clobetasol propionate
Clobetasone butyrate
Clofazimine
Clomazol
Dermatological
Genito-Urinary
Clomifene citrate
Clomipramine hydrochloride
Clonazepam 113, 121
Clonidine
Clonidine BNM
Clonidine hydrochloride
Clopidogrel
Clopine
Clopixol
Clostridium botulinum type A
toxin
Clotrimazole
Dermatological
-
Genito-Urinary58 Clove oil228
Clozapine
Clozaril
Co-trimoxazoie
Coal tar with salicylic acid and
sulphur
Cocaine hydrochloride

	_
Cocaine hydrochloride with	
adrenaline1	07
Codeine phosphate	
Extemporaneously Compounded	
Preparations2	28
Nervous1	
Cogentin1	
Colaspase [L-asparaginase]1	
Colchicine1	02
Colecalciferol	00 00
Colestimethate	22 70
	10
Colestipol hydrochloride	45
Colgout1	
Colifoam	.6
Colistin sulphomethate	
[Colestimethate]	78
Colistin-Link	
Collodion flexible2	
Colloidal bismuth subcitrate	.8
Colofac	
Colony-Stimulating Factors	33
Coloxyl	
Colpocin-T	84
Compound electrolytes	37
Compound electrolytes with glucose	01
	~~
[Dextrose]	31
Compound hydroxybenzoate2	28
Compound sodium lactate	
[Hartmann's solution]	35
[Hartmann's solution]1	24
[Hartmann's solution]1 Concerta1 Condyline	24 57
[Hartmann's solution] Concerta	24 57 58
[Hartmann's solution] Concerta	24 57 58
[Hartmann's solution]	24 57 58 23
[Hartmann's solution]	24 57 58 23 22
[Hartmann's solution]	24 57 58 23 22
[Hartmann's solution]	24 57 58 23 22 55
[Hartmann's solution] Concerta	24 57 58 23 22 55 63
[Hartmann's solution] Concerta	24 57 58 23 22 55 63 66
[Hartmann's solution] Concerta 1 Condyline 1 Contraceptives 1 Contrast Media 2 Copaxone 1 Corticosteroids 1 Dermatological 1 Hormone Preparations 1 Costicotrorelin (ovine) 1	24 57 58 23 22 55 63 66 93
[Hartmann's solution] Concerta 1 Condyline 1 Contraceptives 1 Contract Media 2 Copaxone 1 Corticosteroids 1 Dermatological 1 Hormone Preparations 1 Coticotorrolin (ovine) 1 Cosentyx 1 Cosmegen 1	24 57 58 23 22 55 63 66 93 29
[Hartmann's solution] Concerta 1 Condyline Contraceptives Contrast Media 2 Copaxone 1 Corticosteroids Dermatological Hormone Preparations Corticotrorelin (ovine) Cosentyx 1 Cosmgen 1 Cough Suppressants 2	24 57 58 23 22 55 63 66 93 29 09
[Hartmann's solution] Concerta 1 Condyline Contraceptives Contrast Media 2 Copaxone 11 Corticosteroids Dermatological Hormone Preparations Costicotrorelin (ovine) Cossentyx 11 Cosugen 12 Cough Suppressants 22 Creon 10000	24 57 58 23 22 55 63 66 93 29 09 11
[Hartmann's solution] Concerta 1 Condyline Contraceptives Contrast Media 2 Copaxone 11 Corticosteroids Dermatological Hormone Preparations Corticotrorelin (ovine) Cossentyx 11 Cosuge n 12 Cough Suppressants 22 Creon 10000 Creon 25000	24 57 58 23 22 55 63 66 93 29 09 11
[Hartmann's solution] Concerta 1 Condyline Contraceptives Contract Media 2 Copaxone 1 Corticosteroids Dermatological Hormone Preparations Corticotrorelin (ovine) Cosentyx 1 Cosengen 1 Cough Suppressants 2 Creon 10000 Creon 25000	24 57 58 23 22 55 63 66 93 29 09 11 11
[Hartmann's solution]	24 57 58 23 22 55 63 66 93 29 09 11 11 11 53
[Hartmann's solution] Concerta 1 Condyline Contraceptives Contract Media 2 Copaxone 1 Corticosteroids Dermatological Hormone Preparations Corticotorrelin (ovine) Cosentyx 1 Cough Suppressants 2 Creon 10000 Creon 25000 Creon Micro Crystaderm	24 57 58 23 22 55 63 66 93 29 09 11 11 11 53 52
[Hartmann's solution] Concerta 1 Condyline Contraceptives Contrast Media 2 Copaxone 1 Corticosteroids Dermatological Hormone Preparations Corticotrorelin (ovine) Cosentyx 1 Cough Suppressants 2 Creon 10000 Creon Alcoud Creon Micro Crotamiton Crystaderm CT Plus+	24 57 58 23 22 55 63 66 93 29 09 11 11 11 53 52 24
[Hartmann's solution] Concerta 11 Condyline Contraceptives Contraceptives Contract Media 2 Copaxone 11 Corticosteroids Dermatological Hormone Preparations Corticotrorelin (ovine) Cosentyx 11 Cosmegen 12 Cough Suppressants 22 Creon 10000 Creon 025000 Creon Micro Crotamiton Crystaderm CT Plus+ 22 Cubicin	24 57 58 22 55 63 66 93 29 09 11 11 53 52 24 78
[Hartmann's solution] Concerta 1 Condyline Contraceptives Contrast Media 2 Copaxone 1 Corticosteroids Dermatological Hormone Preparations Corticotrorelin (ovine) Cosentyx 1 Cough Suppressants 2 Creon 10000 Creon Alcoud Creon Micro Crotamiton Crystaderm CT Plus+	24 57 58 22 55 63 66 93 29 09 11 11 53 52 24 78
[Hartmann's solution] Concerta 11 Condyline Contraceptives Contraceptives Contract Media 2 Copaxone 11 Corticosteroids Dermatological Hormone Preparations Corticotrorelin (ovine) Cosentyx 11 Cosmegen 12 Cough Suppressants 22 Creon 10000 Creon 025000 Creon Micro Crotamiton Crystaderm CT Plus+ 22 Cubicin	24 57 58 23 22 55 63 66 93 29 09 11 11 11 53 52 24 78 76
[Hartmann's solution] Concerta 11 Condyline Contraceptives Contraceptives Contrast Media 2 Copaxone 11 Corticosteroids Dermatological Hormone Preparations Corticotrorelin (ovine) Cosentyx 11 Cosnegen 12 Cough Suppressants 22 Creon 10000 Creon 25000 Creon Micro Crotamiton Crystaderm CT Plus+ 2 Cubicin Curam Curosurf	24 57 58 23 22 55 63 66 93 29 09 11 11 53 29 09 11 11 53 24 78 76 11
[Hartmann's solution] Concerta 1 Condyline Contraceptives Contrast Media 2 Copaxone 1 Corticosteroids Dermatological Hormone Preparations Corticotrorelin (ovine) Cosentyx 1 Cough Suppressants 2 Creon 10000 Creon Alcro Crystaderm CT Plus+ Curosurf Quram Curosurf 2 Cvite	24 57 58 23 22 55 63 66 93 29 09 11 11 53 24 78 76 11 22
[Hartmann's solution] Concerta 1 Condyline Contraceptives Contrast Media 2 Copaxone 1 Corticosteroids Dermatological Hormone Preparations Corticotrorelin (ovine) Cosentyx 1 Cogn Suppressants 2 Creon 10000 Creon Micro Crotamiton Crystaderm CT Plus+ Quosurf Quosurf Quosurf Quosurf Quosurf Quosurf 1	24 57 58 22 55 63 69 29 09 11 11 52 24 78 76 11 22 77
[Hartmann's solution] Concerta 1 Condyline Contraceptives Contraceptives Contrast Media 2 Copaxone 1 Corticosteroids Dermatological Hormone Preparations Costicotrorelin (ovine) Cosentyx 1 Cosengen 1 Cough Suppressants 2 Creon 10000 Creon Aicro Crotamiton Crystaderm CT Plus+ 2 Cubicin Curam Curosurf 2 Cvite Cyclizine hydrochloride 1 Cyclizine lactate	24 57 58 22 55 66 69 29 09 11 11 52 24 78 76 11 22 17
[Hartmann's solution] Concerta 1 Condyline Contraceptives Contrast Media 2 Copaxone 1 Corticosteroids Dermatological Hormone Preparations Corticotrorelin (ovine) Cosentyx 1 Cosentyx 1 Cosentyx 1 Cogs Supressants 2 Creon 10000 Creon 25000 Creon Micro Crotamiton Crystaderm CT Plus+ 2 Cuoin Curam Curosurf 2 Cvite Cyclizine hydrochloride 1 Cyclizine lactate 1 Cyclogyl	24 57 58 22 55 66 69 29 11 11 53 24 76 11 22 77 11 22 17
[Hartmann's solution] Concerta 1 Condyline Contraceptives Contraceptives Contrast Media 2 Copaxone 1 Corticosteroids Dermatological Hormone Preparations Costicotrorelin (ovine) Cosentyx 1 Cosengen 1 Cough Suppressants 2 Creon 10000 Creon Alcro Crotamiton Crystaderm CT Plus+ 2 Cubicin Curam Curosurf 2 Cvite Cyclizine hydrochloride 1 Cyclizine lactate	24457785823222555836669322990991111111111111111111111111111111

Cycloserine82
Cymevene
Cyproheptadine hydrochloride206
Cyproterone acetate
Cyprotorono acotato with
ethinyloestradiol
Cystadane
Cysteamine hydrochloride
Cytarabine
Cytotec
- D -
D-Penamine
Dabigatran
Dacarbazine
Dactinomycin [Actinomycin D]
Daivobet
Daivonex
Dalacin C
Danaparoid
Danazol
Dantrium 101
Dantrium IV 101
Dantrolene 101
Daonil10
Dapa-Tabs45
Dapsone82
Daptomycin78
Darunavir87
Dasatinib138
Daunorubicin 129
DBL Acetylcysteine220
DBL Adrenaline47
DBL Amikacin72
DBL Aminophylline211
DBL Bleomycin Sulfate129
DBL Cefotaxime73
DBL Cisplatin137
DBL Dacarbazine 132
DBL Desferrioxamine Mesylate for Inj
BP
DBL Docetaxel144
DBL Ergometrine59
DBL Gentamicin
DBL Leucovorin Calcium 145
DBL Methotrexate Onco-Vial
DBL Morphine Sulphate 110
DBL Naloxone Hydrochloride
DBL Octreotide
DBL Pethidine Hydrochloride
DBL Vincristine Sulfate
De-Worm
Decongestants
Decongestants and
Antiallergics
Decozol
Deferasirox

Deferiprone221
Defibrotide
Definity225
Demeclocycline hydrochloride78
Denosumab97
Deolate
Deoxycoformycin135
Depo-Medrol64
Depo-Provera59
Depo-Testosterone
Deprim
Dermol
Desferrioxamine mesilate
Desflurane 105
Desmopressin acetate71
Desmopressin-PH&T71
Dexamethasone
Hormone Preparations63
Sensory
Dexamethasone phosphate63
Dexamethasone Phosphate
Panpharma
Dexamethasone with framycetin and
gramicidin
Dexamethasone with neomycin
sulphate and polymyxin B
sulphate
Dexamethasone with
tobramycin
Dexamfetamine sulfate
Dexmedetomidine
Dexmedetomidine-Teva
Dexmethsone
Dexrazoxane
Dextrazoxane
Alimentary9
Blood
Extemporaneously Compounded
Preparations
Dextrose with sodium citrate and
citric acid [Acid Citrate Dextrose
A]
DHC Continus
Diabetes
Diacomit
Diagnostic Agents
Vaccines
Various
Diagnostic and Surgical
Preparations
Diamide Relief
Diamox
Diatrizoate meglumine with sodium
amidotrizoate 223
Diatrizoate sodium
Diazepam

Diazoxide	
Alimentary	9
Cardiovascular	48
Dichlorobenzyl alcohol with	
amylmetacresol	. 19
Diclofenac Sandoz	
Diclofenac sodium	
Musculoskeletal	102
Sensory	
Dicobalt edetate	
Diflucan	
Diflucortolone valerate	
Digestives Including Enzymes	
Digoxin	
Digoxin immune Fab	
Dihydrocodeine tartrate	
Dihydroergotamine mesylate	110
Diltiazem hydrochloride	
Dilzem	
Dimercaprol	
Dimercaptosuccinic acid	
Dimethicone	
Dimethyl fumarate	121
Dimethyl sulfoxide	226
Dinoprostone	
Dipentum	
Diphemanil metilsulfate	5/
Diphenoxylate hydrochloride with	_
atropine sulphate	5
Diphtheria antitoxin	220
Diphtheria, tetanus and pertussis	
vaccine	248
Diphtheria, tetanus, pertussis and	
polio vaccine	247
Diphtheria, tetanus, pertussis, polio,	
hepatitis B and haemophilus	
influenzae type B vaccine	247
Diprosone	
Dipyridamole	31
Disodium edetate	216
Disodium hydrogen phosphate with	
sodium dihydrogen	
phosphate	228
Disopyramide phosphate	40
Disulfiram	
Dithranol	228
Diuretics	43
Dobutamine	47
Dobutamine-hameln	47
Docetaxel	144
Docusate sodium	
Alimentary	12
Sensory	219
Docusate sodium with	
sennosides	12
Dolutegravir	88

Domperidone 1	17
Donepezil hydrochloride1	25
Donepezil-Rex1	
Dopamine hydrochloride	47
Dornase alfa	
Dortimopt	
Dorzolamide2	
Dorzolamide with timolol2	17
Dostinex	65
Dosulepin [Dothiepin]	00
hydrochloride 1	10
nyurochionue	12
Dosulepin Mylan 1	
Dotarem2	
Dothiepin1	
Doxapram2	
Doxazosin	39
Doxepin hydrochloride1	
Doxine	
Doxorubicin Ebewe1	29
Doxorubicin hydrochloride1	
Doxycycline	78
DP Lotn HC	55
DP-Allopurinol1	
Dr Reddy's Omeprazole	. 8
Droleptan1	17
Droperidol1	
Drugs Affecting Bone	
Metabolism	95
Dual blood dlucose and blood ketone	
Dual blood glucose and blood ketone	57
diagnostic test meter 2	
diagnostic test meter 2 Duolin	06
diagnostic test meter	06 10
diagnostic test meter	06 10 16
diagnostic test meter	06 10 16 46
diagnostic test meter	06 10 16 46 03
diagnostic test meter	06 10 16 46 03
diagnostic test meter 2 Duolin 2 DuoResp Spiromax 2 Duovisc 2 Duride 2 Dynastat 1 Dysport 1	06 10 16 46 03 01
diagnostic test meter 2 Duolin 2 DuoResp Spiromax 2 Duvisc 2 Duride 2 Dynastat 1 Dysport 1 - E - e-chamber La Grande 2 2	06 10 16 46 03 01 57
diagnostic test meter 2 Duolin 2 DuoResp Spiromax 2 Duvisc 2 Duride 2 Dynastat 1 Dysport 1 - E - - e-chamber La Grande 2 e-chamber Mask 2	06 10 16 46 03 01 57 57
diagnostic test meter 2 Duolin 2 DuoResp Spiromax 2 Duovisc 2 Duride 2 Dynastat 1 Dysport 1 e-chamber La Grande 2 e-chamber Mask 2 e-chamber Turbo 2	06 10 16 46 03 01 57 57 57
diagnostic test meter 2 Duolin 2 DuoResp Spiromax 2 Duovisc 2 Duride 2 Dynastat 1 Dysport 1 e-chamber La Grande 2 e-chamber Turbo 2 E-Mycin 2	06 10 16 46 03 01 57 57 57 75
diagnostic test meter 2 Duolin 2 DuoResp Spiromax 2 Duovisc 2 Duride 2 Dynastat 1 Dysport 1 e-chamber La Grande 2 e-chamber Turbo 2 E-Mycin 2 E-Mycin 2	06 10 16 46 03 01 57 57 57 75 24
diagnostic test meter 2 Duolin 2 DuoResp Spiromax 2 Duovisc 2 Duride 2 Dynastat 1 Dysport 1 e-chamber La Grande 2 e-chamber Turbo 2 E-Mycin 2 E-Y-Cat Dry 2 E-Z-Gas II 2	06 10 16 46 03 01 57 57 57 75 24 24
diagnostic test meter 2 Duolin 2 DuoResp Spiromax 2 Duovisc 2 Duride 2 Dynastat 1 Dysport 1 - E - - e-chamber La Grande 2 e-chamber Turbo 2 E-Mycin 2 E-Z-Cat Dry 2 E-Z-Paste 2	06 10 16 46 03 01 57 57 57 75 24 24 24
diagnostic test meter 2 Duolin 2 DuoResp Spiromax 2 Duvisc 2 Duride 2 Dynastat 1 Dysport 1 - E - - e-chamber La Grande 2 e-chamber Mask 2 E-Z-Cat Dry 2 E-Z-Gas II 2 E-Z-Paste 2 Econazole nitrate 2	06 10 16 46 03 01 57 57 57 75 24 24 24 24 52
diagnostic test meter 2 Duolin 2 DuoResp Spiromax 2 Duvisc 2 Duride 2 Dynastat 1 Dysport 1 - E - - e-chamber La Grande 2 e-chamber Mask 2 E-Z-Cat Dry 2 E-Z-Gas II 2 E-Z-Paste 2 Econazole nitrate 2 Edrophonium chloride 2	06 10 46 03 01 57 57 57 57 24 24 24 24 52 95
diagnostic test meter 2 Duolin 2 DuoResp Spiromax 2 Duvisc 2 Duride 2 Dynastat 1 Dysport 1 -E - - e-chamber La Grande 2 e-chamber Mask 2 E-Mycin 2 E-Z-Cat Dry 2 E-Z-Gas II 2 Econazole nitrate 2 Edrophonium chloride 2	06 10 46 03 01 57 57 57 57 24 24 24 24 52 95
diagnostic test meter 2 Duolin 2 DuoResp Spiromax 2 Duvisc 2 Duride 2 Dynastat 1 Dysport 1 - E - - e-chamber La Grande 2 e-chamber Mask 2 e-chamber Turbo 2 E-Mycin 2 E-Z-Gas II 2 E-Z-Paste 2 Econazole nitrate 2 Edrophonium chloride 2 Efavirenz with emtricitabine and	06 10 16 46 03 01 57 57 75 24 24 24 24 25 85
diagnostic test meter 2 Duolin 2 DuoResp Spiromax 2 Duvisc 2 Duride 2 Dynastat 1 Dysport 1 - E - - e-chamber La Grande 2 e-chamber Mask 2 e-chamber Turbo 2 E-Mycin 2 E-Z-Gas II 2 E-Z-Paste 2 Econazole nitrate 2 Edrophonium chloride 2 Efavirenz with emtricitabine and tenofovir disoproxil	06 10 16 46 03 01 57 57 57 75 24 24 24 24 25 85 85 86
diagnostic test meter 2 Duolin 2 DuoResp Spiromax 2 Duovisc 2 Durde 2 Dynastat 1 Dysport 1 e-chamber La Grande 2 e-chamber Mask 2 e-chamber Turbo 2 E-Mycin 2 E-Z-Cat Dry 2 E-Z-Gas II 2 E-Z-Paste 2 Edrophonium chloride 2 Efavirenz 2 Efavirenz <t< td=""><td>06 10 16 46 03 01 57 57 75 24 24 24 24 52 95 85 86 32</td></t<>	06 10 16 46 03 01 57 57 75 24 24 24 24 52 95 85 86 32
diagnostic test meter 2 Duolin 2 DuoResp Spiromax 2 Duovisc 2 Duride 2 Dynsatat 1 Dysport 1 - E - - e-chamber La Grande 2 e-chamber Turbo 2 E-Aycin 2 E-Cat Dry 2 E-Z-Gas II 2 E-Z-Paste 2 Edrophonium chloride 2 Efavirenz 2 Efavirenz 2 Efavirenz 2 Efavirenz with emtricitabine and tenofovir disoproxil. 2 Effient 2 Efformoterol fumarate 2	06 10 16 46 03 01 57 57 57 57 24 24 24 52 95 85 86 32 10
diagnostic test meter 2 Duolin 2 DuoResp Spiromax 2 Duovisc 2 Durde 2 Dynastat 1 Dysport 1 e-chamber La Grande 2 e-chamber Mask 2 e-chamber Turbo 2 E-Mycin 2 E-Z-Cat Dry 2 E-Z-Gas II 2 E-Z-Paste 2 Edrophonium chloride 2 Efavirenz 2 Efavirenz <t< td=""><td>06 10 16 46 03 01 57 57 57 57 24 24 24 52 95 85 86 32 10</td></t<>	06 10 16 46 03 01 57 57 57 57 24 24 24 52 95 85 86 32 10
diagnostic test meter 2 Duolin 2 DuoResp Spiromax 2 Duovisc 2 Duride 2 Dynastat 1 Dysport 1 - E - - e-chamber La Grande 2 e-chamber Turbo 2 E-Aycin 2 E-Cat Dry 2 E-Z-Gas II 2 E-Z-Paste 2 Edrophonium chloride 2 Efavirenz Efavirenz Effeint 2 Efformoterol fumarate 2 Eformoterol fumarate 2 Eformoterol fumarate 2 Eformoterol fumarate 2	06 10 16 46 03 01 57 57 57 57 24 24 24 52 95 85 86 32 10
diagnostic test meter 2 Duolin 2 DuoResp Spiromax 2 Duovisc 2 Duride 2 Dynastat 1 Dysport 1 e-chamber La Grande 2 e-chamber Turbo 2 E-Z-Gat Dry 2 E-Z-Gas II 2 E-Z-Paste 2 Edrophonium chloride 2 Efavirenz 2 Efavirenz 2 Eformoterol fumarate 2 Eformoterol fumarate 2 Eformoterol fumarate 2 Eftrenonacog alfa [Recombinant 2	06 10 16 46 03 01 57 57 57 57 24 24 24 52 95 85 86 32 10 10
diagnostic test meter 2 Duolin 2 DuoResp Spiromax 2 Duovisc 2 Duride 2 Dynastat 1 Dysport 1 - E - - e-chamber La Grande 2 e-chamber Turbo 2 E-Aycin 2 E-Cat Dry 2 E-Z-Gas II 2 E-Z-Paste 2 Edrophonium chloride 2 Efavirenz Efavirenz Effeint 2 Efformoterol fumarate 2 Eformoterol fumarate 2 Eformoterol fumarate 2 Eformoterol fumarate 2	06 10 16 46 03 01 57 57 57 24 24 24 25 95 85 86 32 10 10 28

Elecare (Unflavoured)	.240
Elecare (Vanilla)	.240
Elecare LCP (Unflavoured)	.240
Electral.	37
Electrolytes	
Elelyso	
Elocon	
Elocon Alcohol Free	
Eltrombopag	00
Emend Tri-Pack	20
EMLA	100
Emtricitabine	
Emtricitabine with tenofovir	00
	~~~
disoproxil	90
Emtriva	86
Emulsifying ointment	
Emulsifying Ointment ADE	
Enalapril maleate	38
Enbrel	
Endocrine Therapy	
Endoxan	
Engerix-B	
Enlafax XR	
Enoxaparin sodium	
Enstilar	56
Ensure (Chocolate)	.246
Ensure (Vanilla)	.246
Ensure Plus (Banana)	.246
Ensure Plus (Chocolate)	.246
Ensure Plus (Fruit of the	
Forest)	. 246
Ensure Plus (Vanilla)	.246
Ensure Plus HN	.245
Ensure Plus HN RTH	
Entacapone	
Entapone	
Entecavir	
Entecavir Sandoz	
Entresto 24/26	
Entresto 49/51	
Entresto 97/103	39
Enzymes	
Ephedrine	47
Epilim IV	
Epirubicin Ebewe	
Epirubicin hydrochloride	129
Eplerenone	. 123
Epoetin alfa	
Epoetin beta	24 25
Epoprostenol	
Eptacog alfa [Recombinant factor	วา
VIIa]	20
Eptifibatide	
Erbitux Ergometrine maleate	
3	
Erlotinib	. 138

<b>-</b> .	
Ertapenem	(2
Erythrocin IV7	75
Erythromycin (as	
ethylsuccinate)7	75
Erythromycin (as lactobionate)	
Erythromycin (as stearate)	0
Esbriet 20	
Escitalopram11	
Escitalopram-Apotex 11	12
Esmolol hydrochloride	11
Essential Prednisolone	
Estradot	
Etanercept	
Ethambutol hydrochloride	
Ethanol 22	
Ethanol with glucose22	20
Ethanol, dehydrated 22	20
Ethics Aspirin10	าต
Ethics Aspirin EC	21
Ethics Lisinopril	
Ethinyloestradiol6	55
Ethinyloestradiol with	
desogestrel	58
Ethinvloestradiol with	
levonorgestrel	58
Ethinyloestradiol with	~
norethisterone	:0
Ethosuximide11	
Ethyl chloride 10	
Etomidate 10	)5
Etopophos 13	33
Etoposide13	32
Etoposide (as phosphate)13	
Etoricoxib	10 10
Etravirine	
Everet	
Everolimus20	
Evista	
Exemestane14	18
Exjade22	21
Extemporaneously Compounded	
Preparations	2 R
Eylea	
Ezetimibe	
Ezetimibe Sandoz	
Ezetimibe with simvastatin	16
- F -	
Factor eight inhibitor bypassing	
fraction	28
Famotidine	
Faslodex14	
Febuxostat10	
FEIBA NF	
Felo 10 ER	
Felo 5 ER	12
Felodipine	12

Fentanyl110
Fentanyl Sandoz110
Ferinject18
Ferodan
Ferric carboxymaltose18
Ferrie subsulfete
Ferric subsulfate
Ferriprox221
Ferro-F-Tabs
Ferro-tab18
Ferrograd18
Ferrosig
Ferraria functional 10
Ferrous fumarate
Ferrous fumarate with folic acid18
Ferrous gluconate with ascorbic
acid18
Ferrous sulfate18
Ferrous sulphate
Ferrous sulphate with ascorbic
acid18
Fexofenadine hydrochloride206
Filgrastim
Finasteride
Fingolimod121
Firazyr205
Flagyl84
FlagyI-S84
Flamazine
Flecainide acetate40
Flecalitide acetate
Flecainide BNM40
Flecainide BNM40 Flecainide Controlled Release
Flecainide BNM
Flecainide BNM       40         Flecainide Controlled Release       40         Fleet Phosphate Enema       13         Flixonase Hayfever & Allergy       206         Flixotide       209         Flixotide Accuhaler       209
Flecainide BNM       40         Flecainide Controlled Release       40         Teva       40         Fleet Phosphate Enema       13         Flixonase Hayfever & Allergy       206         Flixotide       209         Flixotide Accuhaler       209         Florinef       63
Flecainide BNM       40         Flecainide Controlled Release       40         Fleet Phosphate Enema       13         Flixonase Hayfever & Allergy       206         Flixotide       209         Flixotide Accuhaler       209
Flecainide BNM       40         Flecainide Controlled Release       40         Teva       40         Fleet Phosphate Enema       13         Flixonase Hayfever & Allergy       206         Flixotide       209         Flixotide Accuhaler       209         Florinef       63
Flecainide BNM       40         Flecainide Controlled Release       40         Teva       40         Fleet Phosphate Enema       13         Flixonase Hayfever & Allergy       206         Flixotide       209         Florinef       63         Fluanxol       119         Flucil       76
Flecainide BNM       40         Flecainide Controlled Release       40         Fleet Phosphate Enema       13         Flixotide       206         Flixotide Accuhaler       209         Florinef       63         Fluanxol       119         Flucil       76
Flecainide BNM       40         Flecainide Controlled Release       7         Teva.       40         Fleet Phosphate Enema       13         Flixonase Hayfever & Allergy       206         Flixotide       209         Florinef.       63         Fluanxol       119         Flucioxacillin       76         Flucloxin       76
Flecainide BNM       40         Flecainide Controlled Release       40         Teva       40         Fleet Phosphate Enema       13         Flixonase Hayfever & Allergy       206         Flixotide       209         Florinef       63         Fluanxol       119         Flucil       76         Flucloxacillin       76         Fluconazole       80
Flecainide BNM       40         Flecainide Controlled Release       40         Teva       40         Fleet Phosphate Enema       13         Flixonase Hayfever & Allergy       206         Flixotide       209         Florinef       63         Fluanxol       119         Flucina       76         Flucoxacillin       76         Fluconazole       80         Fluconazole       80
Flecainide BNM       40         Flecainide Controlled Release       40         Fleet Phosphate Enema       13         Flixonase Hayfever & Allergy       206         Flixotide       209         Florinef       63         Fluanxol       119         Flucil       76         Fluconazole       80         Fluconazole       80         Fluconazole       80         Flucytosine       82
Flecainide BNM       40         Flecainide Controlled Release       40         Fleet Phosphate Enema       13         Flixonase Hayfever & Allergy       206         Flixotide       209         Florinef       63         Fluanxol       119         Flucil       76         Fluconazole       80         Fluconazole       80         Fluconazole       80         Flucytosine       82
Flecainide BNM         40           Flecainide Controlled Release         40           Teva.         40           Fleet Phosphate Enema         13           Flixonase Hayfever & Allergy         206           Flixotide         209           Flixotide Accuhaler         209           Florinef         63           Fluanxol         119           Flucil         76           Flucloxacillin         76           Fluconazole         80           Flucytosine         82           Fludara Oral         130
Flecainide BNM       40         Flecainide Controlled Release       40         Fleet Phosphate Enema       13         Flixonase Hayfever & Allergy       206         Flixotide       209         Flixotide Accuhaler       209         Florinef       63         Fluanxol       119         Flucil       76         Flucoxacillin       76         Fluconazole       80         Flucytosine       82         Fludara Oral       130         Fludarabine Ebewe       130
Flecainide BNM         40           Flecainide Controlled Release         40           Fleet Phosphate Enema         13           Flixonase Hayfever & Allergy         206           Flixotide         209           Flixotide Accuhaler         209           Florinef         63           Fluanxol         119           Flucil         76           Flucoxacillin         76           Fluconazole         80           Fluconazole         80           Fluconazole         82           Fludara Oral         130           Fludarabine Ebewe         130           Fludarabine phosphate         130
Flecainide BNM       40         Flecainide Controlled Release       7         Teva       40         Fleet Phosphate Enema       13         Flixonase Hayfever & Allergy       206         Flixotide       209         Flixotide Accuhaler       209         Florinef.       63         Fluanxol       119         Flucil       76         Flucloxacillin       76         Fluconazole       80         Fluconazole-Claris       80         Fludara Oral       130         Fludarabine Ebewe       130         Fludarabine phosphate       130         Fludarocritisone acetate       63
Flecainide BNM       40         Flecainide Controlled Release       7         Teva       40         Fleet Phosphate Enema       13         Flixonase Hayfever & Allergy       206         Flixotide       209         Flixotide Accuhaler       209         Florinef.       63         Fluanxol       119         Flucil       76         Flucloxacillin       76         Fluconazole       80         Fluconazole-Claris       80         Fludara Oral       130         Fludarabine Ebewe       130         Fludarabine phosphate       130         Fludarabine acetate       63         Fludrocortisone acetate       63         Fluids and Electrolytes       34
Flecainide BNM       40         Flecainide Controlled Release       7         Teva       40         Fleet Phosphate Enema       13         Flixonase Hayfever & Allergy       206         Flixotide       209         Floixotide Accuhaler       209         Florinef.       63         Fluanxol       119         Flucil       76         Flucloxacillin       76         Fluconazole       80         Fluconazole-Claris       80         Fludara Oral       130         Fludarabine Ebewe       130         Fludarabine phosphate       130         Fludarocritisone acetate       63
Flecainide BNM       40         Flecainide Controlled Release       7eva         Teva       40         Fleet Phosphate Enema       13         Flixotide       209         Flixotide Accuhaler       209         Florinef.       63         Fluanxol       119         Flucil       76         Fluconazole       80         Fluconazole-Claris       80         Fludara Oral       130         Fludarabine Ebewe       130         Fludarabine phosphate       130         Fludarabine acetate       63         Fluidrachine and Electrolytes       34
Flecainide BNM       40         Flecainide Controlled Release       7eva.       40         Fleet Phosphate Enema       13         Flixonase Hayfever & Allergy       206         Flixotide       209         Flixotide Accuhaler       209         Florinef.       63         Fluanxol       119         Flucil       76         Fluconazole       80         Fluconazole-Claris       80         Fludara Oral       130         Fludarabine Ebewe       130         Fludrabine phosphate       130         Fludrabine acetate       63         Fluids and Electrolytes       34         Flumazenil       220
Flecainide BNM       40         Flecainide Controlled Release       Teva.       40         Fleet Phosphate Enema       13         Flixonase Hayfever & Allergy       206         Flixotide       209         Flixotide Accuhaler       209         Florinef.       63         Fluanxol       119         Fluci       76         Flucloxacillin       76         Fluconazole       80         Fluconazole       80         Fludara Oral       130         Fludarabine Ebewe       130         Fludarabine phosphate       130         Fludarabine phosphate       63         Fludarabine phosphate       130         Fludarabine phosphate       130         Fludarabine phosphate       330         Fludarabine phosphate       34         Flumatesone pivalate with       220         Flumatesone pivalate with       214
Flecainide BNM       40         Flecainide Controlled Release       7eva.       40         Fleet Phosphate Enema       13         Flixonase Hayfever & Allergy       206         Flixotide       209         Flixotide Accuhaler       209         Florinef.       63         Fluanxol       119         Flucioxacillin       76         Flucloxacillin       76         Fluconazole       80         Fluconazole       80         Flucata Oral       130         Fludara Dral       130         Fludarabine Ebewe       130         Fludarabine Ebewe       130         Fludarabine phosphate       130         Fludarabine phosphate       33         Fluanzenil       220         Fluidas and Electrolytes       34         Flumazenil       220         Fluentasone pivalate with       214         Fluocortolone caproate with       14
Flecainide BNM       40         Flecainide Controlled Release       Teva.       40         Fleet Phosphate Enema       13         Flixonase Hayfever & Allergy       206         Flixotide       209         Flixotide Accuhaler       209         Florinef.       63         Fluanxol       119         Flucinazole       80         Flucoxacillin       76         Fluconazole       80         Fluconazole       80         Flucytosine       82         Fludara Oral       130         Fludarabine Ebewe       130         Fludarabine Ebewe       130         Fludarabine Ebewe       34         Flumazenil       220         Fludarabine phosphate       32         Fludarabine phosphate       330         Fludarabine phosphate       34         Flumazenil       220         Flumatesone pivalate with       10         Cloquinol       214
Flecainide BNM       40         Flecainide Controlled Release       Teva.       40         Fleet Phosphate Enema       13         Flixonase Hayfever & Allergy       206         Flixotide       209         Flixotide Accuhaler       209         Florinef.       63         Fluanxol       119         Flucinazole       80         Flucoxacillin       76         Fluconazole       80         Fluconazole       80         Flucytosine       82         Fludara Oral       130         Fludarabine Ebewe       130         Fludarabine Ebewe       130         Fludarabine Ebewe       34         Flumazenil       220         Fludarabine phosphate       32         Fludarabine phosphate       330         Fludarabine phosphate       34         Flumazenil       220         Flumatesone pivalate with       10         Clioquinol       214         Fluocortolone caproate with       10         Fluocortolone pivalate and       7
Flecainide BNM       40         Flecainide Controlled Release       Teva.       40         Fleet Phosphate Enema       13         Flixonase Hayfever & Allergy       206         Flixotide       209         Flixotide Accuhaler       209         Florinef.       63         Fluanxol       119         Flucinazole       80         Flucoxacillin       76         Fluconazole       80         Fluconazole       80         Flucytosine       82         Fludara Oral       130         Fludarabine Ebewe       130         Fludarabine Ebewe       130         Fludarabine Ebewe       34         Flumazenil       220         Fludarabine phosphate       32         Fludarabine phosphate       330         Fludarabine phosphate       34         Flumazenil       220         Flumatesone pivalate with       10         Cloquinol       214

hydrochloride	215
Fluorescite	215
Fluorometholone	215
Fluorouracil	
Fluorouracil Ebewe	
Fluorouracil sodium	.57
Fluox	
Fluoxetine hydrochloride	
Flupenthixol decanoate	
Flutamide	
Flutamin	
Fluticasone	209
Fluticasone furoate with	
vilanterol	210
Fluticasone propionate	
Fluticasone with salmeterol	210
FML	215
Foban	. 52
Folic acid	.25
Fondaparinux sodium	
Food Modules	231
Food/Fluid Thickeners	233
Forteo	
Fortisip (Vanilla)	
Fosamax	.95
Fosamax Plus	.96
Foscarnet sodium	. 89
Fosfomycin	
Framycetin sulphate	
Fresenius Kabi	
Blood35	-36
Various	
Fresofol 1% MCT/LCT	106
Frusemide	.44
Frusemide-Claris	.44
Fucidin	.79
Fucithalmic	213
Fulvestrant	146
Fungilin	. 19
Furosemide [Frusemide]	.44
Fusidic acid	
Dermatological52	, <mark>56</mark>
Infections	
Sensory	213
- G -	
Gabapentin	114
Gacet	109
Gadobenic acid	
Gadobutrol	
Gadodiamide	224
Gadoteric acid	
Gadovist 1.0	
Gadoxetate disodium	
Galsulfase	
Galvumet	
Galvus	.11

Ganciclovir	. 89
Gardasil 9	252
Gastrodenol	8
Gastrografin	223
Gazyva	175
Gefitinib	
Gelatine, succinylated	.37
Gelofusine	
Gemcitabine	131
Gemcitabine Ebewe	131
Gemfibrozil	45
Genoptic	
Gentamicin sulphate	
Infections	72
Sensory	
Gestrinone	65
Gilenya	
Ginet	
Glatiramer acetate	
Glaucoma Preparations	122
Glecaprevir with pibrentasvir	00
Glibenclamide	.09
Gliclazide	
Gliolan	
Glipizide	
Glivec	
Glizide	
Glucagen Hypokit	9
Glucagon hydrochloride	9
Glucerna Select (Vanilla)	237
Glucerna Select RTH (Vanilla)	237
Glucobay	9
Glucose [Dextrose]	
Alimentary	9
Blood	. 35
Extemporaneously Compounded	
Preparations	228
Glucose with potassium chloride	. 35
Glucose with potassium chloride and	
sodium chloride	
Glucose with sodium chloride	. 35
Glucose with sucrose and	
fructose	9
Glycerin with sodium saccharin	
Glycerin with sucrose	229
Glycerol	
Alimentary	. 13
Extemporaneously Compounded	
Preparations	229
Glycerol with paraffin	.54
Glyceryl trinitrate	
Alimentary	7
Cardiovascular	.46
Glycine	
Glycopyrronium	206
Glycopyrronium bromide	7

Glycopyrronium with	
indacaterol	207
Glypressin	71
Gonadorelin	66
Goserelin	
Granisetron	
- H -	
Habitrol	127
Habitrol (Fruit)	127
Habitrol (Mint)	127
Haem arginate	15
Haemophilus influenzae type B	
vaccine	2/18
Haldol	120
Haldol Concentrate	120
Haloperidol Haloperidol decanoate	100
Hartmann's solution	
Harvoni	
Havrix	
Havrix Junior	
Healon	
Healon 5	
Healon GV	216
healthE Calamine Aqueous Cream BP	53
healthE Dimethicone 10%	
healthE Dimethicone 4% Lotion	
healthE Dimethicone 5%	52 53
healthE Dimethicone 5%	53
healthE Dimethicone 5% healthE Fatty Cream	53 54
healthE Dimethicone 5% healthE Fatty Cream healthE Glycerol BP Liquid	. 53 . 54 .229
healthE Dimethicone 5% healthE Fatty Cream healthE Glycerol BP Liquid healthE Urea Cream	53 54 .229 55
healthE Dimethicone 5% healthE Fatty Cream healthE Glycerol BP Liquid healthE Urea Cream Heparin sodium	53 54 .229 55 31
healthE Dimethicone 5% healthE Fatty Cream healthE Glycerol BP Liquid healthE Urea Cream Heparin sodium Heparinised saline	53 54 .229 55 31 31
healthE Dimethicone 5% healthE Fatty Cream healthE Glycerol BP Liquid healthE Urea Cream Heparin sodium Heparinised saline Heparon Junior	53 54 55 31 31 .238
healthE Dimethicone 5% healthE Fatty Cream healthE Glycerol BP Liquid healthE Urea Cream Heparin sodium Heparinised saline Heparon Junior Hepatitis A vaccine	53 54 55 31 31 .238
healthE Dimethicone 5% healthE Fatty Cream healthE Glycerol BP Liquid healthE Urea Cream Heparin sodium Heparinised saline Heparon Junior Hepatitis A vaccine Hepatitis B recombinant	53 54 .229 55 31 31 .238 .251
healthE Dimethicone 5% healthE Fatty Cream healthE Glycerol BP Liquid healthE Urea Cream Heparin sodium Heparinised saline Heparon Junior Hepatitis A vaccine Hepatitis B recombinant vaccine	53 54 55 31 31 .238 .251 251
healthE Dimethicone 5% healthE Fatty Cream healthE Glycerol BP Liquid healthE Urea Cream Heparin sodium Heparinised saline Heparon Junior Hepatitis A vaccine Hepatitis B recombinant vaccine Hepsera	53 54 229 55 31 31 .238 .251 88
healthE Dimethicone 5% healthE Fatty Cream healthE Glycerol BP Liquid healthE Urea Cream Heparinsed saline Heparinsed saline Heparon Junior Hepatitis A vaccine Hepatitis B recombinant vaccine Hepsera Herceptin	53 54 55 31 31 .238 .251 88 .198
healthE Dimethicone 5% healthE Fatty Cream healthE Glycerol BP Liquid healthE Urea Cream Heparin sodium Heparinised saline Heparon Junior Hepatitis A vaccine Hepatitis B recombinant vaccine Hepsera Herceptin Hiberix	53 54 229 55 31 238 251 251 88 198 248
healthE Dimethicone 5% healthE Fatty Cream healthE Glycerol BP Liquid healthE Urea Cream Heparin sodium Heparinised saline Heparinised saline Hiperinised saline Hiperinise	53 54 229 55 31 31 238 251 251 88 198 248 79
healthE Dimethicone 5% healthE Fatty Cream healthE Glycerol BP Liquid healthE Urea Cream Heparin sodium Heparinised saline Heparon Junior Hepatitis A vaccine Hepatitis B recombinant vaccine Hepsera Herceptin Hiberix Hiprex Histaclear	53 54 229 55 31 31 238 251 251 88 198 248 79 206
healthE Dimethicone 5% healthE Fatty Cream healthE Glycerol BP Liquid healthE Urea Cream Heparin sodium Heparinised saline Heparon Junior Heparon Junior Hepatitis A vaccine Hepatitis B recombinant vaccine Hepsera Herceptin Hiberix Hiprex Histaclear Histamine acid phosphate	53 54 229 55 31 31 238 251 251 88 198 248 79 206 225
healthE Dimethicone 5% healthE Fatty Cream healthE Glycerol BP Liquid healthE Urea Cream Heparin sodium Heparinised saline Heparon Junior Hepatitis A vaccine Hepatitis B recombinant vaccine Hepsera Herceptin Hiberix Histaclear Histamine acid phosphate Holoxan	53 54 229 55 31 238 251 251 88 198 248 79 206 225 129
healthE Dimethicone 5% healthE Fatty Cream healthE Glycerol BP Liquid healthE Urea Cream Heparin sodium Heparinised saline Heparon Junior Heparon Junior Hepatitis A vaccine Hepatitis B recombinant vaccine Hepsera Herceptin Hiberix Hiprex Histaclear Histamine acid phosphate	53 54 229 55 31 238 251 251 88 198 248 79 206 225 129
healthE Dimethicone 5% healthE Fatty Cream healthE Fatty Cream healthE Glycerol BP Liquid healthE Urea Cream Heparin sodium Heparin sodium Heparinised saline Heparon Junior Hepatitis A vaccine Hepatitis B recombinant vaccine Hepatitis B recombinant vaccine Hepatit	53 54 229 55 31 31 238 251 251 88 198 248 79 206 225 129 64 252
healthE Dimethicone 5% healthE Fatty Cream healthE Fatty Cream healthE Glycerol BP Liquid healthE Urea Cream Heparin sodium Heparin sodium Heparinised saline Heparon Junior Hepatitis A vaccine Hepatitis B recombinant vaccine Hepatitis B	53 54 229 55 31 238 251 251 88 198 248 79 206 2255 129 64 252 10
healthE Dimethicone 5% healthE Fatty Cream healthE Fatty Cream healthE Glycerol BP Liquid healthE Urea Cream Heparin sodium Heparinsed saline Heparinsed saline Hepar	53 54 229 55 31 238 251 251 88 248 248 248 225 129 64 252 04 252 10 10
healthE Dimethicone 5% healthE Fatty Cream healthE Glycerol BP Liquid healthE Urea Cream Heparin sodium Heparinised saline Heparinised saline Histaclear Histaclear Histaclear Hormone Replacement Therapy HPV Humalog Mix 25 Humalog Mix 25 Human papillomavirus (6, 11, 16, 18	53 54 229 55 31 238 251 251 88 248 248 248 225 129 64 252 04 252 10 10
healthE Dimethicone 5% healthE Fatty Cream healthE Glycerol BP Liquid healthE Urea Cream Heparin sodium Heparinised saline Heparinised saline Histaclear Histaclear Histaclear Hormone Replacement Therapy HPV Humalog Mix 25 Humalog Mix 25 Human papillomavirus (6, 11, 16, 18	53 54 229 55 31 238 251 251 88 248 248 248 225 129 64 252 04 252 10 10
healthE Dimethicone 5% healthE Fatty Cream healthE Fatty Cream healthE Glycerol BP Liquid healthE Urea Cream Heparin sodium Heparinsed saline Heparinsed saline Histaclear Histaclear Histaclear Histaclear Histaclear Hormone Replacement Therapy HPV Humalog Mix 25 Humalog Mix 25 Human papillomavirus (6, 11, 16, 18 31, 33, 45, 52 and 58) vaccine	53 54 .229 55 31 31 .238 .251 88 .251 88 .248 79 .206 .225 .129 64 .252 10 10
healthE Dimethicone 5% healthE Fatty Cream healthE Glycerol BP Liquid healthE Urea Cream Heparin sodium Heparinised saline Heparinised saline Histaclear Histaclear Histaclear Hormone Replacement Therapy HPV Humalog Mix 25 Humalog Mix 25 Human papillomavirus (6, 11, 16, 18	53 54 .229 55 31 .238 .251 88 .251 88 .248 79 .206 .225 .129 64 .252 10 10 10
healthE Dimethicone 5% healthE Fatty Cream healthE Fatty Cream healthE Glycerol BP Liquid healthE Urea Cream Heparin sodium Heparinsed saline Heparinsed saline Histaclear Histaclear Histaclear Histaclear Histaclear Hormone Replacement Therapy HPV Humalog Mix 25 Humalog Mix 25 Human papillomavirus (6, 11, 16, 18 31, 33, 45, 52 and 58) vaccine [HPV]	53 54 .229 55 31 .238 .251 88 .248 79 .206 .225 .129 64 .252 10 10 10 72

Hyaluronic acid
Alimentary20
Sensory
Hyaluronic acid with lidocaine
[lignocaine] 20
Hyaluronidase100
Hydralazine hydrochloride 48
Hydrea 133
Hydrocortisone
Dermatological55
Extemporaneously Compounded
Preparations229
Hormone Preparations64
Hydrocortisone (PSM)55
Hydrocortisone acetate
Alimentary6
Dermatological 55
Hydrocortisone acetate with
pramoxine hydrochloride 6
Hydrocortisone and paraffin liquid
and lanolin 55
Hydrocortisone butyrate55, 57
Hydrocortisone with miconazole56
Hydrocortisone with natamycin and
neomycin 56
Hydrogen peroxide52
Hydroxocobalamin
Alimentary21
Various220
hydroxycarbamide 133
Hydroxychloroquine
Hydroxyurea
[hydroxycarbamide] 133
Hygroton
Hylo-Fresh
Hyoscine butylbromide7
Hyoscine hydrobromide117
Hyperuricaemia and Antigout 100
Hypromellose216, 218
Hypromellose with dextran218
- I - Ibiamox76
Ibrance
Ibuprofen
Icatibant
Idarubicin hydrochloride
Idarucizumab27
Idursulfase
Ifosfamide
lkorel
lloprost
Imaging Agents
Imatinib mesilate
Imatinib-AFT140
140

Imigran	116
Impenem with cilastatin	72
Imipenem+Cilastatin RBX	72
Imipramine hydrochloride	112
Imiquimod	57
Immune Modulators	02
Immunosuppressants	
Impact Advanced Recovery	140
Impact Auvanceu Recovery	244
Imuran	203
Incruse Ellipta	
Indacaterol	
Indapamide	45
Indigo carmine	225
Indinavir	87
Indocyanine green	225
Indomethacin	103
Infanrix IPV	247
Infanrix-hexa	247
Infatrini	242
Infliximab	167
Influenza vaccine	252
Influvac Tetra	
(2020 formulation)	253
Inhaled Corticosteroids	209
Inspra	
Instillagel Lido	107
Insulin aspart	
Insulin aspart with insulin aspart	10
protamine	0
protarnine	<del>ع</del> ع 10
Insulin glargine	10
Insulin glulisine	10
Insulin isophane	
Insulin lispro	10
Insulin lispro with insulin lispro	
protamine	10
Insulin neutral	10
Insulin neutral with insulin	
isophane	10
Integrilin	31
Intelence	
Interferon alfa-2a	
Interferon alfa-2b	
Interferon beta-1-alpha	
Interferon beta-1-beta	122
Interferon gamma	92
Intra-uterine device	
	59
Invanz	59 72
Invanz Invega Sustenna	72
Invanz Invega Sustenna	72 120
Invanz Invega Sustenna Iodine	72 120 70
Invanz Invega Sustenna Iodine Iodine with ethanol	72 120 70 222
Invanz Invega Sustenna Iodine Iodine with ethanol Iodised oil	72 120 70 222 223
Invanz Invega Sustenna Iodine Iodine with ethanol Iodised oil Iodixanol	72 120 70 222 223 223
Invanz Invega Sustenna Iodine Iodine with ethanol Iodised oil Iodixanol Iohexol	72 120 70 222 223 223 223
Invanz Invega Sustenna Iodine Iodine with ethanol Iodised oil Iodixanol Iohexol Iopidine	72 120 70 222 223 223 223 218
Invanz Invega Sustenna Iodine Iodine with ethanol Iodised oil Iodixanol Iohexol	72 120 70 222 223 223 223 218 223

Invotronium bromida 000
Ipratropium bromide
Iressa
Irinotecan Actavis 100 133
Irinotecan hydrochloride 133
Iron polymaltose18
Iron sucrose18
Irrigation Solutions226
Isentress88
Isentress HD88
Ismo 2046
Ismo 40 Retard46
Isoflurane105
Isoniazid82
Isoniazid with rifampicin82
Isoprenaline [Isoproterenol]47
Isopropyl alcohol
Isoproterenol
Isoptin
Isoptin SR43
Isopto Carpine
Isosorbide mononitrate
Isotretinoin
Ispaghula (psyllium) husk12
Isradipine
Itch-Soothe
Itraconazole
Itrazole80 Ivabradine40
Ivermectin
Ivermecun
<b>- J -</b> Jadelle59
Jakavi
Jaydess59
Jevity HiCal RTH245
Jevity RTH245
Juno Pemetrexed 131
- K -
Kadcyla200
Kaletra87
Kenacomb214
Kenacort-A 1064
Kenacort-A 4064
Kenalog in Orabase19
Ketalar
Ketamine
Ketamine-Claris 105
Ketocal 3:1 (Unflavoured)243
Ketocal 4:1 (Unflavoured)243
Ketocal 4:1 (Vanilla)243
Ketoconazole
Dermatological
Infections
Ketoprofen 103
Ketorolac trometamol
KetoSens
Ketostix

Keytruda201
Kivexa86
Klacid75
Klean Prep12
Kogenate FS29
Konakion MM29
Konsyl-D12
Kuvan
-L-
L-asparaginase
L-ornithine L-aspartate
Labetalol
Lacosamide
Lactose
Lactulose
Laevolac
Laevolac
Lamivudine
Lamivudine Alphapharm
Lamotrigine
Lanoxin
Lanoxin PG40
Lansoprazole8
Lantus
Lantus SoloStar10
Lanzol Relief8
Lapatinib140
Largactil 118
Laronidase16
Lasix
Latanoprost217
Lax-Suppositories13
Lax-Tabs13
Laxatives 12
Laxsol 12
Ledipasvir with sofosbuvir
Leflunomide
Lenalidomide 133
Letrole148
Letrozole148
Leukotriene Receptor
Antagonists
Leunase
Leuprorelin acetate
Leustatin
Levetiracetam 114
Levetiracetam-AFT 114
Levlen ED
Levocabastine
Levocarnitine
Levodopa with benserazide
Levodopa with carbidopa
Levomepromazine
Levomepromazine
hydrochloride 119
Levonorgestrel

Levosimendan	
Levothyroxine	. 70
Lidocaine [Lignocaine]	107
Lidocaine [Lignocaine]	
hydrochloride	107
Lidocaine [Lignocaine] hydrochloride	
with adrenaline	107
Lidocaine [Lignocaine] hydrochloride	
with adrenaline and tetracaine	107
hydrochloride	107
Lidocaine [Lignocaine] hydrochloride with chlorhexidine	100
Lidocaine [Lignocaine] hydrochloride	100
with phenylephrine	
hydrochloride	100
Lidocaine [Lignocaine] with	100
prilocaine	108
Lidocaine-Claris	
lignocaine	107
Alimentary	20
Nervous107-	
Lincomycin	
Linezolid	
Linezolid Kabi	
Lioresal Intrathecal	101
Liothyronine sodium	
Lipazil	
Lipid-Modifying Agents	45
Lipiodol Ultra Fluid	
Liquibar	224
Lisinopril	.38
Lissamine green	215
Lithicarb FC	
Lithium carbonate	119
LMX4	107
Local Preparations for Anal and	
Rectal Disorders	7
Locoid55	, 57
Locoid Crelo	
Locoid Lipocream	. 55
Lodoxamide	215
Logem	114
Lomide	215
Lomustine	129
Long-Acting Beta-Adrenoceptor	
Agonists	
Loniten	. 48
Loperamide hydrochloride	5
Lopinavir with ritonavir	
Lorafix	
Loratadine	
Lorazepam113,	
Lorfast	
Lormetazepam	122
Lorstat	
Losartan Actavis	. 39

Losartan potassium
Losartan potassium with
hydrochlorothiazide 39
Lovir
Loxamine
Lucrin Depot 1-month
Lucrin Depot 3-month
Lyderm
Lysine acetylsalicylate [Lysine
asprin]
Lysine asprin
- M -
m-Amoxiclav76
m-Eslon110
Mabthera 178
Macrogol 3350 with ascorbic acid,
potassium chloride and sodium
chloride 12
Macrogol 3350 with potassium
chloride, sodium bicarbonate and
sodium chloride 13
Macrogol 3350 with potassium
chloride, sodium bicarbonate,
sodium chloride and sodium
sulphate
Macrogol 400 and propylene glycol
Madopar 125 105
Madopar 125
Madopar 62.5
Madopar HBS
Madopar Rapid
Mafenide acetate
Magnesium amino acid chelate 18
Magnesium chloride 18
Magnesium hydroxide
Alimentary18
Extemporaneously Compounded
Preparations229
Magnesium oxide
Magnesium oxide with magnesium
aspartate, magnesium amino acid
chelate and magnesium
citrate
Magnevist
Malarone Junior
Maldison
Mannitol
Cardiovascular
Various
Mantoux
Maprotiline hydrochloride 112

Marcain	. 106
Marcain Heavy	. 107
Marcain Isobaric	
Marcain with Adrenaline	
Marevan	
Marine Blue Lotion SPF 50+	57
Mask for spacer device	
Mast Cell Stabilisers	210
Maviret	00 2
Maxidex	
Maxitrol	213
Measles, mumps and rubella	
vaccine	
Mebendazole	83
Mebeverine hydrochloride	
Medrol	
Medroxyprogesterone	<mark>65</mark>
Medroxyprogesterone acetate	
Genito-Urinary	59
Hormone Preparations	
Mefenamic acid	
Mefloquine	84
Megestrol acetate	147
Meglumine gadopentetate	
Meglumine iotroxate	225
Melatonin	
Melphalan	
Menactra	
	<b>`</b>
Meningococcal (A, C, Y and W-135	)
conjugate vaccine	) . 248
conjugate vaccine Meningococcal C conjugate	. 248
conjugate vaccine Meningococcal C conjugate vaccine	. 248 . 249
conjugate vaccine Meningococcal C conjugate vaccine Menthol	. 248 . 249 . 229
conjugate vaccine Meningococcal C conjugate vaccine Menthol Mepivacaine hydrochloride	. 248 . 249 . 229 . 108
conjugate vaccine Meningococcal C conjugate vaccine Menthol Mepivacaine hydrochloride Mepolizumab	. 248 . 249 . 229 . 108 . 174
conjugate vaccine Meningococcal C conjugate vaccine Menthol Mepivacaine hydrochloride Mepolizumab Mercaptopurine	. 248 . 249 . 229 . 108 . 174 . 131
conjugate vaccine Meningococcal C conjugate vaccine Menthol Mepivacaine hydrochloride Mepolizumab Mercaptopurine Meropenem	. 248 . 249 . 229 . 108 . 174 . 131 73
conjugate vaccine Meningococcal C conjugate vaccine Menthol Mepolizumab Meropenem Meropenem Ranbaxy	. 248 . 249 . 229 . 108 . 174 . 131 73 73
conjugate vaccine Meningococcal C conjugate vaccine Menthol Mepolizumab Meropolizumab Meropenem Manbaxy Mesalazine	. 248 . 249 . 229 . 108 . 174 . 131 73 73 6
conjugate vaccine Meningococcal C conjugate vaccine Menthol Mepolizumab Meropenem Meropenem Ranbaxy Mesalazine Mesna	. 248 . 249 . 229 . 108 . 174 . 131 73 73 6 . 145
conjugate vaccine Meningococcal C conjugate vaccine Menthol Mepivacaine hydrochloride Meropelizumab Meropenem Ranbaxy Mesalazine Mesalazine Mestinon	. 248 . 249 . 229 . 108 . 174 . 131 73 73 6 . 145 95
conjugate vaccine Meningococcal C conjugate vaccine Menthol Mepivacaine hydrochloride Meropenem Aubaxy Meropenem Ranbaxy Mesalazine Mesinon Mestabolic Disorder Agents	. 248 . 249 . 229 . 108 . 174 . 131 73 73 6 . 145 95 13
conjugate vaccine Meningococcal C conjugate vaccine Menthol Mepivacaine hydrochloride Meropenem Meropenem Ranbaxy Mesalazine Mesalazine Mestinon Metabolic Disorder Agents Metabolic Products	. 248 . 249 . 229 . 108 . 174 . 131 73 73 6 . 145 95 13 233
conjugate vaccine Meningococcal C conjugate vaccine Menthol Mepivacaine hydrochloride Meropenem Aubaxy Meropenem Ranbaxy Mesalazine Mesalazine Mestinon Metabolic Disorder Agents Metabolic Products Metaraminol	. 248 . 249 229 108 174 131 73 6 145 145 133 233 47
conjugate vaccine Meningococcal C conjugate vaccine Menthol Mepolizumab Meropenem Meropenem Ranbaxy Mesalazine Mesalazine Mestinon Metabolic Disorder Agents Metapolic Products Metarminol Meterol	. 248 . 249 . 229 . 108 . 174 . 131 73 6 145 145 135 145 
conjugate vaccine Meningococcal C conjugate vaccine Menthol Mepolizumab Meropenem Anabaxy Meropenem Ranbaxy Mesalazine Mesalazine Mestion Metabolic Disorder Agents Metaaminol Meterol Metformin hydrochloride	. 248 . 249 . 229 . 108 . 174 . 131 73 6 145 13 95 13 233 47 210 11
conjugate vaccine	. 248 . 249 . 229 . 108 . 174 . 131 73 6 145 13 95 13 233 47 210 11
conjugate vaccine Meningococcal C conjugate vaccine Menthol Mepolizumab Meropenem Anabaxy Meropenem Ranbaxy Mesalazine Mesalazine Mestion Metabolic Disorder Agents Metaaminol Meterol Metformin hydrochloride	. 248 . 249 . 229 . 108 . 174 . 131 73 6 145 13 95 13 233 47 210 11
conjugate vaccine	. 248 . 249 229 108 174 131 73 6 145 95 13 95 13 
conjugate vaccine	. 248 . 249 229 108 174 131 73 6 145 95 13 233 273 210 11 225
conjugate vaccine Meningococcal C conjugate vaccine Menthol Mepolizumab Meroaptopurine Meropenem Ranbaxy Mesalazine Mesalazine Mestinon Metabolic Disorder Agents Metabolic Products Metaraminol Metaraminol Metormin hydrochloride Methacholine chloride Methadone hydrochloride	. 248 . 249 229 108 174 131 73 6 145 95 13 95 13 95 
conjugate vaccine	. 248 . 249 229 108 174 131 73 6 145 95 13 95 13 
conjugate vaccine	. 248 . 249 229 108 174 131 73 6 145 95 13 95 13 
conjugate vaccine	. 248 . 249 229 108 174 131 73 6 145 95 13 233 47 210 11 225 I 229 110 110
conjugate vaccine	. 248 . 249 229 108 174 131 73 6 145 95 145 95 
conjugate vaccine	. 248 . 249 229 108 174 131 73 6 145 95 145 95 

Methotrexate131
Methotrexate Ebewe131
Methotrexate Sandoz 131
Methoxsalen
[8-methoxypsoralen]56
Methoxyflurane 108
Methyl aminolevulinate
hydrochloride 57
Methyl hydroxybenzoate229
Methylcellulose
Methylcellulose with glycerin and
sodium saccharin 229
Methylcellulose with glycerin and
sucrose 229
Methyldopa43
Methyldopa Mylan43
Methylene blue 225
Methylnaltrexone bromide12
Methylphenidate ER - Teva 124
Methylphenidate hydrochloride 124
Methylprednisolone (as sodium
succinate) 64
Methylprednisolone aceponate
Methylprednisolone acetate
Methylthioninium chloride [Methylene
blue]
Methylxanthines
Nietociopramide Actavis 10 11/
Metoclopramide Actavis 10 117 Metoclopramide hydrochloride 117
Metoclopramide hydrochloride 117
Metoclopramide hydrochloride 117 Metoclopramide hydrochloride with
Metoclopramide hydrochloride
Metoclopramide hydrochloride       117         Metoclopramide hydrochloride with       116         paracetamol       116         Metolazone       42         Metoprolol succinate       41         Metoprolol succinate       42         Metorpolol tartrate       42         Metronidazole       52         Dermatological       52         Infections       84
Metoclopramide hydrochloride       117         Metoclopramide hydrochloride with       paracetamol         paracetamol       116         Metolazone       45         Metoprolol succinate       41         Metoprolol succinate       42         Metoprolol tartrate       42         Metrogyl       84         Metronidazole       52         Infections       84         Metroprolol IV Mylan       42
Metoclopramide hydrochloride       117         Metoclopramide hydrochloride with       paracetamol         paracetamol       116         Metolazone       45         Metoprolol succinate       41         Metoprolol succinate       42         Metoprolol tartrate       42         Metronidazole       52         Dermatological       52         Infections       84         Metroprolol IV Mylan       42
Metoclopramide hydrochloride       117         Metoclopramide hydrochloride with       paracetamol         paracetamol       116         Metolazone       45         Metoprolol succinate       41         Metoprolol succinate       42         Metrogyl       82         Dermatological       52         Infections       84         Metroprolol IV Mylan       42         Metyrapone       65         Mexiletine hydrochloride       41
Metoclopramide hydrochloride       117         Metoclopramide hydrochloride with       paracetamol         paracetamol       116         Metolazone       45         Metoprolol succinate       41         Metoprolol succinate       42         Metrogyl       84         Metrogyl       84         Metroprolol tartrate       52         Infections       84         Metroprolol IV Mylan       42         Metyrapone       65         Mexiletine hydrochloride       41         Mexiletine Hydrochloride       41
Metoclopramide hydrochloride       117         Metoclopramide hydrochloride with       paracetamol         paracetamol       116         Metolazone       45         Metoprolol succinate       41         Metoprolol succinate       41         Metoprolol tartrate       42         Metronidazole       52         Dermatological       52         Infections       44         Metyrapone       65         Mexiletine hydrochloride       41         Mexiletine Hydrochloride USP       41         Miacalcic       62
Metoclopramide hydrochloride       117         Metoclopramide hydrochloride with       paracetamol         paracetamol       116         Metolazone       45         Metoprolol succinate       41         Metoprolol succinate       41         Metoprolol succinate       42         Metroprolol tartrate       42         Metronidazole       52         Dermatological       52         Infections       84         Metroprolol IV Mylan       42         Metyrapone       65         Mexiletine hydrochloride       41         Mexiletine hydrochloride       41         Miacalcic       62         Mianserin hydrochloride       412
Metoclopramide hydrochloride       117         Metoclopramide hydrochloride with       paracetamol         paracetamol       116         Metolazone       45         Metoprolol succinate       41         Metoprolol succinate       41         Metoprolol succinate       42         Metroprolol tartrate       42         Metronidazole       52         Dermatological       52         Infections       44         Metroprolol IV Mylan       42         Metyrapone       65         Mexiletine Hydrochloride       41         Mexiletine Hydrochloride       42         Miacalcic       62         Mianserin hydrochloride       112         Micolette       112
Metoclopramide hydrochloride       117         Metoclopramide hydrochloride with       paracetamol         paracetamol       116         Metolazone       45         Metoprolol succinate       41         Metoprolol succinate       41         Metoprolol succinate       42         Metroprolol tartrate       42         Metronidazole       52         Dermatological       52         Infections       84         Metroprolol IV Mylan       42         Metyrapone       65         Mexiletine hydrochloride       41         Mexiletine hydrochloride       41         Miacalcic       62         Mianserin hydrochloride       412
Metoclopramide hydrochloride       117         Metoclopramide hydrochloride with       paracetamol         paracetamol       116         Metolazone       45         Metoprolol succinate       41         Metoprolol succinate       42         Metoprolol tartrate       42         Metrogyl       84         Metronidazole       52         Dermatological       52         Infections       84         Metroprolol IV Mylan       42         Metyrapone       65         Mexiletine Hydrochloride       41         Miacalcic       62         Mianserin hydrochloride       112         Micolatte       13         Miconazole       15         Miconazole       15         Miconazole nitrate       15
Metoclopramide hydrochloride       117         Metoclopramide hydrochloride with       paracetamol         paracetamol       116         Metoprolol succinate       42         Metoprolol succinate       42         Metoprolol succinate       42         Metoprolol tartrate       42         Metroprolol tartrate       42         Metronidazole       52         Infections       84         Metroprolol IV Mylan       42         Metyrapone       65         Mexiletine hydrochloride       41         Mexiletine hydrochloride       41         Mexiletine hydrochloride       12         Mianserin hydrochloride       12         Miconazole       16         Miconazole       16         Miconazole       52         Dermatological       52
Metoclopramide hydrochloride       117         Metoclopramide hydrochloride with       paracetamol         paracetamol       116         Metolazone       45         Metoprolol succinate       41         Metoprolol succinate       42         Metoprolol tartrate       42         Metrogyl       84         Metronidazole       52         Dermatological       52         Infections       84         Metroprolol IV Mylan       42         Metyrapone       65         Mexiletine Hydrochloride       41         Miacalcic       62         Mianserin hydrochloride       112         Micolatte       13         Miconazole       15         Miconazole       15         Miconazole nitrate       15
Metoclopramide hydrochloride       117         Metoclopramide hydrochloride with       paracetamol         paracetamol       116         Metolazone       45         Metoprolol succinate       41         Metoprolol succinate       42         Metoprolol tartrate       42         Metrogyl       84         Metronidazole       52         Infections       84         Metroprolol IV Mylan       42         Metyrapone       65         Mexiletine hydrochloride       41         Macalcic       62         Miacalcic       62         Miconazole       12         Miconazole       12         Miconazole       15         Miconazole       15         Miconazole       52         Genito-Urinary.       56         Micreme       56
Metoclopramide hydrochloride       117         Metoclopramide hydrochloride with       paracetamol         paracetamol       116         Metolazone       45         Metoprolol succinate       41         Metoprolol succinate       42         Metoprolol tartrate       42         Metrogyl       84         Metronidazole       52         Infections       84         Metroprolol IV Mylan       42         Metyrapone       65         Mexiletine hydrochloride       41         Mexiletine hydrochloride       41         Micaclici       62         Miconazole       12         Miconazole nitrate       52         Dermatological       52         Miconazole nitrate       52         Dermatological       52         Micone       52         Micreme       56         Micreme H       56
Metoclopramide hydrochloride       117         Metoclopramide hydrochloride with       paracetamol         paracetamol       116         Metolazone       45         Metoprolol succinate       41         Metoprolol succinate       42         Metoprolol tartrate       42         Metronidazole       52         Infections       84         Metroprolol IV Mylan       42         Metyrapone       65         Mexiletine hydrochloride       41         Mexiletine hydrochloride       41         Micolazole       52         Metroprolol IV Mylan       42         Metroprolol IV Mylan       42         Metroprolol IV Mylan       42         Metroprolol IV Mylan       42         Metoprolol IV Mylan       41         Micolette       12         Micolette       13         Miconazole       52         Genito-Urinary       52         Micreme H       56         Microgynon 20 ED       56
Metoclopramide hydrochloride       117         Metoclopramide hydrochloride with       paracetamol         paracetamol       116         Metolazone       45         Metoprolol succinate       41         Metoprolol succinate       42         Metoprolol tartrate       42         Metrogyl       84         Metronidazole       52         Infections       84         Metroprolol IV Mylan       42         Metyrapone       65         Mexiletine hydrochloride       41         Mexiletine Hydrochloride       41         Micaclici       62         Miconazole       12         Miconazole nitrate       52         Dermatological       52         Miconazole nitrate       52         Dermatological       52         Micone       52         Micreme       56         Micreme H       56
Metoclopramide hydrochloride       117         Metoclopramide hydrochloride with       paracetamol         paracetamol       116         Metolazone       45         Metoprolol succinate       41         Metoprolol succinate       42         Metoprolol tartrate       42         Metronidazole       52         Dermatological       52         Infections       84         Metroprolol IV Mylan       44         Metyrapone       65         Mexiletine hydrochloride       41         Miacalcic       62         Mianserin hydrochloride       112         Micolette       13         Miconazole nitrate       52         Dermatological       52         Micreme       56         Micregynon 20 ED       56         Microgynon 50 ED       56

Mifepristone59	)
Milrinone	2
Minerals	
Mini-Wright AFS Low Range 257	(
Mini-Wright Standard257	
Minidiab 10	)
Minims Prednisolone 215	5
Minirin71	Ľ
Minocycline78	3
Minoxidil	
Mirena	
Mirtazapine 112	
Misoprostol	,
Mitomycin C130	
Mitozantrone	)
Mitozantrone Ebewe130	
Mivacron 101	
Mivacurium chloride101	
Mixed salt solution for eye	
irrigation216	3
Moclobemide112	2
Modafinil	
Modavigil 125	
Molaxole	
Mometasone furoate	
Monosodium glutamate with sodium	
aspartate	,
Aspanale	,
Monosodium I-aspartate	(
	)
Montelukast Mylan210	)
Montelukast Mylan210 Moroctocog alfa [Recombinant factor	)
Montelukast Mylan	3
Montelukast Mylan	) 3
Montelukast Mylan	) 3 )
Montelukast Mylan	) 3 )
Montelukast Mylan	) 3 ) )
Montelukast Mylan	3001
Montelukast Mylan	
Montelukast Mylan	
Montelukast Mylan	
Montelukast Mylan	0 800049477
Montelukast Mylan	0 3000191773
Montelukast Mylan	) 3) )) 1) 77 73
Montelukast Mylan	) 3) )) 1) 7 7 3] 7 7
Montelukast Mylan	) 3))) 3)) 3)) 3)) 4) 77 3) 177 4)
Montelukast Mylan	) 3))) 3)) 3)) 3)) 4) 77 3) 177 4)
Montelukast Mylan	) 3))) 3)) 3)) 3)) 4) 7,7 3) 7,7 1
Montelukast Mylan	
Montelukast Mylan	3     3       1     1       1     1
Montelukast Mylan	3       3       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1
Montelukast Mylan	3 3 3 3 3 3 3 3 1 7 4 1 3 1 7 4 1 3 1 7 4 1 3 1 7 4 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 7 1 7 7 7 7 7 7 7 7 7 7 7 7 7
Montelukast Mylan       210         Moroctocog alfa [Recombinant factor       28         Morphine hydrochloride       110         Morphine sulphate       110         Morphine sulphate       110         Morphine sulphate       100         Mortalis       100         Motetis       100         Mouth and Throat       15         Movapo       100         Moxifloxacin       77         Moxifloxacin Kabi       77         Mozobil       33         Mucolytics and Expectorants       211         Mutishance       222         Multiple Sclerosis Treatments       121         Multivitamin and mineral       20         Multivitamin renal       20         Multivitamin renal       20         Multivitamins       21	3 3 3 3 3 3 3 3 1 7 4 1 3 1 7 4 1 3 1 7 4 1 3 1 7 4 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 7 1 7 7 7 7 7 7 7 7 7 7 7 7 7
Montelukast Mylan	
Montelukast Mylan	
Montelukast Mylan       210         Moroctocog alfa [Recombinant factor       210         Morphine hydrochloride       110         Morphine sulphate       110         Morphine sulphate       110         Morphine tartrate       110         Motetis       104         Mouth and Throat       15         Moxapo       104         Moxifloxacin       77         Moxifloxacin Kabi       77         Mozobil       33         Mucolytics and Expectorants       211         Multivitamin and mineral       204         Multivitamin renal       205         Multivitamins       211         Mupirocin       52         Mustivitamins       211         Multivitamins       212         Multivitamins       213         Multivitamins       214         Multivitamins       215         Multivitamins       216         Multivitamins       217         Multivitamins       218         Multivitamins       216         Multivitamins       217         Multivitamins       218         Multivitamins       219         Multivitamins <td></td>	
Montelukast Mylan	
Montelukast Mylan       210         Moroctocog alfa [Recombinant factor       210         Morphine hydrochloride       110         Morphine sulphate       110         Morphine sulphate       110         Morphine tartrate       110         Motetis       104         Mouth and Throat       15         Moxapo       104         Moxifloxacin       77         Moxifloxacin Kabi       77         Mozobil       33         Mucolytics and Expectorants       211         Multivitamin and mineral       204         Multivitamin renal       205         Multivitamins       211         Mupirocin       52         Mustivitamins       211         Multivitamins       212         Multivitamins       213         Multivitamins       214         Multivitamins       215         Multivitamins       216         Multivitamins       217         Multivitamins       218         Multivitamins       216         Multivitamins       217         Multivitamins       218         Multivitamins       219         Multivitamins <td></td>	

Mycophenolate mofetil	.203
Mydriacyl	.218
Mydriatics and Cycloplegics	.218
Mylan Atenolol	41
Mylan Clomiphen	65
Mylan Midazolam	
Myleran	129
Myozyme	13
- N -	
Nadolol	40
Naglazyme	
Naloxone hydrochloride	10
Natioxone nyurochionue	. 220
Naltraccord	
Naltrexone hydrochloride	
Naphazoline hydrochloride	.215
Naphcon Forte	.215
Naprosyn SR 1000	. 103
Naprosyn SR 750	. 103
Naproxen	. 103
Naropin	.108
Natalizumab	.122
Natamycin	.213
Natulan	.135
Nausafix	.118
Nausicalm	.117
Navelbine	.145
Nedocromil	.210
Nefopam hydrochloride	.109
Neisvac-C	
Neo-B12	
Neocate Gold (Unflavoured)	.240
Neocate Junior Vanilla	.240
Neoral	
Neostigmine metilsulfate	
Neostigmine metilsulfate with	
glycopyrronium bromide	95
Neosynephrine HCL	47
Nepro HP (Strawberry)	244
Nepro HP (Vanilla)	244
Nepro HP RTH	244
Neulastim	34
Neupogen	
NeuroTabs	
Nevirapine	
Nevirapine Alphapharm	
Nicardipine hydrochloride	40
Nicorandil	
Nicotine	
Nicotinic acid	
Nifedipine	
Nifuran	
Nilotinib	. 140
Nilstat	
Alimentary	
Genito-Urinary	
Infections	80

Nimodipine	43
Nimotop	43
Nintedanib	207
Nitazoxanide	84
Nitrates	
Nitroderm TTS 10	
Nitroderm TTS 5	46
Nitrofurantoin	79
Nitrolingual Pump Spray	46
Nivestim	07 مح
Nivolumab	
Nodia Noflam 250	0
Noflam 500	103
Non-Steroidal Anti-Inflammatory	
Drugs	102
Nonacog gamma, [Recombinant	
factor IX]	
Noradrenaline	
Noradrenaline BNM	47
Norethisterone	
Genito-Urinary	59
Hormone Preparations	66
Norethisterone with mestranol	58
Norflex	
Norfloxacin	77
Noriday 28	59
Normison	123
Norpress	112
Nortriptyline hydrochloride	211 110
Norvir Novasource Renal (Vanilla)	0/
Nevertuetie	244
Novatretin	56
NovoMix 30 FlexPen	
NovoRapid FlexPen	10
NovoSeven RT	
Noxafil	
Nozinan	119
Nucala	174
Nuelin	211
Nuelin-SR	
Nutrini Energy Multi Fibre	243
Nutrini Low Energy Multifibre	
RTH	243
Nutrini Peptisorb	
Nutrini Peptisorb Energy	240
Nutrison 800 Complete Multi	
Fibre	2/5
Nutrison Concentrated	020 020
Nutrison Energy	
Nyefax Retard	43
Nystatin	
Alimentary	20
Dermatological	
Genito-Urinary	
Infections	80

- 0 -
O/W Fatty Emulsion Cream54
Obinutuzumab 175
Obstetric Preparations59
Ocrelizumab
Ocrevus122
Octocog alfa [Recombinant factor
VIII] (Advate) 29
Octocog alfa [Recombinant factor
VIII] (Kogenate FS) 29
Octreotide
Ocular Lubricants
Oestradiol
Oestradiol valerate
Oestradiol with norethisterone
acetate
Oestriol
Genito-Urinary
Hormone Preparations
Oestrogens
Oestrogens (conjugated equine) 64
Oestrogens with
medroxyprogesterone
acetate
Ofev
Oil in water emulsion
Oily phenol [Phenol oily]7
Olanzapine
Olaparib
Olive oil
Olopatadine
Olopatadine Teva
Olsalazine
Omalizumab
Omeprazole
Omeprazole actavis 10
Omeprazole actavis 20
Omeprazole actavis 40
Omezol IV
Omnipaque
Omnitrope
Onbrez Breezhaler
OncoTICE
Ondansetron
Ondansetron ODT-DRLA 117
Ondansetron ODT-DRLA
One-Alpha
Onrex
Opdivo
Ora-Blend
Ora-Blend SF
Ora-Plus

Ora-Sweet22	9
Ora-Sweet SF22	9
Oratane5	
Ornidazole8	4
Orphenadrine citrate10	1
Oruvail SR 10	3
Oseltamivir	
Osmolite RTH24	
Other Cardiac Agents4	6
Other Endocrine Agents	
Other Oestrogen Preparations	
Other Otological Preparations	a
Other Progestogen	
Preparations 6	5
Other Skin Preparations	7
Ovestin	'
Genito-Urinary	0
Hormone Preparations	
Ox-Pam	1
Oxaliplatin	
Oxaliplatin Accord13	1
Oxandrolone	
Oxazepam	
Oxpentifylline	8
Oxybuprocaine hydrochloride21	
Oxybutynin6	
Oxycodone hydrochloride11	
Oxycodone Sandoz11	1
Oxymetazoline hydrochloride	
OxyNorm	1
Oxytocin	
Oxytocin BNM5	9
Oxytocin with ergometrine maleate	~
maleate	9
Ozurdex21	4
Pacifen	1
Paclitaxel	
Paclitaxel Ebewe	
Palbociclib	
Paliperidone12	0
Pamidronate disodium	6
Pamisol	
Pan-Penicillin G Sodium7	6
Pancreatic enzyme 1	1
Pancuronium bromide	i.
Pantoprazole	
Panzop Relief	
Papaverine hydrochloride4	_
Paper wasp venom	
Para-aminosalicylic Acid	3
Paracare	9
Paracare Double Strength 10	
Paracetamol 10	
Paracetamol Kabi	
Paracetamol with codeine	

	_
Paraffin	
Alimentary	
Dermatological	.54
Extemporaneously Compounded	
Preparations	229
Paraffin liquid with soft white	
paraffin	219
Paraffin liquid with wool fat	219
Paraffin with wool fat	.55
Paraldehyde	
Parecoxib	
Paromomycin	72
Paroxetine	
Paser	
Patent blue V	
Patent blue v	101
Pazopanib	142
Peak flow meter	257
Peanut oil	228
Pedialyte - Bubblegum	
Pediasure (Chocolate)	
Pediasure (Strawberry)	243
Pediasure (Vanilla)	
Pediasure RTH	
Pegaspargase	134
Pegasys	. 92
Pegfilgrastim	. 34
Pegylated interferon alfa-2a	.92
Pembrolizumab	201
Pemetrexed	
Penicillamine	.95
Penicillin G	
Penicillin V	
Pentacarinat	
Pentagastrin	
Pentamidine isethionate	. 00
Pentasa	
Pentostatin [Deoxycoformycin]	125
Pentoxifylline [Oxpentifylline]	
Peptamen OS 1.0 (Vanilla)	.40 000
Peptisoothe	200 0
Perflutren	
Perhexiline maleate	
Pericyazine	
Perindopril	
Perjeta	177
Permethrin	
Perrigo	. 57
Pertuzumab	
Peteha	
Pethidine hydrochloride	
Pexsig	.43
Pfizer Exemestane	148
Pheburane	
Phenasen	132
Phenelzine sulphate	

Phenindione31
Phenobarbitone 114, 123
Phenobarbitone sodium229
Phenol
Extemporaneously Compounded
Preparations
Various
Phenol oily7
Phenol with ioxaglic acid
Phenothrin53
Phenoxybenzamine
hydrochloride
Phenoxymethylpenicillin [Penicillin
V]76
Phentolamine mesylate
Phenylephrine hydrochloride
Cardiovascular
Sensory
Phenytoin114
Phenytoin sodium113–114
Pholcodine
Phosphorus
Phytomenadione
Picibanil
Pilocarpine hydrochloride
Pilocarpine hydrochionde
Pilocarpine nitrate
Pindolol42
Diversity of the test of the second s
Pine tar with trolamine laurilsulfate
and fluorescein 56
and fluorescein

n alva a a la avial a vera a in a	050
polysaccharide vaccine	250
Pneumovax 23	
Podophyllotoxin	
Polidocanol	
Poliomyelitis vaccine	
Poloxamer	12
Poly Gel	218
Poly-Tears	218
Poly-Visc	219
Polyhexamethylene biguanide	
Polyvinyl alcohol with povidone	219
Poractant alfa	
Posaconazole	80
Postinor-1	
Potassium chloride	35.37
Potassium chloride with sodium	,
chloride	35
Potassium citrate	61
Potassium dihydrogen	
phosphate	36
Potassium iodate	50
Alimentary	10
Hormone Preparations	10
Potassium iodate with iodine	10
Potassium perchlorate	
Potassium permanganate	
Povidone K30	229
Povidone-iodine	223
Povidone-iodine with ethanol	
Pradaxa	
Pralidoxime iodide	
Pramipexole hydrochloride	
Prasugrel	
Pravastatin	45
Praxbind	
Praziquantel	
Prazosin	40
Precedex	105
Pred Forte	215
Prednisolone	64
Prednisolone acetate	215
Prednisolone sodium	7
Prednisolone sodium	
phosphate	215
Prednisolone- AFT	215
Prednisone	
Pregabalin	
Pregabalin Pfizer	
Pregnancy test - hCG urine	257
preOp	244
Prevenar 13	
Prezista	
Prilocaine hydrochloride	
Prilocaine hydrochloride with	100
	100
felypressin	
Primacor	48

Primaquine	84
Primidone	
Primolut N	
Primovist	
Priorix	
Probenecid	
Procaine penicillin	.76
Procarbazine hydrochloride	135
Prochlorperazine	118
Proctosedyl	7
Procyclidine hydrochloride	104
Procytox	
Progesterone	59
Proglicem	
Proglycem	
Progynova	
Prolia	
Promethazine hydrochloride	206
Propafenone hydrochloride	.41
Propamidine isethionate	
Propofol	106
Propranolol	. 42
Propylthiouracil	
Prostin E2	. 59
Prostin VR	. 48
Protamine sulphate	. 31
Protionamide	.83
Protirelin	.71
Proveblue	
Provera	.65
Provera HD	
Proxymetacaine hydrochloride	
Pseudoephedrine	
hydrochloride	209
PSM Citalopram	
Psoriasis and Eczema	
Preparations	56
PTU	
Pulmonary Surfactants	
	211
Pulmozyme Puri-nethol	211
Puri-nethol	131
Puria	
Pyrazinamide	
Pyridostigmine bromide	.95
Pyridoxal-5-phosphate	. 16
Pyridoxine hydrochloride	.21
Pyrimethamine	
Pytazen SR	. 31
- Q -	
Q 300	
Quetapel	
Quetiapine	
Quinapril	. 38
Quinapril with	
hydrochlorothiazide	. 38
Quinine dihydrochloride	. 85

<b>INDEX: Generic</b>	Chemicals	and Brands
-----------------------	-----------	------------

	-
Quinine sulphate8	5
Qvar	9
- R -	
RA-Morph110	0
Rabies vaccine	
Raloxifene	
Raltegravir potassium	g
Ramipex 10	5
Ranbaxy-Cefaclor7	0
Ranbaxy-Celacior	3
Ranibizumab17	
Ranitidine	
Rapamune 204	
Rasburicase10	1
Readi-CAT 2 224	
Reandron 10006	2
Recombinant factor IX	8
Recombinant factor VIIa2	8
Recombinant factor VIII	9
Rectogesic	
Red back spider antivenom	í.
Redipred	
Relenza Rotadisk	4
Relistor	
Remicade	
Remifentanil11	1
Remifentanil-AFT11	
ReoPro15	
Resonium A3	
Resource Beneprotein23	
Resource Diabetic (Vanilla)23	7
Respiratory Stimulants21	1
Retinol	1
Retinol Palmitate21	9
ReTrieve5	
Retrovir	
Retrovir IV	
Revlimid	
Revolade	
Rexacrom	2
Ribomustin12	8
Ricit	
Rifabutin8	
Rifadin8	
Rifampicin8	
Rifaximin	
Rifinah8	2
Rilutek104	4
Riluzole104	4
Ringer's solution	
Riodine	
Risedronate Sandoz	
Risedronate sodium	
Risperdal Consta	
Risperidone 119–120	
Pienoridono (Toya)	0
Risperidone (Teva)119	J

Risperon	119
Ritalin	124
Ritalin LA	124
Ritalin SR	124
Ritonavir	87
Rituximab (mabthera)	178
Rituximab (riximyo)	184
Rivaroxaban	31
Rivastigmine	
Rivotril	
Riximyo	
RIXUBIS	
Rizamelt	116
Rizatriptan	
Rocuronium bromide	102
Rolin	
Ropin	
Ropinirole hydrochloride	
Ropivacaine hydrochloride	
Ropivacaine hydrochloride with	
fentanyl	108
Ropivacaine Kabi	108
Rose bengal sodium	
Rotarix	254
Rotavirus oral vaccine	
Roxane	
Roxithromycin	
Rubifen	124
	124
Rubifon SR	
Rubifen SR	124
Rulide D	124 75
Rulide D Rurioctocog alfa pegol [Recombina	124 75 Int
Rulide D Rurioctocog alfa pegol [Recombina factor VIII]	124 75 int 29
Rulide D Rurioctocog alfa pegol [Recombina factor VIII] Ruxolitinib	124 75 int 29
Rulide D Rurioctocog alfa pegol [Recombina factor VIII] Ruxolitinib	124 75 int 29 142
Rulide D Rurioctocog alfa pegol [Recombina factor VIII] Ruxolitinib - S - S26 LBW Gold RTF	124 75 int 29 142 242
Rulide D Rurioctocog alfa pegol [Recombina factor VIII] Ruxolitinib	124 75 .nt 29 142 242 39
Rulide D Rurioctocog alfa pegol [Recombina factor VIII] Ruxolitinib	124 75 .nt 29 142 242 39 208
Rulide D Rurioctocog alfa pegol [Recombina factor VIII] Ruxolitinib Sa - S26 LBW Gold RTF Sacubitril with valsartan SalAir Salazopyrin	124 75 .nt 29 142 242 39 208 7
Rulide D Rurioctocog alfa pegol [Recombina factor VIII] Ruxolitinib Sa - S26 LBW Gold RTF Sacubitril with valsartan SalAir Salazopyrin Salazopyrin EN	124 75 int 29 142 242 39 208 7 7
Rulide D Rurioctocog alfa pegol [Recombina factor VIII] Ruxolitinib - S - S26 LBW Gold RTF Sacubitril with valsartan SalAir Salazopyrin.EN Salazopyrin EN Salbutamol	124 75 int 29 142 242 39 208 7 7
Rulide D Rurioctocog alfa pegol [Recombina factor VIII] Ruxolitinib	124 75 .nt 29 142 242 39 208 7 7 208
Rulide D Rurioctocog alfa pegol [Recombina factor VIII] Ruxolitinib	124 75 int 29 142 242 39 208 7 208 206
Rulide D Rurioctocog alfa pegol [Recombina factor VIII] Ruxolitinib	124 75 int 29 142 242 39 208 7 7 7 7 208 206 229
Rulide D Rurioctocog alfa pegol [Recombina factor VIII] Ruxolitinib	124 75 int 29 142 242 39 208 7 7 7 7 208 206 229 210
Rulide D Rurioctocog alfa pegol [Recombina factor VIII] Ruxolitinib	124 75 .nt 29 142 242 39 208 7 7 7 208 220 220 221
Rulide D Rurioctocog alfa pegol [Recombina factor VIII] Ruxolitinib	124 75 .nt 29 142 242 
Rulide D Rurioctocog alfa pegol [Recombina factor VIII] Ruxolitinib	124 75 .nt 29 242 39 7 7 7 7 
Rulide D Rurioctocog alfa pegol [Recombina factor VIII] Ruxolitinib	124 
Rulide D Rurioctocog alfa pegol [Recombina factor VIII] Ruxolitinib	124 
Rulide D Rurioctocog alfa pegol [Recombina factor VIII]. Ruxolitinib	124 75 int 29 208 208 208 208 220 210 221 211 2116 147 
Rulide D Rurioctocog alfa pegol [Recombina factor VIII]. Ruxolitinib	124 
Rulide D Rurioctocog alfa pegol [Recombina factor VIII] Ruxolitinib	124 
Rulide D Rurioctocog alfa pegol [Recombina factor VIII] Ruxolitinib	124 
Rulide D Rurioctocog alfa pegol [Recombina factor VIII] Ruxolitinib	124 75 int 29 208 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 
Rulide D Rurioctocog alfa pegol [Recombina factor VIII] Ruxolitinib	124 75 int 29 208 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 

Contations and Upmenting	400
Sedatives and Hypnotics	122
Seebri Breezhaler	206
Selegiline hydrochloride	105
Sennosides	13
Consiner	10
Sensipar	62
Serenace	118
Seretide	210
Seretide Accuhaler	210
Serevent	
Serevent Accuhaler	
Sertraline	113
Setrona	113
Sevoflurane	106
Sevredol	110
Shingles vaccine	
Sildenafil	
Siltuximab	194
Silver nitrate	
Dermatological	57
Extemporaneously Compounded	4
	, , ,
Preparations	
Simeticone	5
Simulect	166
Simvastatin	45
Simvastatin Mylan	45
Sincolido	005
Sincalide	220
Sinemet	105
Sinemet CR	
Sirolimus	204
Siterone	
Slow-Lopresor	12
Slow-Lopresor Smith BioMed Rapid Pregnancy	
Test	
Snake antivenom	221
Sodibic	37
Sodium acetate	
Sodium acid phosphate	
	30
Sodium alginate with magnesium	
alginate	5
Sodium alginate with sodium	
bicarbonate and calcium	
carbonate	5
Sodium aurothiomalate	
Soulum auroiniomalaie	
Sodium benzoate	17
Sodium bicarbonate	
Blood	36-37
Extemporaneously Compounded	
Bronarationa	ົງງດ
Preparations	229
Sodium calcium edetate	222
Sodium chloride	
Blood	36–37
Respiratory209	. 211
Various	206
Sodium chloride with sodium	
bicarbonate	209

Sodium citrate
Alimentary5
Extemporaneously Compounded
Preparations
Sodium citrate with sodium chloride
and potassium chloride31
Sodium citrate with sodium lauryl
sulphoacetate
Sodium citro-tartrate61
Sodium cromoglicate
Alimentary7
Respiratory
Sensory
Sodium dihydrogen phosphate
[Sodium acid phosphate]
Sodium fluoride
Sodium fusidate [Fusidic acid]
Dermatological
Infections
Sensory
Sodium hyaluronate [Hyaluronic acid]
Alimentary
Sensory
Sodium hyaluronate [Hyaluronic acid]
with chondroitin sulphate
Sodium hypochlorite
Sodium metabisulfite
Sodium nitrite
Sodium nitroprusside
Sodium nitroprusside Cardiovascular 48
Cardiovascular48
Cardiovascular
Cardiovascular       48         Optional Pharmaceuticals       257         Sodium phenylbutyrate       17         Sodium phosphate with phosphoric       acid         acid       13         Sodium polystyrene sulphonate       37         Sodium stibogluconate       85         Sodium tetradecyl sulphate       27         Sodium thiosulfate       220         Sodium with potassium       227         Solifenacin Mylan       61         Solu-Cortef       64         Solu-Medrol       64         Sotalou       42         Sotalol       42         Soya oil       220         Spacer device       257
Cardiovascular
Cardiovascular
Cardiovascular       48         Optional Pharmaceuticals       257         Sodium phenylbutyrate       17         Sodium phosphate with phosphoric acid       13         acid       13         Sodium polystyrene sulphonate       37         Sodium stibogluconate       85         Sodium tetradecyl sulphate       27         Sodium thiosulfate       220         Sodium valproate       115         Sodium with potassium       227         Solifenacin Mylan       61         Soli-Cortef       64         Solu-Medrol       64         Sotalol       42         Soya oil       220         Spacer device       220         Spacer device       227         Spacer device       237         Spiolto Respimat       207
Cardiovascular
Cardiovascular
Cardiovascular

<b>A A A A</b>	
Spironolactone	44
Sprycel	138
Standard Feeds	.245
Staphlex	
Starch	230
Stavudine	
Sterculia with frangula	40
SteroClear	
Stesolid	
Stimulants / ADHD Treatments	
Stiripentol	
Stocrin	85
Streptomycin sulphate	72
Stromectol	
Sucralfate	8
Sucrose	109
Sugammadex	102
Sulfadiazine silver	
Sulfasalazine	
Sulindac	
Sulphacetamide sodium	
Sulphadiazine	
Sulphur	
Sulprix	
Sumatriptan	
Sunitinip	143
Sunscreen, proprietary	5/
Suprane	105
Surgical Preparations	- 226
Sustagen Diabetic (Vanilla)	237
Sustagen Hospital Formula Active	237
Sustagen Hospital Formula Active (Choc)	237
Sustagen Hospital Formula Active (Choc) Sustagen Hospital Formula Active	237 246
Sustagen Hospital Formula Active (Choc) Sustagen Hospital Formula Active (Van)	237 246 246
Sustagen Hospital Formula Active (Choc) Sustagen Hospital Formula Active	237 246 246
Sustagen Hospital Formula Active (Choc) Sustagen Hospital Formula Active (Van) Sutent Suxamethonium chloride	237 246 246 143 102
Sustagen Hospital Formula Active (Choc) Sustagen Hospital Formula Active (Van) Sutent Suxamethonium chloride	237 246 246 143 102
Sustagen Hospital Formula Active (Choc) Sustagen Hospital Formula Active (Van) Sutent Suxamethonium chloride Sylvant	237 246 246 143 102 194
Sustagen Hospital Formula Active (Choc) Sustagen Hospital Formula Active (Van) Sutent Suxamethonium chloride Sylvant Symmetrel	237 246 246 143 102 194 104
Sustagen Hospital Formula Active (Choc) Sustagen Hospital Formula Active (Van) Sutent Suxamethonium chloride Sylvant Symmetrel Sympathomimetics	237 246 143 102 194 104 47
Sustagen Hospital Formula Active (Choc) Sustagen Hospital Formula Active (Van) Sutent Sylvant Sylvant Symmetrel Sympathomimetics Synacthen	237 246 143 102 194 104 47 66
Sustagen Hospital Formula Active (Choc) Sustagen Hospital Formula Active (Van) Sutent Sylvant Sylvant Symmetrel Sympathomimetics Synacthen Depot	237 246 143 102 194 104 47 66 66
Sustagen Hospital Formula Active (Choc) Sustagen Hospital Formula Active (Van) Sutent Suxamethonium chloride Sylvant Symmetrel Symathomimetics Synacthen Synathen Depot Synflorix	237 246 143 102 194 104 47 66 249
Sustagen Hospital Formula Active (Choc) Sustagen Hospital Formula Active (Van) Sutent Suxamethonium chloride Sylvant Symmetrel Sympathomimetics Synacthen Depot Synforix Syntometrine	237 246 143 102 194 104 47 66 249 59
Sustagen Hospital Formula Active (Choc) Sustagen Hospital Formula Active (Van) Sutent Suxamethonium chloride Sylvant Sylvant Symmetrel Sympathomimetics Synacthen Depot Synforix Syntometrine Syrup	237 246 143 102 194 104 47 66 249 59 230
Sustagen Hospital Formula Active (Choc) Sustagen Hospital Formula Active (Van) Sutent Suxamethonium chloride Sylvant Symmetrel Sympathomimetics Synacthen Depot Synflorix Synflorix Syntometrine Syrup Systane Unit Dose	237 246 143 102 194 104 47 66 249 59 230
Sustagen Hospital Formula Active (Choc) Sustagen Hospital Formula Active (Van) Sutent Sytent Symmetrel Sympathomimetics Synacthen Synacthen Depot Synflorix Syntometrine Syrup Systane Unit Dose - T -	237 246 246 143 102 194 104 104 249 249 230 218
Sustagen Hospital Formula Active (Choc) Sustagen Hospital Formula Active (Van) Sutent Sytent Symmetrel Sympathomimetics Synacthen Synatchen Depot Synflorix Synflorix Syntometrine Sytane Unit Dose T - Tacrolimus	237 246 143 102 194 104 66 66 69 230 230 218 
Sustagen Hospital Formula Active (Choc) Sustagen Hospital Formula Active (Van) Sutent Suxamethonium chloride Sylvant Sylvant Sympathomimetics Synacthen Depot Synacthen Depot Synflorix Syntometrine Syrup Systane Unit Dose Systane Unit Dose Tacrolimus Tacrolimus Sandoz	237 246 246 143 102 194 194 194 
Sustagen Hospital Formula Active (Choc) Sustagen Hospital Formula Active (Van) Sutent Sytent Symmetrel Sympathomimetics Synacthen Depot Synatchen Depot Synflorix Syntometrine Syrup Systane Unit Dose - T - Tacrolimus Tacrolimus Sandoz Tagitol V	237 246 246 143 102 194 104 66 66 249 230 218 218 148 148 148 
Sustagen Hospital Formula Active (Choc) Sustagen Hospital Formula Active (Van) Sutent Sylvant Symmetrel Sympathomimetics Synacthen Depot Synacthen Depot Synflorix Syntometrine Syrup Systane Unit Dose T - Tacrolimus Tacrolimus Sandoz Tagitol V Talc	237 246 246 143 102 194 104 66 66 249 230 218 148 212
Sustagen Hospital Formula Active (Choc) Sustagen Hospital Formula Active (Van) Sutent Suxamethonium chloride Sylvant Symmetrel Sympathomimetics Synacthen Synacthen Depot Synacthen Depot Synflorix Syntometrine Syrup Systane Unit Dose - T - Tacrolimus Tacrolimus Sandoz Tagitol V Talc Taliglucerase alfa	237 246 143 102 194 104 104 194 104 249 230 218 148 224 148 221 17
Sustagen Hospital Formula Active (Choc) Sustagen Hospital Formula Active (Van) Sutent Syumetrel Symmetrel Symathomimetics Synacthen Depot Synacthen Depot Synflorix Syntometrine Systane Unit Dose <b>T</b> - Tacrolimus Sandoz Tagitol V Talc Taliglucerase alfa Tambocor	237 246 246 143 102 194 104 
Sustagen Hospital Formula Active (Choc) Sustagen Hospital Formula Active (Van) Sutent Syutent Sylvant Symmetrel Sympathomimetics Sympathomimetics Synacthen Depot Synacthen Depot Synflorix Syntometrine Syntometrine Systane Unit Dose Systane Unit Dose Tacrolimus Tacrolimus Sandoz Tagitol V Taliglucerase alfa Tambocor Tamoxifen citrate	237 246 246 143 102 194 104 
Sustagen Hospital Formula Active (Choc) Sustagen Hospital Formula Active (Van) Sutent Synacthen Symmetrel Sympathomimetics Synacthen Depot Synacthen Depot Synflorix Syntometrine Systane Unit Dose <b>T</b> - Tacrolimus Sandoz Tagitol V Talc Taliglucerase alfa Tambocor Tamoxifen citrate Tamoxifen Sandoz	237 246 246 143 102 194 104 47 66 249 230 218 218 218 148 224 212 
Sustagen Hospital Formula Active (Choc) Sustagen Hospital Formula Active (Van) Sutent Syutent Sylvant Symmetrel Sympathomimetics Sympathomimetics Synacthen Depot Synacthen Depot Synflorix Syntometrine Syntometrine Systane Unit Dose Systane Unit Dose Tacrolimus Tacrolimus Sandoz Tagitol V Taliglucerase alfa Tambocor Tamoxifen citrate	237 246 246 143 143 102 194 104 66 

Tarceva	138
Tasigna	
Tasmar	
Tecfidera	
Tegretol	
Tegretol CR	113
Teicoplanin	110
Teicoplanin Mylan	73
Temaccord Temazepam	100
Temozolomide	
Tenecteplase	33
Tenofovir disoproxil	88
Tenofovir Disoproxil Teva	
Tenoxicam	
Terazosin	
Terbinafine	
Terbutaline	
Terbutaline sulphate	
Teriflunomide	
Teriparatide	99
Terlipressin	71
Testosterone	62
Testosterone cipionate	62
Testosterone esters	62
Testosterone undecanoate	
Tetrabenazine	
Tetracaine [Amethocaine] hydroch	
Nervous	108
Sensory	
Tetracosactide [Tetracosactrin]	66
Tetracosactrin	
Tetracyclin Wolff	
Tetracycline	
Thalidomide	
Thalomid	
Theobroma oil	
Theophylline	211
Thiamine hydrochloride	
Thioguanine	132
Thiopental [Thiopentone]	
sodium	106
Thiopentone	106
Thiotepa	
Thrombin	
Thymol glycerin	20
Thyroid and Antithyroid	
Preparations	70
Thyrotropin alfa	
Ticagrelor	32
Ticarcillin with clavulanic acid	
Ticlopidine	33
Tigecycline	
Tilcotil	
Timolol	
	2 1 /
Timolol maleate	

Timoptol XE217
Tiotropium bromide207
Tiotropium bromide with
olodaterol 207
Tivicay
TMP
TOBI
Tobradex
Tobramycin
Infections
Sensory
Tobramycin Mylan72
Tobrex
Tocilizumab
Tofranil
Tolcapone105
Topamax115
Topicaine107
Topical Products for Joint and
Muscular Pain 103
Topiramate 115
Topiramate Actavis115
Torbay
Tracrium 101
Tramadol hydrochloride111
Tramal 100 111
Tramal 50 111
Tramal SR 100 111
Tramal SR 150 111
Tramal SR 200 111
Trandate41
Tranexamic acid27
Tranexamic-AFT27
Tranylcypromine sulphate 112
Trastuzumab198
Trastuzumab emtansine
Travoprost
Travopt
Treatments for Dementia
Treatments for Substance
Dependence
Tretinoin
Dermatological
Oncology
Trexate
Tri-sodium citrate230
Triamcinolone acetonide
Alimentary19
Dermatological
Hormone Preparations64
Triamcinolone acetonide with
gramicidin, neomycin and
nystatin 214
Triamcinolone acetonide with
neomycin sulphate, gramicidin
and nystatin 56

Triamcinolone hexacetonide
Triazolam
Trichloracetic acid
Trimethoprim
Trimethoprim with
sulphamethoxazole
[Co-trimoxazole]
Trometamol
Tropicamide
Tropicating 119
Tropisetron
Tuberculin PPD [Mantoux] test
Tubersol
Two Cal HN239
TwoCal HN RTH (Vanilla)239
Tykerb
Tysabri122
- U -
Ultibro Breezhaler
Ultraproct7
Umeclidinium
Umeclidinium with vilanterol207
Univent
Ural61
Urea
Dermatological55
Extemporaneously Compounded
Preparations
Preparations230
Preparations
Preparations
Preparations         230           Urex Forte         44           Urografin         223           Urokinase         33
Preparations         230           Urex Forte         44           Urografin         223           Urokinase         33           Urologicals         60
Preparations         230           Urex Forte         44           Urografin         223           Urokinase         33           Urologicals         60           Uromitexan         145
Preparations         230           Urex Forte         44           Urografin         223           Urokinase         33           Urologicals         60           Uromitexan         145           Ursodeoxycholic acid         11
Preparations         230           Urex Forte         44           Urografin         223           Urokinase         33           Urologicals         60           Uromitexan         145           Ursodeoxycholic acid.         11           Ursosan         11
Preparations         230           Urex Forte         44           Urografin         223           Urokinase         33           Urologicals         60           Uromitexan         145           Ursodeoxycholic acid         11           Ursosan         11           Utrogestan         59           - V -         59
Preparations         230           Urex Forte.         44           Urografin         223           Urokinase         33           Urologicals         60           Uromitexan         145           Ursodeoxycholic acid.         11           Urosesan         11           Utrogestan         59
Preparations         230           Urex Forte         44           Urografin         223           Urokinase         33           Urologicals         60           Uromitexan         145           Ursodeoxycholic acid.         11           Ursosan         11           Utrogestan         59           - V -         Vaclovir.
Preparations         230           Urex Forte         44           Urografin         223           Urokinase         33           Urologicals         60           Uromitexan         145           Ursodeoxycholic acid.         11           Ursosan         11           Utrogestan         59           - V -         Vaclovir           Valaciclovir         89
Preparations         230           Urex Forte         44           Urografin         223           Urokinase         33           Urologicals         60           Uromitexan         145           Ursodeoxycholic acid         11           Ursosan         11           Utrogestan         59           - V -         Vaclovir           Valaciclovir         89           Valganciclovir         89
Preparations         230           Urex Forte         44           Urografin         223           Urokinase         33           Urologicals         60           Uromitexan         145           Ursodeoxycholic acid.         11           Ursosan         11           Utrogestan         59           - V -         Vaclovir           Valaciclovir         89
Preparations         230           Urex Forte         44           Urografin         223           Urokinase         33           Urologicals         60           Uromitexan         145           Ursodeoxycholic acid         11           Ursosan         11           Utrogestan         59           - V -         Vaclovir           Vaglanciclovir         89           Valganciclovir         89           Valganciclovir         89
Preparations         230           Urex Forte         44           Urografin         223           Urokinase         33           Urologicals         60           Uromitexan         145           Ursodeoxycholic acid         11           Ursosan         11           Utrogestan         59           - V -         Vaclovir           Vaglanciclovir         89           Valganciclovir         89           Valganciclovir         79
Preparations       230         Urex Forte       44         Urografin       223         Urokinase       33         Urologicals       60         Uromitexan       145         Ursodeoxycholic acid       11         Ursosan       11         Utrogestan       59         - V -       Vaclovir         Vaganciclovir       89         Valganciclovir       89         Vancomycin       79         Varenicline       127         Varibar - Honey       224
Preparations       230         Urex Forte.       44         Urografin       223         Urokinase       33         Urologicals       60         Uromitexan       145         Ursodeoxycholic acid.       11         Ursosan       11         Utrogestan       59         - V -       Vaclovir.         Valganciclovir       89         Valganciclovir Mylan       89         Varencicline       127         Vareincline       127         Varibar - Honey       224         Varibar - Nectar       224
Preparations       230         Urex Forte.       44         Urografin       223         Urokinase       33         Urologicals       60         Uromitexan       145         Ursodeoxycholic acid.       11         Ursosan       11         Utrogestan       59         - V -       Vaclovir.         Valganciclovir       89         Valganciclovir Mylan       89         Varencicline Pfizer.       127         Varibar - Honey       224         Varibar - Pudding.       224
Preparations       230         Urex Forte       44         Urografin       223         Urokinase       33         Urologicals       60         Uromitexan       145         Ursodeoxycholic acid       11         Ursosan       11         Utrogestan       59         - V -       Vaclovir         Valganciclovir       89         Valganciclovir       89         Valganciclovir Mylan       89         Varenciline       127         Varibar - Honey       224         Varibar - Nectar       224         Varibar - Pudding       224
Preparations       230         Urex Forte       44         Urografin       223         Urokinase       33         Urologicals       60         Uromitexan       145         Ursodeoxycholic acid       11         Ursosan       11         Ursosan       11         Ursosan       59         - V -       Vaclovir         Valganciclovir       89         Valganciclovir       89         Valganciclovir Mylan       89         Varenciline       127         Varibar - Honey       224         Varibar - Nectar       224         Varibar - Thin Liquid       224         Varicella vaccine [Chickenpox       24
Preparations       230         Urex Forte       44         Urografin       223         Urokinase       33         Urologicals       60         Uromitexan       145         Ursodeoxycholic acid       11         Ursosan       11         Utrogestan       59         Vaclovir       89         Valaciclovir       89         Valganciclovir       89         Valganciclovir       79         Varenicline       127         Varibar - Honey       224         Varibar - Thin Liquid       224         Varicella vaccine [Chickenpox       vaccine]         Vaccine]       255
Preparations       230         Urex Forte       44         Urografin       223         Urokinase       33         Urologicals       60         Uromitexan       145         Ursodeoxycholic acid       11         Ursosan       11         Utrogestan       59         Vaclovir       89         Valaciclovir       89         Valganciclovir       89         Valganciclovir       89         Valganciclovir       127         Varenicline       127         Varibar - Honey       224         Varibar - Nectar       224         Varibar - Pudding       224         Varibar - Thin Liquid       224         Varicella vaccine [Chickenpox       vaccine]         vacicine]       255         Varicella zoster vaccine [Shingles
Preparations       230         Urex Forte       44         Urografin       223         Urokinase       33         Urologicals       60         Uromitexan       145         Ursodeoxycholic acid       11         Ursosan       11         Utrogestan       59         Vaclovir       89         Valaciclovir       89         Valganciclovir       89         Valganciclovir       89         Valganciclovir       127         Varenicline       127         Varibar - Honey       224         Varibar - Nectar       224         Varibar - Thin Liquid       224         Varibar - Thin Liquid       224         Varibar - Thin Liquid       224         Varicella vaccine [Chickenpox       vaccine]         Varicella zoster vaccine [Shingles       vaccine]         Varicella zoster vaccine [Shingles       vaccine]
Preparations       230         Urex Forte       44         Urografin       223         Urokinase       33         Urologicals       60         Uromitexan       145         Ursodeoxycholic acid       11         Ursosan       11         Utrogestan       59         Vaclovir       89         Valaciclovir       89         Valganciclovir       89         Valganciclovir       89         Valganciclovir       89         Varenicline       127         Vareincline       127         Varibar - Honey       224         Varibar - Nectar       224         Varibar - Pudding       224         Varibar - Thin Liquid       224         Varibar - Thin Liquid       224         Varicella vaccine [Chickenpox       vaccine]         varccine]       255         Varicella zoster vaccine [Shingles       vaccine]         vaccine]       256         Varivax       255
Preparations       230         Urex Forte       44         Urografin       223         Urokinase       33         Urologicals       60         Uromitexan       145         Ursodeoxycholic acid       11         Ursosan       11         Utrogestan       59         Vaclovir       89         Valaciclovir       89         Valganciclovir       89         Valganciclovir       89         Valganciclovir       127         Varenicline       127         Varibar - Honey       224         Varibar - Nectar       224         Varibar - Thin Liquid       224         Varibar - Thin Liquid       224         Varibar - Thin Liquid       224         Varicella vaccine [Chickenpox       vaccine]         Varicella zoster vaccine [Shingles       vaccine]         Varicella zoster vaccine [Shingles       vaccine]

Vasopressin Agents
Vasorex
Vecuronium bromide
Veletri
Venclexta
Venetoclax
Venlafaxine
Venofer
Ventavis51
Ventolin
Vepesid132
Verapamil hydrochloride43
Vergo 16117
Vesanoid136
Vexazone11
Vfend81
Vigabatrin115
Vildagliptin11
Vildagliptin with metformin
hydrochloride 11
Vimpat
Vinblastine sulphate145
Vincristine sulphate145
Vinorelbine
Viral Vaccines251
Viramune Suspension85
ViruPOS213
Viscoat216
Visipaque223
Vit.D322
VitA-POS
Vital238
Vitamin B complex22
Vitamin B6 25
Vitamins20
Vivonex TEN237
Volibris48
Voltaren 102
Voltaren D102
Voltaren Ophtha215
Volumatic257
VoLumen
Voriconazole81
Votrient 142
Vttack
- W -
Warfarin sodium31
Wart Preparations57
Water
Blood
Various
Wool fat
Dermatological
Extemporaneously Compounded
Preparations230

- X -	Zyvox79
X-Opaque-HD224	
Xanthan	
Xarelto	
Xifaxan9	
Xolair 176	
Xylocaine107	
Xylometazoline hydrochloride	
Xyntha28	
- Y -	
Yellow jacket wasp venom 205	
- Z -	
Zanamivir92	
Zantac8	
Zapril	
Zarontin 113	
Zavedos130	
Zeffix	
Zetlam88	
Ziagen	
Zidovudine [AZT]86	
Zidovudine [AZT] with	
lamivudine	
Zimybe46	
Zinc	
Alimentary 19	
Dermatological	
Zinc and castor oil	
Zinc chloride	
Zinc oxide	
Zinc sulphate19 Zinc with wool fat54	
Zincaps19 Zinforo74	
Zinnoto	
Ziprasidone	
Zista	
Zithromax74	
Zoladex	
Zoledronic acid	
Hormone Preparations	
Musculoskeletal	
Zoledronic acid Mylan63	
Zopiclone 123	
Zostavax256	
Zostrix103	
Zostrix HP108	
Zuclopenthixol acetate119	
Zuclopenthixol decanoate	
Zuclopenthixol hydrochloride	
Zusdone119	
Zyban 126	
Zypine119	
Zypine ODT 119	
Zyprexa Relprevv 120	
Zytiga145	













